{"94943b2fe8a76fe18759ee052d5681c108b2ef3a": [["PACIENTES Y M\u00c9TODO: estudio retrospectivo observacional de pacientes consecutivos ingresados con infecci\u00f3n por SARS-CoV-2 confirmada, con neumon\u00eda por estudio radiol\u00f3gico o tomograf\u00eda de t\u00f3rax, que cumpl\u00edan criterios de STC y que recibieron tratamiento.", [["CoV", "TEST", 116, 119]]], ["Clasificamos a los pacientes en los que recibieron s\u00f3lo pulsos de glucocorticoides (GC), o pulsos de GC y tocilizumab.", [["GC y tocilizumab", "TREATMENT", 101, 117]]], ["Determinamos niveles s\u00e9ricos de ferritina, PCR y d\u00edmeros-D.", [["Determinamos", "TEST", 0, 12]]], ["La variable final fue la supervivencia.", [["fue la supervivencia", "OBSERVATION", 18, 38]]]], "PMC7125843": [["IntroductionLymphoid or homeostatic chemokines, including CCL19, CCL21, CXCL12 and CXCL13, are constitutively expressed in lymphoid organs and regulate the migration and compartmentalization of lymphocytes and antigen presenting cells within lymphoid tissues (Yoshie et al., 1997, Zlotnik et al., 1999).", [["lymphoid organs", "ANATOMY", 123, 138], ["lymphocytes", "ANATOMY", 194, 205], ["antigen presenting cells", "ANATOMY", 210, 234], ["lymphoid tissues", "ANATOMY", 242, 258], ["CCL19", "GENE_OR_GENE_PRODUCT", 58, 63], ["CCL21", "GENE_OR_GENE_PRODUCT", 65, 70], ["CXCL12", "GENE_OR_GENE_PRODUCT", 72, 78], ["CXCL13", "GENE_OR_GENE_PRODUCT", 83, 89], ["lymphoid organs", "MULTI-TISSUE_STRUCTURE", 123, 138], ["lymphocytes", "CELL", 194, 205], ["cells", "CELL", 229, 234], ["lymphoid tissues", "TISSUE", 242, 258], ["homeostatic chemokines", "PROTEIN", 24, 46], ["CCL19", "PROTEIN", 58, 63], ["CCL21", "PROTEIN", 65, 70], ["CXCL12", "PROTEIN", 72, 78], ["CXCL13", "PROTEIN", 83, 89], ["lymphocytes", "CELL_TYPE", 194, 205], ["antigen presenting cells", "CELL_TYPE", 210, 234], ["homeostatic chemokines", "TEST", 24, 46], ["CCL19", "TEST", 58, 63], ["CXCL12", "TEST", 72, 78], ["CXCL13", "TEST", 83, 89], ["lymphocytes", "PROBLEM", 194, 205], ["homeostatic chemokines", "OBSERVATION", 24, 46], ["CCL21", "ANATOMY", 65, 70], ["lymphoid organs", "OBSERVATION", 123, 138], ["migration", "OBSERVATION_MODIFIER", 156, 165], ["lymphocytes", "ANATOMY", 194, 205], ["lymphoid tissues", "OBSERVATION", 242, 258]]], ["CCL19 and CCL21 are ligands for CCR7 and are produced by stromal cells and dendritic cells in the T cell zone (Cyster, 1999).", [["stromal cells", "ANATOMY", 57, 70], ["dendritic cells", "ANATOMY", 75, 90], ["T cell zone", "ANATOMY", 98, 109], ["CCL19", "GENE_OR_GENE_PRODUCT", 0, 5], ["CCL21", "GENE_OR_GENE_PRODUCT", 10, 15], ["CCR7", "GENE_OR_GENE_PRODUCT", 32, 36], ["stromal cells", "CELL", 57, 70], ["dendritic cells", "CELL", 75, 90], ["T cell zone", "CELL", 98, 109], ["CCL19", "PROTEIN", 0, 5], ["CCL21", "PROTEIN", 10, 15], ["CCR7", "PROTEIN", 32, 36], ["stromal cells", "CELL_TYPE", 57, 70], ["dendritic cells", "CELL_TYPE", 75, 90], ["CCL19", "TEST", 0, 5], ["CCR7", "TEST", 32, 36], ["stromal cells", "PROBLEM", 57, 70], ["dendritic cells", "PROBLEM", 75, 90], ["stromal cells", "OBSERVATION", 57, 70], ["dendritic cells", "OBSERVATION", 75, 90], ["T cell", "OBSERVATION", 98, 104], ["zone", "ANATOMY_MODIFIER", 105, 109]]], ["CCL21 is also expressed in endothelial cells in high endothelial venules (HEV) and lymphatic vessels (Cyster, 1999).", [["endothelial cells", "ANATOMY", 27, 44], ["high endothelial venules", "ANATOMY", 48, 72], ["lymphatic vessels", "ANATOMY", 83, 100], ["CCL21", "GENE_OR_GENE_PRODUCT", 0, 5], ["endothelial cells", "CELL", 27, 44], ["high endothelial venules", "TISSUE", 48, 72], ["HEV", "CELL", 74, 77], ["lymphatic vessels", "MULTI-TISSUE_STRUCTURE", 83, 100], ["CCL21", "PROTEIN", 0, 5], ["endothelial cells", "CELL_TYPE", 27, 44], ["HEV", "SPECIES", 74, 77], ["endothelial cells", "OBSERVATION", 27, 44], ["high", "ANATOMY_MODIFIER", 48, 52], ["endothelial venules", "ANATOMY", 53, 72], ["lymphatic vessels", "ANATOMY", 83, 100]]], ["Genetic and functional studies have established an important role for these chemokines in dendritic cell and T cell trafficking to T cell areas of secondary lymphoid organs (Yoshie et al., 1997, M\u00fcller et al., 2003).", [["dendritic cell", "ANATOMY", 90, 104], ["T cell", "ANATOMY", 109, 115], ["T cell", "ANATOMY", 131, 137], ["lymphoid organs", "ANATOMY", 157, 172], ["dendritic cell", "CELL", 90, 104], ["T cell", "CELL", 109, 115], ["T cell", "CELL", 131, 137], ["lymphoid organs", "TISSUE", 157, 172], ["chemokines", "PROTEIN", 76, 86], ["functional studies", "TEST", 12, 30], ["these chemokines in dendritic cell", "TREATMENT", 70, 104], ["T cell trafficking", "TREATMENT", 109, 127], ["dendritic cell", "OBSERVATION", 90, 104], ["secondary lymphoid organs", "OBSERVATION", 147, 172]]], ["CXCL13 is produced by stromal cells in B cell areas (follicles), binds to CXCR5 and regulates homing of B cells and subsets of T cells (follicular B helper T cells) to lymphoid follicles (F\u00f6rster et al., 1996, Legler et al., 1998, Ansel et al., 2000, Moser et al., 2002, M\u00fcller et al., 2003).", [["stromal cells", "ANATOMY", 22, 35], ["B cell areas", "ANATOMY", 39, 51], ["follicles", "ANATOMY", 53, 62], ["B cells", "ANATOMY", 104, 111], ["T cells", "ANATOMY", 127, 134], ["follicular B helper T cells", "ANATOMY", 136, 163], ["lymphoid follicles", "ANATOMY", 168, 186], ["CXCL13", "GENE_OR_GENE_PRODUCT", 0, 6], ["stromal cells", "CELL", 22, 35], ["B cell", "CELL", 39, 45], ["follicles", "MULTI-TISSUE_STRUCTURE", 53, 62], ["CXCR5", "GENE_OR_GENE_PRODUCT", 74, 79], ["B cells", "CELL", 104, 111], ["T cells", "CELL", 127, 134], ["follicular B helper T cells", "CELL", 136, 163], ["lymphoid follicles", "MULTI-TISSUE_STRUCTURE", 168, 186], ["CXCL13", "PROTEIN", 0, 6], ["stromal cells", "CELL_TYPE", 22, 35], ["CXCR5", "PROTEIN", 74, 79], ["B cells", "CELL_TYPE", 104, 111], ["T cells", "CELL_TYPE", 127, 134], ["follicular B helper T cells", "CELL_TYPE", 136, 163], ["CXCL13", "TEST", 0, 6], ["stromal cells", "PROBLEM", 22, 35], ["CXCR5", "TEST", 74, 79], ["B cells", "PROBLEM", 104, 111], ["T cells", "PROBLEM", 127, 134], ["follicular B helper T cells", "TREATMENT", 136, 163], ["stromal cells", "OBSERVATION", 22, 35], ["B cell", "OBSERVATION", 39, 45], ["areas", "OBSERVATION_MODIFIER", 46, 51], ["lymphoid follicles", "OBSERVATION", 168, 186]]], ["CXCL12 is expressed broadly, acts as a potent chemoattractant for different types of immune cells by binding CXCR4, regulates hematopoiesis and, together with CXCL13, mediates germinal center organization in secondary lymphoid organs (Campbell et al., 2003, Allen et al., 2004).", [["immune cells", "ANATOMY", 85, 97], ["germinal center", "ANATOMY", 176, 191], ["lymphoid organs", "ANATOMY", 218, 233], ["CXCL12", "GENE_OR_GENE_PRODUCT", 0, 6], ["immune cells", "CELL", 85, 97], ["CXCR4", "GENE_OR_GENE_PRODUCT", 109, 114], ["CXCL13", "GENE_OR_GENE_PRODUCT", 159, 165], ["germinal center", "MULTI-TISSUE_STRUCTURE", 176, 191], ["lymphoid organs", "MULTI-TISSUE_STRUCTURE", 218, 233], ["CXCL12", "PROTEIN", 0, 6], ["immune cells", "CELL_TYPE", 85, 97], ["CXCR4", "PROTEIN", 109, 114], ["CXCL13", "PROTEIN", 159, 165], ["CXCL12", "TEST", 0, 6], ["immune cells", "PROBLEM", 85, 97], ["binding CXCR4", "TEST", 101, 114], ["CXCL13", "TEST", 159, 165], ["immune cells", "OBSERVATION", 85, 97], ["germinal center", "OBSERVATION", 176, 191], ["secondary lymphoid organs", "OBSERVATION", 208, 233]]], ["Chemokine expression in T and B cell areas of lymphoid organs is dependent on lymphotoxin (LT) \u03b11\u03b22 and tumor necrosis factor (TNF) signaling through the LT\u03b2R and TNFR1, respectively (Mackay and Browning, 1998, Ngo et al., 1999, Fu and Chaplin, 1999).IntroductionOver the past several years it has become evident that, in addition to their role in lymphoid tissue development and maintenance, lymphoid chemokines are also implicated in inflammation.", [["T", "ANATOMY", 24, 25], ["B cell areas", "ANATOMY", 30, 42], ["lymphoid organs", "ANATOMY", 46, 61], ["lymphoid tissue", "ANATOMY", 348, 363], ["lymphoid", "ANATOMY", 393, 401], ["necrosis", "DISEASE", 110, 118], ["inflammation", "DISEASE", 436, 448], ["Chemokine", "GENE_OR_GENE_PRODUCT", 0, 9], ["T", "CELL", 24, 25], ["B cell", "CELL", 30, 36], ["lymphoid organs", "MULTI-TISSUE_STRUCTURE", 46, 61], ["lymphotoxin (LT) \u03b11\u03b22", "GENE_OR_GENE_PRODUCT", 78, 99], ["tumor necrosis factor", "GENE_OR_GENE_PRODUCT", 104, 125], ["TNF", "GENE_OR_GENE_PRODUCT", 127, 130], ["LT\u03b2R", "GENE_OR_GENE_PRODUCT", 154, 158], ["TNFR1", "GENE_OR_GENE_PRODUCT", 163, 168], ["lymphoid tissue", "TISSUE", 348, 363], ["lymphoid chemokines", "CELL", 393, 412], ["Chemokine", "PROTEIN", 0, 9], ["lymphotoxin (LT) \u03b11\u03b22", "PROTEIN", 78, 99], ["tumor necrosis factor", "PROTEIN", 104, 125], ["TNF", "PROTEIN", 127, 130], ["LT", "PROTEIN", 154, 156], ["\u03b2R", "PROTEIN", 156, 158], ["TNFR1", "PROTEIN", 163, 168], ["lymphoid chemokines", "PROTEIN", 393, 412], ["Chemokine expression in T", "PROBLEM", 0, 25], ["lymphoid organs", "PROBLEM", 46, 61], ["lymphotoxin (LT) \u03b1", "TEST", 78, 96], ["tumor necrosis factor", "PROBLEM", 104, 125], ["TNF", "TEST", 127, 130], ["lymphoid tissue development", "TREATMENT", 348, 375], ["lymphoid chemokines", "TREATMENT", 393, 412], ["inflammation", "PROBLEM", 436, 448], ["lymphoid organs", "OBSERVATION", 46, 61], ["dependent", "OBSERVATION_MODIFIER", 65, 74], ["tumor", "OBSERVATION_MODIFIER", 104, 109], ["necrosis", "OBSERVATION", 110, 118], ["LT", "ANATOMY_MODIFIER", 154, 156], ["TNFR1", "ANATOMY", 163, 168], ["lymphoid tissue", "OBSERVATION", 348, 363], ["lymphoid chemokines", "OBSERVATION", 393, 412], ["inflammation", "OBSERVATION", 436, 448]]], ["Since the early 70's histopathologists have observed that in chronic inflammatory conditions, like autoimmunity and infections, the immune cells infiltrating the target organs may organize themselves in structures that resemble the T and B cell areas of secondary lymphoid organs, the so called tertiary or ectopic lymphoid organs (Hjelmstr\u00f6m, 2001).", [["immune cells", "ANATOMY", 132, 144], ["organs", "ANATOMY", 169, 175], ["structures", "ANATOMY", 203, 213], ["T", "ANATOMY", 232, 233], ["B cell", "ANATOMY", 238, 244], ["lymphoid organs", "ANATOMY", 264, 279], ["ectopic lymphoid organs", "ANATOMY", 307, 330], ["autoimmunity", "DISEASE", 99, 111], ["infections", "DISEASE", 116, 126], ["immune cells", "CELL", 132, 144], ["organs", "ORGAN", 169, 175], ["T", "CELL", 232, 233], ["B cell", "CELL", 238, 244], ["lymphoid organs", "MULTI-TISSUE_STRUCTURE", 264, 279], ["lymphoid organs", "MULTI-TISSUE_STRUCTURE", 315, 330], ["immune cells", "CELL_TYPE", 132, 144], ["chronic inflammatory conditions", "PROBLEM", 61, 92], ["autoimmunity", "PROBLEM", 99, 111], ["infections", "PROBLEM", 116, 126], ["the immune cells", "TREATMENT", 128, 144], ["secondary lymphoid organs", "PROBLEM", 254, 279], ["ectopic lymphoid organs", "PROBLEM", 307, 330], ["chronic", "OBSERVATION_MODIFIER", 61, 68], ["inflammatory", "OBSERVATION", 69, 81], ["infections", "OBSERVATION", 116, 126], ["secondary lymphoid organs", "OBSERVATION", 254, 279], ["ectopic lymphoid organs", "OBSERVATION", 307, 330]]], ["The discovery that lymphoid chemokines are involved in the formation of ectopic lymphoid tissue has led to the recognition that this process (also termed lymphoid neogenesis) shares similar mechanisms with lymphoid organogenesis (Cupedo and Mebius, 2003).", [["lymphoid", "ANATOMY", 19, 27], ["ectopic lymphoid tissue", "ANATOMY", 72, 95], ["lymphoid", "ANATOMY", 154, 162], ["lymphoid", "ANATOMY", 206, 214], ["lymphoid chemokines", "CELL", 19, 38], ["ectopic lymphoid tissue", "TISSUE", 72, 95], ["lymphoid", "MULTI-TISSUE_STRUCTURE", 154, 162], ["lymphoid", "CELL", 206, 214], ["lymphoid chemokines", "PROTEIN", 19, 38], ["lymphoid chemokines", "TREATMENT", 19, 38], ["ectopic lymphoid tissue", "PROBLEM", 72, 95], ["lymphoid neogenesis", "PROBLEM", 154, 173], ["lymphoid organogenesis", "PROBLEM", 206, 228], ["lymphoid chemokines", "OBSERVATION", 19, 38], ["ectopic lymphoid tissue", "OBSERVATION", 72, 95], ["lymphoid neogenesis", "OBSERVATION", 154, 173], ["lymphoid organogenesis", "OBSERVATION", 206, 228]]], ["Following the initial observation that CXCL13 is expressed in Helicobacter pylori-induced gastric mucosa-associated lymphoid structures (Mazzucchelli et al., 1999) and the findings of elegant studies showing that transgenic expression of LT (Kratz et al., 1996, Drayton et al., 2003) or individual lymphoid chemokines (Fan et al., 2000, Luther et al., 2000, Luther et al., 2002, Chen et al., 2002b, Martin et al., 2004) in non-lymphoid tissues (pancreas, thyroid) leads to formation of lymphoid-like structures, the role of lymphoid chemokines in regulating immune cell trafficking and organization of ectopic lymphoid tissue in inflammatory conditions has received increasing attention (Aloisi and Pujol-Borrell, 2006, Drayton et al., 2006).", [["gastric mucosa-associated lymphoid structures", "ANATOMY", 90, 135], ["lymphoid", "ANATOMY", 298, 306], ["non-lymphoid tissues", "ANATOMY", 423, 443], ["pancreas", "ANATOMY", 445, 453], ["thyroid", "ANATOMY", 455, 462], ["lymphoid-like structures", "ANATOMY", 486, 510], ["lymphoid", "ANATOMY", 524, 532], ["immune cell", "ANATOMY", 558, 569], ["ectopic lymphoid tissue", "ANATOMY", 602, 625], ["CXCL13", "GENE_OR_GENE_PRODUCT", 39, 45], ["Helicobacter pylori-", "ORGANISM", 62, 82], ["gastric mucosa-associated lymphoid structures", "TISSUE", 90, 135], ["lymphoid chemokines", "CELL", 298, 317], ["non-lymphoid tissues", "TISSUE", 423, 443], ["pancreas", "ORGAN", 445, 453], ["thyroid", "ORGAN", 455, 462], ["lymphoid-like structures", "TISSUE", 486, 510], ["lymphoid", "CELL", 524, 532], ["immune cell", "CELL", 558, 569], ["lymphoid tissue", "TISSUE", 610, 625], ["CXCL13", "PROTEIN", 39, 45], ["LT", "PROTEIN", 238, 240], ["lymphoid chemokines", "PROTEIN", 298, 317], ["lymphoid chemokines", "PROTEIN", 524, 543], ["the initial observation", "TEST", 10, 33], ["CXCL13", "TEST", 39, 45], ["Helicobacter pylori-induced gastric mucosa-associated lymphoid structures", "PROBLEM", 62, 135], ["elegant studies", "TEST", 184, 199], ["lymphoid-like structures", "PROBLEM", 486, 510], ["lymphoid chemokines", "TREATMENT", 524, 543], ["immune cell trafficking", "TREATMENT", 558, 581], ["ectopic lymphoid tissue", "PROBLEM", 602, 625], ["inflammatory conditions", "PROBLEM", 629, 652], ["gastric", "ANATOMY", 90, 97], ["mucosa-associated lymphoid", "OBSERVATION", 98, 124], ["lymphoid chemokines", "OBSERVATION", 298, 317], ["non-lymphoid tissues", "ANATOMY", 423, 443], ["pancreas", "ANATOMY", 445, 453], ["thyroid", "ANATOMY", 455, 462], ["lymphoid", "ANATOMY", 486, 494], ["lymphoid chemokines", "OBSERVATION", 524, 543], ["immune cell trafficking", "OBSERVATION", 558, 581], ["ectopic lymphoid tissue", "OBSERVATION", 602, 625], ["inflammatory", "OBSERVATION_MODIFIER", 629, 641]]], ["Formation of ectopic lymphoid tissue is viewed as part of an adaptive response against infection but may also have the potential to support autoimmunity through expansion and activation of autoreactive B and T lymphocytes (reviewed in Aloisi and Pujol-Borrell, 2006).", [["ectopic lymphoid tissue", "ANATOMY", 13, 36], ["autoreactive B", "ANATOMY", 189, 203], ["T lymphocytes", "ANATOMY", 208, 221], ["infection", "DISEASE", 87, 96], ["autoimmunity", "DISEASE", 140, 152], ["ectopic lymphoid tissue", "TISSUE", 13, 36], ["autoreactive B", "CELL", 189, 203], ["T lymphocytes", "CELL", 208, 221], ["autoreactive B and T lymphocytes", "CELL_TYPE", 189, 221], ["ectopic lymphoid tissue", "PROBLEM", 13, 36], ["infection", "PROBLEM", 87, 96], ["autoimmunity through expansion", "PROBLEM", 140, 170], ["autoreactive B and T lymphocytes", "PROBLEM", 189, 221], ["ectopic lymphoid tissue", "OBSERVATION", 13, 36], ["infection", "OBSERVATION", 87, 96]]], ["In this article, we summarize current knowledge of lymphoid chemokines in neuroinflammation, particularly in multiple sclerosis, the most common inflammatory disease of the central nervous system (CNS), and the animal model experimental autoimmune encephalomyelitis (EAE), as these are the disease conditions in which lymphoid chemokines have been mostly investigated.", [["lymphoid", "ANATOMY", 51, 59], ["central nervous system", "ANATOMY", 173, 195], ["CNS", "ANATOMY", 197, 200], ["lymphoid", "ANATOMY", 318, 326], ["neuroinflammation", "DISEASE", 74, 91], ["multiple sclerosis", "DISEASE", 109, 127], ["disease of the central nervous system", "DISEASE", 158, 195], ["autoimmune encephalomyelitis", "DISEASE", 237, 265], ["EAE", "DISEASE", 267, 270], ["lymphoid chemokines", "CELL", 51, 70], ["central nervous system", "ANATOMICAL_SYSTEM", 173, 195], ["CNS", "ANATOMICAL_SYSTEM", 197, 200], ["lymphoid chemokines", "CELL", 318, 337], ["lymphoid chemokines", "PROTEIN", 51, 70], ["lymphoid chemokines", "PROTEIN", 318, 337], ["lymphoid chemokines", "PROBLEM", 51, 70], ["neuroinflammation", "PROBLEM", 74, 91], ["multiple sclerosis", "PROBLEM", 109, 127], ["the most common inflammatory disease of the central nervous system", "PROBLEM", 129, 195], ["the animal model experimental autoimmune encephalomyelitis", "PROBLEM", 207, 265], ["the disease conditions", "PROBLEM", 286, 308], ["lymphoid chemokines", "TREATMENT", 318, 337], ["lymphoid chemokines", "OBSERVATION", 51, 70], ["multiple", "OBSERVATION_MODIFIER", 109, 117], ["sclerosis", "OBSERVATION", 118, 127], ["most common", "OBSERVATION_MODIFIER", 133, 144], ["inflammatory", "OBSERVATION_MODIFIER", 145, 157], ["central", "ANATOMY_MODIFIER", 173, 180], ["nervous system", "ANATOMY", 181, 195], ["CNS", "ANATOMY", 197, 200], ["experimental", "OBSERVATION_MODIFIER", 224, 236], ["autoimmune encephalomyelitis", "OBSERVATION", 237, 265], ["lymphoid chemokines", "OBSERVATION", 318, 337]]], ["We also review how the study of this particular set of molecules has led us to achieve novel and unexpected insights into the elusive aetiopathogenesis of MS.CCL19 and CCL21 ::: Expression of lymphoid chemokines in the inflamed CNSIn an early study addressing the role of lymphoid chemokines in the CNS, Sergio Lira's group showed that contrary to what had been observed in the pancreas, transgenic expression of CCL21 in the brain parenchyma was not associated with lymphocyte recruitment or lymphoid neogenesis (Chen et al., 2002a), suggesting the existence of tissue-specific requirements for the biological activity of CCL21.", [["lymphoid", "ANATOMY", 192, 200], ["lymphoid", "ANATOMY", 272, 280], ["CNS", "ANATOMY", 299, 302], ["pancreas", "ANATOMY", 378, 386], ["brain parenchyma", "ANATOMY", 426, 442], ["lymphocyte", "ANATOMY", 467, 477], ["lymphoid", "ANATOMY", 493, 501], ["tissue", "ANATOMY", 563, 569], ["MS.CCL19", "GENE_OR_GENE_PRODUCT", 155, 163], ["CCL21", "GENE_OR_GENE_PRODUCT", 168, 173], ["lymphoid chemokines", "CELL", 192, 211], ["CNSIn", "CANCER", 228, 233], ["lymphoid chemokines", "CELL", 272, 291], ["CNS", "ANATOMICAL_SYSTEM", 299, 302], ["pancreas", "ORGAN", 378, 386], ["CCL21", "GENE_OR_GENE_PRODUCT", 413, 418], ["brain parenchyma", "MULTI-TISSUE_STRUCTURE", 426, 442], ["lymphocyte", "CELL", 467, 477], ["tissue", "TISSUE", 563, 569], ["CCL21", "GENE_OR_GENE_PRODUCT", 623, 628], ["MS.CCL19", "PROTEIN", 155, 163], ["CCL21", "PROTEIN", 168, 173], ["lymphoid chemokines", "PROTEIN", 192, 211], ["lymphoid chemokines", "PROTEIN", 272, 291], ["CCL21", "PROTEIN", 413, 418], ["CCL21", "PROTEIN", 623, 628], ["the study", "TEST", 19, 28], ["lymphoid chemokines", "TREATMENT", 192, 211], ["lymphoid chemokines", "TREATMENT", 272, 291], ["Sergio Lira's group", "TEST", 304, 323], ["transgenic expression of CCL21 in the brain parenchyma", "PROBLEM", 388, 442], ["lymphocyte recruitment", "PROBLEM", 467, 489], ["lymphoid neogenesis", "PROBLEM", 493, 512], ["lymphoid chemokines", "OBSERVATION", 192, 211], ["inflamed", "OBSERVATION_MODIFIER", 219, 227], ["lymphoid chemokines", "OBSERVATION", 272, 291], ["CNS", "ANATOMY", 299, 302], ["pancreas", "ANATOMY", 378, 386], ["CCL21", "ANATOMY_MODIFIER", 413, 418], ["brain", "ANATOMY", 426, 431], ["parenchyma", "ANATOMY_MODIFIER", 432, 442], ["not associated with", "UNCERTAINTY", 447, 466], ["lymphocyte recruitment", "OBSERVATION", 467, 489], ["lymphoid neogenesis", "OBSERVATION", 493, 512]]], ["Concomitantly, Alt et al. (2002) described functional expression of CCL19 and CCL21 in inflamed venules in the brain and spinal cord of mice with EAE and suggested that these chemokines besides regulating lymphocyte trafficking in lymphoid organs were also involved in the migration of encephalitogenic T cells in the CNS.", [["inflamed venules", "ANATOMY", 87, 103], ["brain", "ANATOMY", 111, 116], ["spinal cord", "ANATOMY", 121, 132], ["lymphocyte", "ANATOMY", 205, 215], ["lymphoid organs", "ANATOMY", 231, 246], ["encephalitogenic T cells", "ANATOMY", 286, 310], ["CNS", "ANATOMY", 318, 321], ["EAE", "DISEASE", 146, 149], ["CCL19", "GENE_OR_GENE_PRODUCT", 68, 73], ["CCL21", "GENE_OR_GENE_PRODUCT", 78, 83], ["venules", "MULTI-TISSUE_STRUCTURE", 96, 103], ["brain", "ORGAN", 111, 116], ["spinal cord", "ORGAN", 121, 132], ["mice", "ORGANISM", 136, 140], ["lymphocyte", "CELL", 205, 215], ["lymphoid organs", "MULTI-TISSUE_STRUCTURE", 231, 246], ["encephalitogenic T cells", "CELL", 286, 310], ["CNS", "ANATOMICAL_SYSTEM", 318, 321], ["CCL19", "PROTEIN", 68, 73], ["CCL21", "PROTEIN", 78, 83], ["chemokines", "PROTEIN", 175, 185], ["encephalitogenic T cells", "CELL_TYPE", 286, 310], ["mice", "SPECIES", 136, 140], ["mice", "SPECIES", 136, 140], ["CCL19", "TEST", 68, 73], ["inflamed venules in the brain", "PROBLEM", 87, 116], ["these chemokines", "TEST", 169, 185], ["lymphocyte trafficking in lymphoid organs", "PROBLEM", 205, 246], ["encephalitogenic T cells", "TREATMENT", 286, 310], ["inflamed venules", "OBSERVATION", 87, 103], ["brain", "ANATOMY", 111, 116], ["spinal cord", "ANATOMY", 121, 132], ["lymphocyte trafficking", "OBSERVATION", 205, 227], ["lymphoid organs", "OBSERVATION", 231, 246], ["migration", "OBSERVATION_MODIFIER", 273, 282], ["encephalitogenic T cells", "OBSERVATION", 286, 310], ["CNS", "ANATOMY", 318, 321]]], ["We and others also found upregulation of CCL19, CCL21 and their common receptor CCR7 in CNS inflammatory lesions of mice with EAE, particularly during the chronic phase (Columba-Cabezas et al., 2003, Bagaeva et al., 2006, Bielecki et al., 2007).CCL19 and CCL21 ::: Expression of lymphoid chemokines in the inflamed CNSFurther support to the idea that CCR7-binding chemokines could play a role in neuroinflammation was provided by analyses of brain tissue and cerebrospinal fluid (CSF) from patients with inflammatory neurological diseases.", [["CNS inflammatory lesions", "ANATOMY", 88, 112], ["lymphoid", "ANATOMY", 279, 287], ["brain tissue", "ANATOMY", 442, 454], ["cerebrospinal fluid", "ANATOMY", 459, 478], ["neurological", "ANATOMY", 517, 529], ["EAE", "DISEASE", 126, 129], ["neuroinflammation", "DISEASE", 396, 413], ["inflammatory neurological diseases", "DISEASE", 504, 538], ["CCL19", "GENE_OR_GENE_PRODUCT", 41, 46], ["CCL21", "GENE_OR_GENE_PRODUCT", 48, 53], ["CCR7", "GENE_OR_GENE_PRODUCT", 80, 84], ["CNS inflammatory lesions", "PATHOLOGICAL_FORMATION", 88, 112], ["mice", "ORGANISM", 116, 120], ["CCL19", "GENE_OR_GENE_PRODUCT", 245, 250], ["CCL21", "GENE_OR_GENE_PRODUCT", 255, 260], ["lymphoid chemokines", "CELL", 279, 298], ["CNSFurther", "GENE_OR_GENE_PRODUCT", 315, 325], ["CCR7", "GENE_OR_GENE_PRODUCT", 351, 355], ["brain tissue", "TISSUE", 442, 454], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 459, 478], ["CSF", "ORGANISM_SUBSTANCE", 480, 483], ["patients", "ORGANISM", 490, 498], ["CCL19", "PROTEIN", 41, 46], ["CCL21", "PROTEIN", 48, 53], ["CCR7", "PROTEIN", 80, 84], ["CCL19", "PROTEIN", 245, 250], ["CCL21", "PROTEIN", 255, 260], ["lymphoid chemokines", "PROTEIN", 279, 298], ["CCR7", "PROTEIN", 351, 355], ["binding chemokines", "PROTEIN", 356, 374], ["mice", "SPECIES", 116, 120], ["patients", "SPECIES", 490, 498], ["mice", "SPECIES", 116, 120], ["CCL19", "TEST", 41, 46], ["CCL21", "TEST", 48, 53], ["CNS inflammatory lesions", "PROBLEM", 88, 112], ["EAE", "PROBLEM", 126, 129], ["lymphoid chemokines", "TREATMENT", 279, 298], ["the inflamed CNSFurther support", "TREATMENT", 302, 333], ["neuroinflammation", "PROBLEM", 396, 413], ["brain tissue", "TEST", 442, 454], ["cerebrospinal fluid (CSF", "TEST", 459, 483], ["inflammatory neurological diseases", "PROBLEM", 504, 538], ["CCR7", "ANATOMY", 80, 84], ["CNS", "ANATOMY", 88, 91], ["inflammatory", "OBSERVATION_MODIFIER", 92, 104], ["lymphoid chemokines", "OBSERVATION", 279, 298], ["brain tissue", "ANATOMY", 442, 454], ["cerebrospinal", "ANATOMY", 459, 472], ["fluid", "OBSERVATION", 473, 478], ["inflammatory", "OBSERVATION_MODIFIER", 504, 516]]], ["Several studies showed increased amounts of CCL19 in the CSF of patients with MS and with infectious diseases of the CNS as compared to patients with non-inflammatory neurological disease, whereas CCL21 was less consistently detected (Pashenkov et al., 2003, Giunti et al., 2003, Krumbholz et al., 2007).", [["CNS", "ANATOMY", 117, 120], ["neurological", "ANATOMY", 167, 179], ["MS", "DISEASE", 78, 80], ["infectious diseases of the CNS", "DISEASE", 90, 120], ["neurological disease", "DISEASE", 167, 187], ["CCL19", "GENE_OR_GENE_PRODUCT", 44, 49], ["CSF", "GENE_OR_GENE_PRODUCT", 57, 60], ["patients", "ORGANISM", 64, 72], ["CNS", "ANATOMICAL_SYSTEM", 117, 120], ["patients", "ORGANISM", 136, 144], ["CCL21", "GENE_OR_GENE_PRODUCT", 197, 202], ["CCL19", "PROTEIN", 44, 49], ["CCL21", "PROTEIN", 197, 202], ["patients", "SPECIES", 64, 72], ["patients", "SPECIES", 136, 144], ["Several studies", "TEST", 0, 15], ["increased amounts of CCL19", "PROBLEM", 23, 49], ["MS", "PROBLEM", 78, 80], ["infectious diseases of the CNS", "PROBLEM", 90, 120], ["non-inflammatory neurological disease", "PROBLEM", 150, 187], ["CCL21", "TEST", 197, 202], ["increased", "OBSERVATION_MODIFIER", 23, 32], ["amounts", "OBSERVATION_MODIFIER", 33, 40], ["CCL19", "OBSERVATION", 44, 49], ["infectious", "OBSERVATION", 90, 100], ["CNS", "ANATOMY", 117, 120], ["non-inflammatory", "OBSERVATION_MODIFIER", 150, 166], ["neurological disease", "OBSERVATION", 167, 187]]], ["Krumbholz et al. (2007) also described constitutive gene expression of CCL19 in normal brain tissue and elevation of CCL19 transcripts in MS lesions, suggesting a role for CCL19 both in normal immune surveillance of the CNS and in inflammatory conditions.", [["brain tissue", "ANATOMY", 87, 99], ["MS lesions", "ANATOMY", 138, 148], ["CNS", "ANATOMY", 220, 223], ["CCL19", "GENE_OR_GENE_PRODUCT", 71, 76], ["brain tissue", "TISSUE", 87, 99], ["CCL19", "GENE_OR_GENE_PRODUCT", 117, 122], ["MS lesions", "CANCER", 138, 148], ["CCL19", "GENE_OR_GENE_PRODUCT", 172, 177], ["CNS", "ANATOMICAL_SYSTEM", 220, 223], ["CCL19", "PROTEIN", 71, 76], ["CCL19 transcripts", "RNA", 117, 134], ["CCL19", "PROTEIN", 172, 177], ["elevation of CCL19 transcripts", "PROBLEM", 104, 134], ["MS lesions", "PROBLEM", 138, 148], ["CCL19", "TEST", 172, 177], ["inflammatory conditions", "PROBLEM", 231, 254], ["brain tissue", "ANATOMY", 87, 99], ["elevation", "OBSERVATION_MODIFIER", 104, 113], ["CCL19 transcripts", "OBSERVATION", 117, 134], ["lesions", "OBSERVATION", 141, 148], ["normal immune", "OBSERVATION", 186, 199], ["CNS", "ANATOMY", 220, 223], ["inflammatory", "OBSERVATION", 231, 243]]], ["In the MS CSF, CCL19 levels were found to correlate with intrathecal Ig production, but only weakly with CSF cell counts (Pashenkov et al., 2003, Krumbholz et al., 2007).", [["CSF cell", "ANATOMY", 105, 113], ["CSF", "GENE_OR_GENE_PRODUCT", 10, 13], ["CCL19", "GENE_OR_GENE_PRODUCT", 15, 20], ["Ig", "GENE_OR_GENE_PRODUCT", 69, 71], ["CSF cell", "CELL", 105, 113], ["CCL19", "PROTEIN", 15, 20], ["Ig", "PROTEIN", 69, 71], ["the MS CSF", "TEST", 3, 13], ["CCL19 levels", "TEST", 15, 27], ["intrathecal Ig production", "TEST", 57, 82], ["CSF cell counts", "TEST", 105, 120]]], ["The observation that CCL21 mRNA and protein are undetectable in MS inflammatory lesions and meninges (Kivis\u00e4kk et al., 2004, Serafini et al., 2004, Krumbholz et al., 2007) is consistent with the absence of markers of HEV and lymphatic vessels in the MS brain (Serafini et al., 2006; Serafini and Aloisi, unpublished data).", [["MS inflammatory lesions", "ANATOMY", 64, 87], ["meninges", "ANATOMY", 92, 100], ["lymphatic vessels", "ANATOMY", 225, 242], ["MS brain", "ANATOMY", 250, 258], ["CCL21", "GENE_OR_GENE_PRODUCT", 21, 26], ["lesions", "PATHOLOGICAL_FORMATION", 80, 87], ["meninges", "ORGAN", 92, 100], ["HEV", "ORGANISM", 217, 220], ["lymphatic vessels", "MULTI-TISSUE_STRUCTURE", 225, 242], ["brain", "ORGAN", 253, 258], ["CCL21 mRNA", "RNA", 21, 31], ["HEV", "SPECIES", 217, 220], ["The observation", "TEST", 0, 15], ["CCL21 mRNA", "TEST", 21, 31], ["protein", "TEST", 36, 43], ["MS inflammatory lesions", "PROBLEM", 64, 87], ["inflammatory", "OBSERVATION_MODIFIER", 67, 79], ["meninges", "ANATOMY", 92, 100], ["consistent with", "UNCERTAINTY", 175, 190], ["HEV", "OBSERVATION", 217, 220], ["lymphatic vessels", "ANATOMY", 225, 242], ["brain", "ANATOMY", 253, 258]]], ["These findings are in contrast with data obtained in the EAE model (Cannella et al., 1990, Alt et al., 2002, Columba-Cabezas et al., 2003), suggesting species differences and/or existence of disease-specific mechanisms in the acquisition of HEV-like features by CNS blood vessels.", [["CNS blood vessels", "ANATOMY", 262, 279], ["EAE", "DISEASE", 57, 60], ["HEV", "ORGANISM", 241, 244], ["CNS blood vessels", "MULTI-TISSUE_STRUCTURE", 262, 279], ["HEV", "SPECIES", 241, 244], ["Alt et al.", "TEST", 91, 101], ["species differences", "PROBLEM", 151, 170], ["disease", "PROBLEM", 191, 198], ["HEV", "PROBLEM", 241, 244], ["species differences", "OBSERVATION", 151, 170], ["disease", "OBSERVATION", 191, 198], ["HEV", "OBSERVATION", 241, 244], ["vessels", "ANATOMY", 272, 279]]], ["However, Kivis\u00e4kk et al. (2004) reported expression of CCL21 in the human choroid plexus in both non-inflammatory and inflammatory CNS conditions.CCL19 and CCL21 ::: Expression of lymphoid chemokines in the inflamed CNSInterestingly, abundant expression of CCR7 was found in activated, resident microglia and myeloid dendritic cells but not in lymphocytes infiltrating MS lesions (Kivis\u00e4kk et al., 2004, Serafini et al., 2006), whereas CCR7 was consistently found on most CD4+ memory T cells obtained from the CSF of individuals without CNS inflammation and of patients with MS (Giunti et al., 2003, Kivis\u00e4kk et al., 2003).", [["choroid plexus", "ANATOMY", 74, 88], ["CNS", "ANATOMY", 131, 134], ["lymphoid", "ANATOMY", 180, 188], ["microglia", "ANATOMY", 295, 304], ["myeloid dendritic cells", "ANATOMY", 309, 332], ["lymphocytes", "ANATOMY", 344, 355], ["MS lesions", "ANATOMY", 369, 379], ["CD4+ memory T cells", "ANATOMY", 472, 491], ["CNS", "ANATOMY", 537, 540], ["inflammation", "DISEASE", 541, 553], ["MS", "DISEASE", 575, 577], ["CCL21", "GENE_OR_GENE_PRODUCT", 55, 60], ["human", "ORGANISM", 68, 73], ["choroid plexus", "MULTI-TISSUE_STRUCTURE", 74, 88], ["CNS", "ANATOMICAL_SYSTEM", 131, 134], ["CCL19", "GENE_OR_GENE_PRODUCT", 146, 151], ["CCL21", "GENE_OR_GENE_PRODUCT", 156, 161], ["lymphoid chemokines", "CELL", 180, 199], ["CNSInterestingly", "CANCER", 216, 232], ["CCR7", "GENE_OR_GENE_PRODUCT", 257, 261], ["microglia", "CELL", 295, 304], ["myeloid dendritic cells", "CELL", 309, 332], ["lymphocytes", "CELL", 344, 355], ["MS lesions", "PATHOLOGICAL_FORMATION", 369, 379], ["CCR7", "GENE_OR_GENE_PRODUCT", 436, 440], ["CD4", "GENE_OR_GENE_PRODUCT", 472, 475], ["CSF", "ORGANISM_SUBSTANCE", 510, 513], ["CNS", "ANATOMICAL_SYSTEM", 537, 540], ["patients", "ORGANISM", 561, 569], ["CCL21", "PROTEIN", 55, 60], ["CCL19", "PROTEIN", 146, 151], ["CCL21", "PROTEIN", 156, 161], ["lymphoid chemokines", "PROTEIN", 180, 199], ["CCR7", "PROTEIN", 257, 261], ["resident microglia", "CELL_TYPE", 286, 304], ["myeloid dendritic cells", "CELL_TYPE", 309, 332], ["lymphocytes", "CELL_TYPE", 344, 355], ["CCR7", "PROTEIN", 436, 440], ["CD4+ memory T cells", "CELL_TYPE", 472, 491], ["human", "SPECIES", 68, 73], ["patients", "SPECIES", 561, 569], ["human", "SPECIES", 68, 73], ["CCL21", "TEST", 55, 60], ["both non-inflammatory and inflammatory CNS conditions", "PROBLEM", 92, 145], ["lymphoid chemokines", "PROBLEM", 180, 199], ["myeloid dendritic cells", "PROBLEM", 309, 332], ["lymphocytes infiltrating MS lesions", "PROBLEM", 344, 379], ["CCR7", "TEST", 436, 440], ["the CSF", "TEST", 506, 513], ["CNS inflammation", "PROBLEM", 537, 553], ["human", "ANATOMY_MODIFIER", 68, 73], ["choroid plexus", "ANATOMY", 74, 88], ["both", "ANATOMY_MODIFIER", 92, 96], ["non-inflammatory", "OBSERVATION", 97, 113], ["inflammatory CNS", "OBSERVATION", 118, 134], ["lymphoid chemokines", "OBSERVATION", 180, 199], ["inflamed", "OBSERVATION_MODIFIER", 207, 215], ["CCR7", "ANATOMY", 257, 261], ["myeloid dendritic cells", "OBSERVATION", 309, 332], ["without", "UNCERTAINTY", 529, 536], ["CNS", "ANATOMY", 537, 540], ["inflammation", "OBSERVATION", 541, 553]]], ["About 30% of the dendritic cells present in the CSF of MS patients were also found to express CCR7 (Kivis\u00e4kk et al., 2004).", [["dendritic cells", "ANATOMY", 17, 32], ["CSF", "ANATOMY", 48, 51], ["MS", "DISEASE", 55, 57], ["dendritic cells", "CELL", 17, 32], ["CSF", "GENE_OR_GENE_PRODUCT", 48, 51], ["patients", "ORGANISM", 58, 66], ["CCR7", "GENE_OR_GENE_PRODUCT", 94, 98], ["dendritic cells", "CELL_TYPE", 17, 32], ["CCR7", "PROTEIN", 94, 98], ["patients", "SPECIES", 58, 66], ["the dendritic cells", "PROBLEM", 13, 32], ["dendritic cells", "OBSERVATION", 17, 32]]], ["The latter findings suggest that CCL19 could be involved in the trafficking of CCR7+ T lymphocytes and antigen presenting cells through the ventricular compartment and perhaps from this compartment to CNS-draining lymph nodes.", [["T lymphocytes", "ANATOMY", 85, 98], ["cells", "ANATOMY", 122, 127], ["ventricular compartment", "ANATOMY", 140, 163], ["compartment", "ANATOMY", 186, 197], ["CNS", "ANATOMY", 201, 204], ["lymph nodes", "ANATOMY", 214, 225], ["CCL19", "GENE_OR_GENE_PRODUCT", 33, 38], ["CCR7", "GENE_OR_GENE_PRODUCT", 79, 83], ["T lymphocytes", "CELL", 85, 98], ["antigen presenting", "GENE_OR_GENE_PRODUCT", 103, 121], ["cells", "CELL", 122, 127], ["ventricular compartment", "MULTI-TISSUE_STRUCTURE", 140, 163], ["CNS", "ANATOMICAL_SYSTEM", 201, 204], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 214, 225], ["CCL19", "PROTEIN", 33, 38], ["CCR7", "PROTEIN", 79, 83], ["T lymphocytes", "CELL_TYPE", 85, 98], ["antigen presenting cells", "CELL_TYPE", 103, 127], ["CCL19", "TEST", 33, 38], ["T lymphocytes", "TEST", 85, 98], ["draining lymph nodes", "PROBLEM", 205, 225], ["CCL19", "OBSERVATION", 33, 38], ["CCR7", "ANATOMY", 79, 83], ["lymphocytes", "ANATOMY", 87, 98], ["ventricular", "ANATOMY", 140, 151], ["compartment", "ANATOMY_MODIFIER", 152, 163], ["CNS", "ANATOMY", 201, 204], ["draining", "OBSERVATION_MODIFIER", 205, 213], ["lymph nodes", "OBSERVATION", 214, 225]]], ["Upregulation of CCR7 on activated microglia is intriguing as it suggests regulation of microglia migratory properties or function by lymphoid chemokines (Dijkstra et al., 2006).CXCL12 ::: Expression of lymphoid chemokines in the inflamed CNSCXCL12 is a chemokine that is constitutively expressed in the CNS (Lazarini et al., 2003) and is upregulated during inflammation.", [["microglia", "ANATOMY", 34, 43], ["microglia", "ANATOMY", 87, 96], ["lymphoid", "ANATOMY", 133, 141], ["lymphoid", "ANATOMY", 202, 210], ["CNS", "ANATOMY", 303, 306], ["inflammation", "DISEASE", 357, 369], ["CCR7", "GENE_OR_GENE_PRODUCT", 16, 20], ["microglia", "CELL", 34, 43], ["microglia", "CELL", 87, 96], ["lymphoid chemokines", "CELL", 133, 152], ["CXCL12", "GENE_OR_GENE_PRODUCT", 177, 183], ["CNSCXCL12", "GENE_OR_GENE_PRODUCT", 238, 247], ["CNS", "ANATOMICAL_SYSTEM", 303, 306], ["CCR7", "PROTEIN", 16, 20], ["microglia", "CELL_TYPE", 34, 43], ["lymphoid chemokines", "PROTEIN", 133, 152], ["CXCL12", "PROTEIN", 177, 183], ["lymphoid chemokines", "PROTEIN", 202, 221], ["CNSCXCL12", "PROTEIN", 238, 247], ["chemokine", "PROTEIN", 253, 262], ["Upregulation of CCR7", "PROBLEM", 0, 20], ["activated microglia", "PROBLEM", 24, 43], ["CXCL12", "TEST", 177, 183], ["lymphoid chemokines", "TREATMENT", 202, 221], ["inflammation", "PROBLEM", 357, 369], ["CCR7", "ANATOMY", 16, 20], ["microglia migratory", "OBSERVATION", 87, 106], ["lymphoid chemokines", "OBSERVATION", 133, 152], ["lymphoid chemokines", "OBSERVATION", 202, 221], ["inflamed", "OBSERVATION_MODIFIER", 229, 237], ["CNS", "ANATOMY", 303, 306], ["inflammation", "OBSERVATION", 357, 369]]], ["Increased levels of CXCL12 have been detected in the CSF of patients with MS and other inflammatory neurological diseases (Pashenkov et al., 2003;Giunti et al., 2003, Corcione et al., 2004Krumbholz et al., 2006).", [["neurological", "ANATOMY", 100, 112], ["MS", "DISEASE", 74, 76], ["neurological diseases", "DISEASE", 100, 121], ["CXCL12", "GENE_OR_GENE_PRODUCT", 20, 26], ["CSF", "ORGANISM_SUBSTANCE", 53, 56], ["patients", "ORGANISM", 60, 68], ["CXCL12", "PROTEIN", 20, 26], ["patients", "SPECIES", 60, 68], ["Increased levels of CXCL12", "PROBLEM", 0, 26], ["MS", "PROBLEM", 74, 76], ["other inflammatory neurological diseases", "PROBLEM", 81, 121], ["inflammatory", "OBSERVATION_MODIFIER", 87, 99]]], ["Cerebrovascular endothelia and astrocytes have been identified as major sources of CXCL12 in inflamed MS lesions (Ambrosini et al., 2005, Krumbholz et al., 2006).", [["Cerebrovascular endothelia", "ANATOMY", 0, 26], ["astrocytes", "ANATOMY", 31, 41], ["MS lesions", "ANATOMY", 102, 112], ["MS", "DISEASE", 102, 104], ["Cerebrovascular endothelia", "CELL", 0, 26], ["astrocytes", "CELL", 31, 41], ["CXCL12", "GENE_OR_GENE_PRODUCT", 83, 89], ["MS lesions", "PATHOLOGICAL_FORMATION", 102, 112], ["astrocytes", "CELL_TYPE", 31, 41], ["CXCL12", "PROTEIN", 83, 89], ["Cerebrovascular endothelia and astrocytes", "PROBLEM", 0, 41], ["CXCL12 in inflamed MS lesions", "PROBLEM", 83, 112], ["endothelia", "ANATOMY", 16, 26], ["astrocytes", "OBSERVATION", 31, 41], ["inflamed", "OBSERVATION_MODIFIER", 93, 101]]], ["Because CXCR4 is expressed on immature myeloid dendritic cells, plasmacytoid dendritic cells, T cells, B cells and plasma cells (Campbell et al., 2003), it is likely that CXCL12 production in the CNS regulates intracerebral homing of different immune cell populations.", [["myeloid dendritic cells", "ANATOMY", 39, 62], ["plasmacytoid dendritic cells", "ANATOMY", 64, 92], ["T cells", "ANATOMY", 94, 101], ["B cells", "ANATOMY", 103, 110], ["plasma cells", "ANATOMY", 115, 127], ["CNS", "ANATOMY", 196, 199], ["intracerebral", "ANATOMY", 210, 223], ["immune cell", "ANATOMY", 244, 255], ["CXCR4", "GENE_OR_GENE_PRODUCT", 8, 13], ["myeloid dendritic cells", "CELL", 39, 62], ["plasmacytoid dendritic cells", "CELL", 64, 92], ["T cells", "CELL", 94, 101], ["B cells", "CELL", 103, 110], ["plasma cells", "CELL", 115, 127], ["CXCL12", "GENE_OR_GENE_PRODUCT", 171, 177], ["CNS", "ANATOMICAL_SYSTEM", 196, 199], ["intracerebral", "IMMATERIAL_ANATOMICAL_ENTITY", 210, 223], ["immune cell populations", "CELL", 244, 267], ["CXCR4", "PROTEIN", 8, 13], ["immature myeloid dendritic cells", "CELL_TYPE", 30, 62], ["plasmacytoid dendritic cells", "CELL_TYPE", 64, 92], ["T cells", "CELL_TYPE", 94, 101], ["B cells", "CELL_TYPE", 103, 110], ["plasma cells", "CELL_TYPE", 115, 127], ["CXCL12", "PROTEIN", 171, 177], ["immune cell populations", "CELL_TYPE", 244, 267], ["CXCR4", "TEST", 8, 13], ["immature myeloid dendritic cells", "PROBLEM", 30, 62], ["plasmacytoid dendritic cells", "PROBLEM", 64, 92], ["T cells", "PROBLEM", 94, 101], ["plasma cells", "TEST", 115, 127], ["CXCL12 production", "PROBLEM", 171, 188], ["different immune cell populations", "TREATMENT", 234, 267], ["immature myeloid dendritic cells", "OBSERVATION", 30, 62], ["plasmacytoid dendritic cells", "OBSERVATION", 64, 92], ["plasma cells", "OBSERVATION", 115, 127], ["is likely", "UNCERTAINTY", 156, 165], ["CXCL12 production", "OBSERVATION", 171, 188], ["CNS", "ANATOMY", 196, 199], ["immune cell populations", "OBSERVATION", 244, 267]]], ["Using in vitro assays, we demonstrated that human astrocytes release biologically relevant amounts of B-, T- and dendritic cell-attracting chemokines, including CXCL12 (Ambrosini et al., 2003, Ambrosini et al., 2005).", [["astrocytes", "ANATOMY", 50, 60], ["dendritic cell", "ANATOMY", 113, 127], ["human", "ORGANISM", 44, 49], ["astrocytes", "CELL", 50, 60], ["B", "GENE_OR_GENE_PRODUCT", 102, 103], ["T", "GENE_OR_GENE_PRODUCT", 106, 107], ["dendritic cell", "CELL", 113, 127], ["CXCL12", "GENE_OR_GENE_PRODUCT", 161, 167], ["human astrocytes", "CELL_TYPE", 44, 60], ["B-, T- and dendritic cell", "CELL_TYPE", 102, 127], ["chemokines", "PROTEIN", 139, 149], ["CXCL12", "PROTEIN", 161, 167], ["human", "SPECIES", 44, 49], ["human", "SPECIES", 44, 49], ["vitro assays", "TEST", 9, 21], ["B", "TEST", 102, 103], ["dendritic cell", "OBSERVATION", 113, 127]]], ["It is interesting to note that some plasma cells infiltrate the parenchyma in chronic MS lesions (Serafini et al., 2004), where abundant expression of CXCL12 in activated astrocytes is also noted (Ambrosini et al., 2005).", [["plasma cells", "ANATOMY", 36, 48], ["parenchyma", "ANATOMY", 64, 74], ["MS lesions", "ANATOMY", 86, 96], ["astrocytes", "ANATOMY", 171, 181], ["MS", "DISEASE", 86, 88], ["plasma cells", "CELL", 36, 48], ["parenchyma", "TISSUE", 64, 74], ["MS lesions", "PATHOLOGICAL_FORMATION", 86, 96], ["CXCL12", "GENE_OR_GENE_PRODUCT", 151, 157], ["astrocytes", "CELL", 171, 181], ["plasma cells", "CELL_TYPE", 36, 48], ["CXCL12", "PROTEIN", 151, 157], ["activated astrocytes", "CELL_TYPE", 161, 181], ["some plasma cells infiltrate the parenchyma", "PROBLEM", 31, 74], ["chronic MS lesions", "PROBLEM", 78, 96], ["CXCL12 in activated astrocytes", "PROBLEM", 151, 181], ["plasma cells", "OBSERVATION", 36, 48], ["infiltrate", "OBSERVATION", 49, 59], ["parenchyma", "ANATOMY", 64, 74], ["chronic", "OBSERVATION_MODIFIER", 78, 85], ["MS", "OBSERVATION_MODIFIER", 86, 88], ["lesions", "OBSERVATION", 89, 96], ["activated astrocytes", "OBSERVATION", 161, 181]]], ["Because plasma blasts can use CXCL12 as a chemoattractant, it is likely that the CXCL12\u2013CXCR4 axis plays a role in creating, together with B-cell survival factors like BAFF (Krumbholz et al., 2005), a survival niche for antibody-producing cells inside the brain parenchyma.CXCL13 ::: Expression of lymphoid chemokines in the inflamed CNSBecause abnormal humoral immune responses characterized by intrathecal accumulation of B cells and plasma cells, B-cell clonal expansions and Ig synthesis are a prominent feature of MS and several infectious diseases of the CNS (reviewed in Uccelli et al., 2005), several recent studies have addressed the role of the B-cell attracting chemokine CXCL13 in CNS inflammation.", [["plasma blasts", "ANATOMY", 8, 21], ["B-cell", "ANATOMY", 139, 145], ["cells", "ANATOMY", 239, 244], ["brain", "ANATOMY", 256, 261], ["lymphoid", "ANATOMY", 298, 306], ["B cells", "ANATOMY", 424, 431], ["plasma cells", "ANATOMY", 436, 448], ["B-cell", "ANATOMY", 450, 456], ["CNS", "ANATOMY", 561, 564], ["B-cell", "ANATOMY", 655, 661], ["CNS", "ANATOMY", 693, 696], ["MS", "DISEASE", 519, 521], ["infectious diseases of the CNS", "DISEASE", 534, 564], ["inflammation", "DISEASE", 697, 709], ["plasma", "ORGANISM_SUBSTANCE", 8, 14], ["blasts", "CELL", 15, 21], ["CXCL12", "GENE_OR_GENE_PRODUCT", 30, 36], ["CXCL12", "GENE_OR_GENE_PRODUCT", 81, 87], ["CXCR4", "GENE_OR_GENE_PRODUCT", 88, 93], ["B-cell", "CELL", 139, 145], ["BAFF", "GENE_OR_GENE_PRODUCT", 168, 172], ["cells", "CELL", 239, 244], ["brain", "ORGAN", 256, 261], ["parenchyma.CXCL13", "GENE_OR_GENE_PRODUCT", 262, 279], ["lymphoid chemokines", "CELL", 298, 317], ["CNSBecause", "CELL", 334, 344], ["B cells", "CELL", 424, 431], ["plasma cells", "CELL", 436, 448], ["B-cell clonal", "CELL", 450, 463], ["Ig", "GENE_OR_GENE_PRODUCT", 479, 481], ["CNS", "ANATOMICAL_SYSTEM", 561, 564], ["B-cell", "CELL", 655, 661], ["CXCL13", "GENE_OR_GENE_PRODUCT", 683, 689], ["CNS", "ANATOMICAL_SYSTEM", 693, 696], ["plasma blasts", "CELL_TYPE", 8, 21], ["CXCL12", "PROTEIN", 30, 36], ["CXCL12", "PROTEIN", 81, 87], ["CXCR4", "PROTEIN", 88, 93], ["B-cell survival factors", "PROTEIN", 139, 162], ["BAFF", "PROTEIN", 168, 172], ["antibody-producing cells", "CELL_TYPE", 220, 244], ["parenchyma.CXCL13", "PROTEIN", 262, 279], ["lymphoid chemokines", "PROTEIN", 298, 317], ["B cells", "CELL_TYPE", 424, 431], ["plasma cells", "CELL_TYPE", 436, 448], ["B-cell attracting chemokine", "PROTEIN", 655, 682], ["CXCL13", "PROTEIN", 683, 689], ["plasma blasts", "PROBLEM", 8, 21], ["CXCL12", "TREATMENT", 30, 36], ["the CXCL12", "TEST", 77, 87], ["B-cell survival factors", "PROBLEM", 139, 162], ["antibody", "TEST", 220, 228], ["lymphoid chemokines", "PROBLEM", 298, 317], ["the inflamed CNSBecause abnormal humoral immune responses", "PROBLEM", 321, 378], ["intrathecal accumulation of B cells", "PROBLEM", 396, 431], ["plasma cells", "PROBLEM", 436, 448], ["B-cell clonal expansions", "PROBLEM", 450, 474], ["Ig synthesis", "PROBLEM", 479, 491], ["MS", "PROBLEM", 519, 521], ["several infectious diseases of the CNS", "PROBLEM", 526, 564], ["several recent studies", "TEST", 601, 623], ["CNS inflammation", "PROBLEM", 693, 709], ["is likely", "UNCERTAINTY", 62, 71], ["brain", "ANATOMY", 256, 261], ["lymphoid chemokines", "OBSERVATION", 298, 317], ["humoral immune", "OBSERVATION", 354, 368], ["B cells", "OBSERVATION", 424, 431], ["plasma cells", "OBSERVATION", 436, 448], ["cell", "OBSERVATION", 452, 456], ["clonal expansions", "OBSERVATION", 457, 474], ["prominent feature", "OBSERVATION_MODIFIER", 498, 515], ["several", "OBSERVATION_MODIFIER", 526, 533], ["infectious", "OBSERVATION", 534, 544], ["CNS", "ANATOMY", 561, 564], ["CNS", "ANATOMY", 693, 696], ["inflammation", "OBSERVATION", 697, 709]]], ["In 2004, our group reported induction of CXCL13 mRNA in the CNS of mice with EAE and by using immunohistochemical techniques showed that CXCL13-expressing cells were present inside large B-cell aggregates in the inflamed brain meninges (Magliozzi et al., 2004).", [["CNS", "ANATOMY", 60, 63], ["cells", "ANATOMY", 155, 160], ["B-cell aggregates", "ANATOMY", 187, 204], ["brain meninges", "ANATOMY", 221, 235], ["EAE", "DISEASE", 77, 80], ["CXCL13", "GENE_OR_GENE_PRODUCT", 41, 47], ["CNS", "ANATOMICAL_SYSTEM", 60, 63], ["mice", "ORGANISM", 67, 71], ["CXCL13", "GENE_OR_GENE_PRODUCT", 137, 143], ["cells", "CELL", 155, 160], ["B-cell aggregates", "CELL", 187, 204], ["brain meninges", "MULTI-TISSUE_STRUCTURE", 221, 235], ["CXCL13 mRNA", "RNA", 41, 52], ["CXCL13", "PROTEIN", 137, 143], ["expressing cells", "CELL_TYPE", 144, 160], ["B-cell aggregates", "CELL_TYPE", 187, 204], ["mice", "SPECIES", 67, 71], ["mice", "SPECIES", 67, 71], ["CXCL13 mRNA", "TEST", 41, 52], ["immunohistochemical techniques", "TEST", 94, 124], ["CXCL13", "TEST", 137, 143], ["expressing cells", "PROBLEM", 144, 160], ["large", "OBSERVATION_MODIFIER", 181, 186], ["B-cell aggregates", "OBSERVATION", 187, 204], ["inflamed", "ANATOMY_MODIFIER", 212, 220], ["brain meninges", "ANATOMY", 221, 235]]], ["We also provided evidence that such abnormal B-cell aggregates exhibited some features of germinal center organization as they comprised proliferating B cells and a reticulum of stromal/follicular dendritic cells, which constitutively produce CXCL13 in B-cell follicles of secondary lymphoid organs.", [["B-cell", "ANATOMY", 45, 51], ["germinal center", "ANATOMY", 90, 105], ["B cells", "ANATOMY", 151, 158], ["reticulum", "ANATOMY", 165, 174], ["stromal/follicular dendritic cells", "ANATOMY", 178, 212], ["B-cell follicles", "ANATOMY", 253, 269], ["lymphoid organs", "ANATOMY", 283, 298], ["B-cell aggregates", "CELL", 45, 62], ["germinal center", "MULTI-TISSUE_STRUCTURE", 90, 105], ["B cells", "CELL", 151, 158], ["reticulum", "CELLULAR_COMPONENT", 165, 174], ["stromal", "CELL", 178, 185], ["follicular dendritic cells", "CELL", 186, 212], ["CXCL13", "GENE_OR_GENE_PRODUCT", 243, 249], ["B-cell", "CELL", 253, 259], ["follicles", "MULTI-TISSUE_STRUCTURE", 260, 269], ["lymphoid organs", "MULTI-TISSUE_STRUCTURE", 283, 298], ["abnormal B-cell aggregates", "CELL_TYPE", 36, 62], ["proliferating B cells", "CELL_TYPE", 137, 158], ["stromal/follicular dendritic cells", "CELL_TYPE", 178, 212], ["CXCL13", "PROTEIN", 243, 249], ["such abnormal B-cell aggregates", "PROBLEM", 31, 62], ["germinal center organization", "PROBLEM", 90, 118], ["proliferating B cells", "PROBLEM", 137, 158], ["stromal/follicular dendritic cells", "PROBLEM", 178, 212], ["CXCL13", "TEST", 243, 249], ["-cell", "OBSERVATION_MODIFIER", 46, 51], ["germinal center", "OBSERVATION", 90, 105], ["proliferating B cells", "OBSERVATION", 137, 158], ["reticulum", "OBSERVATION_MODIFIER", 165, 174], ["stromal/follicular dendritic cells", "OBSERVATION", 178, 212], ["CXCL13", "OBSERVATION_MODIFIER", 243, 249], ["B-cell follicles", "OBSERVATION", 253, 269], ["secondary lymphoid organs", "OBSERVATION", 273, 298]]], ["These observations led us to propose that CNS inflammation, through local production of LT\u03b11\u03b22 and TNF by tissue-infiltrating immune cells (Columba-Cabezas et al., 2006), induces expression of CXCL13 which in turn attracts B cells and promotes their compartmentalization with formation of germinal centers in the inflamed CNS meninges.", [["CNS", "ANATOMY", 42, 45], ["tissue-infiltrating immune cells", "ANATOMY", 106, 138], ["B cells", "ANATOMY", 223, 230], ["germinal centers", "ANATOMY", 289, 305], ["CNS meninges", "ANATOMY", 322, 334], ["inflammation", "DISEASE", 46, 58], ["CNS", "ANATOMICAL_SYSTEM", 42, 45], ["LT\u03b11\u03b22", "GENE_OR_GENE_PRODUCT", 88, 94], ["TNF", "GENE_OR_GENE_PRODUCT", 99, 102], ["tissue-infiltrating immune cells", "CELL", 106, 138], ["CXCL13", "GENE_OR_GENE_PRODUCT", 193, 199], ["B cells", "CELL", 223, 230], ["germinal centers", "MULTI-TISSUE_STRUCTURE", 289, 305], ["CNS meninges", "MULTI-TISSUE_STRUCTURE", 322, 334], ["LT", "PROTEIN", 88, 90], ["1\u03b22", "PROTEIN", 91, 94], ["TNF", "PROTEIN", 99, 102], ["infiltrating immune cells", "CELL_TYPE", 113, 138], ["CXCL13", "PROTEIN", 193, 199], ["B cells", "CELL_TYPE", 223, 230], ["CNS inflammation", "PROBLEM", 42, 58], ["infiltrating immune cells", "PROBLEM", 113, 138], ["CXCL13", "PROBLEM", 193, 199], ["the inflamed CNS meninges", "PROBLEM", 309, 334], ["CNS", "ANATOMY", 42, 45], ["inflammation", "OBSERVATION", 46, 58], ["LT", "ANATOMY", 88, 90], ["TNF", "ANATOMY", 99, 102], ["infiltrating immune cells", "OBSERVATION", 113, 138], ["germinal centers", "OBSERVATION", 289, 305], ["inflamed", "ANATOMY_MODIFIER", 313, 321], ["CNS meninges", "ANATOMY", 322, 334]]], ["In agreement with our findings, Bagaeva et al. (2006) found upregulation of CXCL13 mRNA and protein and infiltration of CXCR5+ cells in the spinal cord of EAE-affected mice.CXCL13 ::: Expression of lymphoid chemokines in the inflamed CNSThe subsequent step was to find out whether CXCL13 and germinal center-like structures could be detected in the MS brain.", [["CXCR5+ cells", "ANATOMY", 120, 132], ["spinal cord", "ANATOMY", 140, 151], ["lymphoid", "ANATOMY", 198, 206], ["germinal center-like structures", "ANATOMY", 292, 323], ["brain", "ANATOMY", 352, 357], ["EAE", "DISEASE", 155, 158], ["CXCL13", "GENE_OR_GENE_PRODUCT", 76, 82], ["CXCR5", "GENE_OR_GENE_PRODUCT", 120, 125], ["spinal cord", "ORGAN", 140, 151], ["mice.CXCL13", "GENE_OR_GENE_PRODUCT", 168, 179], ["lymphoid chemokines", "CELL", 198, 217], ["CXCL13", "GENE_OR_GENE_PRODUCT", 281, 287], ["germinal center-like structures", "TISSUE", 292, 323], ["brain", "ORGAN", 352, 357], ["CXCL13 mRNA", "RNA", 76, 87], ["CXCR5", "PROTEIN", 120, 125], ["mice.CXCL13", "PROTEIN", 168, 179], ["lymphoid chemokines", "PROTEIN", 198, 217], ["CXCL13", "PROTEIN", 281, 287], ["CXCL13 mRNA", "TEST", 76, 87], ["protein", "TEST", 92, 99], ["infiltration", "TEST", 104, 116], ["CXCR5", "TEST", 120, 125], ["cells in the spinal cord", "PROBLEM", 127, 151], ["lymphoid chemokines", "TREATMENT", 198, 217], ["CXCL13 and germinal center-like structures", "PROBLEM", 281, 323], ["infiltration", "OBSERVATION", 104, 116], ["CXCR5+ cells", "OBSERVATION", 120, 132], ["spinal cord", "ANATOMY", 140, 151], ["lymphoid chemokines", "OBSERVATION", 198, 217], ["germinal center", "OBSERVATION", 292, 307], ["brain", "ANATOMY", 352, 357]]], ["In a first immunohistochemical analysis of post-mortem brain tissue from 6 MS cases with relapsing-remitting and progressive clinical courses, we observed the presence of B-cell aggregates containing a well developed network of CXCL13-expressing cells, numerous proliferating B cells, plasma cells and T cells in the subarachnoid space (the space lying between the pial and arachnoid membranes and filled with CSF) of 2 of 3 cases with secondary progressive MS (Serafini et al., 2004).", [["brain tissue", "ANATOMY", 55, 67], ["B-cell aggregates", "ANATOMY", 171, 188], ["cells", "ANATOMY", 246, 251], ["B cells", "ANATOMY", 276, 283], ["plasma cells", "ANATOMY", 285, 297], ["T cells", "ANATOMY", 302, 309], ["subarachnoid space", "ANATOMY", 317, 335], ["pial", "ANATOMY", 365, 369], ["arachnoid membranes", "ANATOMY", 374, 393], ["MS", "DISEASE", 75, 77], ["MS", "DISEASE", 458, 460], ["brain tissue", "TISSUE", 55, 67], ["B-cell aggregates", "CELL", 171, 188], ["CXCL13", "GENE_OR_GENE_PRODUCT", 228, 234], ["cells", "CELL", 246, 251], ["B cells", "CELL", 276, 283], ["plasma cells", "CELL", 285, 297], ["T cells", "CELL", 302, 309], ["subarachnoid space", "MULTI-TISSUE_STRUCTURE", 317, 335], ["pial", "MULTI-TISSUE_STRUCTURE", 365, 369], ["arachnoid membranes", "MULTI-TISSUE_STRUCTURE", 374, 393], ["CXCL13", "PROTEIN", 228, 234], ["expressing cells", "CELL_TYPE", 235, 251], ["proliferating B cells", "CELL_TYPE", 262, 283], ["plasma cells", "CELL_TYPE", 285, 297], ["T cells", "CELL_TYPE", 302, 309], ["post-mortem brain tissue", "PROBLEM", 43, 67], ["relapsing-remitting", "PROBLEM", 89, 108], ["B-cell aggregates", "PROBLEM", 171, 188], ["CXCL13", "TEST", 228, 234], ["numerous proliferating B cells", "PROBLEM", 253, 283], ["plasma cells", "PROBLEM", 285, 297], ["T cells in the subarachnoid space", "PROBLEM", 302, 335], ["CSF)", "TEST", 410, 414], ["secondary progressive MS", "PROBLEM", 436, 460], ["brain tissue", "ANATOMY", 55, 67], ["progressive", "OBSERVATION_MODIFIER", 113, 124], ["cell aggregates", "OBSERVATION", 173, 188], ["numerous", "OBSERVATION_MODIFIER", 253, 261], ["proliferating B cells", "OBSERVATION", 262, 283], ["plasma cells", "OBSERVATION", 285, 297], ["subarachnoid space", "ANATOMY", 317, 335], ["pial", "ANATOMY_MODIFIER", 365, 369], ["arachnoid membranes", "ANATOMY", 374, 393], ["progressive", "OBSERVATION_MODIFIER", 446, 457]]], ["Notably, despite prominent, perivascular accumulation of B cells and plasma cells in chronic white matter lesions, neither CXCL13 nor proliferating B cells were detected at these sites, suggesting that the meninges, but not the Virchow\u2013Robin space surrounding CNS intraparenchymal blood vessels, provide a permissive milieu for lymphoid neogenesis.", [["perivascular", "ANATOMY", 28, 40], ["B cells", "ANATOMY", 57, 64], ["plasma cells", "ANATOMY", 69, 81], ["white matter lesions", "ANATOMY", 93, 113], ["B cells", "ANATOMY", 148, 155], ["sites", "ANATOMY", 179, 184], ["meninges", "ANATOMY", 206, 214], ["CNS intraparenchymal blood vessels", "ANATOMY", 260, 294], ["lymphoid", "ANATOMY", 328, 336], ["white matter lesions", "DISEASE", 93, 113], ["perivascular", "IMMATERIAL_ANATOMICAL_ENTITY", 28, 40], ["B cells", "CELL", 57, 64], ["plasma cells", "CELL", 69, 81], ["chronic white matter lesions", "PATHOLOGICAL_FORMATION", 85, 113], ["CXCL13", "GENE_OR_GENE_PRODUCT", 123, 129], ["B cells", "CELL", 148, 155], ["meninges", "ORGAN", 206, 214], ["CNS intraparenchymal blood vessels", "MULTI-TISSUE_STRUCTURE", 260, 294], ["lymphoid", "CELL", 328, 336], ["B cells", "CELL_TYPE", 57, 64], ["plasma cells", "CELL_TYPE", 69, 81], ["CXCL13", "PROTEIN", 123, 129], ["proliferating B cells", "CELL_TYPE", 134, 155], ["prominent, perivascular accumulation of B cells", "PROBLEM", 17, 64], ["plasma cells", "PROBLEM", 69, 81], ["chronic white matter lesions", "PROBLEM", 85, 113], ["CXCL13", "TEST", 123, 129], ["proliferating B cells", "PROBLEM", 134, 155], ["lymphoid neogenesis", "PROBLEM", 328, 347], ["prominent", "OBSERVATION_MODIFIER", 17, 26], ["perivascular", "ANATOMY_MODIFIER", 28, 40], ["accumulation of B cells", "OBSERVATION", 41, 64], ["plasma cells", "OBSERVATION", 69, 81], ["chronic", "OBSERVATION_MODIFIER", 85, 92], ["white matter", "OBSERVATION_MODIFIER", 93, 105], ["lesions", "OBSERVATION", 106, 113], ["proliferating B cells", "OBSERVATION", 134, 155], ["meninges", "OBSERVATION", 206, 214], ["Robin space", "OBSERVATION", 236, 247], ["CNS", "ANATOMY", 260, 263], ["intraparenchymal", "ANATOMY_MODIFIER", 264, 280], ["blood vessels", "ANATOMY", 281, 294], ["lymphoid neogenesis", "OBSERVATION", 328, 347]]], ["Because chemokine-producing stromal cells in lymphoid organs are of mesenchymal origin (Parsonage et al., 2005), we hypothesized that stromal cells involved in the organization of MS ectopic follicles could differentiate from precursors residing in the meninges or migrating there from the blood circulation (Serafini et al., 2004).", [["stromal cells", "ANATOMY", 28, 41], ["lymphoid organs", "ANATOMY", 45, 60], ["mesenchymal", "ANATOMY", 68, 79], ["stromal cells", "ANATOMY", 134, 147], ["ectopic follicles", "ANATOMY", 183, 200], ["meninges", "ANATOMY", 253, 261], ["blood", "ANATOMY", 290, 295], ["stromal cells", "CELL", 28, 41], ["lymphoid organs", "MULTI-TISSUE_STRUCTURE", 45, 60], ["mesenchymal", "CELL", 68, 79], ["stromal cells", "CELL", 134, 147], ["ectopic follicles", "MULTI-TISSUE_STRUCTURE", 183, 200], ["meninges", "ORGAN", 253, 261], ["blood", "ORGANISM_SUBSTANCE", 290, 295], ["chemokine", "PROTEIN", 8, 17], ["stromal cells", "CELL_TYPE", 28, 41], ["stromal cells", "CELL_TYPE", 134, 147], ["chemokine", "TEST", 8, 17], ["stromal cells in lymphoid organs", "PROBLEM", 28, 60], ["stromal cells", "PROBLEM", 134, 147], ["MS ectopic follicles", "PROBLEM", 180, 200], ["stromal cells", "OBSERVATION", 28, 41], ["lymphoid organs", "OBSERVATION", 45, 60], ["mesenchymal origin", "OBSERVATION", 68, 86], ["stromal cells", "OBSERVATION", 134, 147], ["ectopic follicles", "OBSERVATION", 183, 200], ["meninges", "ANATOMY", 253, 261]]], ["The above findings were confirmed in a larger set of brain specimens from cases with primary and secondary progressive MS (n= 36) (Magliozzi et al., 2007).", [["brain specimens", "ANATOMY", 53, 68], ["MS", "DISEASE", 119, 121], ["brain specimens", "CANCER", 53, 68], ["secondary progressive MS", "PROBLEM", 97, 121], ["brain", "ANATOMY", 53, 58], ["progressive", "OBSERVATION_MODIFIER", 107, 118]]], ["Variable numbers of intrameningeal B cell follicles, all containing CXCL13-producing stromal cells, were detected only in the brain of a proportion of cases that had developed secondary progressive MS (12 out of 29 examined), but in none of the 7 cases with primary progressive MS analyzed.", [["intrameningeal B cell follicles", "ANATOMY", 20, 51], ["stromal cells", "ANATOMY", 85, 98], ["brain", "ANATOMY", 126, 131], ["MS", "DISEASE", 198, 200], ["MS", "DISEASE", 278, 280], ["B cell", "CELL", 35, 41], ["follicles", "MULTI-TISSUE_STRUCTURE", 42, 51], ["CXCL13", "GENE_OR_GENE_PRODUCT", 68, 74], ["stromal cells", "CELL", 85, 98], ["brain", "ORGAN", 126, 131], ["CXCL13", "PROTEIN", 68, 74], ["stromal cells", "CELL_TYPE", 85, 98], ["intrameningeal B cell follicles", "PROBLEM", 20, 51], ["CXCL13", "TEST", 68, 74], ["stromal cells", "PROBLEM", 85, 98], ["progressive MS", "PROBLEM", 186, 200], ["primary progressive MS analyzed", "PROBLEM", 258, 289], ["numbers", "OBSERVATION_MODIFIER", 9, 16], ["intrameningeal B cell follicles", "OBSERVATION", 20, 51], ["stromal cells", "OBSERVATION", 85, 98], ["brain", "ANATOMY", 126, 131], ["progressive", "OBSERVATION_MODIFIER", 186, 197], ["MS", "OBSERVATION", 198, 200]]], ["In Fig. 1, an intrameningeal B-cell follicle stained for the pan B-cell marker CD20 and for CXCL13 is shown (panels A and B, respectively).CXCL13 ::: Expression of lymphoid chemokines in the inflamed CNSAt variance with our findings (Serafini et al., 2004, Magliozzi et al., 2007), Krumbholz et al. (2006) reported increased CXCL13 immunoreactivity in active MS lesions, both in the perivascular cuffs and inside the parenchyma, and confirmed CXCL13 expression in MS brain tissue by using real time PCR.", [["B-cell follicle", "ANATOMY", 29, 44], ["B-cell", "ANATOMY", 65, 71], ["lymphoid", "ANATOMY", 164, 172], ["MS lesions", "ANATOMY", 359, 369], ["perivascular cuffs", "ANATOMY", 383, 401], ["parenchyma", "ANATOMY", 417, 427], ["MS brain tissue", "ANATOMY", 464, 479], ["B-cell follicle", "CELL", 29, 44], ["CD20", "GENE_OR_GENE_PRODUCT", 79, 83], ["CXCL13", "GENE_OR_GENE_PRODUCT", 92, 98], ["CXCL13", "GENE_OR_GENE_PRODUCT", 139, 145], ["lymphoid chemokines", "CELL", 164, 183], ["CNSAt", "CANCER", 200, 205], ["CXCL13", "GENE_OR_GENE_PRODUCT", 325, 331], ["MS lesions", "PATHOLOGICAL_FORMATION", 359, 369], ["perivascular cuffs", "TISSUE", 383, 401], ["parenchyma", "TISSUE", 417, 427], ["CXCL13", "GENE_OR_GENE_PRODUCT", 443, 449], ["brain tissue", "TISSUE", 467, 479], ["CD20", "PROTEIN", 79, 83], ["CXCL13", "PROTEIN", 92, 98], ["CXCL13", "PROTEIN", 139, 145], ["lymphoid chemokines", "PROTEIN", 164, 183], ["CXCL13", "PROTEIN", 325, 331], ["CXCL13", "PROTEIN", 443, 449], ["an intrameningeal B-cell follicle", "TEST", 11, 44], ["the pan B", "TEST", 57, 66], ["CXCL13", "TEST", 92, 98], ["CXCL13", "TEST", 139, 145], ["lymphoid chemokines", "PROBLEM", 164, 183], ["increased CXCL13 immunoreactivity", "PROBLEM", 315, 348], ["active MS lesions", "PROBLEM", 352, 369], ["CXCL13 expression in MS brain tissue", "PROBLEM", 443, 479], ["real time PCR", "TEST", 489, 502], ["-cell follicle stained", "OBSERVATION", 30, 52], ["lymphoid chemokines", "OBSERVATION", 164, 183], ["inflamed", "OBSERVATION_MODIFIER", 191, 199], ["increased", "OBSERVATION_MODIFIER", 315, 324], ["CXCL13 immunoreactivity", "OBSERVATION", 325, 348], ["active", "OBSERVATION_MODIFIER", 352, 358], ["MS", "OBSERVATION_MODIFIER", 359, 361], ["lesions", "OBSERVATION", 362, 369], ["perivascular cuffs", "ANATOMY", 383, 401], ["parenchyma", "ANATOMY", 417, 427], ["CXCL13 expression", "OBSERVATION", 443, 460], ["brain tissue", "ANATOMY", 467, 479]]], ["Since it has been reported that macrophages and dendritic cells can produce CXCL13 under inflammatory conditions (Perrier et al., 2004, Carlsen et al., 2004), discrepant immunohistochemical findings in the MS brain could be due to technical issues or differences in the inflammatory activity of the lesions analyzed.", [["macrophages", "ANATOMY", 32, 43], ["dendritic cells", "ANATOMY", 48, 63], ["brain", "ANATOMY", 209, 214], ["lesions", "ANATOMY", 299, 306], ["MS", "DISEASE", 206, 208], ["macrophages", "CELL", 32, 43], ["dendritic cells", "CELL", 48, 63], ["CXCL13", "GENE_OR_GENE_PRODUCT", 76, 82], ["brain", "ORGAN", 209, 214], ["lesions", "PATHOLOGICAL_FORMATION", 299, 306], ["macrophages", "CELL_TYPE", 32, 43], ["dendritic cells", "CELL_TYPE", 48, 63], ["CXCL13", "PROTEIN", 76, 82], ["macrophages", "PROBLEM", 32, 43], ["dendritic cells", "PROBLEM", 48, 63], ["CXCL13 under inflammatory conditions", "PROBLEM", 76, 112], ["discrepant immunohistochemical findings in the MS brain", "PROBLEM", 159, 214], ["technical issues", "PROBLEM", 231, 247], ["the inflammatory activity of the lesions", "PROBLEM", 266, 306], ["macrophages", "OBSERVATION", 32, 43], ["dendritic cells", "OBSERVATION", 48, 63], ["inflammatory", "OBSERVATION_MODIFIER", 89, 101], ["brain", "ANATOMY", 209, 214], ["could be due to", "UNCERTAINTY", 215, 230], ["inflammatory", "OBSERVATION_MODIFIER", 270, 282], ["lesions", "OBSERVATION", 299, 306]]], ["Krumbholz et al. (2006) also demonstrated increased levels of CXCL13 in the CSF of patients with MS and other inflammatory neurological diseases and found a correlation between CXCL13 concentration and presence of B cells, plasma blasts, T cells and intrathecally produced Ig in the CSF.", [["CSF", "ANATOMY", 76, 79], ["neurological", "ANATOMY", 123, 135], ["B cells", "ANATOMY", 214, 221], ["plasma blasts", "ANATOMY", 223, 236], ["T cells", "ANATOMY", 238, 245], ["MS", "DISEASE", 97, 99], ["neurological diseases", "DISEASE", 123, 144], ["CXCL13", "GENE_OR_GENE_PRODUCT", 62, 68], ["CSF", "ORGANISM_SUBSTANCE", 76, 79], ["patients", "ORGANISM", 83, 91], ["CXCL13", "GENE_OR_GENE_PRODUCT", 177, 183], ["B cells", "CELL", 214, 221], ["plasma blasts", "CELL", 223, 236], ["T cells", "CELL", 238, 245], ["Ig", "GENE_OR_GENE_PRODUCT", 273, 275], ["CSF", "GENE_OR_GENE_PRODUCT", 283, 286], ["CXCL13", "PROTEIN", 62, 68], ["CXCL13", "PROTEIN", 177, 183], ["B cells", "CELL_TYPE", 214, 221], ["plasma blasts", "CELL_TYPE", 223, 236], ["T cells", "CELL_TYPE", 238, 245], ["Ig", "PROTEIN", 273, 275], ["patients", "SPECIES", 83, 91], ["increased levels of CXCL13", "PROBLEM", 42, 68], ["MS", "PROBLEM", 97, 99], ["other inflammatory neurological diseases", "PROBLEM", 104, 144], ["CXCL13 concentration", "TEST", 177, 197], ["B cells", "PROBLEM", 214, 221], ["plasma blasts", "TEST", 223, 236], ["T cells", "PROBLEM", 238, 245], ["intrathecally produced Ig in the CSF", "PROBLEM", 250, 286], ["increased", "OBSERVATION_MODIFIER", 42, 51], ["inflammatory", "OBSERVATION_MODIFIER", 110, 122], ["CSF", "ANATOMY", 283, 286]]], ["In addition, the same group detected expression of the CXCL13 receptor CXCR5 on nearly all B cells and on a proportion of T cells isolated from the CSF of MS patients.CXCL13 ::: Expression of lymphoid chemokines in the inflamed CNSTaken together, the above studies link CXCL13 expression in the CNS with the degree of inflammation and the development of ectopic lymphoid structures and point to CXCL13 as an attractive target for therapeutic interventions aimed at blocking B-cell recruitment and/or lymphoid neogenesis in the inflamed CNS.", [["B cells", "ANATOMY", 91, 98], ["T cells", "ANATOMY", 122, 129], ["CSF", "ANATOMY", 148, 151], ["lymphoid", "ANATOMY", 192, 200], ["CNS", "ANATOMY", 295, 298], ["ectopic lymphoid structures", "ANATOMY", 354, 381], ["B-cell", "ANATOMY", 474, 480], ["lymphoid", "ANATOMY", 500, 508], ["CNS", "ANATOMY", 536, 539], ["MS", "DISEASE", 155, 157], ["inflammation", "DISEASE", 318, 330], ["CXCL13", "GENE_OR_GENE_PRODUCT", 55, 61], ["CXCR5", "GENE_OR_GENE_PRODUCT", 71, 76], ["B cells", "CELL", 91, 98], ["T cells", "CELL", 122, 129], ["CSF", "ORGANISM_SUBSTANCE", 148, 151], ["patients", "ORGANISM", 158, 166], ["CXCL13", "GENE_OR_GENE_PRODUCT", 167, 173], ["lymphoid", "CELL", 192, 200], ["CNSTaken", "GENE_OR_GENE_PRODUCT", 228, 236], ["CXCL13", "GENE_OR_GENE_PRODUCT", 270, 276], ["CNS", "ANATOMICAL_SYSTEM", 295, 298], ["lymphoid structures", "TISSUE", 362, 381], ["CXCL13", "GENE_OR_GENE_PRODUCT", 395, 401], ["B-cell", "CELL", 474, 480], ["lymphoid", "CELL", 500, 508], ["CNS", "ANATOMICAL_SYSTEM", 536, 539], ["CXCL13 receptor", "PROTEIN", 55, 70], ["CXCR5", "PROTEIN", 71, 76], ["B cells", "CELL_TYPE", 91, 98], ["T cells", "CELL_TYPE", 122, 129], ["CXCL13", "PROTEIN", 167, 173], ["lymphoid chemokines", "PROTEIN", 192, 211], ["CXCL13", "PROTEIN", 270, 276], ["CXCL13", "PROTEIN", 395, 401], ["patients", "SPECIES", 158, 166], ["the CXCL13 receptor CXCR5", "TEST", 51, 76], ["T cells", "PROBLEM", 122, 129], ["CXCL13", "TEST", 167, 173], ["lymphoid chemokines", "TREATMENT", 192, 211], ["the above studies", "TEST", 247, 264], ["inflammation", "PROBLEM", 318, 330], ["ectopic lymphoid structures", "PROBLEM", 354, 381], ["CXCL13", "TEST", 395, 401], ["therapeutic interventions", "TREATMENT", 430, 455], ["blocking B-cell recruitment", "TREATMENT", 465, 492], ["lymphoid neogenesis", "PROBLEM", 500, 519], ["lymphoid chemokines", "OBSERVATION", 192, 211], ["inflamed", "OBSERVATION_MODIFIER", 219, 227], ["CNS", "ANATOMY", 295, 298], ["inflammation", "OBSERVATION", 318, 330], ["ectopic lymphoid structures", "OBSERVATION", 354, 381], ["cell recruitment", "OBSERVATION", 476, 492], ["lymphoid neogenesis", "OBSERVATION", 500, 519], ["inflamed CNS", "ANATOMY", 527, 539]]], ["In a study performed in the EAE model we found that blocking LT\u03b11\u03b22 signaling with the fusion protein LT\u03b2R-Ig, which acts as a decoy receptor (Browning et al., 1997), reduced EAE severity and prevented induction of CXCL13 and formation of organized B-cell follicles in the meninges, but failed to inhibit intrameningeal B-cell migration and aggregation (Columba-Cabezas et al., 2006).", [["B-cell follicles", "ANATOMY", 249, 265], ["meninges", "ANATOMY", 273, 281], ["intrameningeal B-cell", "ANATOMY", 305, 326], ["EAE", "DISEASE", 175, 178], ["LT\u03b11\u03b22", "GENE_OR_GENE_PRODUCT", 61, 67], ["R-Ig", "GENE_OR_GENE_PRODUCT", 105, 109], ["CXCL13", "GENE_OR_GENE_PRODUCT", 215, 221], ["B-cell follicles", "TISSUE", 249, 265], ["meninges", "ORGAN", 273, 281], ["B-cell", "CELL", 320, 326], ["LT", "PROTEIN", 61, 63], ["\u03b11\u03b22", "PROTEIN", 63, 67], ["fusion protein", "PROTEIN", 87, 101], ["LT", "PROTEIN", 102, 104], ["Ig", "PROTEIN", 107, 109], ["decoy receptor", "PROTEIN", 127, 141], ["CXCL13", "PROTEIN", 215, 221], ["a study", "TEST", 3, 10], ["the fusion protein LT", "TEST", 83, 104], ["reduced EAE severity", "PROBLEM", 167, 187], ["CXCL13", "TEST", 215, 221], ["organized B-cell follicles", "PROBLEM", 239, 265], ["intrameningeal B-cell migration", "PROBLEM", 305, 336], ["aggregation", "PROBLEM", 341, 352], ["organized", "OBSERVATION_MODIFIER", 239, 248], ["B-cell follicles", "OBSERVATION", 249, 265], ["meninges", "ANATOMY", 273, 281], ["cell migration", "OBSERVATION", 322, 336]]], ["We interpreted these findings as evidence that CXCL13 may be more important for the development of ectopic lymphoid tissue than for B-cell recruitment in the CNS.", [["ectopic lymphoid tissue", "ANATOMY", 99, 122], ["B-cell", "ANATOMY", 132, 138], ["CNS", "ANATOMY", 158, 161], ["CXCL13", "GENE_OR_GENE_PRODUCT", 47, 53], ["lymphoid tissue", "TISSUE", 107, 122], ["B-cell", "CELL", 132, 138], ["CNS", "ANATOMICAL_SYSTEM", 158, 161], ["CXCL13", "PROTEIN", 47, 53], ["CXCL13", "TEST", 47, 53], ["ectopic lymphoid tissue", "PROBLEM", 99, 122], ["B-cell recruitment", "TREATMENT", 132, 150], ["ectopic lymphoid tissue", "OBSERVATION", 99, 122], ["cell recruitment", "OBSERVATION", 134, 150], ["CNS", "ANATOMY", 158, 161]]], ["Along the same lines, Bagaeva et al. (2006) showed that both CXCL13-deficiency and treatment with anti-CXCL13 neutralizing antibodies reduced clinical severity in EAE and proposed that CXCL13 may coordinate the localization and interactions of immune cells within the CNS rather than attracting CXCR5+ cells from the periphery.", [["immune cells", "ANATOMY", 244, 256], ["CNS", "ANATOMY", 268, 271], ["CXCR5+ cells", "ANATOMY", 295, 307], ["EAE", "DISEASE", 163, 166], ["lines", "CELL", 15, 20], ["CXCL13", "GENE_OR_GENE_PRODUCT", 61, 67], ["anti-CXCL13", "GENE_OR_GENE_PRODUCT", 98, 109], ["CXCL13", "GENE_OR_GENE_PRODUCT", 185, 191], ["immune cells", "CELL", 244, 256], ["CNS", "ANATOMICAL_SYSTEM", 268, 271], ["CXCR5", "GENE_OR_GENE_PRODUCT", 295, 300], ["CXCL13", "PROTEIN", 61, 67], ["anti-CXCL13 neutralizing antibodies", "PROTEIN", 98, 133], ["CXCL13", "PROTEIN", 185, 191], ["immune cells", "CELL_TYPE", 244, 256], ["CXCR5", "PROTEIN", 295, 300], ["both CXCL13-deficiency", "PROBLEM", 56, 78], ["treatment", "TREATMENT", 83, 92], ["anti-CXCL13 neutralizing antibodies", "TREATMENT", 98, 133], ["CXCL13", "TEST", 185, 191], ["immune cells", "PROBLEM", 244, 256], ["both", "OBSERVATION_MODIFIER", 56, 60], ["CXCL13", "OBSERVATION", 61, 67], ["CNS", "ANATOMY", 268, 271], ["periphery", "ANATOMY_MODIFIER", 317, 326]]], ["Interestingly, CXCL13 expression was not induced in the CNS of mice developing encephalomyelitis after infection with neurotropic coronavirus despite prominent accumulation of virus-specific antibody-secreting cells in the target tissue, a finding that may suggest lack of ectopic B-cell follicle formation (Tschen et al., 2006).", [["CNS", "ANATOMY", 56, 59], ["cells", "ANATOMY", 210, 215], ["tissue", "ANATOMY", 230, 236], ["B-cell follicle", "ANATOMY", 281, 296], ["encephalomyelitis", "DISEASE", 79, 96], ["infection", "DISEASE", 103, 112], ["neurotropic coronavirus", "DISEASE", 118, 141], ["CXCL13", "GENE_OR_GENE_PRODUCT", 15, 21], ["CNS", "ANATOMICAL_SYSTEM", 56, 59], ["mice", "ORGANISM", 63, 67], ["neurotropic coronavirus", "ORGANISM", 118, 141], ["cells", "CELL", 210, 215], ["tissue", "TISSUE", 230, 236], ["B-cell follicle", "TISSUE", 281, 296], ["CXCL13", "PROTEIN", 15, 21], ["secreting cells", "CELL_TYPE", 200, 215], ["mice", "SPECIES", 63, 67], ["mice", "SPECIES", 63, 67], ["neurotropic coronavirus", "SPECIES", 118, 141], ["CXCL13 expression", "TEST", 15, 32], ["mice developing encephalomyelitis", "PROBLEM", 63, 96], ["infection", "PROBLEM", 103, 112], ["neurotropic coronavirus", "PROBLEM", 118, 141], ["prominent accumulation of virus", "PROBLEM", 150, 181], ["specific antibody", "TEST", 182, 199], ["secreting cells", "PROBLEM", 200, 215], ["ectopic B-cell follicle formation", "PROBLEM", 273, 306], ["encephalomyelitis", "OBSERVATION", 79, 96], ["prominent", "OBSERVATION_MODIFIER", 150, 159], ["accumulation of virus", "OBSERVATION", 160, 181], ["antibody", "OBSERVATION_MODIFIER", 191, 199], ["secreting cells", "OBSERVATION", 200, 215], ["target tissue", "OBSERVATION_MODIFIER", 223, 236], ["may suggest", "UNCERTAINTY", 253, 264], ["ectopic B-cell follicle formation", "OBSERVATION", 273, 306]]], ["In this model, CXCL9 and CXCL10, both of which act on plasma blasts through CXCR3, have been implicated in the recruitment of antibody-producing cells in the infected CNS (Tschen et al., 2006).CXCL13 ::: Expression of lymphoid chemokines in the inflamed CNSIncreased expression of CXCL13 was also found in the brain and CSF of patients with Lyme neuroborreliosis, a chronic infection in which B-cell activation, plasma cell infiltration and enhanced Ig production in the CNS are a prominent feature (Narayan et al., 2005, Rupprecht et al., 2006).", [["plasma blasts", "ANATOMY", 54, 67], ["cells", "ANATOMY", 145, 150], ["CNS", "ANATOMY", 167, 170], ["lymphoid", "ANATOMY", 218, 226], ["brain", "ANATOMY", 310, 315], ["B-cell", "ANATOMY", 393, 399], ["plasma cell", "ANATOMY", 412, 423], ["CNS", "ANATOMY", 471, 474], ["Lyme neuroborreliosis", "DISEASE", 341, 362], ["chronic infection", "DISEASE", 366, 383], ["CXCL9", "GENE_OR_GENE_PRODUCT", 15, 20], ["CXCL10", "GENE_OR_GENE_PRODUCT", 25, 31], ["plasma blasts", "CELL", 54, 67], ["CXCR3", "GENE_OR_GENE_PRODUCT", 76, 81], ["cells", "CELL", 145, 150], ["CNS", "ANATOMICAL_SYSTEM", 167, 170], ["CXCL13", "GENE_OR_GENE_PRODUCT", 193, 199], ["lymphoid", "CELL", 218, 226], ["CXCL13", "GENE_OR_GENE_PRODUCT", 281, 287], ["brain", "ORGAN", 310, 315], ["CSF", "ORGANISM_SUBSTANCE", 320, 323], ["patients", "ORGANISM", 327, 335], ["B-cell", "CELL", 393, 399], ["plasma cell", "CELL", 412, 423], ["Ig", "GENE_OR_GENE_PRODUCT", 450, 452], ["CNS", "ANATOMICAL_SYSTEM", 471, 474], ["CXCL9", "PROTEIN", 15, 20], ["CXCL10", "PROTEIN", 25, 31], ["plasma blasts", "CELL_TYPE", 54, 67], ["CXCR3", "PROTEIN", 76, 81], ["antibody-producing cells", "CELL_TYPE", 126, 150], ["CXCL13", "PROTEIN", 193, 199], ["lymphoid chemokines", "PROTEIN", 218, 237], ["CXCL13", "PROTEIN", 281, 287], ["Ig", "PROTEIN", 450, 452], ["patients", "SPECIES", 327, 335], ["CXCL9", "TEST", 15, 20], ["CXCL10", "TEST", 25, 31], ["plasma blasts", "TEST", 54, 67], ["CXCR3", "TEST", 76, 81], ["antibody", "TEST", 126, 134], ["CXCL13", "TEST", 193, 199], ["lymphoid chemokines", "PROBLEM", 218, 237], ["CXCL13", "TEST", 281, 287], ["Lyme neuroborreliosis", "PROBLEM", 341, 362], ["a chronic infection", "PROBLEM", 364, 383], ["B-cell activation", "PROBLEM", 393, 410], ["plasma cell infiltration", "PROBLEM", 412, 436], ["enhanced Ig production in the CNS", "PROBLEM", 441, 474], ["recruitment", "OBSERVATION_MODIFIER", 111, 122], ["infected CNS", "ANATOMY", 158, 170], ["lymphoid chemokines", "OBSERVATION", 218, 237], ["inflamed", "OBSERVATION_MODIFIER", 245, 253], ["brain", "ANATOMY", 310, 315], ["CSF", "ANATOMY", 320, 323], ["chronic", "OBSERVATION_MODIFIER", 366, 373], ["infection", "OBSERVATION", 374, 383], ["cell activation", "OBSERVATION", 395, 410], ["plasma cell infiltration", "OBSERVATION", 412, 436], ["enhanced", "OBSERVATION_MODIFIER", 441, 449], ["Ig production", "OBSERVATION", 450, 463], ["CNS", "ANATOMY", 471, 474], ["prominent", "OBSERVATION_MODIFIER", 481, 490]]], ["Moreover, CXCL13 has been detected in primary CNS lymphoma where it is produced by malignant B cells and transported on the luminal surface of cerebrovascular endothelial cells (Smith et al., 2003, Brunn et al., 2007), suggesting that this chemokine may influence tumor development and localization in the CNS.Pathological relevance of ectopic lymphoid tissue in MSBecause ectopic lymphoid tissue forming in an inflamed tissue could sustain a local immune response against microbial or self antigens, the discovery of B-cell follicles in the MS brain raised a number of questions concerning the possible contribution of these structures to MS immunopathology, particularly to intrathecal Ig synthesis (Serafini et al., 2004, Aloisi and Pujol-Borrell, 2006).Pathological relevance of ectopic lymphoid tissue in MSCareful analysis of the cerebral cortex adjacent to ectopic B-cell follicles revealed the presence of demyelinated lesions whose extension and degree of neuronal loss and microglia activation were greater than those observed in the cerebral cortex of MS cases with lower meningeal inflammation (Magliozzi et al., 2007).", [["primary CNS lymphoma", "ANATOMY", 38, 58], ["malignant B cells", "ANATOMY", 83, 100], ["luminal surface", "ANATOMY", 124, 139], ["cerebrovascular endothelial cells", "ANATOMY", 143, 176], ["tumor", "ANATOMY", 264, 269], ["CNS", "ANATOMY", 306, 309], ["ectopic lymphoid tissue", "ANATOMY", 336, 359], ["ectopic lymphoid tissue", "ANATOMY", 373, 396], ["tissue", "ANATOMY", 420, 426], ["B-cell follicles", "ANATOMY", 518, 534], ["MS brain", "ANATOMY", 542, 550], ["ectopic lymphoid tissue", "ANATOMY", 783, 806], ["cerebral cortex", "ANATOMY", 836, 851], ["B-cell follicles", "ANATOMY", 872, 888], ["demyelinated lesions", "ANATOMY", 914, 934], ["neuronal", "ANATOMY", 965, 973], ["microglia", "ANATOMY", 983, 992], ["cerebral cortex", "ANATOMY", 1044, 1059], ["lower meningeal", "ANATOMY", 1077, 1092], ["primary CNS lymphoma", "DISEASE", 38, 58], ["luminal", "CHEMICAL", 124, 131], ["tumor", "DISEASE", 264, 269], ["MS", "DISEASE", 542, 544], ["immunopathology", "DISEASE", 643, 658], ["neuronal loss", "DISEASE", 965, 978], ["MS", "DISEASE", 1063, 1065], ["meningeal inflammation", "DISEASE", 1083, 1105], ["CXCL13", "GENE_OR_GENE_PRODUCT", 10, 16], ["CNS lymphoma", "CANCER", 46, 58], ["malignant B cells", "CELL", 83, 100], ["luminal surface", "CELLULAR_COMPONENT", 124, 139], ["cerebrovascular endothelial cells", "CELL", 143, 176], ["tumor", "CANCER", 264, 269], ["CNS", "ANATOMICAL_SYSTEM", 306, 309], ["ectopic lymphoid tissue", "TISSUE", 336, 359], ["MSBecause ectopic lymphoid tissue", "TISSUE", 363, 396], ["tissue", "TISSUE", 420, 426], ["B-cell", "CELL", 518, 524], ["follicles", "MULTI-TISSUE_STRUCTURE", 525, 534], ["brain", "ORGAN", 545, 550], ["Ig", "GENE_OR_GENE_PRODUCT", 688, 690], ["ectopic lymphoid tissue", "TISSUE", 783, 806], ["cerebral cortex", "MULTI-TISSUE_STRUCTURE", 836, 851], ["B-cell follicles", "MULTI-TISSUE_STRUCTURE", 872, 888], ["demyelinated lesions", "PATHOLOGICAL_FORMATION", 914, 934], ["neuronal", "CELL", 965, 973], ["microglia", "CELL", 983, 992], ["cerebral cortex", "MULTI-TISSUE_STRUCTURE", 1044, 1059], ["CXCL13", "PROTEIN", 10, 16], ["malignant B cells", "CELL_TYPE", 83, 100], ["cerebrovascular endothelial cells", "CELL_TYPE", 143, 176], ["chemokine", "PROTEIN", 240, 249], ["microglia", "CELL_TYPE", 983, 992], ["CXCL13", "TEST", 10, 16], ["primary CNS lymphoma", "PROBLEM", 38, 58], ["malignant B cells", "PROBLEM", 83, 100], ["this chemokine", "PROBLEM", 235, 249], ["influence tumor development", "PROBLEM", 254, 281], ["ectopic lymphoid tissue", "PROBLEM", 336, 359], ["ectopic lymphoid tissue", "PROBLEM", 373, 396], ["an inflamed tissue", "PROBLEM", 408, 426], ["microbial or self antigens", "PROBLEM", 473, 499], ["B-cell follicles", "PROBLEM", 518, 534], ["MS immunopathology", "PROBLEM", 640, 658], ["ectopic lymphoid tissue", "PROBLEM", 783, 806], ["MSCareful analysis", "TEST", 810, 828], ["ectopic B-cell follicles", "PROBLEM", 864, 888], ["demyelinated lesions", "PROBLEM", 914, 934], ["neuronal loss", "PROBLEM", 965, 978], ["microglia activation", "PROBLEM", 983, 1003], ["lower meningeal inflammation", "PROBLEM", 1077, 1105], ["primary", "OBSERVATION_MODIFIER", 38, 45], ["CNS lymphoma", "OBSERVATION", 46, 58], ["malignant B cells", "OBSERVATION", 83, 100], ["luminal", "ANATOMY_MODIFIER", 124, 131], ["surface", "ANATOMY_MODIFIER", 132, 139], ["cerebrovascular endothelial", "ANATOMY", 143, 170], ["tumor", "OBSERVATION", 264, 269], ["CNS", "ANATOMY", 306, 309], ["ectopic lymphoid tissue", "OBSERVATION", 336, 359], ["ectopic lymphoid tissue", "OBSERVATION", 373, 396], ["inflamed tissue", "OBSERVATION", 411, 426], ["B-cell follicles", "OBSERVATION", 518, 534], ["brain", "ANATOMY", 545, 550], ["ectopic lymphoid tissue", "OBSERVATION", 783, 806], ["cerebral cortex", "ANATOMY", 836, 851], ["ectopic B-cell follicles", "OBSERVATION", 864, 888], ["demyelinated", "OBSERVATION_MODIFIER", 914, 926], ["lesions", "OBSERVATION", 927, 934], ["degree", "OBSERVATION_MODIFIER", 955, 961], ["neuronal loss", "OBSERVATION", 965, 978], ["microglia activation", "OBSERVATION", 983, 1003], ["greater", "OBSERVATION_MODIFIER", 1009, 1016], ["cerebral cortex", "ANATOMY", 1044, 1059], ["lower", "ANATOMY_MODIFIER", 1077, 1082], ["meningeal", "ANATOMY", 1083, 1092], ["inflammation", "OBSERVATION", 1093, 1105]]], ["Of importance, such a dramatic pattern of cortical pathology correlated with a more severe disease course in MS cases with follicles compared to those without (Magliozzi et al., 2007).", [["cortical", "ANATOMY", 42, 50], ["follicles", "ANATOMY", 123, 132], ["MS", "DISEASE", 109, 111], ["cortical", "MULTI-TISSUE_STRUCTURE", 42, 50], ["follicles", "MULTI-TISSUE_STRUCTURE", 123, 132], ["cortical pathology", "PROBLEM", 42, 60], ["a more severe disease course", "PROBLEM", 77, 105], ["follicles", "PROBLEM", 123, 132], ["dramatic", "OBSERVATION_MODIFIER", 22, 30], ["cortical pathology", "OBSERVATION", 42, 60], ["severe", "OBSERVATION_MODIFIER", 84, 90], ["disease", "OBSERVATION", 91, 98]]], ["These findings suggested the possibility that ectopic B-cell follicles are a source of diffusible factors, such as (auto)antibodies, pro-inflammatory cytokines and/or proteolytic enzymes, that cause injury to neural cells directly or through induction of microglia activation.Pathological relevance of ectopic lymphoid tissue in MSFurther immunohistochemical analysis revealed that ectopic B-cell follicles in MS meninges also contain numerous CD8+ cytotoxic T cells and plasmacytoid dendritic cells, both of which play an essential role in antiviral responses.", [["B-cell follicles", "ANATOMY", 54, 70], ["neural cells", "ANATOMY", 209, 221], ["microglia", "ANATOMY", 255, 264], ["ectopic lymphoid tissue", "ANATOMY", 302, 325], ["B-cell follicles", "ANATOMY", 390, 406], ["MS meninges", "ANATOMY", 410, 421], ["CD8+ cytotoxic T cells", "ANATOMY", 444, 466], ["plasmacytoid dendritic cells", "ANATOMY", 471, 499], ["B-cell", "CELL", 54, 60], ["follicles", "MULTI-TISSUE_STRUCTURE", 61, 70], ["neural cells", "CELL", 209, 221], ["microglia", "CELL", 255, 264], ["ectopic lymphoid tissue", "TISSUE", 302, 325], ["B-cell follicles", "MULTI-TISSUE_STRUCTURE", 390, 406], ["meninges", "ORGAN", 413, 421], ["CD8", "GENE_OR_GENE_PRODUCT", 444, 447], ["plasmacytoid dendritic cells", "CELL", 471, 499], ["diffusible factors", "PROTEIN", 87, 105], ["(auto)antibodies", "PROTEIN", 115, 131], ["pro-inflammatory cytokines", "PROTEIN", 133, 159], ["proteolytic enzymes", "PROTEIN", 167, 186], ["neural cells", "CELL_TYPE", 209, 221], ["microglia", "CELL_TYPE", 255, 264], ["CD8+ cytotoxic T cells", "CELL_TYPE", 444, 466], ["plasmacytoid dendritic cells", "CELL_TYPE", 471, 499], ["ectopic B-cell follicles", "PROBLEM", 46, 70], ["diffusible factors", "PROBLEM", 87, 105], ["auto)antibodies", "TEST", 116, 131], ["pro-inflammatory cytokines", "TEST", 133, 159], ["proteolytic enzymes", "TEST", 167, 186], ["injury to neural cells", "PROBLEM", 199, 221], ["microglia activation", "PROBLEM", 255, 275], ["ectopic lymphoid tissue", "PROBLEM", 302, 325], ["MSFurther immunohistochemical analysis", "TEST", 329, 367], ["ectopic B-cell follicles in MS meninges", "PROBLEM", 382, 421], ["cytotoxic T cells", "PROBLEM", 449, 466], ["plasmacytoid dendritic cells", "PROBLEM", 471, 499], ["suggested the possibility", "UNCERTAINTY", 15, 40], ["ectopic", "OBSERVATION_MODIFIER", 46, 53], ["cell follicles", "OBSERVATION", 56, 70], ["neural cells", "OBSERVATION", 209, 221], ["microglia activation", "OBSERVATION", 255, 275], ["ectopic lymphoid tissue", "OBSERVATION", 302, 325], ["ectopic B-cell follicles", "OBSERVATION", 382, 406], ["numerous", "OBSERVATION_MODIFIER", 435, 443], ["CD8+", "OBSERVATION", 444, 448], ["cytotoxic T cells", "OBSERVATION", 449, 466], ["plasmacytoid dendritic cells", "OBSERVATION", 471, 499], ["antiviral responses", "OBSERVATION", 541, 560]]], ["This observation prompted us to search for the presence of a viral agent inside these abnormal structures (Serafini et al., 2007).", [["This observation", "TEST", 0, 16], ["a viral agent", "TREATMENT", 59, 72], ["these abnormal structures", "PROBLEM", 80, 105]]], ["The most likely candidate appeared to be Epstein\u2013Barr virus (EBV) for two main reasons.", [["Epstein\u2013Barr virus", "ORGANISM", 41, 59], ["EBV", "ORGANISM", 61, 64], ["Epstein\u2013Barr virus", "SPECIES", 41, 59], ["EBV", "SPECIES", 61, 64], ["Epstein\u2013Barr virus", "PROBLEM", 41, 59], ["most likely", "UNCERTAINTY", 4, 15], ["Barr virus", "OBSERVATION", 49, 59]]], ["The first one stems from the bulk of seroepidemiological data and immunological findings supporting an association between EBV infection and MS (reviewed in Ascherio and Munger, 2007, L\u00fcnemann et al., 2007).", [["EBV infection", "DISEASE", 123, 136], ["MS", "DISEASE", 141, 143], ["EBV", "ORGANISM", 123, 126], ["EBV", "SPECIES", 123, 126], ["seroepidemiological data", "TEST", 37, 61], ["immunological findings", "PROBLEM", 66, 88], ["EBV infection", "PROBLEM", 123, 136], ["MS", "PROBLEM", 141, 143], ["infection", "OBSERVATION", 127, 136]]], ["The second one was related to the unique ability of EBV to establish a latent infection in B cells and, through expression of viral latency proteins, to drive B-cell proliferation and activation (Thorley-Lawson, 2001), these features being compatible with the presence of expanded B cell clones and Ig-producing plasma cells in the MS brain (Uccelli et al., 2005).", [["B cells", "ANATOMY", 91, 98], ["B-cell", "ANATOMY", 159, 165], ["B cell clones", "ANATOMY", 281, 294], ["plasma cells", "ANATOMY", 312, 324], ["MS brain", "ANATOMY", 332, 340], ["infection", "DISEASE", 78, 87], ["EBV", "ORGANISM", 52, 55], ["B cells", "CELL", 91, 98], ["B-cell", "CELL", 159, 165], ["B cell clones", "CELL", 281, 294], ["Ig", "GENE_OR_GENE_PRODUCT", 299, 301], ["plasma cells", "CELL", 312, 324], ["brain", "ORGAN", 335, 340], ["B cells", "CELL_TYPE", 91, 98], ["viral latency proteins", "PROTEIN", 126, 148], ["B cell clones", "CELL_LINE", 281, 294], ["Ig-producing plasma cells", "CELL_TYPE", 299, 324], ["EBV", "PROBLEM", 52, 55], ["a latent infection in B cells", "PROBLEM", 69, 98], ["viral latency proteins", "PROBLEM", 126, 148], ["expanded B cell clones", "PROBLEM", 272, 294], ["Ig", "TEST", 299, 301], ["plasma cells", "PROBLEM", 312, 324], ["latent", "OBSERVATION_MODIFIER", 71, 77], ["infection", "OBSERVATION", 78, 87], ["viral latency", "OBSERVATION", 126, 139], ["cell proliferation", "OBSERVATION", 161, 179], ["expanded B cell clones", "OBSERVATION", 272, 294], ["plasma cells", "OBSERVATION", 312, 324], ["brain", "ANATOMY", 335, 340]]], ["The prediction turned out to be correct as in situ hybridization for EBV-encoded small RNAs (EBER) and immunohistochemical stainings for two EBV latency proteins (EBNA-2, LMP1) revealed that ectopic B-cell follicles were highly enriched in EBV-infected cells (Serafini et al., 2007) (see Fig. 1C, D for EBER and LMP1 stainings, respectively).", [["B-cell follicles", "ANATOMY", 199, 215], ["cells", "ANATOMY", 253, 258], ["EBV", "ORGANISM", 69, 72], ["-encoded small RNAs", "GENE_OR_GENE_PRODUCT", 72, 91], ["EBER", "GENE_OR_GENE_PRODUCT", 93, 97], ["EBV", "ORGANISM", 141, 144], ["EBNA-2", "GENE_OR_GENE_PRODUCT", 163, 169], ["LMP1", "GENE_OR_GENE_PRODUCT", 171, 175], ["B-cell", "CELL", 199, 205], ["follicles", "MULTI-TISSUE_STRUCTURE", 206, 215], ["EBV", "ORGANISM", 240, 243], ["cells", "CELL", 253, 258], ["EBER", "GENE_OR_GENE_PRODUCT", 303, 307], ["LMP1", "GENE_OR_GENE_PRODUCT", 312, 316], ["EBV-encoded small RNAs", "RNA", 69, 91], ["EBER", "RNA", 93, 97], ["EBV latency proteins", "PROTEIN", 141, 161], ["EBNA", "PROTEIN", 163, 167], ["LMP1", "PROTEIN", 171, 175], ["EBV-infected cells", "CELL_TYPE", 240, 258], ["LMP1", "PROTEIN", 312, 316], ["EBV", "SPECIES", 69, 72], ["EBV", "PROBLEM", 69, 72], ["immunohistochemical stainings", "TEST", 103, 132], ["two EBV latency proteins", "TEST", 137, 161], ["EBNA", "TEST", 163, 167], ["LMP1", "TEST", 171, 175], ["ectopic B-cell follicles", "PROBLEM", 191, 215], ["infected cells", "PROBLEM", 244, 258], ["EBER and LMP1 stainings", "TEST", 303, 326], ["small RNAs", "OBSERVATION", 81, 91], ["ectopic B-cell follicles", "OBSERVATION", 191, 215], ["infected cells", "OBSERVATION", 244, 258]]], ["EBER+ cells were identified essentially as B cells and plasma cells.", [["EBER+ cells", "ANATOMY", 0, 11], ["B cells", "ANATOMY", 43, 50], ["plasma cells", "ANATOMY", 55, 67], ["EBER", "GENE_OR_GENE_PRODUCT", 0, 4], ["B cells", "CELL", 43, 50], ["plasma cells", "CELL", 55, 67], ["B cells", "CELL_TYPE", 43, 50], ["plasma cells", "CELL_TYPE", 55, 67], ["EBER+ cells", "TEST", 0, 11], ["plasma cells", "TEST", 55, 67], ["+ cells", "OBSERVATION", 4, 11], ["plasma cells", "OBSERVATION", 55, 67]]], ["Variable numbers of EBV-infected cells were also detected in the meninges and perivascular immune infiltrates of active white matter lesions in nearly 100% of the MS cases analyzed (21 out of 22 with different clinical courses), their frequency being correlated with the degree of inflammation.", [["cells", "ANATOMY", 33, 38], ["meninges", "ANATOMY", 65, 73], ["perivascular immune infiltrates", "ANATOMY", 78, 109], ["white matter lesions", "ANATOMY", 120, 140], ["white matter lesions", "DISEASE", 120, 140], ["MS", "DISEASE", 163, 165], ["inflammation", "DISEASE", 281, 293], ["EBV", "ORGANISM", 20, 23], ["cells", "CELL", 33, 38], ["meninges", "TISSUE", 65, 73], ["perivascular immune infiltrates", "PATHOLOGICAL_FORMATION", 78, 109], ["white matter lesions", "PATHOLOGICAL_FORMATION", 120, 140], ["EBV", "PROBLEM", 20, 23], ["infected cells", "PROBLEM", 24, 38], ["perivascular immune infiltrates", "PROBLEM", 78, 109], ["active white matter lesions", "PROBLEM", 113, 140], ["the MS cases", "TEST", 159, 171], ["inflammation", "PROBLEM", 281, 293], ["EBV", "OBSERVATION", 20, 23], ["infected cells", "OBSERVATION", 24, 38], ["meninges", "ANATOMY", 65, 73], ["perivascular immune", "ANATOMY", 78, 97], ["active", "OBSERVATION_MODIFIER", 113, 119], ["white matter", "OBSERVATION_MODIFIER", 120, 132], ["lesions", "OBSERVATION", 133, 140], ["inflammation", "OBSERVATION", 281, 293]]], ["Expression of markers of the EBV lytic cycle appeared restricted to acute inflammatory lesions in the white matter of MS cases with progressive disease and was abundant in the highly inflamed brain of cases with very severe, fulminant MS. Of note, EBV lytic proteins were consistently found in ectopic B-cell follicles indicating that these structures represent major occult sites of viral reactivation in the MS brain (Serafini et al., 2007).Pathological relevance of ectopic lymphoid tissue in MSWe also provided evidence that CD8+ T cells accumulating in ectopic follicles and active MS lesions show signs of activation, such as proliferation and IFN-\u03b3 production, and display cytotoxic activity toward EBV-infected B cells/plasma cells (Serafini et al., 2007).", [["acute inflammatory lesions", "ANATOMY", 68, 94], ["white matter", "ANATOMY", 102, 114], ["brain", "ANATOMY", 192, 197], ["B-cell follicles", "ANATOMY", 302, 318], ["sites", "ANATOMY", 375, 380], ["brain", "ANATOMY", 413, 418], ["ectopic lymphoid tissue", "ANATOMY", 469, 492], ["CD8+ T cells", "ANATOMY", 529, 541], ["ectopic follicles", "ANATOMY", 558, 575], ["MS lesions", "ANATOMY", 587, 597], ["B cells", "ANATOMY", 719, 726], ["plasma cells", "ANATOMY", 727, 739], ["MS", "DISEASE", 118, 120], ["MS", "DISEASE", 235, 237], ["MS", "DISEASE", 410, 412], ["EBV", "ORGANISM", 29, 32], ["inflammatory lesions", "PATHOLOGICAL_FORMATION", 74, 94], ["brain", "ORGAN", 192, 197], ["EBV", "ORGANISM", 248, 251], ["B-cell follicles", "CELL", 302, 318], ["brain", "ORGAN", 413, 418], ["ectopic lymphoid tissue", "TISSUE", 469, 492], ["CD8", "GENE_OR_GENE_PRODUCT", 529, 532], ["ectopic follicles", "MULTI-TISSUE_STRUCTURE", 558, 575], ["MS lesions", "PATHOLOGICAL_FORMATION", 587, 597], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 650, 655], ["EBV", "ORGANISM", 706, 709], ["B cells", "CELL", 719, 726], ["plasma cells", "CELL", 727, 739], ["EBV lytic proteins", "PROTEIN", 248, 266], ["ectopic B-cell follicles", "CELL_TYPE", 294, 318], ["CD8", "PROTEIN", 529, 532], ["T cells", "CELL_TYPE", 534, 541], ["IFN", "PROTEIN", 650, 653], ["EBV-infected B cells", "CELL_TYPE", 706, 726], ["plasma cells", "CELL_TYPE", 727, 739], ["EBV", "SPECIES", 248, 251], ["the EBV lytic cycle", "TEST", 25, 44], ["acute inflammatory lesions", "PROBLEM", 68, 94], ["progressive disease", "PROBLEM", 132, 151], ["very severe, fulminant MS", "PROBLEM", 212, 237], ["EBV lytic proteins", "TEST", 248, 266], ["ectopic B-cell follicles", "PROBLEM", 294, 318], ["viral reactivation in the MS brain", "PROBLEM", 384, 418], ["ectopic lymphoid tissue", "PROBLEM", 469, 492], ["CD8", "TEST", 529, 532], ["T cells", "PROBLEM", 534, 541], ["ectopic follicles", "PROBLEM", 558, 575], ["active MS lesions", "PROBLEM", 580, 597], ["activation", "PROBLEM", 612, 622], ["proliferation", "PROBLEM", 632, 645], ["IFN-\u03b3 production", "PROBLEM", 650, 666], ["cytotoxic activity", "PROBLEM", 680, 698], ["EBV", "TEST", 706, 709], ["infected B cells", "PROBLEM", 710, 726], ["plasma cells", "TEST", 727, 739], ["acute", "OBSERVATION_MODIFIER", 68, 73], ["inflammatory", "OBSERVATION_MODIFIER", 74, 86], ["lesions", "OBSERVATION", 87, 94], ["white matter", "OBSERVATION_MODIFIER", 102, 114], ["progressive", "OBSERVATION_MODIFIER", 132, 143], ["disease", "OBSERVATION", 144, 151], ["highly", "OBSERVATION_MODIFIER", 176, 182], ["inflamed", "OBSERVATION", 183, 191], ["brain", "ANATOMY", 192, 197], ["very", "OBSERVATION_MODIFIER", 212, 216], ["severe", "OBSERVATION_MODIFIER", 217, 223], ["fulminant", "OBSERVATION_MODIFIER", 225, 234], ["MS", "OBSERVATION", 235, 237], ["lytic", "OBSERVATION_MODIFIER", 252, 257], ["ectopic B-cell follicles", "OBSERVATION", 294, 318], ["viral reactivation", "OBSERVATION", 384, 402], ["brain", "ANATOMY", 413, 418], ["ectopic lymphoid tissue", "OBSERVATION", 469, 492], ["ectopic follicles", "OBSERVATION", 558, 575], ["active", "OBSERVATION_MODIFIER", 580, 586], ["MS", "OBSERVATION_MODIFIER", 587, 589], ["lesions", "OBSERVATION", 590, 597], ["cytotoxic activity", "OBSERVATION", 680, 698], ["plasma cells", "OBSERVATION", 727, 739]]], ["These findings led us to propose that a CNS compartmentalized and dysregulated infection with EBV drives MS-associated immunopathology through expansion and activation of latently infected B cells, periodic viral reactivation, and induction of an EBV-specific cytotoxic immune response.", [["CNS", "ANATOMY", 40, 43], ["B cells", "ANATOMY", 189, 196], ["infection", "DISEASE", 79, 88], ["MS", "DISEASE", 105, 107], ["immunopathology", "DISEASE", 119, 134], ["CNS", "ANATOMICAL_SYSTEM", 40, 43], ["EBV", "ORGANISM", 94, 97], ["B cells", "CELL", 189, 196], ["EBV", "ORGANISM", 247, 250], ["latently infected B cells", "CELL_TYPE", 171, 196], ["EBV", "SPECIES", 94, 97], ["EBV", "SPECIES", 247, 250], ["a CNS compartmentalized and dysregulated infection", "PROBLEM", 38, 88], ["EBV drives MS", "PROBLEM", 94, 107], ["immunopathology through expansion", "PROBLEM", 119, 152], ["latently infected B cells", "PROBLEM", 171, 196], ["periodic viral reactivation", "PROBLEM", 198, 225], ["an EBV", "TEST", 244, 250], ["dysregulated", "OBSERVATION_MODIFIER", 66, 78], ["infection", "OBSERVATION", 79, 88], ["latently", "OBSERVATION_MODIFIER", 171, 179], ["infected", "OBSERVATION_MODIFIER", 180, 188], ["B cells", "OBSERVATION", 189, 196], ["viral reactivation", "OBSERVATION", 207, 225], ["cytotoxic immune response", "OBSERVATION", 260, 285]]], ["Most probably, the latter plays a major role in mediating CNS tissue damage.Pathological relevance of ectopic lymphoid tissue in MSInterestingly, analysis of post-mortem CSF revealed the presence of significantly higher levels of CXCL13 in the MS cases with ectopic follicles and a higher frequency of CNS-infiltrating EBV-infected cells as compared to the MS cases with less brain inflammation and a lower frequency of EBV-infected cells (Fig. 1E).", [["CNS tissue", "ANATOMY", 58, 68], ["ectopic lymphoid tissue", "ANATOMY", 102, 125], ["ectopic follicles", "ANATOMY", 258, 275], ["CNS", "ANATOMY", 302, 305], ["cells", "ANATOMY", 332, 337], ["brain", "ANATOMY", 376, 381], ["cells", "ANATOMY", 433, 438], ["MS", "DISEASE", 244, 246], ["MS", "DISEASE", 357, 359], ["brain inflammation", "DISEASE", 376, 394], ["CNS tissue", "TISSUE", 58, 68], ["ectopic lymphoid tissue", "TISSUE", 102, 125], ["CSF", "GENE_OR_GENE_PRODUCT", 170, 173], ["CXCL13", "GENE_OR_GENE_PRODUCT", 230, 236], ["ectopic follicles", "MULTI-TISSUE_STRUCTURE", 258, 275], ["CNS-infiltrating", "CELL", 302, 318], ["EBV", "ORGANISM", 319, 322], ["cells", "CELL", 332, 337], ["brain", "ORGAN", 376, 381], ["EBV", "ORGANISM", 420, 423], ["cells", "CELL", 433, 438], ["CXCL13", "PROTEIN", 230, 236], ["CNS-infiltrating EBV-infected cells", "CELL_TYPE", 302, 337], ["EBV-infected cells", "CELL_TYPE", 420, 438], ["EBV", "SPECIES", 420, 423], ["CNS tissue damage", "PROBLEM", 58, 75], ["ectopic lymphoid tissue", "PROBLEM", 102, 125], ["post-mortem CSF", "TEST", 158, 173], ["significantly higher levels of CXCL13", "PROBLEM", 199, 236], ["ectopic follicles", "PROBLEM", 258, 275], ["infiltrating EBV", "PROBLEM", 306, 322], ["infected cells", "PROBLEM", 323, 337], ["less brain inflammation", "PROBLEM", 371, 394], ["a lower frequency of EBV", "PROBLEM", 399, 423], ["infected cells", "PROBLEM", 424, 438], ["CNS tissue", "ANATOMY", 58, 68], ["damage", "OBSERVATION", 69, 75], ["ectopic lymphoid tissue", "OBSERVATION", 102, 125], ["ectopic follicles", "OBSERVATION", 258, 275], ["CNS", "ANATOMY", 302, 305], ["infiltrating EBV", "OBSERVATION", 306, 322], ["infected cells", "OBSERVATION", 323, 337], ["less", "OBSERVATION_MODIFIER", 371, 375], ["brain", "ANATOMY", 376, 381], ["inflammation", "OBSERVATION", 382, 394], ["lower frequency", "OBSERVATION_MODIFIER", 401, 416], ["infected cells", "OBSERVATION", 424, 438]]], ["This finding suggests that CXCL13 could play a key role in the compartmentalization of EBV-infected B cells within intrameningeal niches, allowing their expansion and organization in germinal center-like structures.", [["B cells", "ANATOMY", 100, 107], ["intrameningeal niches", "ANATOMY", 115, 136], ["germinal center-like structures", "ANATOMY", 183, 214], ["CXCL13", "GENE_OR_GENE_PRODUCT", 27, 33], ["EBV", "ORGANISM", 87, 90], ["B cells", "CELL", 100, 107], ["intrameningeal niches", "MULTI-TISSUE_STRUCTURE", 115, 136], ["germinal center-like structures", "TISSUE", 183, 214], ["CXCL13", "PROTEIN", 27, 33], ["EBV-infected B cells", "CELL_TYPE", 87, 107], ["CXCL13", "TEST", 27, 33], ["EBV", "PROBLEM", 87, 90], ["infected B cells within intrameningeal niches", "PROBLEM", 91, 136], ["CXCL13", "OBSERVATION", 27, 33], ["EBV", "OBSERVATION", 87, 90], ["infected B cells", "OBSERVATION", 91, 107], ["intrameningeal niches", "OBSERVATION", 115, 136], ["expansion", "OBSERVATION_MODIFIER", 153, 162], ["germinal center", "OBSERVATION", 183, 198]]], ["Of interest, a recent study has shown that lymphoid chemokines (CCL19, CCL21, CXCL12 and CXCL13), in addition to their chemoattractant properties, are able to enhance the survival of chronic lymphocytic leukemia B cells, but not of normal B cells, in vitro (Ticchioni et al., 2007).", [["lymphoid", "ANATOMY", 43, 51], ["chronic lymphocytic leukemia B cells", "ANATOMY", 183, 219], ["B cells", "ANATOMY", 239, 246], ["chronic lymphocytic leukemia B", "DISEASE", 183, 213], ["lymphoid chemokines", "CELL", 43, 62], ["CCL19", "GENE_OR_GENE_PRODUCT", 64, 69], ["CCL21", "GENE_OR_GENE_PRODUCT", 71, 76], ["CXCL12", "GENE_OR_GENE_PRODUCT", 78, 84], ["CXCL13", "GENE_OR_GENE_PRODUCT", 89, 95], ["chronic lymphocytic leukemia B cells", "CELL", 183, 219], ["normal B cells", "CELL", 232, 246], ["lymphoid chemokines", "PROTEIN", 43, 62], ["CCL19", "PROTEIN", 64, 69], ["CCL21", "PROTEIN", 71, 76], ["CXCL12", "PROTEIN", 78, 84], ["CXCL13", "PROTEIN", 89, 95], ["chronic lymphocytic leukemia B cells", "CELL_LINE", 183, 219], ["normal B cells", "CELL_TYPE", 232, 246], ["a recent study", "TEST", 13, 27], ["lymphoid chemokines", "TEST", 43, 62], ["CCL19", "TEST", 64, 69], ["CCL21", "TEST", 71, 76], ["CXCL12", "TEST", 78, 84], ["CXCL13", "TEST", 89, 95], ["chronic lymphocytic leukemia B cells", "PROBLEM", 183, 219], ["lymphoid chemokines", "OBSERVATION", 43, 62], ["chronic", "OBSERVATION_MODIFIER", 183, 190], ["lymphocytic leukemia B cells", "OBSERVATION", 191, 219], ["B cells", "OBSERVATION", 239, 246]]], ["The hypothesis that lymphoid chemokines might play a role in promoting the survival of EBV-infected B cells should therefore be tested.Concluding remarksThe work summarized in this article provides a remarkable example of how the study of lymphoid chemokines as markers of chronic inflammation in a complex neurological disease like MS has helped to direct (or redirect) the focus of neuropathological analyses on a compartment, the meninges, that has received little attention during the past decades (Guseo and Jellinger, 1975, Prineas and Wright, 1978, Lassmann et al., 2007).", [["lymphoid", "ANATOMY", 20, 28], ["B cells", "ANATOMY", 100, 107], ["lymphoid", "ANATOMY", 239, 247], ["neurological", "ANATOMY", 307, 319], ["meninges", "ANATOMY", 433, 441], ["inflammation", "DISEASE", 281, 293], ["neurological disease", "DISEASE", 307, 327], ["MS", "DISEASE", 333, 335], ["lymphoid chemokines", "CELL", 20, 39], ["EBV", "ORGANISM", 87, 90], ["B cells", "CELL", 100, 107], ["lymphoid chemokines", "CELL", 239, 258], ["meninges", "MULTI-TISSUE_STRUCTURE", 433, 441], ["lymphoid chemokines", "PROTEIN", 20, 39], ["EBV-infected B cells", "CELL_TYPE", 87, 107], ["lymphoid chemokines", "PROTEIN", 239, 258], ["EBV", "SPECIES", 87, 90], ["lymphoid chemokines", "TREATMENT", 20, 39], ["EBV", "PROBLEM", 87, 90], ["infected B cells", "TREATMENT", 91, 107], ["the study", "TEST", 226, 235], ["lymphoid chemokines", "TREATMENT", 239, 258], ["chronic inflammation", "PROBLEM", 273, 293], ["a complex neurological disease like MS", "PROBLEM", 297, 335], ["lymphoid chemokines", "OBSERVATION", 20, 39], ["chronic", "OBSERVATION_MODIFIER", 273, 280], ["inflammation", "OBSERVATION", 281, 293], ["complex", "OBSERVATION_MODIFIER", 299, 306], ["neurological disease", "OBSERVATION", 307, 327], ["meninges", "ANATOMY", 433, 441]]], ["Immune surveillance of the CNS routinely occurs across the meningeal-ventricular compartment (Engelhardt and Ransohoff, 2005) and it is therefore plausible that events taking place therein play an important role in MS pathogenesis.", [["CNS", "ANATOMY", 27, 30], ["meningeal-ventricular compartment", "ANATOMY", 59, 92], ["MS", "DISEASE", 215, 217], ["CNS", "ANATOMICAL_SYSTEM", 27, 30], ["meningeal-ventricular compartment", "MULTI-TISSUE_STRUCTURE", 59, 92], ["MS pathogenesis", "PROBLEM", 215, 230], ["CNS", "ANATOMY", 27, 30], ["meningeal", "ANATOMY", 59, 68], ["ventricular compartment", "ANATOMY", 69, 92]]], ["Because the analysis of CXCL13 in the MS brain has been the starting point for the identification of intrameningeal B-cell follicles, their characterization as foci of EBV infection, and the recognition of a link between dysregulated EBV infection and inflammatory activity in MS lesions, it is fair to state that research on lymphoid chemokines has played a key role in advancing our comprehension of this complex disease.", [["MS brain", "ANATOMY", 38, 46], ["B-cell follicles", "ANATOMY", 116, 132], ["MS lesions", "ANATOMY", 277, 287], ["lymphoid", "ANATOMY", 326, 334], ["EBV infection", "DISEASE", 168, 181], ["EBV infection", "DISEASE", 234, 247], ["MS", "DISEASE", 277, 279], ["CXCL13", "GENE_OR_GENE_PRODUCT", 24, 30], ["brain", "ORGAN", 41, 46], ["B-cell follicles", "MULTI-TISSUE_STRUCTURE", 116, 132], ["EBV", "ORGANISM", 168, 171], ["EBV", "ORGANISM", 234, 237], ["MS lesions", "CANCER", 277, 287], ["lymphoid chemokines", "CELL", 326, 345], ["CXCL13", "PROTEIN", 24, 30], ["intrameningeal B-cell follicles", "CELL_TYPE", 101, 132], ["lymphoid chemokines", "PROTEIN", 326, 345], ["EBV", "SPECIES", 168, 171], ["EBV", "SPECIES", 234, 237], ["the analysis", "TEST", 8, 20], ["CXCL13", "TEST", 24, 30], ["intrameningeal B-cell follicles", "PROBLEM", 101, 132], ["EBV infection", "PROBLEM", 168, 181], ["dysregulated EBV infection", "PROBLEM", 221, 247], ["inflammatory activity in MS lesions", "PROBLEM", 252, 287], ["lymphoid chemokines", "TREATMENT", 326, 345], ["this complex disease", "PROBLEM", 402, 422], ["brain", "ANATOMY", 41, 46], ["cell follicles", "OBSERVATION", 118, 132], ["foci", "OBSERVATION_MODIFIER", 160, 164], ["EBV infection", "OBSERVATION", 168, 181], ["dysregulated", "OBSERVATION_MODIFIER", 221, 233], ["EBV", "OBSERVATION_MODIFIER", 234, 237], ["infection", "OBSERVATION", 238, 247], ["inflammatory", "OBSERVATION_MODIFIER", 252, 264], ["activity", "OBSERVATION_MODIFIER", 265, 273], ["lesions", "OBSERVATION", 280, 287], ["lymphoid chemokines", "OBSERVATION", 326, 345]]]], "PMC7368601": [], "7870870602f0a4edb3a7ea468659e2eb23cb2202": [["IntroductionEntamoeba histolytica is the protozoan parasite that causes amoebiasis in humans.", [["Entamoeba histolytica", "DISEASE", 12, 33], ["amoebiasis", "DISEASE", 72, 82], ["Entamoeba histolytica", "ORGANISM", 12, 33], ["humans", "ORGANISM", 86, 92], ["Entamoeba histolytica", "SPECIES", 12, 33], ["humans", "SPECIES", 86, 92], ["Entamoeba histolytica", "SPECIES", 12, 33], ["humans", "SPECIES", 86, 92], ["IntroductionEntamoeba histolytica", "TREATMENT", 0, 33], ["the protozoan parasite", "PROBLEM", 37, 59], ["amoebiasis in humans", "PROBLEM", 72, 92], ["protozoan parasite", "OBSERVATION", 41, 59], ["amoebiasis", "OBSERVATION", 72, 82]]], ["This disease is widely prevalent in population of developing countries with poor living conditions and hygiene.", [["This disease", "PROBLEM", 0, 12], ["disease", "OBSERVATION", 5, 12], ["widely", "OBSERVATION_MODIFIER", 16, 22], ["prevalent", "OBSERVATION_MODIFIER", 23, 32]]], ["The parasite has been estimated to infect 40 million people around the world, although the real number of E. histolytica cases is unknown due to the inclusion in this estimation of cases with the morphologically identical E. dispar and E. moshkovskii species.", [["people", "ORGANISM", 53, 59], ["E. histolytica", "ORGANISM", 106, 120], ["E. dispar", "ORGANISM", 222, 231], ["E. moshkovskii species", "ORGANISM", 236, 258], ["people", "SPECIES", 53, 59], ["E. histolytica", "SPECIES", 106, 120], ["E. dispar", "SPECIES", 222, 231], ["E. moshkovskii", "SPECIES", 236, 250], ["E. histolytica", "SPECIES", 106, 120], ["E. dispar", "SPECIES", 222, 231], ["E. moshkovskii", "SPECIES", 236, 250], ["E. histolytica cases", "TEST", 106, 126], ["parasite", "OBSERVATION", 4, 12], ["moshkovskii species", "OBSERVATION", 239, 258]]], ["However, since E. histolytica is the unique specie considered as pathogen for humans, it appears to be responsible for 10 million cases of amoebic dysentery/amoebic liver abscesses and about 100,000 deaths every year [1] .", [["liver abscesses", "ANATOMY", 165, 180], ["amoebic dysentery", "DISEASE", 139, 156], ["amoebic liver abscesses", "DISEASE", 157, 180], ["deaths", "DISEASE", 199, 205], ["E. histolytica", "ORGANISM", 15, 29], ["humans", "ORGANISM", 78, 84], ["liver", "ORGAN", 165, 170], ["E. histolytica", "SPECIES", 15, 29], ["humans", "SPECIES", 78, 84], ["E. histolytica", "SPECIES", 15, 29], ["humans", "SPECIES", 78, 84], ["amoebic dysentery", "PROBLEM", 139, 156], ["amoebic liver abscesses", "PROBLEM", 157, 180], ["amoebic", "OBSERVATION_MODIFIER", 139, 146], ["amoebic", "OBSERVATION_MODIFIER", 157, 164], ["liver", "ANATOMY", 165, 170], ["abscesses", "OBSERVATION", 171, 180]]], ["In Mexico, amoebiasis was ranked as the sixth highest cause of morbidity with an incidence of 498 cases per 100,000 habitants in 2008 [2] .IntroductionAmoebiasis treatment relies on the use of imidazole derivatives such as metronidazole, which is highly effective but has the drawback of inducing side effects, is mutagenic at high concentrations, and induces the development of cellular resistance [3] .", [["cellular", "ANATOMY", 379, 387], ["amoebiasis", "DISEASE", 11, 21], ["Amoebiasis", "CHEMICAL", 151, 161], ["imidazole", "CHEMICAL", 193, 202], ["metronidazole", "CHEMICAL", 223, 236], ["imidazole", "CHEMICAL", 193, 202], ["metronidazole", "CHEMICAL", 223, 236], ["imidazole derivatives", "SIMPLE_CHEMICAL", 193, 214], ["metronidazole", "SIMPLE_CHEMICAL", 223, 236], ["cellular", "CELL", 379, 387], ["amoebiasis", "PROBLEM", 11, 21], ["morbidity", "PROBLEM", 63, 72], ["IntroductionAmoebiasis treatment", "TREATMENT", 139, 171], ["imidazole derivatives", "TREATMENT", 193, 214], ["metronidazole", "TREATMENT", 223, 236], ["inducing side effects", "PROBLEM", 288, 309], ["cellular resistance", "PROBLEM", 379, 398], ["amoebiasis", "OBSERVATION", 11, 21], ["high concentrations", "OBSERVATION_MODIFIER", 327, 346], ["cellular resistance", "OBSERVATION", 379, 398]]], ["Thus, there are reports of in vitro induction of resistant cultures to high concentrations of metronidazole by continuous exposure to increasing concentrations of the drug as well as the description of patients with amoebic 2 BioMed Research International liver abscesses reluctant to the treatment [4] .", [["cultures", "ANATOMY", 59, 67], ["liver abscesses", "ANATOMY", 256, 271], ["metronidazole", "CHEMICAL", 94, 107], ["amoebic", "DISEASE", 216, 223], ["liver abscesses", "DISEASE", 256, 271], ["metronidazole", "CHEMICAL", 94, 107], ["metronidazole", "SIMPLE_CHEMICAL", 94, 107], ["patients", "ORGANISM", 202, 210], ["liver", "ORGAN", 256, 261], ["resistant cultures", "CELL_LINE", 49, 67], ["patients", "SPECIES", 202, 210], ["resistant cultures", "PROBLEM", 49, 67], ["metronidazole", "TREATMENT", 94, 107], ["International liver abscesses", "PROBLEM", 242, 271], ["liver", "ANATOMY", 256, 261], ["abscesses", "OBSERVATION", 262, 271]]], ["Another option that has been shuffled for controlling amoebiasis is the development of a vaccine.", [["amoebiasis", "DISEASE", 54, 64], ["controlling amoebiasis", "PROBLEM", 42, 64], ["a vaccine", "TREATMENT", 87, 96]]], ["In this regard, there have been many trials of immunization in experimental animals using different amoeba antigens in combination with adjuvant [5] .IntroductionThe galactose-binding lectin is among the antigens most commonly used for protection assays.", [["galactose", "CHEMICAL", 166, 175], ["galactose", "CHEMICAL", 166, 175], ["galactose-binding lectin", "GENE_OR_GENE_PRODUCT", 166, 190], ["galactose-binding lectin", "PROTEIN", 166, 190], ["antigens", "PROTEIN", 204, 212], ["immunization", "TREATMENT", 47, 59], ["different amoeba antigens", "TREATMENT", 90, 115], ["The galactose-binding lectin", "TREATMENT", 162, 190], ["the antigens", "TREATMENT", 200, 212]]], ["This is a protein complex of three subunits that are preferably located at the surface of the parasite and whose main component, the heavy subunit of 170 kDa, is also one of the most immunogenic E. histolytica molecules [6] .", [["surface", "ANATOMY", 79, 86], ["surface", "CELLULAR_COMPONENT", 79, 86], ["E. histolytica", "ORGANISM", 195, 209], ["protein complex", "PROTEIN", 10, 25], ["heavy subunit", "PROTEIN", 133, 146], ["170 kDa", "PROTEIN", 150, 157], ["E. histolytica", "SPECIES", 195, 209], ["E. histolytica", "SPECIES", 195, 209], ["surface", "OBSERVATION_MODIFIER", 79, 86], ["parasite", "OBSERVATION", 94, 102], ["main", "OBSERVATION_MODIFIER", 113, 117], ["component", "OBSERVATION_MODIFIER", 118, 127], ["heavy", "OBSERVATION_MODIFIER", 133, 138], ["170 kDa", "OBSERVATION_MODIFIER", 150, 157], ["histolytica molecules", "OBSERVATION", 198, 219]]], ["Along with other proteins, such as the family of serine-rich proteins [7] and the 29 kDa cysteine-rich Alkyl hydroperoxide reductase [8] , the Gal-lectin is considered as one of the main targets for an effective vaccine against amoebiasis.", [["Alkyl hydroperoxide", "CHEMICAL", 103, 122], ["Gal-lectin", "CHEMICAL", 143, 153], ["amoebiasis", "DISEASE", 228, 238], ["serine", "CHEMICAL", 49, 55], ["cysteine", "CHEMICAL", 89, 97], ["Alkyl hydroperoxide", "CHEMICAL", 103, 122], ["serine", "AMINO_ACID", 49, 55], ["cysteine-rich Alkyl hydroperoxide reductase", "GENE_OR_GENE_PRODUCT", 89, 132], ["Gal-lectin", "GENE_OR_GENE_PRODUCT", 143, 153], ["amoebiasis", "CANCER", 228, 238], ["serine-rich proteins", "PROTEIN", 49, 69], ["29 kDa cysteine-rich Alkyl hydroperoxide reductase", "PROTEIN", 82, 132], ["Gal-lectin", "PROTEIN", 143, 153], ["the 29 kDa cysteine-rich Alkyl hydroperoxide reductase", "TREATMENT", 78, 132], ["an effective vaccine", "TREATMENT", 199, 219], ["amoebiasis", "PROBLEM", 228, 238]]], ["The gal-lectin, with its cysteine-rich portion of the 170 kDa lectin subunit, is the target for serum of 95% of patients with amoebic liver abscess [9] as well as IgG and IgA anti-Gal-lectin antibodies recovered from serum and feces of patients with intestinal amoebiasis, respectively [10, 11] .", [["serum", "ANATOMY", 96, 101], ["liver abscess", "ANATOMY", 134, 147], ["serum", "ANATOMY", 217, 222], ["feces", "ANATOMY", 227, 232], ["intestinal", "ANATOMY", 250, 260], ["amoebic liver abscess", "DISEASE", 126, 147], ["intestinal amoebiasis", "DISEASE", 250, 271], ["cysteine", "CHEMICAL", 25, 33], ["gal-lectin", "GENE_OR_GENE_PRODUCT", 4, 14], ["cysteine", "AMINO_ACID", 25, 33], ["lectin", "GENE_OR_GENE_PRODUCT", 62, 68], ["serum", "ORGANISM_SUBSTANCE", 96, 101], ["patients", "ORGANISM", 112, 120], ["liver", "ORGAN", 134, 139], ["IgG", "GENE_OR_GENE_PRODUCT", 163, 166], ["IgA anti-Gal-lectin antibodies", "GENE_OR_GENE_PRODUCT", 171, 201], ["serum", "ORGANISM_SUBSTANCE", 217, 222], ["feces", "ORGANISM_SUBSTANCE", 227, 232], ["patients", "ORGANISM", 236, 244], ["intestinal", "ORGAN", 250, 260], ["gal-lectin", "PROTEIN", 4, 14], ["cysteine-rich portion", "PROTEIN", 25, 46], ["170 kDa lectin subunit", "PROTEIN", 54, 76], ["IgG", "PROTEIN", 163, 166], ["IgA", "PROTEIN", 171, 174], ["anti-Gal", "PROTEIN", 175, 183], ["lectin antibodies", "PROTEIN", 184, 201], ["patients", "SPECIES", 112, 120], ["patients", "SPECIES", 236, 244], ["its cysteine-rich portion", "TREATMENT", 21, 46], ["the 170 kDa lectin subunit", "TREATMENT", 50, 76], ["serum", "TEST", 96, 101], ["amoebic liver abscess", "PROBLEM", 126, 147], ["IgG", "TEST", 163, 166], ["IgA anti-Gal", "TEST", 171, 183], ["lectin antibodies", "TEST", 184, 201], ["serum", "TEST", 217, 222], ["intestinal amoebiasis", "PROBLEM", 250, 271], ["gal", "ANATOMY_MODIFIER", 4, 7], ["amoebic", "OBSERVATION_MODIFIER", 126, 133], ["liver", "ANATOMY", 134, 139], ["abscess", "OBSERVATION", 140, 147], ["intestinal", "ANATOMY", 250, 260], ["amoebiasis", "OBSERVATION", 261, 271]]], ["Oral or nasal immunization of mice, gerbils, and nonhuman primates with the cystein-rich section of galactose-inhibitable lectin LC3 and cholera toxin as adjuvant induced high level of specific serum IgG and fecal IgA [12, 13] antibodies that inhibit in vitro E. histolytica adherence to CHO cells [14] .", [["Oral", "ANATOMY", 0, 4], ["nasal", "ANATOMY", 8, 13], ["serum", "ANATOMY", 194, 199], ["CHO cells", "ANATOMY", 288, 297], ["cystein", "CHEMICAL", 76, 83], ["galactose", "CHEMICAL", 100, 109], ["cholera toxin", "CHEMICAL", 137, 150], ["galactose", "CHEMICAL", 100, 109], ["Oral", "ORGANISM_SUBDIVISION", 0, 4], ["nasal", "ORGANISM_SUBDIVISION", 8, 13], ["mice", "ORGANISM", 30, 34], ["gerbils", "ORGANISM", 36, 43], ["nonhuman", "ORGANISM", 49, 57], ["primates", "ORGANISM", 58, 66], ["cystein", "SIMPLE_CHEMICAL", 76, 83], ["galactose", "SIMPLE_CHEMICAL", 100, 109], ["lectin LC3", "GENE_OR_GENE_PRODUCT", 122, 132], ["cholera toxin", "SIMPLE_CHEMICAL", 137, 150], ["serum", "ORGANISM_SUBSTANCE", 194, 199], ["IgG", "ORGANISM_SUBSTANCE", 200, 203], ["fecal", "ORGANISM_SUBSTANCE", 208, 213], ["IgA", "GENE_OR_GENE_PRODUCT", 214, 217], ["E. histolytica", "ORGANISM", 260, 274], ["CHO cells", "CELL", 288, 297], ["galactose-inhibitable lectin LC3", "PROTEIN", 100, 132], ["cholera toxin", "PROTEIN", 137, 150], ["serum IgG", "PROTEIN", 194, 203], ["fecal IgA [12, 13] antibodies", "PROTEIN", 208, 237], ["CHO cells", "CELL_LINE", 288, 297], ["mice", "SPECIES", 30, 34], ["gerbils", "SPECIES", 36, 43], ["E. histolytica", "SPECIES", 260, 274], ["mice", "SPECIES", 30, 34], ["gerbils", "SPECIES", 36, 43], ["E. histolytica", "SPECIES", 260, 274], ["Oral or nasal immunization of mice, gerbils", "TREATMENT", 0, 43], ["the cystein", "TREATMENT", 72, 83], ["galactose", "TEST", 100, 109], ["inhibitable lectin LC3", "TREATMENT", 110, 132], ["cholera toxin", "TREATMENT", 137, 150], ["adjuvant", "TREATMENT", 154, 162], ["specific serum IgG", "TEST", 185, 203], ["fecal IgA", "TEST", 208, 217], ["antibodies", "TEST", 227, 237], ["CHO cells", "PROBLEM", 288, 297], ["nasal", "ANATOMY", 8, 13], ["fecal", "ANATOMY", 208, 213]]], ["Moreover, intraperitoneal immunization of gerbils with the LC3 fragment with Titermax adjuvant elicited IgG antibodies that conferred 71% of protection against ALA [15] .", [["intraperitoneal", "ANATOMY", 10, 25], ["Titermax", "CHEMICAL", 77, 85], ["ALA", "CHEMICAL", 160, 163], ["ALA", "CHEMICAL", 160, 163], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 10, 25], ["gerbils", "ORGANISM", 42, 49], ["LC3", "GENE_OR_GENE_PRODUCT", 59, 62], ["Titermax", "SIMPLE_CHEMICAL", 77, 85], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 104, 118], ["ALA", "SIMPLE_CHEMICAL", 160, 163], ["LC3 fragment", "PROTEIN", 59, 71], ["IgG antibodies", "PROTEIN", 104, 118], ["gerbils", "SPECIES", 42, 49], ["intraperitoneal immunization of gerbils", "TREATMENT", 10, 49], ["the LC3 fragment", "PROBLEM", 55, 71], ["Titermax adjuvant", "TREATMENT", 77, 94], ["IgG antibodies", "TEST", 104, 118], ["intraperitoneal", "ANATOMY", 10, 25], ["LC3 fragment", "OBSERVATION", 59, 71]]], ["Recently, it was demonstrated that LC3 is one of the main targets of antibodies elicited by natural infection of female baboons with E. histolytica [16] .", [["infection", "DISEASE", 100, 109], ["LC3", "GENE_OR_GENE_PRODUCT", 35, 38], ["female baboons", "ORGANISM", 113, 127], ["E. histolytica", "ORGANISM", 133, 147], ["LC3", "PROTEIN", 35, 38], ["antibodies", "PROTEIN", 69, 79], ["E. histolytica", "SPECIES", 133, 147], ["E. histolytica", "SPECIES", 133, 147], ["LC3", "PROBLEM", 35, 38], ["antibodies", "PROBLEM", 69, 79], ["natural infection", "PROBLEM", 92, 109], ["E. histolytica", "PROBLEM", 133, 147], ["LC3", "OBSERVATION", 35, 38], ["main", "OBSERVATION_MODIFIER", 53, 57], ["natural", "OBSERVATION_MODIFIER", 92, 99], ["infection", "OBSERVATION", 100, 109]]], ["Thus, 73% and 46% of such animals showed serum anti-LC3 IgG and IgA antibodies, respectively, and 49% exhibited fecal anti-LC3 secretory IgA antibodies.", [["serum", "ANATOMY", 41, 46], ["animals", "ORGANISM", 26, 33], ["serum", "ORGANISM_SUBSTANCE", 41, 46], ["LC3", "GENE_OR_GENE_PRODUCT", 52, 55], ["IgA", "GENE_OR_GENE_PRODUCT", 64, 67], ["IgA", "GENE_OR_GENE_PRODUCT", 137, 140], ["serum anti", "PROTEIN", 41, 51], ["LC3 IgG", "PROTEIN", 52, 59], ["IgA antibodies", "PROTEIN", 64, 78], ["fecal anti-LC3 secretory IgA antibodies", "PROTEIN", 112, 151], ["such animals", "TEST", 21, 33], ["serum anti", "TEST", 41, 51], ["LC3 IgG", "TEST", 52, 59], ["IgA antibodies", "TEST", 64, 78], ["fecal anti-LC3 secretory IgA antibodies", "PROBLEM", 112, 151], ["IgA antibodies", "OBSERVATION", 137, 151]]], ["Noteworthy, the specificity of recognition of epitopes in LC3 and the native Gal-lectin by the infected baboons was similar to the specificity of recognition of human asymptomatic subjects and ALA patients [16] .IntroductionAlthough promising results have been obtained in protection assays against amoebiasis using various experimental models such as mice, hamsters, and gerbils, the use of these strategies to protect humans in the future is hampered by the use of adjuvants that are potentially toxic and proinflammatory to mammals, such as bacterial toxins or oil-based adjuvants.", [["oil", "ANATOMY", 564, 567], ["Gal-lectin", "CHEMICAL", 77, 87], ["ALA", "CHEMICAL", 193, 196], ["amoebiasis", "DISEASE", 299, 309], ["ALA", "CHEMICAL", 193, 196], ["LC3", "GENE_OR_GENE_PRODUCT", 58, 61], ["Gal-lectin", "GENE_OR_GENE_PRODUCT", 77, 87], ["baboons", "ORGANISM", 104, 111], ["human", "ORGANISM", 161, 166], ["patients", "ORGANISM", 197, 205], ["mice", "ORGANISM", 352, 356], ["hamsters", "ORGANISM", 358, 366], ["gerbils", "ORGANISM", 372, 379], ["humans", "ORGANISM", 420, 426], ["oil", "SIMPLE_CHEMICAL", 564, 567], ["epitopes", "PROTEIN", 46, 54], ["LC3", "PROTEIN", 58, 61], ["native Gal-lectin", "PROTEIN", 70, 87], ["human", "SPECIES", 161, 166], ["patients", "SPECIES", 197, 205], ["mice", "SPECIES", 352, 356], ["hamsters", "SPECIES", 358, 366], ["humans", "SPECIES", 420, 426], ["human", "SPECIES", 161, 166], ["mice", "SPECIES", 352, 356], ["hamsters", "SPECIES", 358, 366], ["gerbils", "SPECIES", 372, 379], ["humans", "SPECIES", 420, 426], ["epitopes in LC3", "PROBLEM", 46, 61], ["human asymptomatic subjects", "PROBLEM", 161, 188], ["amoebiasis", "PROBLEM", 299, 309], ["these strategies", "TREATMENT", 392, 408], ["adjuvants", "TREATMENT", 467, 476], ["bacterial toxins", "PROBLEM", 544, 560], ["oil-based adjuvants", "TREATMENT", 564, 583], ["infected", "OBSERVATION", 95, 103]]], ["In a previous report, we proposed the use of viral vectors such as the baculovirus as a strategy for the delivery of amoebic antigens in studies of protection [17] .", [["amoebic", "DISEASE", 117, 124], ["baculovirus", "ORGANISM", 71, 82], ["amoebic antigens", "PROTEIN", 117, 133], ["baculovirus", "SPECIES", 71, 82], ["viral vectors", "TREATMENT", 45, 58], ["the baculovirus", "TREATMENT", 67, 82], ["a strategy", "TREATMENT", 86, 96], ["amoebic antigens", "PROBLEM", 117, 133]]], ["Baculoviruses are insect viruses capable of infecting mammalian cells, but not of replicating in them.", [["cells", "ANATOMY", 64, 69], ["Baculoviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["mammalian cells", "CELL", 54, 69], ["mammalian cells", "CELL_TYPE", 54, 69], ["Baculoviruses", "TREATMENT", 0, 13], ["infecting mammalian cells", "PROBLEM", 44, 69], ["infecting mammalian cells", "OBSERVATION", 44, 69]]], ["The most promising is Autographa californica, an envelope and double-stranded DNA nucleopolyhedrovirus that can drive the expression of foreign genes in mammalian cells without causing cytotoxic effects [18] .", [["cells", "ANATOMY", 163, 168], ["Autographa californica", "ORGANISM", 22, 44], ["DNA", "CELLULAR_COMPONENT", 78, 81], ["mammalian cells", "CELL", 153, 168], ["envelope and double-stranded DNA nucleopolyhedrovirus", "DNA", 49, 102], ["foreign genes", "DNA", 136, 149], ["mammalian cells", "CELL_TYPE", 153, 168], ["Autographa californica", "SPECIES", 22, 44], ["Autographa californica", "SPECIES", 22, 44], ["nucleopolyhedrovirus", "SPECIES", 82, 102], ["Autographa californica", "TREATMENT", 22, 44], ["an envelope", "PROBLEM", 46, 57], ["double-stranded DNA nucleopolyhedrovirus", "TREATMENT", 62, 102], ["foreign genes in mammalian cells", "PROBLEM", 136, 168], ["cytotoxic effects", "PROBLEM", 185, 202], ["Autographa californica", "OBSERVATION", 22, 44], ["foreign genes", "OBSERVATION", 136, 149]]], ["This virus has the ability to transduce a wide range of mammalian cells, including liver and kidney cells, and therefore it has been proposed as a delivery vector for human gene therapy, mainly as oncolytic agent.", [["cells", "ANATOMY", 66, 71], ["liver", "ANATOMY", 83, 88], ["kidney cells", "ANATOMY", 93, 105], ["mammalian cells", "CELL", 56, 71], ["liver", "ORGAN", 83, 88], ["kidney cells", "CELL", 93, 105], ["human", "ORGANISM", 167, 172], ["mammalian cells", "CELL_TYPE", 56, 71], ["liver and kidney cells", "CELL_TYPE", 83, 105], ["human", "SPECIES", 167, 172], ["human", "SPECIES", 167, 172], ["This virus", "PROBLEM", 0, 10], ["liver and kidney cells", "PROBLEM", 83, 105], ["a delivery vector", "TREATMENT", 145, 162], ["human gene therapy", "TREATMENT", 167, 185], ["oncolytic agent", "TREATMENT", 197, 212], ["mammalian cells", "OBSERVATION", 56, 71], ["liver", "ANATOMY", 83, 88], ["kidney", "ANATOMY", 93, 99], ["cells", "OBSERVATION", 100, 105]]], ["In this sense, A. californica has been proposed as a tool for targeting and transferring therapeutic genes into carcinoma cells from patients with prostate [19] , colorectal [20] , and lung [21] cancer as well as ameliorating the collateral ischaemia in organ transplantation [22] .", [["carcinoma cells", "ANATOMY", 112, 127], ["prostate", "ANATOMY", 147, 155], ["colorectal", "ANATOMY", 163, 173], ["lung [21] cancer", "ANATOMY", 185, 201], ["collateral", "ANATOMY", 230, 240], ["organ", "ANATOMY", 254, 259], ["carcinoma", "DISEASE", 112, 121], ["lung [21] cancer", "DISEASE", 185, 201], ["collateral ischaemia", "DISEASE", 230, 250], ["A. californica", "ORGANISM", 15, 29], ["carcinoma cells", "CELL", 112, 127], ["patients", "ORGANISM", 133, 141], ["prostate", "CANCER", 147, 155], ["colorectal", "MULTI-TISSUE_STRUCTURE", 163, 173], ["lung [21] cancer", "CANCER", 185, 201], ["collateral", "MULTI-TISSUE_STRUCTURE", 230, 240], ["organ", "ORGAN", 254, 259], ["therapeutic genes", "DNA", 89, 106], ["carcinoma cells", "CELL_TYPE", 112, 127], ["A. californica", "SPECIES", 15, 29], ["patients", "SPECIES", 133, 141], ["A. californica", "SPECIES", 15, 29], ["carcinoma cells", "PROBLEM", 112, 127], ["prostate", "TEST", 147, 155], ["lung [21] cancer", "PROBLEM", 185, 201], ["the collateral ischaemia", "PROBLEM", 226, 250], ["organ transplantation", "TREATMENT", 254, 275], ["carcinoma", "OBSERVATION", 112, 121], ["prostate", "ANATOMY", 147, 155], ["lung", "ANATOMY", 185, 189], ["cancer", "OBSERVATION", 195, 201], ["collateral", "OBSERVATION_MODIFIER", 230, 240], ["ischaemia", "OBSERVATION", 241, 250], ["organ", "ANATOMY", 254, 259], ["transplantation", "OBSERVATION", 260, 275]]], ["Noteworthy, from 27 nonhuman virus species that are in preclinical studies, A. californica was classified in the category of \"negligible\" regarding the relative environmental risk [18] , suggesting that its use in human for any medical purpose, including gene therapy and vaccines, is safe.", [["A. californica", "ORGANISM", 76, 90], ["human", "ORGANISM", 214, 219], ["A. californica", "SPECIES", 76, 90], ["human", "SPECIES", 214, 219], ["A. californica", "SPECIES", 76, 90], ["human", "SPECIES", 214, 219], ["nonhuman virus species", "PROBLEM", 20, 42], ["gene therapy", "TREATMENT", 255, 267], ["vaccines", "TREATMENT", 272, 280]]], ["As vaccine delivery strategy, the baculovirus A. californica has the advantage of priming the immune response by itself, innate and adaptive as well as humoral and cellular [23] , preventing the need for adjuvants with potential adverse effects such as bacterial toxins and oil-based formula.", [["cellular", "ANATOMY", 164, 172], ["baculovirus", "ORGANISM", 34, 45], ["A. californica", "ORGANISM", 46, 60], ["cellular", "CELL", 164, 172], ["oil", "SIMPLE_CHEMICAL", 274, 277], ["A. californica", "SPECIES", 46, 60], ["baculovirus", "SPECIES", 34, 45], ["A. californica", "SPECIES", 46, 60], ["vaccine delivery strategy", "TREATMENT", 3, 28], ["the baculovirus A. californica", "TREATMENT", 30, 60], ["adjuvants", "TREATMENT", 204, 213], ["potential adverse effects", "PROBLEM", 219, 244], ["bacterial toxins", "TREATMENT", 253, 269]]], ["Thus, baculovirus displaying target antigens on their surface and/or driving the expression of them under the control of a cytomegalovirus promoter has been highly efficient in inducing immune responses that confer protection against viral and parasitic infections in experimental models [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] .IntroductionIn a previous report, we described the potential of an A. californica nucleopolyhedrovirus (AcNPV) system driving the expression of E. histolytica Gal-lectin LC3 fragment of conferring sterile or partial protection against ALA in 79% of orally and 21% of nasally immunized hamsters.", [["surface", "ANATOMY", 54, 61], ["orally", "ANATOMY", 598, 604], ["viral and parasitic infections", "DISEASE", 234, 264], ["ALA", "CHEMICAL", 584, 587], ["[24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34]", "CHEMICAL", 288, 342], ["ALA", "CHEMICAL", 584, 587], ["baculovirus", "ORGANISM", 6, 17], ["surface", "CELLULAR_COMPONENT", 54, 61], ["cytomegalovirus", "ORGANISM", 123, 138], ["[24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35]", "SIMPLE_CHEMICAL", 288, 347], ["A. californica", "ORGANISM", 416, 430], ["nucleopolyhedrovirus", "ORGANISM", 431, 451], ["AcNPV", "ORGANISM", 453, 458], ["E. histolytica", "ORGANISM", 493, 507], ["Gal-lectin LC3", "GENE_OR_GENE_PRODUCT", 508, 522], ["ALA", "SIMPLE_CHEMICAL", 584, 587], ["hamsters", "ORGANISM", 634, 642], ["cytomegalovirus promoter", "DNA", 123, 147], ["E. histolytica Gal-lectin LC3 fragment", "PROTEIN", 493, 531], ["A. californica nucleopolyhedrovirus", "SPECIES", 416, 451], ["E. histolytica", "SPECIES", 493, 507], ["hamsters", "SPECIES", 634, 642], ["baculovirus", "SPECIES", 6, 17], ["A. californica nucleopolyhedrovirus", "SPECIES", 416, 451], ["E. histolytica", "SPECIES", 493, 507], ["hamsters", "SPECIES", 634, 642], ["baculovirus", "TREATMENT", 6, 17], ["a cytomegalovirus promoter", "TREATMENT", 121, 147], ["viral and parasitic infections", "PROBLEM", 234, 264], ["experimental models", "TEST", 268, 287], ["an A. californica nucleopolyhedrovirus (AcNPV) system", "TREATMENT", 413, 466], ["ALA", "TEST", 584, 587], ["nasally immunized hamsters", "TREATMENT", 616, 642], ["parasitic", "OBSERVATION_MODIFIER", 244, 253], ["infections", "OBSERVATION", 254, 264], ["californica nucleopolyhedrovirus", "OBSERVATION", 419, 451], ["LC3 fragment", "OBSERVATION", 519, 531]]], ["Although the protection was associated with the development of an antiamoebic cellular immune response measured in spleen, the underlying cytokines and cell populations responsible were not identified.", [["cellular", "ANATOMY", 78, 86], ["spleen", "ANATOMY", 115, 121], ["cell", "ANATOMY", 152, 156], ["cellular", "CELL", 78, 86], ["spleen", "ORGAN", 115, 121], ["cell populations", "CELL", 152, 168], ["cytokines", "PROTEIN", 138, 147], ["an antiamoebic cellular immune response", "PROBLEM", 63, 102], ["the underlying cytokines and cell populations", "PROBLEM", 123, 168], ["cellular immune response", "OBSERVATION", 78, 102], ["spleen", "ANATOMY", 115, 121], ["cytokines", "OBSERVATION", 138, 147], ["cell populations", "OBSERVATION", 152, 168]]], ["Herein, we complement the previous study by evaluating the potential of an intramuscular immunization with the AcNPV/CMV/Gal-lectin LC3 system for conferring protection against ALA in hamsters, determining whether this route of immunization confer a greater level protection than the mucosal delivery and evaluating in the liver the locally produced cytokines and cell populations responsible for protection.Cells and Cultures.Axenic HM1: IMSS trophozoites were maintained in TYI-S-33 medium supplemented with 15% of adult bovine serum (Biofluids International Inc., MD, USA) and 3% of Diamond's vitamin mix (JRH Biosciences, Kansas, USA).", [["intramuscular", "ANATOMY", 75, 88], ["mucosal", "ANATOMY", 284, 291], ["liver", "ANATOMY", 323, 328], ["cell", "ANATOMY", 364, 368], ["Cells", "ANATOMY", 408, 413], ["Cultures", "ANATOMY", 418, 426], ["trophozoites", "ANATOMY", 444, 456], ["serum", "ANATOMY", 530, 535], ["ALA", "CHEMICAL", 177, 180], ["TYI-S-33", "CHEMICAL", 476, 484], ["vitamin mix", "CHEMICAL", 596, 607], ["ALA", "CHEMICAL", 177, 180], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 75, 88], ["AcNPV", "GENE_OR_GENE_PRODUCT", 111, 116], ["CMV", "ORGANISM", 117, 120], ["Gal-lectin", "GENE_OR_GENE_PRODUCT", 121, 131], ["LC3", "GENE_OR_GENE_PRODUCT", 132, 135], ["ALA", "SIMPLE_CHEMICAL", 177, 180], ["hamsters", "ORGANISM", 184, 192], ["mucosal", "MULTI-TISSUE_STRUCTURE", 284, 291], ["liver", "ORGAN", 323, 328], ["cell populations", "CELL", 364, 380], ["Cells", "CELL", 408, 413], ["Cultures", "CELL", 418, 426], ["IMSS trophozoites", "CELL", 439, 456], ["TYI-S-33", "CELL", 476, 484], ["bovine", "ORGANISM", 523, 529], ["serum", "ORGANISM_SUBSTANCE", 530, 535], ["vitamin", "SIMPLE_CHEMICAL", 596, 603], ["AcNPV", "PROTEIN", 111, 116], ["LC3", "PROTEIN", 132, 135], ["cytokines", "PROTEIN", 350, 359], ["Axenic HM1: IMSS trophozoites", "CELL_LINE", 427, 456], ["hamsters", "SPECIES", 184, 192], ["bovine", "SPECIES", 523, 529], ["hamsters", "SPECIES", 184, 192], ["bovine", "SPECIES", 523, 529], ["the previous study", "TEST", 22, 40], ["an intramuscular immunization", "TREATMENT", 72, 101], ["the AcNPV", "TREATMENT", 107, 116], ["Gal-lectin LC3 system", "TREATMENT", 121, 142], ["ALA in hamsters", "TREATMENT", 177, 192], ["immunization", "TREATMENT", 228, 240], ["a greater level protection", "TREATMENT", 248, 274], ["the mucosal delivery", "TREATMENT", 280, 300], ["cell populations", "TREATMENT", 364, 380], ["Cells", "TEST", 408, 413], ["Cultures", "TEST", 418, 426], ["IMSS trophozoites", "TREATMENT", 439, 456], ["adult bovine serum", "TREATMENT", 517, 535], ["Diamond's vitamin mix", "TREATMENT", 586, 607], ["liver", "ANATOMY", 323, 328], ["cytokines", "OBSERVATION", 350, 359], ["cell populations", "OBSERVATION", 364, 380]]], ["Trophozoites virulence was maintained through successive passages into hamster's liver.Cells and Cultures.sf9 insect cells (Spodoptera frugiperda) (Invitrogen, San Diego, CA) were cultivated as a suspension in Grace's medium (Invitrogen, USA) supplemented with 10% heat inactivated fetal bovine serum (Invitrogen, Carlsbad, CA), 1% penicillin/streptomycin (100 U/mL), and 0.1% pluronic F-68 (Invitrogen, USA).", [["hamster", "ANATOMY", 71, 78], ["liver", "ANATOMY", 81, 86], ["Cells", "ANATOMY", 87, 92], ["Cultures", "ANATOMY", 97, 105], ["cells", "ANATOMY", 117, 122], ["serum", "ANATOMY", 295, 300], ["penicillin", "CHEMICAL", 332, 342], ["streptomycin", "CHEMICAL", 343, 355], ["pluronic F-68", "CHEMICAL", 377, 390], ["penicillin", "CHEMICAL", 332, 342], ["streptomycin", "CHEMICAL", 343, 355], ["pluronic F-68", "CHEMICAL", 377, 390], ["hamster", "ORGANISM", 71, 78], ["liver", "ORGAN", 81, 86], ["Cells", "CELL", 87, 92], ["Cultures", "CELL", 97, 105], ["sf9 insect cells", "CELL", 106, 122], ["Spodoptera frugiperda", "ORGANISM", 124, 145], ["San Diego", "ORGANISM", 160, 169], ["bovine", "ORGANISM", 288, 294], ["serum", "ORGANISM_SUBSTANCE", 295, 300], ["Invitrogen", "SIMPLE_CHEMICAL", 302, 312], ["penicillin", "SIMPLE_CHEMICAL", 332, 342], ["streptomycin", "SIMPLE_CHEMICAL", 343, 355], ["pluronic F-68", "SIMPLE_CHEMICAL", 377, 390], ["sf9 insect cells", "CELL_LINE", 106, 122], ["hamster", "SPECIES", 71, 78], ["Spodoptera frugiperda", "SPECIES", 124, 145], ["bovine", "SPECIES", 288, 294], ["hamster", "SPECIES", 71, 78], ["Spodoptera frugiperda", "SPECIES", 124, 145], ["bovine", "SPECIES", 288, 294], ["Trophozoites virulence", "PROBLEM", 0, 22], ["Cells", "TEST", 87, 92], ["Cultures", "TEST", 97, 105], ["Grace's medium", "TREATMENT", 210, 224], ["fetal bovine serum", "TEST", 282, 300], ["Invitrogen", "TEST", 302, 312], ["Carlsbad", "TEST", 314, 322], ["CA", "TEST", 324, 326], ["penicillin", "TREATMENT", 332, 342], ["streptomycin", "TREATMENT", 343, 355], ["liver", "ANATOMY", 81, 86]]], ["AcNPV-LC3 baculovirus production was described in [17] .", [["AcNPV", "GENE_OR_GENE_PRODUCT", 0, 5], ["LC3", "GENE_OR_GENE_PRODUCT", 6, 9], ["AcNPV", "PROTEIN", 0, 5], ["LC3", "PROTEIN", 6, 9], ["baculovirus", "SPECIES", 10, 21], ["AcNPV", "TEST", 0, 5], ["LC3 baculovirus production", "PROBLEM", 6, 32], ["LC3 baculovirus", "OBSERVATION", 6, 21]]], ["Recombinant AcNPV-LC3 baculovirus was amplified by infecting sf9 insect cells at a multiplicity of infection (MOI) of 0.1 and purifying them from culture's supernatants 6 days after and concentrated by ultracentrifugation, resuspended in PBS and titered by using a plaque assay following the manufacturer's instructions (Invitrogen, USA).Immunization and Challenge Protocols.Male Syrian golden hamsters (Mesocricetus auratus) 4 to 6 weeks of age were maintained free of pathogens with water and food ad libitum.", [["cells", "ANATOMY", 72, 77], ["supernatants", "ANATOMY", 156, 168], ["plaque", "ANATOMY", 265, 271], ["infection", "DISEASE", 99, 108], ["AcNPV", "GENE_OR_GENE_PRODUCT", 12, 17], ["LC3", "GENE_OR_GENE_PRODUCT", 18, 21], ["sf9 insect cells", "CELL", 61, 77], ["Male", "ORGANISM", 375, 379], ["Syrian golden hamsters", "ORGANISM", 380, 402], ["Mesocricetus auratus", "ORGANISM", 404, 424], ["AcNPV", "PROTEIN", 12, 17], ["LC3", "PROTEIN", 18, 21], ["sf9 insect cells", "CELL_TYPE", 61, 77], ["Syrian golden hamsters", "SPECIES", 380, 402], ["Mesocricetus auratus", "SPECIES", 404, 424], ["baculovirus", "SPECIES", 22, 33], ["Syrian golden hamsters", "SPECIES", 380, 402], ["Mesocricetus auratus", "SPECIES", 404, 424], ["Recombinant AcNPV", "TREATMENT", 0, 17], ["LC3 baculovirus", "TREATMENT", 18, 33], ["infection", "PROBLEM", 99, 108], ["culture's supernatants", "TEST", 146, 168], ["Immunization", "TREATMENT", 338, 350], ["LC3 baculovirus", "OBSERVATION", 18, 33], ["infection", "OBSERVATION", 99, 108]]], ["Following a protocol approved by the Institutional Animal Care Committee, animals were divided in 2 groups of 20 hamsters (AcNPV-WT and AcNPV-LC3 groups) and 1 group of 10 hamsters (sham group).", [["hamsters", "ORGANISM", 113, 121], ["LC3", "GENE_OR_GENE_PRODUCT", 142, 145], ["hamsters", "ORGANISM", 172, 180], ["hamsters", "SPECIES", 172, 180], ["a protocol", "TREATMENT", 10, 20]]], ["Hamsters of groups AcNPV-WT and AcNPV-LC3 were intramuscularly immunized with three doses at two-week intervals with 1\u00d710 8 PFU of wild-type or LC3 recombinant baculovirus prepared in 20 L PBS, pH 7.4, respectively.", [["Hamsters", "ORGANISM", 0, 8], ["AcNPV-WT", "ORGANISM", 19, 27], ["AcNPV-LC3", "GENE_OR_GENE_PRODUCT", 32, 41], ["LC3", "GENE_OR_GENE_PRODUCT", 144, 147], ["baculovirus", "ORGANISM", 160, 171], ["LC3", "PROTEIN", 38, 41], ["LC3", "PROTEIN", 144, 147], ["Hamsters", "SPECIES", 0, 8], ["baculovirus", "SPECIES", 160, 171], ["AcNPV", "TEST", 19, 24], ["WT", "TEST", 25, 27], ["AcNPV-LC3", "TREATMENT", 32, 41], ["LC3 recombinant baculovirus", "TREATMENT", 144, 171], ["pH", "TEST", 194, 196]]], ["Sham group received 20 L of PBS by intramuscular route following the same protocol.", [["intramuscular", "ANATOMY", 35, 48], ["PBS", "TREATMENT", 28, 31], ["the same protocol", "TREATMENT", 65, 82]]], ["Two weeks after the last immunization, all animal were infected by intraportal route with virulent E. histolytica trophozoites.", [["trophozoites", "ANATOMY", 114, 126], ["E. histolytica", "ORGANISM", 99, 113], ["trophozoites", "CELL", 114, 126], ["E. histolytica", "SPECIES", 99, 113], ["E. histolytica", "SPECIES", 99, 113], ["the last immunization", "TREATMENT", 16, 37], ["virulent E. histolytica trophozoites", "PROBLEM", 90, 126], ["infected", "OBSERVATION", 55, 63], ["histolytica trophozoites", "OBSERVATION", 102, 126]]], ["In brief, hamsters were anesthetized with sodium pentobarbital (50 mg/kg; Anestesal, Pfizer), a laparatomy practiced in aseptic conditions, and 10 6 trophozoites in 100 L PBS were directly injected in the portal vein.", [["trophozoites", "ANATOMY", 149, 161], ["portal vein", "ANATOMY", 205, 216], ["sodium pentobarbital", "CHEMICAL", 42, 62], ["sodium pentobarbital", "CHEMICAL", 42, 62], ["hamsters", "ORGANISM", 10, 18], ["sodium", "SIMPLE_CHEMICAL", 42, 48], ["pentobarbital", "SIMPLE_CHEMICAL", 49, 62], ["trophozoites", "CELL", 149, 161], ["portal vein", "MULTI-TISSUE_STRUCTURE", 205, 216], ["hamsters", "SPECIES", 10, 18], ["hamsters", "SPECIES", 10, 18], ["sodium pentobarbital", "TREATMENT", 42, 62], ["a laparatomy", "TREATMENT", 94, 106], ["aseptic conditions", "TREATMENT", 120, 138], ["100 L PBS", "TREATMENT", 165, 174], ["laparatomy", "OBSERVATION", 96, 106], ["aseptic conditions", "OBSERVATION", 120, 138], ["portal vein", "ANATOMY", 205, 216]]], ["The site of injection was immediately obtruded by applying a gel foam pad, intestine carefully returned to the abdominal cavity, and the abdominal layers sutured with surgical staples (Reflex 9, USA).", [["intestine", "ANATOMY", 75, 84], ["abdominal cavity", "ANATOMY", 111, 127], ["abdominal layers", "ANATOMY", 137, 153], ["intestine", "ORGAN", 75, 84], ["abdominal cavity", "MULTI-TISSUE_STRUCTURE", 111, 127], ["abdominal layers", "TISSUE", 137, 153], ["injection", "TREATMENT", 12, 21], ["a gel foam pad", "TREATMENT", 59, 73], ["surgical staples", "TREATMENT", 167, 183], ["intestine", "ANATOMY", 75, 84], ["abdominal cavity", "ANATOMY", 111, 127], ["abdominal", "ANATOMY", 137, 146], ["layers", "ANATOMY_MODIFIER", 147, 153], ["surgical staples", "OBSERVATION", 167, 183]]], ["Blood samples were collected from all animals before treatment and after immunization prior to challenge.", [["Blood samples", "ANATOMY", 0, 13], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["Blood samples", "TEST", 0, 13], ["treatment", "TREATMENT", 53, 62], ["immunization", "TREATMENT", 73, 85]]], ["Sera were obtained by centrifugation and stored at \u221270 \u2218 C until use.2.3.ELISA. 96 well plates were coated overnight with 500 ng/ well of trophozoite's total extract in carbonate buffer, pH 9.6 at 4 \u2218 C. After blocking with 1% BSA-Tween 20, hamster's sera diluted in 1% BSA (1 : 50) were added to the wells and incubated 1 h at 37 \u2218 C. After extensive washings with PBS-Tween 20, a HRP-conjugated anti-hamster IgG antibody (Becton Dickinson, USA) was added to 1 : 1000 dilution and incubated for 1 h at 37 \u2218 C. The wells were washed and the antigen-antibody complexes were developed with OPD and read at 490 nm in a spectrophotometer.Cytokine Determination.Cytokine determination was performed in soluble liver extract from hamsters with commercially available mouse IFN , IL-12 p70, IL-4, and IL-10 ELISA MAX Standard kits (BioLegend) according to manufacturer's instruction (capture ELISA).", [["Sera", "ANATOMY", 0, 4], ["trophozoite", "ANATOMY", 138, 149], ["extract", "ANATOMY", 158, 165], ["sera", "ANATOMY", 251, 255], ["liver extract", "ANATOMY", 705, 718], ["carbonate", "CHEMICAL", 169, 178], ["BSA-Tween 20", "CHEMICAL", 227, 239], ["BSA", "CHEMICAL", 270, 273], ["carbonate", "CHEMICAL", 169, 178], ["Tween 20", "CHEMICAL", 231, 239], ["Tween 20", "CHEMICAL", 370, 378], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["trophozoite", "CELL", 138, 149], ["carbonate", "SIMPLE_CHEMICAL", 169, 178], ["BSA-Tween 20", "SIMPLE_CHEMICAL", 227, 239], ["hamster", "ORGANISM", 241, 248], ["sera", "ORGANISM_SUBSTANCE", 251, 255], ["BSA", "SIMPLE_CHEMICAL", 270, 273], ["PBS-Tween 20", "SIMPLE_CHEMICAL", 366, 378], ["HRP", "SIMPLE_CHEMICAL", 382, 385], ["Cytokine", "GENE_OR_GENE_PRODUCT", 634, 642], ["liver", "ORGAN", 705, 710], ["extract", "ORGANISM_SUBSTANCE", 711, 718], ["hamsters", "ORGANISM", 724, 732], ["mouse", "ORGANISM", 761, 766], ["IL-12 p70", "GENE_OR_GENE_PRODUCT", 773, 782], ["IL-4", "GENE_OR_GENE_PRODUCT", 784, 788], ["IL-10", "GENE_OR_GENE_PRODUCT", 794, 799], ["HRP-conjugated anti-hamster IgG antibody", "PROTEIN", 382, 422], ["antigen-antibody complexes", "PROTEIN", 541, 567], ["Cytokine", "PROTEIN", 634, 642], ["Cytokine", "PROTEIN", 657, 665], ["IFN", "PROTEIN", 767, 770], ["p70", "PROTEIN", 779, 782], ["IL", "PROTEIN", 784, 786], ["IL", "PROTEIN", 794, 796], ["BioLegend", "PROTEIN", 825, 834], ["hamster", "SPECIES", 241, 248], ["hamsters", "SPECIES", 724, 732], ["mouse", "SPECIES", 761, 766], ["hamster", "SPECIES", 241, 248], ["hamsters", "SPECIES", 724, 732], ["mouse", "SPECIES", 761, 766], ["Sera", "TEST", 0, 4], ["trophozoite", "TREATMENT", 138, 149], ["carbonate buffer", "TREATMENT", 169, 185], ["pH", "TEST", 187, 189], ["hamster's sera", "TREATMENT", 241, 255], ["extensive washings", "TEST", 342, 360], ["PBS", "TEST", 366, 369], ["a HRP", "TEST", 380, 385], ["the antigen-antibody complexes", "TEST", 537, 567], ["a spectrophotometer", "TEST", 614, 633], ["Cytokine Determination", "TEST", 634, 656], ["Cytokine determination", "TEST", 657, 679], ["IL", "TEST", 773, 775], ["IL", "TEST", 784, 786], ["IL", "TREATMENT", 794, 796], ["ELISA MAX Standard kits (BioLegend)", "TREATMENT", 800, 835], ["liver", "ANATOMY", 705, 710]]], ["Each cytokine assay was performed in triplicate each time.", [["cytokine", "PROTEIN", 5, 13], ["Each cytokine assay", "TEST", 0, 19]]], ["In brief, liver extracts were obtained by sonication (three times, 30 sec each on ice) of tissue fragments, containing or not ALA, in the diluent solution provided with the kit in the presence of complete protease inhibitor cocktail (Roche).", [["liver extracts", "ANATOMY", 10, 24], ["tissue fragments", "ANATOMY", 90, 106], ["ALA", "CHEMICAL", 126, 129], ["ALA", "CHEMICAL", 126, 129], ["liver extracts", "ORGANISM_SUBSTANCE", 10, 24], ["tissue", "TISSUE", 90, 96], ["ALA", "SIMPLE_CHEMICAL", 126, 129], ["tissue fragments", "PROBLEM", 90, 106], ["the diluent solution", "TREATMENT", 134, 154], ["complete protease inhibitor cocktail", "TREATMENT", 196, 232], ["liver", "ANATOMY", 10, 15], ["tissue", "ANATOMY", 90, 96], ["fragments", "OBSERVATION", 97, 106]]], ["Extracts were centrifuged at 5000 rpm for 10 min at 4 \u2218 C and the soluble fraction, once determining protein concentration by the Lowry method, stored at \u221220 \u2218 C until use.", [["Extracts", "ANATOMY", 0, 8], ["Extracts", "ORGANISM_SUBSTANCE", 0, 8], ["the soluble fraction", "TREATMENT", 62, 82]]], ["For cytokine determination, each well was added with 5 g of extract in 100 L of diluent solution and incubated for 2 h at room temperature.", [["extract", "ANATOMY", 60, 67], ["cytokine", "PROTEIN", 4, 12], ["cytokine determination", "TEST", 4, 26], ["extract", "TREATMENT", 60, 67], ["diluent solution", "TREATMENT", 80, 96]]], ["Secondary antibodies were used 1 : 200 dilution in diluent solution for 1 h at room temperature and the immune complex developed using Avidine-HRP/TMB substrate and reading at 650 nm in a spectrophotometer.Spleen Cells Proliferation by Flow Cytometry.After sacrifice at 7 days after challenge, hamster's spleens were removed and its cellular fraction obtained by perfusion in 2 mL supplemented RPMI medium.", [["Spleen Cells", "ANATOMY", 206, 218], ["hamster", "ANATOMY", 294, 301], ["spleens", "ANATOMY", 304, 311], ["cellular", "ANATOMY", 333, 341], ["Avidine", "CHEMICAL", 135, 142], ["Avidine", "CHEMICAL", 135, 142], ["TMB", "CHEMICAL", 147, 150], ["Avidine-HRP", "SIMPLE_CHEMICAL", 135, 146], ["TMB", "SIMPLE_CHEMICAL", 147, 150], ["Spleen Cells", "CELL", 206, 218], ["hamster", "ORGANISM", 294, 301], ["spleens", "ORGAN", 304, 311], ["cellular", "CELL", 333, 341], ["antibodies", "PROTEIN", 10, 20], ["immune complex", "PROTEIN", 104, 118], ["HRP", "PROTEIN", 143, 146], ["hamster", "SPECIES", 294, 301], ["hamster", "SPECIES", 294, 301], ["Secondary antibodies", "PROBLEM", 0, 20], ["Avidine-HRP/TMB substrate", "TREATMENT", 135, 160], ["Flow Cytometry", "TEST", 236, 250], ["hamster's spleens", "TREATMENT", 294, 311], ["its cellular fraction", "TEST", 329, 350], ["Cells Proliferation", "OBSERVATION", 213, 232], ["Flow Cytometry", "OBSERVATION", 236, 250], ["spleens", "ANATOMY", 304, 311]]], ["The cells were incubated with hemolysis solution and washed by centrifugation with RPMI media.", [["cells", "ANATOMY", 4, 9], ["hemolysis", "DISEASE", 30, 39], ["cells", "CELL", 4, 9], ["hemolysis solution", "TREATMENT", 30, 48], ["RPMI media", "TREATMENT", 83, 93]]], ["After the erythrocytes lysis, 1 \u00d7 10 6 lymphocytes were gating with 1 mL of PBS/0.1% BSA solution and incubated with 5 mM/mL of CFSE (CellTrace CFSE Cell Proliferation Kit C34554, INVITROGEN) during 10 min at 37 \u2218 C. After the incubation, the cells were washed in RPMI media and cultivated in 96-well plates at 37 \u2218 C with 5% CO 2 and 95% humidity for 72 h in RPMI medium alone or stimulated with concanavalin A (1 g/well), or amebic total extract (50 g/well).", [["erythrocytes", "ANATOMY", 10, 22], ["lymphocytes", "ANATOMY", 39, 50], ["Cell", "ANATOMY", 149, 153], ["cells", "ANATOMY", 243, 248], ["extract", "ANATOMY", 440, 447], ["CFSE", "CHEMICAL", 128, 132], ["concanavalin A", "CHEMICAL", 397, 411], ["amebic", "DISEASE", 427, 433], ["CFSE", "CHEMICAL", 128, 132], ["CFSE", "CHEMICAL", 144, 148], ["CO", "CHEMICAL", 326, 328], ["erythrocytes", "CELL", 10, 22], ["lymphocytes", "CELL", 39, 50], ["BSA", "SIMPLE_CHEMICAL", 85, 88], ["CFSE", "SIMPLE_CHEMICAL", 128, 132], ["cells", "CELL", 243, 248], ["concanavalin A", "SIMPLE_CHEMICAL", 397, 411], ["erythrocytes", "CELL_TYPE", 10, 22], ["lymphocytes", "CELL_TYPE", 39, 50], ["the erythrocytes lysis", "TEST", 6, 28], ["lymphocytes", "TEST", 39, 50], ["PBS/0.1% BSA solution", "TREATMENT", 76, 97], ["CFSE (CellTrace CFSE Cell Proliferation", "TREATMENT", 128, 167], ["Kit", "TEST", 168, 171], ["the incubation", "TREATMENT", 223, 237], ["the cells", "TREATMENT", 239, 248], ["RPMI media", "TREATMENT", 264, 274], ["concanavalin A", "TREATMENT", 397, 411], ["amebic total extract", "TREATMENT", 427, 447], ["erythrocytes lysis", "OBSERVATION", 10, 28]]], ["Finally, the lymphocytes were harvested and fixed with 3.7% of formaldehyde solution.", [["lymphocytes", "ANATOMY", 13, 24], ["formaldehyde", "CHEMICAL", 63, 75], ["formaldehyde", "CHEMICAL", 63, 75], ["lymphocytes", "CELL", 13, 24], ["formaldehyde", "SIMPLE_CHEMICAL", 63, 75], ["lymphocytes", "CELL_TYPE", 13, 24], ["formaldehyde solution", "TREATMENT", 63, 84], ["lymphocytes", "ANATOMY", 13, 24], ["harvested", "OBSERVATION_MODIFIER", 30, 39]]], ["All the treatments were carried out by triplicate for each animal.", [["All the treatments", "TREATMENT", 0, 18]]], ["Samples were analyzed on a FACSCanto II flow cytometer (BD) on a minimum of 20,000 events using the DIVA software.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["a FACSCanto II flow cytometer", "TREATMENT", 25, 54], ["the DIVA software", "TREATMENT", 96, 113]]], ["The computational analysis was carried out in FACSDiva Software Version 6.", [["The computational analysis", "TEST", 0, 26]]], ["The statistical analysis was performed with Batch Analysis Report.", [["The statistical analysis", "TEST", 0, 24]]], ["Proliferation data from each experimental group was obtained by pooling the means of the triplicate for each animal and is presented as mean \u00b1 SD.Spleen Cells Proliferation by Flow Cytometry.2.6.", [["Spleen Cells", "ANATOMY", 146, 158], ["Spleen Cells", "CELL", 146, 158], ["Proliferation data", "TEST", 0, 18], ["Flow Cytometry", "TEST", 176, 190], ["Cells Proliferation", "OBSERVATION", 153, 172], ["Flow Cytometry", "OBSERVATION", 176, 190]]], ["Assay for Liver Function.", [["Liver", "ANATOMY", 10, 15], ["Liver", "ORGAN", 10, 15], ["Assay", "TEST", 0, 5], ["Liver Function", "TEST", 10, 24], ["Liver", "ANATOMY", 10, 15]]], ["Blood samples were obtained from hamsters at day of sacrifice.", [["Blood samples", "ANATOMY", 0, 13], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["hamsters", "ORGANISM", 33, 41], ["Blood samples", "TEST", 0, 13]]], ["Serum was separated from the blood samples by centrifugation at 5000 rpm for 10 min at room temperature.", [["Serum", "ANATOMY", 0, 5], ["blood samples", "ANATOMY", 29, 42], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["blood samples", "ORGANISM_SUBSTANCE", 29, 42], ["Serum", "TEST", 0, 5], ["the blood samples", "TEST", 25, 42]]], ["The serum marker of liver function alanine amino transferase (ALT) was determined by the method EAGLE-UV at Department of Pathology, Faculty of Veterinary Medicine, UNAM.Statistical Analysis.The comparison of the infection rates was done using Fisher's exact test.", [["serum", "ANATOMY", 4, 9], ["liver", "ANATOMY", 20, 25], ["alanine", "CHEMICAL", 35, 42], ["infection", "DISEASE", 213, 222], ["alanine", "CHEMICAL", 35, 42], ["amino", "CHEMICAL", 43, 48], ["serum", "ORGANISM_SUBSTANCE", 4, 9], ["liver", "ORGAN", 20, 25], ["alanine amino transferase", "GENE_OR_GENE_PRODUCT", 35, 60], ["ALT", "SIMPLE_CHEMICAL", 62, 65], ["alanine amino transferase", "PROTEIN", 35, 60], ["ALT", "PROTEIN", 62, 65], ["The serum marker", "TEST", 0, 16], ["liver function alanine amino transferase", "TEST", 20, 60], ["ALT", "TEST", 62, 65], ["Statistical Analysis", "TEST", 170, 190], ["the infection rates", "PROBLEM", 209, 228], ["Fisher's exact test", "TEST", 244, 263], ["liver", "ANATOMY", 20, 25], ["infection", "OBSERVATION", 213, 222]]], ["The Kruskal-Wallis test was used to compare antibody and proliferation of lymphocytes between groups.", [["lymphocytes", "ANATOMY", 74, 85], ["lymphocytes", "CELL", 74, 85], ["lymphocytes", "CELL_TYPE", 74, 85], ["The Kruskal-Wallis test", "TEST", 0, 23], ["lymphocytes", "OBSERVATION", 74, 85]]], ["A value < 0.05 was considered statistically significant in these analyses.", [["A value", "TEST", 0, 7], ["these analyses", "TEST", 59, 73]]], ["All statistical analyses were performed using SPSS statistical software version 19.0.Intramuscular Immunization with AcNPV-LC3 Inhibits the Development of ALA in Hamsters.In order to evaluate the potential of recombinant baculovirus driving the expression of the amoebic Gal-lectin LC3 fragment of protecting against ALA, hamsters were intramuscularly immunized with the viral particles and intraportally challenged with virulent E. histolytica trophozoites.", [["Intramuscular", "ANATOMY", 85, 98], ["trophozoites", "ANATOMY", 445, 457], ["ALA", "CHEMICAL", 155, 158], ["ALA", "CHEMICAL", 317, 320], ["ALA", "CHEMICAL", 155, 158], ["ALA", "CHEMICAL", 317, 320], ["AcNPV-LC3", "GENE_OR_GENE_PRODUCT", 117, 126], ["ALA", "SIMPLE_CHEMICAL", 155, 158], ["Hamsters", "ORGANISM", 162, 170], ["baculovirus", "ORGANISM", 221, 232], ["LC3", "GENE_OR_GENE_PRODUCT", 282, 285], ["ALA", "SIMPLE_CHEMICAL", 317, 320], ["hamsters", "ORGANISM", 322, 330], ["E. histolytica", "ORGANISM", 430, 444], ["trophozoites", "ORGANISM", 445, 457], ["AcNPV", "PROTEIN", 117, 122], ["LC3", "PROTEIN", 123, 126], ["amoebic Gal-lectin LC3 fragment", "PROTEIN", 263, 294], ["Hamsters", "SPECIES", 162, 170], ["hamsters", "SPECIES", 322, 330], ["E. histolytica", "SPECIES", 430, 444], ["Hamsters", "SPECIES", 162, 170], ["baculovirus", "SPECIES", 221, 232], ["hamsters", "SPECIES", 322, 330], ["E. histolytica", "SPECIES", 430, 444], ["All statistical analyses", "TEST", 0, 24], ["SPSS statistical software version", "TEST", 46, 79], ["Intramuscular Immunization", "TREATMENT", 85, 111], ["AcNPV", "TREATMENT", 117, 122], ["ALA in Hamsters", "TREATMENT", 155, 170], ["recombinant baculovirus", "TREATMENT", 209, 232], ["the amoebic Gal-lectin LC3 fragment", "PROBLEM", 259, 294], ["ALA, hamsters", "TREATMENT", 317, 330], ["the viral particles", "TREATMENT", 367, 386], ["virulent E. histolytica trophozoites", "TREATMENT", 421, 457], ["ALA", "OBSERVATION_MODIFIER", 155, 158], ["amoebic", "OBSERVATION_MODIFIER", 263, 270], ["LC3 fragment", "OBSERVATION", 282, 294], ["histolytica trophozoites", "OBSERVATION", 433, 457]]], ["Description on how the recombinant baculoviruses were obtained and evaluated for driving the expression of the Gal-lectin LC3 fragment was previously reported [17] .Intramuscular Immunization with AcNPV-LC3 Inhibits the Development of ALA in Hamsters.A comparative macroscopic description of livers showed variable grades of ALA development (Figure 1 ).", [["Intramuscular", "ANATOMY", 165, 178], ["livers", "ANATOMY", 292, 298], ["ALA", "CHEMICAL", 235, 238], ["ALA", "CHEMICAL", 325, 328], ["ALA", "CHEMICAL", 235, 238], ["ALA", "CHEMICAL", 325, 328], ["baculoviruses", "ORGANISM", 35, 48], ["Gal-lectin LC3", "GENE_OR_GENE_PRODUCT", 111, 125], ["AcNPV-LC3", "GENE_OR_GENE_PRODUCT", 197, 206], ["ALA", "SIMPLE_CHEMICAL", 235, 238], ["Hamsters", "ORGANISM", 242, 250], ["livers", "ORGAN", 292, 298], ["ALA", "SIMPLE_CHEMICAL", 325, 328], ["recombinant baculoviruses", "PROTEIN", 23, 48], ["Gal-lectin LC3 fragment", "PROTEIN", 111, 134], ["AcNPV", "PROTEIN", 197, 202], ["LC3", "PROTEIN", 203, 206], ["Hamsters", "SPECIES", 242, 250], ["Hamsters", "SPECIES", 242, 250], ["the recombinant baculoviruses", "TREATMENT", 19, 48], ["the Gal-lectin LC3 fragment", "PROBLEM", 107, 134], ["Intramuscular Immunization", "TREATMENT", 165, 191], ["AcNPV", "TREATMENT", 197, 202], ["ALA in Hamsters", "TREATMENT", 235, 250], ["A comparative macroscopic description of livers", "TEST", 251, 298], ["variable grades of ALA development", "PROBLEM", 306, 340], ["LC3 fragment", "OBSERVATION", 122, 134], ["ALA", "OBSERVATION_MODIFIER", 235, 238], ["livers", "ANATOMY", 292, 298], ["variable", "OBSERVATION_MODIFIER", 306, 314], ["ALA", "OBSERVATION_MODIFIER", 325, 328]]], ["Massive development of ALA extended throughout the liver was observed in 8 out of 10 (80%) nonimmunized but challenged hamsters (Sham group; Figures 1(e) and 1(f) and Table 1 ).", [["liver", "ANATOMY", 51, 56], ["ALA", "CHEMICAL", 23, 26], ["ALA", "CHEMICAL", 23, 26], ["ALA", "SIMPLE_CHEMICAL", 23, 26], ["liver", "ORGAN", 51, 56], ["hamsters", "ORGANISM", 119, 127], ["hamsters", "SPECIES", 119, 127], ["hamsters", "SPECIES", 119, 127], ["Massive development of ALA", "PROBLEM", 0, 26], ["ALA", "OBSERVATION", 23, 26], ["liver", "ANATOMY", 51, 56]]], ["By contrast, the development of ALA was variable in immunized and challenged animals.", [["ALA", "CHEMICAL", 32, 35], ["ALA", "CHEMICAL", 32, 35], ["ALA", "SIMPLE_CHEMICAL", 32, 35], ["ALA", "OBSERVATION_MODIFIER", 32, 35], ["variable", "OBSERVATION_MODIFIER", 40, 48]]], ["Thus, 11 out of 20 hamsters immunized with the recombinant baculovirus AcNPV-LC3 and 5 out of 20 immunized with the wild-type baculovirus showed no gross (Figures 1(a) and 1(b) ) or microscopic evidence (not shown), of ALA development, suggesting that intramuscular immunization with the baculovirus per se is capable of giving up to 25% sterile protection, which is increased to more than twice (55%) by immunizing with the recombinant baculovirus of LC3 (Table 1) .", [["intramuscular", "ANATOMY", 252, 265], ["ALA", "CHEMICAL", 219, 222], ["ALA", "CHEMICAL", 219, 222], ["hamsters", "ORGANISM", 19, 27], ["baculovirus", "ORGANISM", 59, 70], ["AcNPV-LC3", "GENE_OR_GENE_PRODUCT", 71, 80], ["baculovirus", "ORGANISM", 126, 137], ["ALA", "SIMPLE_CHEMICAL", 219, 222], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 252, 265], ["baculovirus", "ORGANISM", 288, 299], ["baculovirus", "ORGANISM", 437, 448], ["LC3", "GENE_OR_GENE_PRODUCT", 452, 455], ["AcNPV", "PROTEIN", 71, 76], ["LC3", "PROTEIN", 77, 80], ["recombinant baculovirus", "PROTEIN", 425, 448], ["LC3", "PROTEIN", 452, 455], ["Table 1", "PROTEIN", 457, 464], ["hamsters", "SPECIES", 19, 27], ["hamsters", "SPECIES", 19, 27], ["baculovirus", "SPECIES", 59, 70], ["baculovirus", "SPECIES", 126, 137], ["baculovirus", "SPECIES", 288, 299], ["baculovirus", "SPECIES", 437, 448], ["the recombinant baculovirus AcNPV", "TREATMENT", 43, 76], ["the wild-type baculovirus", "TEST", 112, 137], ["microscopic evidence", "TEST", 182, 202], ["ALA development", "PROBLEM", 219, 234], ["intramuscular immunization", "TREATMENT", 252, 278], ["the baculovirus", "TREATMENT", 284, 299], ["the recombinant baculovirus of LC3", "TREATMENT", 421, 455], ["no", "UNCERTAINTY", 145, 147], ["increased", "OBSERVATION_MODIFIER", 367, 376]]], ["Moreover, within the immunized animals that developed ALA, 1 out of 5 animals immunized with the wild virus and 4 out of 9 immunized with AcNPV-LC3 showed partial protection (Table 1) , some showing few millimetric abscesses scattered throughout the liver (Figure 1(c) ) or no more than 5 large abscesses usually located in one lobe (Figure 1(d) ).Intramuscular Immunization with AcNPV-LC3 Inhibits the Development of ALA in Hamsters.The protection against the development of ALA was confirmed by analyzing the hepatomegaly associated and by testing liver function, in particular the determination of alanine aminotransferase (ALT), a pyridoxal cytoplasmic phosphatedependent enzyme involved in cellular nitrogen metabolism, amino metabolism acid, and liver gluconeogenesis.", [["abscesses", "ANATOMY", 215, 224], ["liver", "ANATOMY", 250, 255], ["abscesses", "ANATOMY", 295, 304], ["lobe", "ANATOMY", 328, 332], ["Intramuscular", "ANATOMY", 348, 361], ["liver", "ANATOMY", 550, 555], ["cytoplasmic", "ANATOMY", 645, 656], ["cellular", "ANATOMY", 695, 703], ["liver", "ANATOMY", 752, 757], ["ALA", "CHEMICAL", 54, 57], ["abscesses", "DISEASE", 215, 224], ["abscesses", "DISEASE", 295, 304], ["ALA", "CHEMICAL", 418, 421], ["ALA", "CHEMICAL", 476, 479], ["hepatomegaly", "DISEASE", 511, 523], ["alanine", "CHEMICAL", 601, 608], ["pyridoxal", "CHEMICAL", 635, 644], ["nitrogen", "CHEMICAL", 704, 712], ["amino metabolism acid", "CHEMICAL", 725, 746], ["ALA", "CHEMICAL", 54, 57], ["ALA", "CHEMICAL", 418, 421], ["ALA", "CHEMICAL", 476, 479], ["alanine", "CHEMICAL", 601, 608], ["pyridoxal", "CHEMICAL", 635, 644], ["nitrogen", "CHEMICAL", 704, 712], ["amino", "CHEMICAL", 725, 730], ["ALA", "SIMPLE_CHEMICAL", 54, 57], ["animals", "ORGANISM", 70, 77], ["AcNPV-LC3", "GENE_OR_GENE_PRODUCT", 138, 147], ["liver", "ORGAN", 250, 255], ["abscesses", "PATHOLOGICAL_FORMATION", 295, 304], ["lobe", "ORGAN", 328, 332], ["AcNPV-LC3", "GENE_OR_GENE_PRODUCT", 380, 389], ["ALA", "SIMPLE_CHEMICAL", 418, 421], ["Hamsters", "ORGANISM", 425, 433], ["ALA", "SIMPLE_CHEMICAL", 476, 479], ["liver", "ORGAN", 550, 555], ["alanine aminotransferase", "GENE_OR_GENE_PRODUCT", 601, 625], ["ALT", "GENE_OR_GENE_PRODUCT", 627, 630], ["pyridoxal", "SIMPLE_CHEMICAL", 635, 644], ["cytoplasmic", "ORGANISM_SUBSTANCE", 645, 656], ["cellular", "CELL", 695, 703], ["nitrogen", "SIMPLE_CHEMICAL", 704, 712], ["amino", "AMINO_ACID", 725, 730], ["acid", "AMINO_ACID", 742, 746], ["liver", "ORGAN", 752, 757], ["AcNPV", "PROTEIN", 138, 143], ["LC3", "PROTEIN", 144, 147], ["AcNPV", "PROTEIN", 380, 385], ["LC3", "PROTEIN", 386, 389], ["alanine aminotransferase", "PROTEIN", 601, 625], ["ALT", "PROTEIN", 627, 630], ["pyridoxal cytoplasmic phosphatedependent enzyme", "PROTEIN", 635, 682], ["Hamsters", "SPECIES", 425, 433], ["AcNPV", "SPECIES", 138, 143], ["Hamsters", "SPECIES", 425, 433], ["ALA", "TEST", 54, 57], ["the wild virus", "PROBLEM", 93, 107], ["AcNPV", "TEST", 138, 143], ["few millimetric abscesses", "PROBLEM", 199, 224], ["5 large abscesses", "PROBLEM", 287, 304], ["Intramuscular Immunization", "TREATMENT", 348, 374], ["AcNPV", "TREATMENT", 380, 385], ["ALA in Hamsters", "TREATMENT", 418, 433], ["The protection", "TREATMENT", 434, 448], ["ALA", "PROBLEM", 476, 479], ["the hepatomegaly", "PROBLEM", 507, 523], ["testing liver function", "TEST", 542, 564], ["alanine aminotransferase", "TEST", 601, 625], ["ALT", "TEST", 627, 630], ["a pyridoxal cytoplasmic phosphatedependent enzyme", "TEST", 633, 682], ["cellular nitrogen metabolism", "PROBLEM", 695, 723], ["amino metabolism acid", "TEST", 725, 746], ["liver gluconeogenesis", "PROBLEM", 752, 773], ["partial protection", "OBSERVATION", 155, 173], ["few", "OBSERVATION_MODIFIER", 199, 202], ["millimetric", "OBSERVATION_MODIFIER", 203, 214], ["abscesses", "OBSERVATION", 215, 224], ["liver", "ANATOMY", 250, 255], ["no more", "UNCERTAINTY", 274, 281], ["large", "OBSERVATION_MODIFIER", 289, 294], ["abscesses", "OBSERVATION", 295, 304], ["one lobe", "ANATOMY", 324, 332], ["ALA", "OBSERVATION_MODIFIER", 418, 421], ["ALA", "OBSERVATION", 476, 479], ["hepatomegaly", "OBSERVATION", 511, 523], ["liver", "ANATOMY", 550, 555], ["cellular", "OBSERVATION", 695, 703], ["nitrogen metabolism", "OBSERVATION", 704, 723], ["liver", "ANATOMY", 752, 757]]], ["ALT levels are often low in blood but increased in the case of liver diseases or events that include damage of that tissue [36] .", [["blood", "ANATOMY", 28, 33], ["liver", "ANATOMY", 63, 68], ["tissue", "ANATOMY", 116, 122], ["liver diseases", "DISEASE", 63, 77], ["ALT", "SIMPLE_CHEMICAL", 0, 3], ["blood", "ORGANISM_SUBSTANCE", 28, 33], ["liver", "ORGAN", 63, 68], ["tissue", "TISSUE", 116, 122], ["ALT", "PROTEIN", 0, 3], ["ALT levels", "TEST", 0, 10], ["often low in blood", "PROBLEM", 15, 33], ["liver diseases", "PROBLEM", 63, 77], ["damage of that tissue", "PROBLEM", 101, 122], ["increased", "OBSERVATION_MODIFIER", 38, 47], ["liver", "ANATOMY", 63, 68], ["diseases", "OBSERVATION", 69, 77]]], ["The results showed high levels of ALT, about three times above the reference value, in the serum of nonimmunized and infected animals (sham group), which correlates with an increase of more than twice the weight of the liver as a result of abscesses (Table 1) .", [["serum", "ANATOMY", 91, 96], ["liver", "ANATOMY", 219, 224], ["abscesses", "ANATOMY", 240, 249], ["abscesses", "DISEASE", 240, 249], ["ALT", "SIMPLE_CHEMICAL", 34, 37], ["serum", "ORGANISM_SUBSTANCE", 91, 96], ["liver", "ORGAN", 219, 224], ["abscesses", "PATHOLOGICAL_FORMATION", 240, 249], ["ALT", "PROTEIN", 34, 37], ["high levels of ALT", "PROBLEM", 19, 37], ["the serum", "TEST", 87, 96], ["nonimmunized", "PROBLEM", 100, 112], ["abscesses", "PROBLEM", 240, 249], ["high", "OBSERVATION_MODIFIER", 19, 23], ["infected", "OBSERVATION", 117, 125], ["increase", "OBSERVATION_MODIFIER", 173, 181], ["liver", "ANATOMY", 219, 224], ["abscesses", "OBSERVATION", 240, 249]]], ["By contrast, the liver weight and ALT levels in the serum of immunized animals correlated with the degree of protection, being these normal values in hamsters fully protected (ALT < 87 U/L and liver around 6 g) and intermediate in animals showing partial protection (Table 1) .Intramuscular Immunization with AcNPV-LC3 Inhibits the Development of ALA in Hamsters.Overall, it can be considered that 75% of hamsters immunized with the recombinant baculovirus ( < 0.002 versus WT group by Fisher's test) and 30% of hamsters immunized with the wild baculovirus ( < 0.02 versus AcNPV-LC3 group by Fisher's test) showed any evidence of protection against the development of ALA (Table 2) .Intramuscular Immunization with the Recombinant Baculovirus AcNPV-LC3 Induces High Levels of Serum Anti-Amoebic Antibodies in Hamsters.Analysis of sera from hamsters by ELISA against whole amoeba antigen showed the development of high levels of specific IgG antibodies after intramuscular immunization with the recombinant baculoviruses AcNPV-LC3 (Figure 2 ; white bars; < 0.001 versus control groups).", [["liver", "ANATOMY", 17, 22], ["serum", "ANATOMY", 52, 57], ["liver", "ANATOMY", 193, 198], ["Intramuscular", "ANATOMY", 277, 290], ["sera", "ANATOMY", 830, 834], ["intramuscular", "ANATOMY", 958, 971], ["ALA", "CHEMICAL", 347, 350], ["ALA", "CHEMICAL", 668, 671], ["ALA", "CHEMICAL", 347, 350], ["ALA", "CHEMICAL", 668, 671], ["liver", "ORGAN", 17, 22], ["ALT", "SIMPLE_CHEMICAL", 34, 37], ["serum", "ORGANISM_SUBSTANCE", 52, 57], ["hamsters", "ORGANISM", 150, 158], ["liver", "ORGAN", 193, 198], ["AcNPV-LC3", "GENE_OR_GENE_PRODUCT", 309, 318], ["ALA", "SIMPLE_CHEMICAL", 347, 350], ["Hamsters", "ORGANISM", 354, 362], ["hamsters", "ORGANISM", 405, 413], ["baculovirus", "ORGANISM", 445, 456], ["hamsters", "ORGANISM", 512, 520], ["baculovirus", "ORGANISM", 545, 556], ["LC3", "GENE_OR_GENE_PRODUCT", 579, 582], ["ALA", "SIMPLE_CHEMICAL", 668, 671], ["Baculovirus", "ORGANISM", 731, 742], ["LC3", "GENE_OR_GENE_PRODUCT", 749, 752], ["Serum", "ORGANISM_SUBSTANCE", 776, 781], ["Hamsters", "ORGANISM", 809, 817], ["sera", "ORGANISM_SUBSTANCE", 830, 834], ["hamsters", "ORGANISM", 840, 848], ["whole amoeba antigen", "GENE_OR_GENE_PRODUCT", 866, 886], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 937, 951], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 958, 971], ["LC3", "GENE_OR_GENE_PRODUCT", 1026, 1029], ["ALT", "PROTEIN", 34, 37], ["AcNPV", "PROTEIN", 309, 314], ["LC3", "PROTEIN", 315, 318], ["AcNPV", "PROTEIN", 573, 578], ["LC3", "PROTEIN", 579, 582], ["LC3", "PROTEIN", 749, 752], ["Serum Anti-Amoebic Antibodies", "PROTEIN", 776, 805], ["IgG antibodies", "PROTEIN", 937, 951], ["AcNPV", "PROTEIN", 1020, 1025], ["LC3", "PROTEIN", 1026, 1029], ["Hamsters", "SPECIES", 354, 362], ["hamsters", "SPECIES", 405, 413], ["hamsters", "SPECIES", 512, 520], ["Hamsters", "SPECIES", 809, 817], ["hamsters", "SPECIES", 840, 848], ["hamsters", "SPECIES", 150, 158], ["Hamsters", "SPECIES", 354, 362], ["hamsters", "SPECIES", 405, 413], ["baculovirus", "SPECIES", 445, 456], ["hamsters", "SPECIES", 512, 520], ["baculovirus", "SPECIES", 545, 556], ["Baculovirus", "SPECIES", 731, 742], ["Hamsters", "SPECIES", 809, 817], ["hamsters", "SPECIES", 840, 848], ["the liver weight", "TEST", 13, 29], ["ALT levels", "TEST", 34, 44], ["the serum", "TEST", 48, 57], ["ALT", "TEST", 176, 179], ["Intramuscular Immunization", "TREATMENT", 277, 303], ["AcNPV", "TREATMENT", 309, 314], ["ALA in Hamsters", "TREATMENT", 347, 362], ["the recombinant baculovirus", "TREATMENT", 429, 456], ["Fisher's test", "TEST", 486, 499], ["the wild baculovirus", "TREATMENT", 536, 556], ["Fisher's test", "TEST", 592, 605], ["Intramuscular Immunization", "TREATMENT", 683, 709], ["the Recombinant Baculovirus", "TREATMENT", 715, 742], ["Serum Anti-Amoebic Antibodies", "TREATMENT", 776, 805], ["Analysis of sera from hamsters", "TEST", 818, 848], ["ELISA", "TEST", 852, 857], ["whole amoeba antigen", "TEST", 866, 886], ["high levels of specific IgG antibodies", "PROBLEM", 913, 951], ["intramuscular immunization", "TREATMENT", 958, 984], ["the recombinant baculoviruses AcNPV", "TREATMENT", 990, 1025], ["white bars", "TEST", 1042, 1052], ["liver", "ANATOMY", 17, 22], ["liver", "ANATOMY", 193, 198], ["partial protection", "OBSERVATION", 247, 265], ["ALA", "OBSERVATION_MODIFIER", 347, 350]]], ["Since the sera of animals immunized with wild baculovirus, as well as sham control animals, did not show reaction against the antigen of amoeba, antibodies from hyperimmune sera of immunized hamsters were assumed to be directed against the LC3 fragment Gal-lectin ( Figure 2 ).Intramuscular Immunization with the Recombinant Baculovirus AcNPV-LC3 Induces a Cell-Mediated AntiamoebicResponse in Hamsters.", [["sera", "ANATOMY", 10, 14], ["sera", "ANATOMY", 173, 177], ["Cell", "ANATOMY", 357, 361], ["sera", "ORGANISM_SUBSTANCE", 10, 14], ["wild baculovirus", "ORGANISM", 41, 57], ["hyperimmune", "ORGANISM", 161, 172], ["sera", "ORGANISM_SUBSTANCE", 173, 177], ["hamsters", "ORGANISM", 191, 199], ["LC3", "GENE_OR_GENE_PRODUCT", 240, 243], ["Baculovirus", "ORGANISM", 325, 336], ["LC3", "GENE_OR_GENE_PRODUCT", 343, 346], ["Cell", "CELL", 357, 361], ["antibodies", "PROTEIN", 145, 155], ["LC3 fragment Gal-lectin", "PROTEIN", 240, 263], ["Recombinant Baculovirus AcNPV-LC3", "PROTEIN", 313, 346], ["hyperimmune", "SPECIES", 161, 172], ["hamsters", "SPECIES", 191, 199], ["Hamsters", "SPECIES", 394, 402], ["baculovirus", "SPECIES", 46, 57], ["hyperimmune", "SPECIES", 161, 172], ["hamsters", "SPECIES", 191, 199], ["Baculovirus", "SPECIES", 325, 336], ["wild baculovirus", "TREATMENT", 41, 57], ["sham control animals", "TREATMENT", 70, 90], ["reaction", "PROBLEM", 105, 113], ["amoeba", "PROBLEM", 137, 143], ["antibodies", "PROBLEM", 145, 155], ["hyperimmune sera of immunized hamsters", "TREATMENT", 161, 199], ["Intramuscular Immunization", "TREATMENT", 277, 303], ["the Recombinant Baculovirus", "TREATMENT", 309, 336], ["LC3 fragment", "OBSERVATION", 240, 252]]], ["Antigen specific proliferation of lymphocytes was determined in sensitized spleen cells from hamsters, by incubating splenocytes in the presence of whole amoeba antigen.", [["lymphocytes", "ANATOMY", 34, 45], ["spleen cells", "ANATOMY", 75, 87], ["splenocytes", "ANATOMY", 117, 128], ["lymphocytes", "CELL", 34, 45], ["spleen cells", "CELL", 75, 87], ["hamsters", "ORGANISM", 93, 101], ["splenocytes", "CELL", 117, 128], ["lymphocytes", "CELL_TYPE", 34, 45], ["sensitized spleen cells", "CELL_TYPE", 64, 87], ["splenocytes", "CELL_TYPE", 117, 128], ["whole amoeba antigen", "PROTEIN", 148, 168], ["hamsters", "SPECIES", 93, 101], ["hamsters", "SPECIES", 93, 101], ["Antigen specific proliferation of lymphocytes", "PROBLEM", 0, 45], ["sensitized spleen cells", "PROBLEM", 64, 87], ["incubating splenocytes", "PROBLEM", 106, 128], ["whole amoeba antigen", "PROBLEM", 148, 168], ["proliferation", "OBSERVATION_MODIFIER", 17, 30], ["lymphocytes", "OBSERVATION", 34, 45], ["sensitized spleen cells", "OBSERVATION", 64, 87], ["incubating splenocytes", "OBSERVATION", 106, 128], ["amoeba antigen", "OBSERVATION", 154, 168]]], ["The results showed that the level of proliferation correlated with the degree of protection obtained with the recombinant baculovirus AcNPV-LC3 (Figure 3 ), being greater in the immunized animals protected entirely (rate 20) followed by those which were partially protected (rate 13; Figure 3 (c), < 0.05 between them; < 0.001 versus the other groups).", [["baculovirus", "ORGANISM", 122, 133], ["AcNPV-LC3", "GENE_OR_GENE_PRODUCT", 134, 143], ["AcNPV", "PROTEIN", 134, 139], ["LC3", "PROTEIN", 140, 143], ["baculovirus", "SPECIES", 122, 133], ["the recombinant baculovirus AcNPV", "TREATMENT", 106, 139], ["rate", "TEST", 275, 279], ["Figure", "TEST", 284, 290], ["proliferation", "OBSERVATION", 37, 50], ["greater", "OBSERVATION_MODIFIER", 163, 170]]], ["Proliferation in the AcNPV-LC3 immunized but not protected hamsters was twice of the animals from control groups, but not statistically different.", [["AcNPV", "GENE_OR_GENE_PRODUCT", 21, 26], ["LC3", "GENE_OR_GENE_PRODUCT", 27, 30], ["hamsters", "ORGANISM", 59, 67], ["LC3", "PROTEIN", 27, 30], ["hamsters", "SPECIES", 59, 67], ["hamsters", "SPECIES", 59, 67], ["Proliferation", "PROBLEM", 0, 13], ["the AcNPV", "TREATMENT", 17, 26], ["AcNPV", "ANATOMY", 21, 26]]], ["By contrast, animals not protected and even those totally or partially protected by immunization with the wild baculovirus did not show any degree of splenocyte's proliferation against whole amoeba antigen (Figure 3 ).Protection against ALA Correlated with the Local Production of IFN and IL-4.In order to identify soluble elements of the local cellular immune response associated with the protection obtained against ALA, the Th1 (IFN and IL-12) and Th2 (IL-4 and IL-10) associated cytokines in extracts of livers from protected hamsters were evaluated.", [["splenocyte", "ANATOMY", 150, 160], ["cellular", "ANATOMY", 345, 353], ["extracts", "ANATOMY", 496, 504], ["livers", "ANATOMY", 508, 514], ["ALA", "CHEMICAL", 237, 240], ["ALA", "CHEMICAL", 418, 421], ["ALA", "CHEMICAL", 237, 240], ["ALA", "CHEMICAL", 418, 421], ["baculovirus", "ORGANISM", 111, 122], ["splenocyte", "CELL", 150, 160], ["whole amoeba antigen", "GENE_OR_GENE_PRODUCT", 185, 205], ["ALA", "SIMPLE_CHEMICAL", 237, 240], ["IFN", "GENE_OR_GENE_PRODUCT", 281, 284], ["IL-4", "GENE_OR_GENE_PRODUCT", 289, 293], ["cellular", "CELL", 345, 353], ["ALA", "SIMPLE_CHEMICAL", 418, 421], ["Th1", "GENE_OR_GENE_PRODUCT", 427, 430], ["IFN", "GENE_OR_GENE_PRODUCT", 432, 435], ["IL-12", "GENE_OR_GENE_PRODUCT", 440, 445], ["IL-4", "GENE_OR_GENE_PRODUCT", 456, 460], ["IL-10", "GENE_OR_GENE_PRODUCT", 465, 470], ["extracts", "ORGANISM_SUBSTANCE", 496, 504], ["livers", "ORGAN", 508, 514], ["hamsters", "ORGANISM", 530, 538], ["splenocyte", "CELL_TYPE", 150, 160], ["whole amoeba antigen", "PROTEIN", 185, 205], ["IFN", "PROTEIN", 281, 284], ["IL-4", "PROTEIN", 289, 293], ["IFN", "PROTEIN", 432, 435], ["Th2 (IL-4 and IL-10", "PROTEIN", 451, 470], ["cytokines", "PROTEIN", 483, 492], ["hamsters", "SPECIES", 530, 538], ["baculovirus", "SPECIES", 111, 122], ["hamsters", "SPECIES", 530, 538], ["immunization", "TREATMENT", 84, 96], ["the wild baculovirus", "TEST", 102, 122], ["splenocyte's proliferation", "PROBLEM", 150, 176], ["whole amoeba antigen", "TEST", 185, 205], ["IFN and IL", "TREATMENT", 281, 291], ["ALA", "TEST", 418, 421], ["the Th1 (IFN and IL", "TREATMENT", 423, 442], ["Th2 (IL-4 and IL", "TREATMENT", 451, 467], ["splenocyte", "ANATOMY", 150, 160], ["cellular immune response", "OBSERVATION", 345, 369], ["Th1", "ANATOMY", 427, 430], ["cytokines", "OBSERVATION", 483, 492], ["livers", "ANATOMY", 508, 514]]], ["The results animals immunized with AcNPV-LC3 and completely protected had on average 9-fold more IFN than infected animals (450 pg/mL versus 50 pg/mL, < 0.01), and almost twice the levels in partially protected hamsters, but with no statistical significance (Figure 4(a) ).", [["AcNPV-LC3", "GENE_OR_GENE_PRODUCT", 35, 44], ["IFN", "GENE_OR_GENE_PRODUCT", 97, 100], ["hamsters", "ORGANISM", 211, 219], ["AcNPV", "PROTEIN", 35, 40], ["LC3", "PROTEIN", 41, 44], ["IFN", "PROTEIN", 97, 100], ["hamsters", "SPECIES", 211, 219], ["AcNPV", "TEST", 35, 40]]], ["Similarly, there was no statistical difference between the IFN levels from liver of the partially protected and the nonprotected animals.", [["liver", "ANATOMY", 75, 80], ["IFN", "GENE_OR_GENE_PRODUCT", 59, 62], ["liver", "ORGAN", 75, 80], ["IFN", "PROTEIN", 59, 62], ["statistical difference", "PROBLEM", 24, 46], ["the IFN levels", "TEST", 55, 69], ["no", "UNCERTAINTY", 21, 23], ["statistical", "OBSERVATION_MODIFIER", 24, 35], ["difference", "OBSERVATION", 36, 46], ["liver", "ANATOMY", 75, 80]]], ["In the same way, this trend was observed in AcNPV-WT group, where totally protected animals have 6 times average of IFN more than infected animals (396.5 pg/mL versus 65.2 pg/mL, < 0.05, Figure 4 (a)) and twice with respect to animals that showed partial protection.", [["AcNPV-WT", "ORGANISM", 44, 52], ["IFN", "GENE_OR_GENE_PRODUCT", 116, 119], ["IFN", "PROTEIN", 116, 119], ["IFN", "PROBLEM", 116, 119], ["partial protection", "OBSERVATION", 247, 265]]], ["Finally, no difference between groups was observed for the other Th1 cytokine IL-12 (data not shown).Protection against ALA Correlated with the Local Production of IFN and IL-4.With respect to the Th2 cytokine profile, differences were only observed in the levels of IL-4, but not IL-10 (data not shown).", [["ALA", "CHEMICAL", 120, 123], ["ALA", "CHEMICAL", 120, 123], ["IL-12", "GENE_OR_GENE_PRODUCT", 78, 83], ["ALA", "SIMPLE_CHEMICAL", 120, 123], ["IFN", "GENE_OR_GENE_PRODUCT", 164, 167], ["IL-4", "GENE_OR_GENE_PRODUCT", 172, 176], ["IL-4", "GENE_OR_GENE_PRODUCT", 267, 271], ["IL-10", "GENE_OR_GENE_PRODUCT", 281, 286], ["Th1 cytokine IL-12", "PROTEIN", 65, 83], ["IFN", "PROTEIN", 164, 167], ["IL-4", "PROTEIN", 172, 176], ["Th2 cytokine", "PROTEIN", 197, 209], ["IL", "PROTEIN", 267, 269], ["IL", "PROTEIN", 281, 283], ["the other Th1 cytokine IL", "TEST", 55, 80], ["IFN and IL", "TREATMENT", 164, 174], ["the Th2 cytokine profile", "TEST", 193, 217], ["IL", "TEST", 281, 283], ["no", "UNCERTAINTY", 9, 11]]], ["As with IFN , IL-4 was on average 8-fold higher in the livers of animals fully protected compared with immunized and infected animals (80 pg/mL versus 10 pg/mL, < 0.01, Figure 4(b) ).", [["livers", "ANATOMY", 55, 61], ["IL-4", "GENE_OR_GENE_PRODUCT", 14, 18], ["livers", "ORGAN", 55, 61], ["IFN", "PROTEIN", 8, 11], ["IL-4", "PROTEIN", 14, 18], ["IFN", "TEST", 8, 11], ["IL", "TEST", 14, 16], ["livers", "ANATOMY", 55, 61]]], ["In the same way, the partially protected hamsters showed a tendency to have higher concentrations of IL-4 than the infected, but the difference was not statistically significant.", [["hamsters", "ORGANISM", 41, 49], ["IL-4", "GENE_OR_GENE_PRODUCT", 101, 105], ["IL", "PROTEIN", 101, 103], ["higher concentrations of IL", "PROBLEM", 76, 103], ["higher", "OBSERVATION_MODIFIER", 76, 82], ["concentrations", "OBSERVATION_MODIFIER", 83, 97], ["infected", "OBSERVATION", 115, 123]]], ["With regard to AcNPV-WT immunized group, the totally protected animals showed IL-4 six times higher more than infected animals.DiscussionIn a previous study, we demonstrated the potential of A. californica nucleopolyhedrovirus (AcNPV) driving the expression of the E. histolytica Gal-lectin LC3 fragment of conferring sterile or partial protection against ALA in 79% of orally and 21% of nasally immunized hamsters, but the underlying cytokines and cell populations responsible were not identified [17] .", [["orally", "ANATOMY", 370, 376], ["cell", "ANATOMY", 449, 453], ["ALA", "CHEMICAL", 356, 359], ["ALA", "CHEMICAL", 356, 359], ["AcNPV-WT immunized", "ORGANISM", 15, 33], ["animals", "ORGANISM", 63, 70], ["IL-4", "GENE_OR_GENE_PRODUCT", 78, 82], ["A. californica", "ORGANISM", 191, 205], ["nucleopolyhedrovirus", "ORGANISM", 206, 226], ["AcNPV", "ORGANISM", 228, 233], ["E. histolytica", "ORGANISM", 265, 279], ["Gal-lectin LC3", "GENE_OR_GENE_PRODUCT", 280, 294], ["ALA", "SIMPLE_CHEMICAL", 356, 359], ["hamsters", "ORGANISM", 406, 414], ["cell populations", "CELL", 449, 465], ["AcNPV", "PROTEIN", 15, 20], ["IL", "PROTEIN", 78, 80], ["E. histolytica Gal-lectin LC3 fragment", "PROTEIN", 265, 303], ["cytokines", "PROTEIN", 435, 444], ["A. californica nucleopolyhedrovirus", "SPECIES", 191, 226], ["E. histolytica", "SPECIES", 265, 279], ["hamsters", "SPECIES", 406, 414], ["A. californica nucleopolyhedrovirus", "SPECIES", 191, 226], ["AcNPV", "SPECIES", 228, 233], ["E. histolytica", "SPECIES", 265, 279], ["hamsters", "SPECIES", 406, 414], ["AcNPV", "TEST", 15, 20], ["IL", "TEST", 78, 80], ["a previous study", "TEST", 140, 156], ["A. californica nucleopolyhedrovirus (AcNPV", "TREATMENT", 191, 233], ["ALA", "TEST", 356, 359], ["nasally immunized hamsters", "TREATMENT", 388, 414], ["the underlying cytokines and cell populations", "PROBLEM", 420, 465], ["californica nucleopolyhedrovirus", "OBSERVATION", 194, 226], ["LC3 fragment", "OBSERVATION", 291, 303], ["cell populations", "OBSERVATION", 449, 465]]], ["In this report we aimed to determine whether the intramuscular immunization of hamsters with the same AcNPV-LC3 recombinant baculovirus was able to confer a greater level of protection than the mucosal vaccination against the development of ALA following an intraportal challenge with virulent amoebic trophozoites and whether the protection was correlated with a particular type of local immune response.DiscussionThe results showed that intramuscular immunization of hamsters with the AcNPV-LC3 recombinant baculovirus confers an overall level of protection similar to that previously obtained with the oral route (75% versus 79%, resp.).", [["intramuscular", "ANATOMY", 49, 62], ["mucosal", "ANATOMY", 194, 201], ["trophozoites", "ANATOMY", 302, 314], ["intramuscular", "ANATOMY", 439, 452], ["oral", "ANATOMY", 605, 609], ["ALA", "CHEMICAL", 241, 244], ["amoebic trophozoites", "DISEASE", 294, 314], ["ALA", "CHEMICAL", 241, 244], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 49, 62], ["hamsters", "ORGANISM", 79, 87], ["AcNPV", "GENE_OR_GENE_PRODUCT", 102, 107], ["LC3", "GENE_OR_GENE_PRODUCT", 108, 111], ["baculovirus", "ORGANISM", 124, 135], ["mucosal", "ORGANISM_SUBDIVISION", 194, 201], ["ALA", "SIMPLE_CHEMICAL", 241, 244], ["trophozoites", "CELL", 302, 314], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 439, 452], ["hamsters", "ORGANISM", 469, 477], ["AcNPV", "GENE_OR_GENE_PRODUCT", 487, 492], ["LC3", "GENE_OR_GENE_PRODUCT", 493, 496], ["baculovirus", "ORGANISM", 509, 520], ["oral", "ORGANISM_SUBDIVISION", 605, 609], ["AcNPV", "PROTEIN", 102, 107], ["LC3", "PROTEIN", 108, 111], ["AcNPV", "PROTEIN", 487, 492], ["LC3", "PROTEIN", 493, 496], ["hamsters", "SPECIES", 79, 87], ["baculovirus", "SPECIES", 124, 135], ["hamsters", "SPECIES", 469, 477], ["baculovirus", "SPECIES", 509, 520], ["the intramuscular immunization of hamsters", "TREATMENT", 45, 87], ["the same AcNPV", "TREATMENT", 93, 107], ["LC3 recombinant baculovirus", "TREATMENT", 108, 135], ["the mucosal vaccination", "TREATMENT", 190, 213], ["ALA", "PROBLEM", 241, 244], ["an intraportal challenge", "TREATMENT", 255, 279], ["virulent amoebic trophozoites", "TREATMENT", 285, 314], ["intramuscular immunization of hamsters", "TREATMENT", 439, 477], ["the AcNPV", "TREATMENT", 483, 492], ["LC3 recombinant baculovirus", "TREATMENT", 493, 520]]], ["Moreover, the sterile protection levels obtained by both routes were also similar (55% oral versus 58% intramuscular).", [["oral", "ANATOMY", 87, 91], ["oral", "ORGANISM_SUBDIVISION", 87, 91], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 103, 116], ["the sterile protection levels", "TEST", 10, 39]]], ["This result was unexpected because being ALA a systemic type infection, it was more probably that the intramuscular route of immunization had higher efficiency to induce a systemic protective response than the oral route.", [["intramuscular", "ANATOMY", 102, 115], ["oral", "ANATOMY", 210, 214], ["ALA", "CHEMICAL", 41, 44], ["systemic type infection", "DISEASE", 47, 70], ["ALA", "CHEMICAL", 41, 44], ["ALA", "SIMPLE_CHEMICAL", 41, 44], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 102, 115], ["oral", "ORGANISM_SUBDIVISION", 210, 214], ["ALA a systemic type infection", "PROBLEM", 41, 70], ["immunization", "TREATMENT", 125, 137], ["higher efficiency", "PROBLEM", 142, 159], ["a systemic protective response", "PROBLEM", 170, 200], ["systemic", "OBSERVATION_MODIFIER", 47, 55], ["type", "OBSERVATION_MODIFIER", 56, 60], ["infection", "OBSERVATION", 61, 70]]], ["Therefore, this supports the proposal by our group and others that the oral route may be the appropriate to administer a vaccine against amoebiasis in general, because, in addition to the classic advantages of this route as its manageability, noninvasion, and no needs for specialized personnel, oral route triggers local and systemic immune responses that in addition to conferring protection against intestinal amoebiasis, may also protect against the development of liver abscesses if trophozoites manage to pass from the intestine to the liver.", [["oral", "ANATOMY", 71, 75], ["oral", "ANATOMY", 296, 300], ["intestinal", "ANATOMY", 402, 412], ["liver abscesses", "ANATOMY", 469, 484], ["trophozoites", "ANATOMY", 488, 500], ["intestine", "ANATOMY", 525, 534], ["liver", "ANATOMY", 542, 547], ["amoebiasis", "DISEASE", 137, 147], ["intestinal amoebiasis", "DISEASE", 402, 423], ["liver abscesses", "DISEASE", 469, 484], ["oral", "ORGANISM_SUBDIVISION", 71, 75], ["oral", "ORGANISM_SUBDIVISION", 296, 300], ["intestinal", "ORGAN", 402, 412], ["liver", "ORGAN", 469, 474], ["trophozoites", "CELL", 488, 500], ["intestine", "ORGAN", 525, 534], ["liver", "ORGAN", 542, 547], ["the oral route", "TREATMENT", 67, 81], ["a vaccine", "TREATMENT", 119, 128], ["amoebiasis", "PROBLEM", 137, 147], ["this route", "TREATMENT", 210, 220], ["oral route", "TREATMENT", 296, 306], ["intestinal amoebiasis", "PROBLEM", 402, 423], ["liver abscesses", "PROBLEM", 469, 484], ["trophozoites", "PROBLEM", 488, 500], ["intestinal", "ANATOMY", 402, 412], ["amoebiasis", "OBSERVATION", 413, 423], ["liver", "ANATOMY", 469, 474], ["abscesses", "OBSERVATION", 475, 484], ["intestine", "ANATOMY", 525, 534], ["liver", "ANATOMY", 542, 547]]], ["This is noteworthy as extraintestinal amoebiasis, and in particular, ALA is considered the main cause of human death by E. histolytica [37] .", [["amoebiasis", "DISEASE", 38, 48], ["ALA", "CHEMICAL", 69, 72], ["death", "DISEASE", 111, 116], ["ALA", "CHEMICAL", 69, 72], ["ALA", "SIMPLE_CHEMICAL", 69, 72], ["human", "ORGANISM", 105, 110], ["E. histolytica", "ORGANISM", 120, 134], ["human", "SPECIES", 105, 110], ["E. histolytica", "SPECIES", 120, 134], ["human", "SPECIES", 105, 110], ["E. histolytica", "SPECIES", 120, 134], ["extraintestinal amoebiasis", "PROBLEM", 22, 48], ["human death", "PROBLEM", 105, 116], ["extraintestinal", "OBSERVATION_MODIFIER", 22, 37], ["amoebiasis", "OBSERVATION", 38, 48]]], ["The effectiveness of the Gal-lectin as vaccine against amoebiasis has been extensively studied [5] .", [["Gal-lectin", "CHEMICAL", 25, 35], ["amoebiasis", "DISEASE", 55, 65], ["Gal-lectin", "CHEMICAL", 25, 35], ["Gal-lectin", "SIMPLE_CHEMICAL", 25, 35], ["amoebiasis", "CANCER", 55, 65], ["the Gal-lectin as vaccine", "TREATMENT", 21, 46], ["amoebiasis", "PROBLEM", 55, 65]]], ["Recently, a new model of intestinal infection with E. histolytica in baboons (Papio sp) and the efficacy of nasal vaccination against amoebic colitis using a Gal-lectin synthetic peptide was reported [38] .", [["intestinal", "ANATOMY", 25, 35], ["nasal", "ANATOMY", 108, 113], ["intestinal infection", "DISEASE", 25, 45], ["amoebic colitis", "DISEASE", 134, 149], ["Gal-lectin", "CHEMICAL", 158, 168], ["intestinal", "ORGAN", 25, 35], ["E. histolytica", "ORGANISM", 51, 65], ["baboons", "ORGANISM", 69, 76], ["Papio sp", "ORGANISM", 78, 86], ["nasal", "ORGANISM_SUBDIVISION", 108, 113], ["Gal-lectin", "SIMPLE_CHEMICAL", 158, 168], ["E. histolytica", "SPECIES", 51, 65], ["E. histolytica", "SPECIES", 51, 65], ["intestinal infection", "PROBLEM", 25, 45], ["E. histolytica", "PROBLEM", 51, 65], ["nasal vaccination", "TREATMENT", 108, 125], ["amoebic colitis", "PROBLEM", 134, 149], ["a Gal-lectin synthetic peptide", "TREATMENT", 156, 186], ["new", "OBSERVATION_MODIFIER", 12, 15], ["intestinal", "ANATOMY", 25, 35], ["infection", "OBSERVATION", 36, 45], ["histolytica", "OBSERVATION_MODIFIER", 54, 65], ["nasal", "ANATOMY", 108, 113]]], ["Notably, a vaccination schedule of four doses of 1600 g peptide/nostril in combination with cholera toxin as adjuvant once a week was able to eradicate amoebic infection in all baboons by the 51st day after intracecal challenge with trophozoites.", [["intracecal", "ANATOMY", 207, 217], ["trophozoites", "ANATOMY", 233, 245], ["cholera toxin", "CHEMICAL", 92, 105], ["amoebic infection", "DISEASE", 152, 169], ["nostril", "ORGANISM_SUBDIVISION", 64, 71], ["cholera toxin", "SIMPLE_CHEMICAL", 92, 105], ["baboons", "ORGANISM", 177, 184], ["trophozoites", "CELL", 233, 245], ["a vaccination schedule", "TREATMENT", 9, 31], ["1600 g peptide", "TREATMENT", 49, 63], ["nostril", "TREATMENT", 64, 71], ["cholera toxin", "TREATMENT", 92, 105], ["amoebic infection", "PROBLEM", 152, 169], ["intracecal challenge", "TREATMENT", 207, 227], ["trophozoites", "PROBLEM", 233, 245], ["amoebic", "OBSERVATION_MODIFIER", 152, 159], ["infection", "OBSERVATION", 160, 169]]], ["Moreover, serum IgG and IgA antibodies induced by natural infection of baboons with E. histolytica are directed to epitopes present in the LC3 fragment of the Gal-lectin, and this immunodominance is shared with humans carrying asymptomatic E. histolytica infection or recently cured of ALA [14] .", [["serum", "ANATOMY", 10, 15], ["infection", "DISEASE", 58, 67], ["E. histolytica infection", "DISEASE", 240, 264], ["ALA", "CHEMICAL", 286, 289], ["ALA", "CHEMICAL", 286, 289], ["serum", "ORGANISM_SUBSTANCE", 10, 15], ["IgG", "GENE_OR_GENE_PRODUCT", 16, 19], ["IgA antibodies", "GENE_OR_GENE_PRODUCT", 24, 38], ["baboons", "ORGANISM", 71, 78], ["E. histolytica", "ORGANISM", 84, 98], ["LC3", "GENE_OR_GENE_PRODUCT", 139, 142], ["Gal-lectin", "GENE_OR_GENE_PRODUCT", 159, 169], ["humans", "ORGANISM", 211, 217], ["E. histolytica", "ORGANISM", 240, 254], ["ALA", "SIMPLE_CHEMICAL", 286, 289], ["serum IgG", "PROTEIN", 10, 19], ["IgA antibodies", "PROTEIN", 24, 38], ["epitopes", "PROTEIN", 115, 123], ["LC3 fragment", "PROTEIN", 139, 151], ["Gal-lectin", "PROTEIN", 159, 169], ["E. histolytica", "SPECIES", 84, 98], ["humans", "SPECIES", 211, 217], ["E. histolytica", "SPECIES", 240, 254], ["E. histolytica", "SPECIES", 84, 98], ["humans", "SPECIES", 211, 217], ["E. histolytica", "SPECIES", 240, 254], ["serum IgG", "TEST", 10, 19], ["IgA antibodies", "TEST", 24, 38], ["natural infection of baboons", "PROBLEM", 50, 78], ["E. histolytica", "TREATMENT", 84, 98], ["humans carrying asymptomatic E. histolytica infection", "PROBLEM", 211, 264], ["infection", "OBSERVATION", 58, 67], ["LC3 fragment", "OBSERVATION", 139, 151], ["Gal-lectin", "ANATOMY", 159, 169], ["histolytica", "OBSERVATION_MODIFIER", 243, 254], ["infection", "OBSERVATION", 255, 264]]], ["These results, together with the obtained by our group, previously and reported here, using recombinant baculoviruses driving the expression of the LC3 fragment [17] as well as other protection assays using LC3 as immunogen [15] , highly support that Gal-lectin, in particular its LC3 fragment, is the target of protective antibodies and cellular immune responses resolving intraand extraintestinal amoebiasis, and, therefore, it should be the basic component of an effective vaccine against human amoebiasis.DiscussionThe immune elements responsible for protection against intestinal amebiasis or ALA are not entirely known.", [["cellular", "ANATOMY", 338, 346], ["intestinal", "ANATOMY", 574, 584], ["Gal-lectin", "CHEMICAL", 251, 261], ["amoebiasis", "DISEASE", 399, 409], ["amoebiasis", "DISEASE", 498, 508], ["amebiasis", "DISEASE", 585, 594], ["ALA", "CHEMICAL", 598, 601], ["ALA", "CHEMICAL", 598, 601], ["LC3", "GENE_OR_GENE_PRODUCT", 148, 151], ["LC3", "GENE_OR_GENE_PRODUCT", 207, 210], ["Gal-lectin", "SIMPLE_CHEMICAL", 251, 261], ["LC3", "GENE_OR_GENE_PRODUCT", 281, 284], ["cellular", "CELL", 338, 346], ["human", "ORGANISM", 492, 497], ["intestinal", "ORGAN", 574, 584], ["ALA", "SIMPLE_CHEMICAL", 598, 601], ["LC3 fragment", "PROTEIN", 148, 160], ["LC3", "PROTEIN", 207, 210], ["Gal-lectin", "PROTEIN", 251, 261], ["LC3 fragment", "PROTEIN", 281, 293], ["immune elements", "DNA", 523, 538], ["human", "SPECIES", 492, 497], ["human", "SPECIES", 492, 497], ["recombinant baculoviruses", "TREATMENT", 92, 117], ["the LC3 fragment", "PROBLEM", 144, 160], ["other protection assays", "TEST", 177, 200], ["LC3 as immunogen", "TREATMENT", 207, 223], ["its LC3 fragment", "PROBLEM", 277, 293], ["protective antibodies", "TREATMENT", 312, 333], ["intraand extraintestinal amoebiasis", "PROBLEM", 374, 409], ["an effective vaccine", "TREATMENT", 463, 483], ["human amoebiasis", "PROBLEM", 492, 508], ["The immune elements", "TREATMENT", 519, 538], ["protection", "TREATMENT", 555, 565], ["intestinal amebiasis", "PROBLEM", 574, 594], ["ALA", "PROBLEM", 598, 601], ["LC3 fragment", "OBSERVATION", 148, 160], ["LC3 fragment", "OBSERVATION", 281, 293], ["extraintestinal", "OBSERVATION_MODIFIER", 383, 398], ["amoebiasis", "OBSERVATION", 399, 409], ["intestinal", "ANATOMY", 574, 584], ["amebiasis", "OBSERVATION", 585, 594]]], ["In this study, we found an association of sterile protection against ALA with the local production of high levels of IFN , a cytokine of Th1 profile.", [["ALA", "CHEMICAL", 69, 72], ["ALA", "CHEMICAL", 69, 72], ["ALA", "SIMPLE_CHEMICAL", 69, 72], ["IFN", "GENE_OR_GENE_PRODUCT", 117, 120], ["IFN", "PROTEIN", 117, 120], ["cytokine", "PROTEIN", 125, 133], ["this study", "TEST", 3, 13], ["sterile protection", "TREATMENT", 42, 60], ["ALA", "PROBLEM", 69, 72], ["high levels of IFN", "PROBLEM", 102, 120], ["high levels", "OBSERVATION_MODIFIER", 102, 113]]], ["This result is in agreement with previous studies where protection against ALA in hamsters correlated with the production of the same cytokine in protective assays using the EhCPADH surface complex as immunogen [39] .", [["ALA", "CHEMICAL", 75, 78], ["ALA", "CHEMICAL", 75, 78], ["ALA", "SIMPLE_CHEMICAL", 75, 78], ["hamsters", "ORGANISM", 82, 90], ["cytokine", "PROTEIN", 134, 142], ["EhCPADH surface complex", "PROTEIN", 174, 197], ["hamsters", "SPECIES", 82, 90], ["previous studies", "TEST", 33, 49], ["ALA in hamsters", "TREATMENT", 75, 90], ["the EhCPADH surface complex", "TREATMENT", 170, 197]]], ["In addition, relevance of IFN as playing a role in the innate immunity against ALA came from studies in SCID mice with targeted disruption of the IFN receptor gene [40] .", [["IFN", "CHEMICAL", 26, 29], ["ALA", "CHEMICAL", 79, 82], ["ALA", "CHEMICAL", 79, 82], ["IFN", "GENE_OR_GENE_PRODUCT", 26, 29], ["ALA", "SIMPLE_CHEMICAL", 79, 82], ["SCID mice", "ORGANISM", 104, 113], ["IFN receptor", "GENE_OR_GENE_PRODUCT", 146, 158], ["IFN", "PROTEIN", 26, 29], ["IFN receptor gene", "DNA", 146, 163], ["mice", "SPECIES", 109, 113], ["mice", "SPECIES", 109, 113], ["IFN", "TREATMENT", 26, 29], ["the IFN receptor gene", "TREATMENT", 142, 163]]], ["Moreover, T cell derived IFN and IL-17 were also essential for protection against intestinal amoebiasis in a murine model vaccinated with recombinant LecA fragment of the Gal-lectin, determined by adoptive T cell transfer and IFN /Il-17 neutralizing assays [41, 42] .", [["T cell", "ANATOMY", 10, 16], ["intestinal", "ANATOMY", 82, 92], ["T cell", "ANATOMY", 206, 212], ["intestinal amoebiasis", "DISEASE", 82, 103], ["T cell", "CELL", 10, 16], ["IFN", "GENE_OR_GENE_PRODUCT", 25, 28], ["IL-17", "GENE_OR_GENE_PRODUCT", 33, 38], ["intestinal", "ORGAN", 82, 92], ["murine", "ORGANISM", 109, 115], ["Gal-lectin", "GENE_OR_GENE_PRODUCT", 171, 181], ["T cell", "CELL", 206, 212], ["IFN", "GENE_OR_GENE_PRODUCT", 226, 229], ["IFN", "PROTEIN", 25, 28], ["IL-17", "PROTEIN", 33, 38], ["recombinant LecA fragment", "PROTEIN", 138, 163], ["Gal-lectin", "PROTEIN", 171, 181], ["IFN", "PROTEIN", 226, 229], ["murine", "SPECIES", 109, 115], ["IL", "TEST", 33, 35], ["protection", "TREATMENT", 63, 73], ["intestinal amoebiasis", "PROBLEM", 82, 103], ["a murine model vaccinated", "TREATMENT", 107, 132], ["adoptive T cell transfer", "TREATMENT", 197, 221], ["IFN /Il", "TREATMENT", 226, 233], ["neutralizing assays", "TEST", 237, 256], ["intestinal", "ANATOMY", 82, 92], ["amoebiasis", "OBSERVATION", 93, 103]]], ["The source of the protective IFN in our assays is unknown, but it could be from T cells responding specifically to the amoeba antigen as observed in the cell proliferation assays, in which the best protected animals showed higher response to the amoeba extract.", [["T cells", "ANATOMY", 80, 87], ["cell", "ANATOMY", 153, 157], ["extract", "ANATOMY", 253, 260], ["IFN", "GENE_OR_GENE_PRODUCT", 29, 32], ["T cells", "CELL", 80, 87], ["cell", "CELL", 153, 157], ["animals", "ORGANISM", 208, 215], ["IFN", "PROTEIN", 29, 32], ["T cells", "CELL_TYPE", 80, 87], ["amoeba antigen", "PROTEIN", 119, 133], ["the protective IFN", "PROBLEM", 14, 32], ["our assays", "TEST", 36, 46], ["T cells", "PROBLEM", 80, 87], ["the amoeba antigen", "TEST", 115, 133], ["the cell proliferation assays", "TEST", 149, 178], ["protective", "OBSERVATION_MODIFIER", 18, 28], ["IFN", "OBSERVATION", 29, 32], ["cell proliferation assays", "OBSERVATION", 153, 178], ["higher response", "OBSERVATION", 223, 238], ["amoeba extract", "OBSERVATION", 246, 260]]], ["However, NKTs cells as source of the early production of IFN in the liver during the ALA are also well known [43] .", [["NKTs cells", "ANATOMY", 9, 19], ["liver", "ANATOMY", 68, 73], ["ALA", "CHEMICAL", 85, 88], ["ALA", "CHEMICAL", 85, 88], ["NKTs cells", "CELL", 9, 19], ["IFN", "GENE_OR_GENE_PRODUCT", 57, 60], ["liver", "ORGAN", 68, 73], ["ALA", "SIMPLE_CHEMICAL", 85, 88], ["NKTs cells", "CELL_LINE", 9, 19], ["IFN", "PROTEIN", 57, 60], ["NKTs cells", "PROBLEM", 9, 19], ["the early production of IFN in the liver", "PROBLEM", 33, 73], ["early", "OBSERVATION_MODIFIER", 37, 42], ["production", "OBSERVATION_MODIFIER", 43, 53], ["IFN", "OBSERVATION", 57, 60], ["liver", "ANATOMY", 68, 73]]], ["In this regard, interestingly, the wild-type baculovirus was able to confer up to 25% protection by itself, which was also associated with local production of high levels of IFN , suggesting that activation of the innate immune response by the baculovirus, probably IFN from local NKT cells, is partly responsible for the observed protection.", [["NKT cells", "ANATOMY", 281, 290], ["baculovirus", "ORGANISM", 45, 56], ["IFN", "GENE_OR_GENE_PRODUCT", 174, 177], ["baculovirus", "ORGANISM", 244, 255], ["IFN", "GENE_OR_GENE_PRODUCT", 266, 269], ["NKT cells", "CELL", 281, 290], ["IFN", "PROTEIN", 174, 177], ["IFN", "PROTEIN", 266, 269], ["NKT cells", "CELL_TYPE", 281, 290], ["baculovirus", "SPECIES", 45, 56], ["baculovirus", "SPECIES", 244, 255], ["the wild-type baculovirus", "TREATMENT", 31, 56], ["high levels of IFN", "PROBLEM", 159, 177], ["the baculovirus", "TREATMENT", 240, 255], ["IFN", "PROBLEM", 266, 269], ["local NKT cells", "TREATMENT", 275, 290], ["high levels", "OBSERVATION_MODIFIER", 159, 170], ["local NKT cells", "OBSERVATION", 275, 290]]], ["Thus, it has been demonstrated that baculovirus recognition by TL9 leads to the production of various cytokines that triggers innate immunity, including IFN [23] , which in turn has the potential to confer high levels of protection in several experimental models, such as influenza where intranasal immunization with a wild-type baculovirus protected 100% of mice from a lethal challenge [44] .DiscussionIn this report, a correlation of partial and sterile protection against ALA with the local production of high levels of IL-4 was also observed (Figure 4(b) ).", [["influenza", "DISEASE", 272, 281], ["ALA", "CHEMICAL", 476, 479], ["ALA", "CHEMICAL", 476, 479], ["baculovirus", "ORGANISM", 36, 47], ["TL9", "GENE_OR_GENE_PRODUCT", 63, 66], ["baculovirus", "ORGANISM", 329, 340], ["mice", "ORGANISM", 359, 363], ["ALA", "SIMPLE_CHEMICAL", 476, 479], ["IL-4", "GENE_OR_GENE_PRODUCT", 524, 528], ["TL9", "PROTEIN", 63, 66], ["cytokines", "PROTEIN", 102, 111], ["IFN", "PROTEIN", 153, 156], ["IL", "PROTEIN", 524, 526], ["mice", "SPECIES", 359, 363], ["baculovirus", "SPECIES", 36, 47], ["baculovirus", "SPECIES", 329, 340], ["mice", "SPECIES", 359, 363], ["baculovirus recognition", "TREATMENT", 36, 59], ["protection", "TREATMENT", 221, 231], ["influenza", "PROBLEM", 272, 281], ["intranasal immunization", "TREATMENT", 288, 311], ["a wild-type baculovirus", "TREATMENT", 317, 340], ["a lethal challenge", "TREATMENT", 369, 387], ["partial and sterile protection", "TREATMENT", 437, 467], ["ALA", "TREATMENT", 476, 479]]], ["Although the production of IL-4 has been associated with susceptibility to intestinal infection by amoeba [45] , a previous study by our group using lactoferrin as an oral therapy for the treatment of intestinal amebiasis in C3H/HeJ mice showed production of this cytokine in tissue of ceca from animal cured [46] .", [["intestinal", "ANATOMY", 75, 85], ["oral", "ANATOMY", 167, 171], ["intestinal", "ANATOMY", 201, 211], ["tissue", "ANATOMY", 276, 282], ["ceca", "ANATOMY", 286, 290], ["intestinal infection", "DISEASE", 75, 95], ["intestinal amebiasis", "DISEASE", 201, 221], ["IL-4", "GENE_OR_GENE_PRODUCT", 27, 31], ["intestinal", "ORGAN", 75, 85], ["lactoferrin", "GENE_OR_GENE_PRODUCT", 149, 160], ["oral", "ORGANISM_SUBDIVISION", 167, 171], ["intestinal amebiasis", "PATHOLOGICAL_FORMATION", 201, 221], ["C3H/HeJ mice", "ORGANISM", 225, 237], ["tissue", "TISSUE", 276, 282], ["ceca", "ORGAN", 286, 290], ["IL-4", "PROTEIN", 27, 31], ["lactoferrin", "PROTEIN", 149, 160], ["cytokine", "PROTEIN", 264, 272], ["mice", "SPECIES", 233, 237], ["mice", "SPECIES", 233, 237], ["intestinal infection", "PROBLEM", 75, 95], ["a previous study", "TEST", 113, 129], ["lactoferrin", "TREATMENT", 149, 160], ["an oral therapy", "TREATMENT", 164, 179], ["the treatment", "TREATMENT", 184, 197], ["intestinal amebiasis", "PROBLEM", 201, 221], ["C3H/HeJ mice", "TREATMENT", 225, 237], ["intestinal", "ANATOMY", 75, 85], ["infection", "OBSERVATION", 86, 95], ["intestinal", "ANATOMY", 201, 211], ["amebiasis", "OBSERVATION", 212, 221], ["ceca", "ANATOMY", 286, 290]]], ["As we suggest in such paper, it is likely that the production of IL-4 is the result of a feedback mechanism for controlling excessive inflammation (a typical feature of the intestinal mouse and liver hamster amoebiasis), restoring the physiological antiinflammatory state that predominates in both intestine and liver.", [["intestinal", "ANATOMY", 173, 183], ["liver hamster", "ANATOMY", 194, 207], ["intestine", "ANATOMY", 298, 307], ["liver", "ANATOMY", 312, 317], ["inflammation", "DISEASE", 134, 146], ["amoebiasis", "DISEASE", 208, 218], ["IL-4", "GENE_OR_GENE_PRODUCT", 65, 69], ["intestinal", "ORGAN", 173, 183], ["mouse", "ORGANISM", 184, 189], ["liver", "ORGAN", 194, 199], ["hamster amoebiasis", "ORGANISM", 200, 218], ["intestine", "ORGAN", 298, 307], ["liver", "ORGAN", 312, 317], ["IL-4", "PROTEIN", 65, 69], ["mouse", "SPECIES", 184, 189], ["hamster", "SPECIES", 200, 207], ["mouse", "SPECIES", 184, 189], ["hamster", "SPECIES", 200, 207], ["a feedback mechanism", "PROBLEM", 87, 107], ["excessive inflammation", "PROBLEM", 124, 146], ["the intestinal mouse and liver hamster amoebiasis", "PROBLEM", 169, 218], ["the physiological antiinflammatory state", "PROBLEM", 231, 271], ["inflammation", "OBSERVATION", 134, 146], ["intestinal mouse", "ANATOMY", 173, 189], ["liver", "ANATOMY", 194, 199], ["antiinflammatory state", "OBSERVATION", 249, 271], ["both", "ANATOMY_MODIFIER", 293, 297], ["intestine", "ANATOMY", 298, 307], ["liver", "ANATOMY", 312, 317]]], ["IL-4 also augments fibroblast growth and collagen production during granulomas formation, a characteristic mark of the chronic development of ALA [47] , a reaction trying to contain the infection.", [["fibroblast", "ANATOMY", 19, 29], ["granulomas", "ANATOMY", 68, 78], ["granulomas", "DISEASE", 68, 78], ["ALA", "CHEMICAL", 142, 145], ["infection", "DISEASE", 186, 195], ["ALA", "CHEMICAL", 142, 145], ["IL-4", "GENE_OR_GENE_PRODUCT", 0, 4], ["fibroblast", "CELL", 19, 29], ["collagen", "GENE_OR_GENE_PRODUCT", 41, 49], ["granulomas", "PATHOLOGICAL_FORMATION", 68, 78], ["ALA", "SIMPLE_CHEMICAL", 142, 145], ["IL-4", "PROTEIN", 0, 4], ["collagen", "PROTEIN", 41, 49], ["IL", "TREATMENT", 0, 2], ["augments fibroblast growth", "TREATMENT", 10, 36], ["collagen production during granulomas formation", "PROBLEM", 41, 88], ["a reaction", "PROBLEM", 153, 163], ["the infection", "PROBLEM", 182, 195], ["fibroblast", "OBSERVATION_MODIFIER", 19, 29], ["growth", "OBSERVATION_MODIFIER", 30, 36], ["collagen production", "OBSERVATION", 41, 60], ["granulomas", "OBSERVATION", 68, 78], ["mark", "OBSERVATION_MODIFIER", 107, 111], ["chronic", "OBSERVATION_MODIFIER", 119, 126], ["ALA", "OBSERVATION_MODIFIER", 142, 145], ["infection", "OBSERVATION", 186, 195]]], ["Thus, it is possible that the role of IL-4 depends on whether liver abscesses develop or not, so contributing to the formation of granulomas at later stages if ALA develops or decreasing excessive inflammation at earlier stages.DiscussionProtection against ALA in hamsters was also associated with the induction of serum anti-amoebic antibodies, particularly IgG (Figure 2 ).", [["liver abscesses", "ANATOMY", 62, 77], ["granulomas", "ANATOMY", 130, 140], ["serum", "ANATOMY", 315, 320], ["liver abscesses", "DISEASE", 62, 77], ["granulomas", "DISEASE", 130, 140], ["ALA", "CHEMICAL", 160, 163], ["inflammation", "DISEASE", 197, 209], ["ALA", "CHEMICAL", 257, 260], ["ALA", "CHEMICAL", 160, 163], ["ALA", "CHEMICAL", 257, 260], ["IL-4", "GENE_OR_GENE_PRODUCT", 38, 42], ["liver", "ORGAN", 62, 67], ["abscesses", "PATHOLOGICAL_FORMATION", 68, 77], ["granulomas", "PATHOLOGICAL_FORMATION", 130, 140], ["ALA", "SIMPLE_CHEMICAL", 160, 163], ["ALA", "SIMPLE_CHEMICAL", 257, 260], ["hamsters", "ORGANISM", 264, 272], ["serum", "ORGANISM_SUBSTANCE", 315, 320], ["IL-4", "PROTEIN", 38, 42], ["serum anti-amoebic antibodies", "PROTEIN", 315, 344], ["IgG", "PROTEIN", 359, 362], ["hamsters", "SPECIES", 264, 272], ["liver abscesses", "PROBLEM", 62, 77], ["granulomas", "PROBLEM", 130, 140], ["ALA", "PROBLEM", 160, 163], ["decreasing excessive inflammation", "PROBLEM", 176, 209], ["serum anti-amoebic antibodies", "TEST", 315, 344], ["liver", "ANATOMY", 62, 67], ["abscesses", "OBSERVATION", 68, 77], ["granulomas", "OBSERVATION", 130, 140], ["decreasing", "OBSERVATION_MODIFIER", 176, 186], ["excessive", "OBSERVATION_MODIFIER", 187, 196], ["inflammation", "OBSERVATION", 197, 209]]], ["This is consistent with a variety of previous studies demonstrating that antibodies are important in protection against amoeba, particularly secretory IgA against intestinal amebiasis, and serum IgG and IgA against hepatic amoebiasis [48, 49] .", [["intestinal", "ANATOMY", 163, 173], ["serum", "ANATOMY", 189, 194], ["hepatic", "ANATOMY", 215, 222], ["intestinal amebiasis", "DISEASE", 163, 183], ["hepatic amoebiasis", "DISEASE", 215, 233], ["IgA", "GENE_OR_GENE_PRODUCT", 151, 154], ["intestinal", "ORGAN", 163, 173], ["serum", "ORGANISM_SUBSTANCE", 189, 194], ["IgG", "GENE_OR_GENE_PRODUCT", 195, 198], ["IgA", "GENE_OR_GENE_PRODUCT", 203, 206], ["antibodies", "PROTEIN", 73, 83], ["secretory IgA", "PROTEIN", 141, 154], ["serum IgG", "PROTEIN", 189, 198], ["IgA", "PROTEIN", 203, 206], ["previous studies", "TEST", 37, 53], ["antibodies", "PROBLEM", 73, 83], ["amoeba", "PROBLEM", 120, 126], ["secretory IgA", "TEST", 141, 154], ["intestinal amebiasis", "PROBLEM", 163, 183], ["serum IgG", "TEST", 189, 198], ["IgA", "TEST", 203, 206], ["hepatic amoebiasis", "PROBLEM", 215, 233], ["consistent with", "UNCERTAINTY", 8, 23], ["intestinal", "ANATOMY", 163, 173], ["amebiasis", "OBSERVATION", 174, 183], ["hepatic", "ANATOMY", 215, 222], ["amoebiasis", "OBSERVATION", 223, 233]]], ["It is possible that the high levels of IFN observed in protected hamsters have also contributed to the increased production of IgG antibodies mentioned, mainly IgG2a isotype (Th1 response), linking the two arms of the immune response in the liver infection by E. histolytica.", [["liver", "ANATOMY", 241, 246], ["IFN", "CHEMICAL", 39, 42], ["liver infection", "DISEASE", 241, 256], ["IFN", "GENE_OR_GENE_PRODUCT", 39, 42], ["hamsters", "ORGANISM", 65, 73], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 127, 141], ["IgG2a", "GENE_OR_GENE_PRODUCT", 160, 165], ["liver", "ORGAN", 241, 246], ["E. histolytica", "ORGANISM", 260, 274], ["IFN", "PROTEIN", 39, 42], ["IgG antibodies", "PROTEIN", 127, 141], ["IgG2a isotype", "PROTEIN", 160, 173], ["E. histolytica", "SPECIES", 260, 274], ["hamsters", "SPECIES", 65, 73], ["E. histolytica", "SPECIES", 260, 274], ["the high levels of IFN", "PROBLEM", 20, 42], ["the increased production of IgG antibodies", "PROBLEM", 99, 141], ["the liver infection", "PROBLEM", 237, 256], ["high", "OBSERVATION_MODIFIER", 24, 28], ["increased", "OBSERVATION_MODIFIER", 103, 112], ["IgG antibodies", "OBSERVATION", 127, 141], ["IgG2a isotype", "OBSERVATION", 160, 173], ["immune response", "OBSERVATION", 218, 233], ["liver", "ANATOMY", 241, 246], ["infection", "OBSERVATION", 247, 256]]], ["Taken together, the results suggest that both responses, cellular and humoral anti-LC3 fragment of the Gal-lectin, are important for the development of resistance in hamsters against ALA.DiscussionImmunization in humans has always faced with the difficulty of identifying safe adjuvants that do not generate unwanted side effects.", [["cellular", "ANATOMY", 57, 65], ["ALA", "CHEMICAL", 183, 186], ["ALA", "CHEMICAL", 183, 186], ["cellular", "CELL", 57, 65], ["Gal-lectin", "GENE_OR_GENE_PRODUCT", 103, 113], ["hamsters", "ORGANISM", 166, 174], ["ALA", "SIMPLE_CHEMICAL", 183, 186], ["humans", "ORGANISM", 213, 219], ["anti-LC3 fragment", "PROTEIN", 78, 95], ["Gal-lectin", "PROTEIN", 103, 113], ["hamsters", "SPECIES", 166, 174], ["humans", "SPECIES", 213, 219], ["hamsters", "SPECIES", 166, 174], ["humans", "SPECIES", 213, 219], ["cellular and humoral anti-LC3 fragment", "PROBLEM", 57, 95], ["ALA", "PROBLEM", 183, 186], ["safe adjuvants", "TREATMENT", 272, 286], ["Gal-lectin", "ANATOMY", 103, 113], ["resistance", "OBSERVATION", 152, 162]]], ["Most protection assays against intestinal and/or liver amoebiasis described above used toxins derived from bacteria or mineral or vegetable oils suspensions, which although inducing a good immune response also usually generate local or systemic inflammatory responses that can have implications for the health of the vaccinated subject [50] .", [["intestinal", "ANATOMY", 31, 41], ["liver", "ANATOMY", 49, 54], ["vegetable oils", "ANATOMY", 130, 144], ["amoebiasis", "DISEASE", 55, 65], ["intestinal", "ORGAN", 31, 41], ["liver", "ORGAN", 49, 54], ["mineral", "SIMPLE_CHEMICAL", 119, 126], ["intestinal and/or liver amoebiasis", "PROBLEM", 31, 65], ["toxins", "PROBLEM", 87, 93], ["bacteria", "PROBLEM", 107, 115], ["mineral or vegetable oils suspensions", "TREATMENT", 119, 156], ["systemic inflammatory responses", "PROBLEM", 236, 267], ["intestinal", "ANATOMY", 31, 41], ["liver", "ANATOMY", 49, 54], ["amoebiasis", "OBSERVATION", 55, 65], ["inflammatory", "OBSERVATION", 245, 257]]], ["In this work, we reinforce the probability of using recombinant baculovirus system as an alternative approach to the use of toxic adjuvants for the safe release of amoeba antigens into mammals, due to its per se capacity of stimulating the innate immune response, and, thus, conditioning the generation of a specific antiamoeba adaptive immune response.", [["baculovirus", "ORGANISM", 64, 75], ["amoeba antigens", "PROTEIN", 164, 179], ["baculovirus", "SPECIES", 64, 75], ["recombinant baculovirus system", "TREATMENT", 52, 82], ["toxic adjuvants", "TREATMENT", 124, 139], ["the safe release of amoeba antigens", "TREATMENT", 144, 179]]], ["In this sense, many studies demonstrating the phenotypic and functional maturation of dendritic cells and macrophages as well as direct activation of B cells induced by AcNPV, resulting in antigen presentation and Th1 responses, have been reported [51, 52] .", [["dendritic cells", "ANATOMY", 86, 101], ["macrophages", "ANATOMY", 106, 117], ["B cells", "ANATOMY", 150, 157], ["dendritic cells", "CELL", 86, 101], ["macrophages", "CELL", 106, 117], ["B cells", "CELL", 150, 157], ["AcNPV", "GENE_OR_GENE_PRODUCT", 169, 174], ["dendritic cells", "CELL_TYPE", 86, 101], ["macrophages", "CELL_TYPE", 106, 117], ["B cells", "CELL_TYPE", 150, 157], ["AcNPV", "PROTEIN", 169, 174], ["many studies", "TEST", 15, 27], ["the phenotypic", "PROBLEM", 42, 56], ["dendritic cells", "PROBLEM", 86, 101], ["macrophages", "PROBLEM", 106, 117], ["B cells", "PROBLEM", 150, 157], ["AcNPV", "TREATMENT", 169, 174], ["dendritic cells", "OBSERVATION", 86, 101]]], ["Noteworthy, the acceptability for using baculovirus in humans has been recently increased with ongoing trials of gene therapy based on the use of such viruses as delivery system [53] , which lays the foundation for safe and extended use of recombinant baculovirus systems in other areas such as vaccines [54] .DiscussionFinally, further studies of T cell adoptive transfer and neutralization of cytokines, IFN and probably IL-17, are needed for determining the mechanisms underlying protection against ALA in baculovirus-immunized hamsters, as well as immunization studies using AcNPV-LC3 in an animal model closer to humans such as primates, in order to determine the safety and effectiveness of this system with view to its use as a strategy of vaccination against amoebiasis in humans.", [["T cell", "ANATOMY", 348, 354], ["ALA", "CHEMICAL", 502, 505], ["amoebiasis", "DISEASE", 767, 777], ["ALA", "CHEMICAL", 502, 505], ["baculovirus", "ORGANISM", 40, 51], ["humans", "ORGANISM", 55, 61], ["baculovirus", "ORGANISM", 252, 263], ["T cell", "CELL", 348, 354], ["IFN", "GENE_OR_GENE_PRODUCT", 406, 409], ["IL-17", "GENE_OR_GENE_PRODUCT", 423, 428], ["ALA", "SIMPLE_CHEMICAL", 502, 505], ["baculovirus", "ORGANISM", 509, 520], ["hamsters", "ORGANISM", 531, 539], ["AcNPV-LC3", "GENE_OR_GENE_PRODUCT", 579, 588], ["humans", "ORGANISM", 618, 624], ["primates", "ORGANISM", 633, 641], ["humans", "ORGANISM", 781, 787], ["cytokines", "PROTEIN", 395, 404], ["IFN", "PROTEIN", 406, 409], ["IL-17", "PROTEIN", 423, 428], ["AcNPV", "PROTEIN", 579, 584], ["LC3", "PROTEIN", 585, 588], ["humans", "SPECIES", 55, 61], ["hamsters", "SPECIES", 531, 539], ["humans", "SPECIES", 618, 624], ["humans", "SPECIES", 781, 787], ["baculovirus", "SPECIES", 40, 51], ["humans", "SPECIES", 55, 61], ["baculovirus", "SPECIES", 252, 263], ["baculovirus", "SPECIES", 509, 520], ["hamsters", "SPECIES", 531, 539], ["humans", "SPECIES", 618, 624], ["humans", "SPECIES", 781, 787], ["baculovirus", "TREATMENT", 40, 51], ["gene therapy", "TREATMENT", 113, 125], ["such viruses as delivery system", "TREATMENT", 146, 177], ["recombinant baculovirus systems", "TREATMENT", 240, 271], ["further studies", "TEST", 329, 344], ["T cell adoptive transfer", "TREATMENT", 348, 372], ["neutralization of cytokines", "TREATMENT", 377, 404], ["IFN", "TREATMENT", 406, 409], ["IL", "TEST", 423, 425], ["ALA in baculovirus", "TREATMENT", 502, 520], ["immunization studies", "TEST", 552, 572], ["AcNPV", "TREATMENT", 579, 584], ["LC3", "TREATMENT", 585, 588], ["a strategy of vaccination", "TREATMENT", 733, 758], ["amoebiasis in humans", "PROBLEM", 767, 787]]]], "3d56e7b050105e0caa25bf0767740e0d71467340": [["more than 1.5 billion students, and 63 million teachers of children found themselves confined.", [["children", "ORGANISM", 59, 67], ["children", "SPECIES", 59, 67]]]], "85f0fe06df221d355fc228db1495a4f940e7c9b7": [[": Utility estimates under main model, all participants.", [["participants", "SPECIES", 42, 54], ["main model", "OBSERVATION_MODIFIER", 26, 36]]], ["The utility for all unlisted levels are set to 0.", [["all unlisted levels", "TEST", 16, 35]]], ["For the all-participant, the utility for 180 deaths is anchored to \u2212 .", [["deaths", "DISEASE", 45, 51]]], ["For mortality-averse and expenditure-averse results, 95% CI is the 95% equal-tailed confidence interval for the posterior mean utility.", [["the posterior mean utility", "TEST", 108, 134], ["posterior", "ANATOMY_MODIFIER", 112, 121]]]], "0239ee460a61e7ec69c58fcd98bd6b4f87d87aeb": [["IntroductionUnder genome stresses such as DNA damage, hypoxia, and aberrant oncogene signals, cells can trigger self-defensive mechanisms to fight against acute perturbations from the outside [1] [2] [3] .", [["cells", "ANATOMY", 94, 99], ["hypoxia", "DISEASE", 54, 61], ["DNA", "CELLULAR_COMPONENT", 42, 45], ["cells", "CELL", 94, 99], ["DNA damage", "PROBLEM", 42, 52], ["hypoxia", "PROBLEM", 54, 61], ["aberrant oncogene signals", "PROBLEM", 67, 92], ["acute perturbations", "PROBLEM", 155, 174]]], ["One of the critical responses is the activation of the p53 tumor suppressor, which is the pivotal anticancer gene within the cell [3, 4] . p53 can induce or repress transcription and translation of a series of downstream genes, and further control cell cycle arrest and apoptosis [3] [4] [5] .", [["tumor", "ANATOMY", 59, 64], ["anticancer", "ANATOMY", 98, 108], ["cell", "ANATOMY", 125, 129], ["cell", "ANATOMY", 248, 252], ["tumor", "DISEASE", 59, 64], ["p53", "GENE_OR_GENE_PRODUCT", 55, 58], ["tumor", "CANCER", 59, 64], ["anticancer", "CANCER", 98, 108], ["cell", "CELL", 125, 129], ["p53", "GENE_OR_GENE_PRODUCT", 139, 142], ["cell", "CELL", 248, 252], ["[3] [4] [5]", "SIMPLE_CHEMICAL", 280, 291], ["p53 tumor suppressor", "DNA", 55, 75], ["p53", "PROTEIN", 139, 142], ["downstream genes", "DNA", 210, 226], ["the p53 tumor suppressor", "TREATMENT", 51, 75], ["a series of downstream genes", "TREATMENT", 198, 226], ["further control cell cycle arrest", "TREATMENT", 232, 265], ["apoptosis", "TEST", 270, 279], ["p53", "OBSERVATION", 55, 58], ["tumor suppressor", "OBSERVATION", 59, 75], ["pivotal", "OBSERVATION_MODIFIER", 90, 97], ["anticancer gene", "OBSERVATION", 98, 113]]], ["These functions are important to repair DNA damage and to eliminate abnormal cells with DNA damage or deregulated proliferation, especially to modulate the activity of anticancer agents [6] [7] [8] .IntroductionRecently, several models have been proposed to explain the damped oscillations of p53 in cell populations [6] [7] [8] [9] [10] [11] .", [["cells", "ANATOMY", 77, 82], ["anticancer", "ANATOMY", 168, 178], ["cell", "ANATOMY", 300, 304], ["DNA", "CELLULAR_COMPONENT", 40, 43], ["cells", "CELL", 77, 82], ["DNA", "CELLULAR_COMPONENT", 88, 91], ["anticancer", "CANCER", 168, 178], ["[6] [7] [8]", "SIMPLE_CHEMICAL", 186, 197], ["p53", "GENE_OR_GENE_PRODUCT", 293, 296], ["cell", "CELL", 300, 304], ["[6] [7] [8] [9] [10] [11]", "SIMPLE_CHEMICAL", 317, 342], ["abnormal cells", "CELL_TYPE", 68, 82], ["p53", "PROTEIN", 293, 296], ["DNA damage", "PROBLEM", 40, 50], ["abnormal cells", "PROBLEM", 68, 82], ["DNA damage", "PROBLEM", 88, 98], ["deregulated proliferation", "PROBLEM", 102, 127], ["anticancer agents", "TREATMENT", 168, 185], ["the damped oscillations of p53 in cell populations", "PROBLEM", 266, 316], ["deregulated proliferation", "OBSERVATION", 102, 127]]], ["However, the complicated mechanisms of cellular responses to genome stresses need to be further addressed.", [["cellular", "ANATOMY", 39, 47], ["cellular", "CELL", 39, 47], ["cellular responses", "PROBLEM", 39, 57], ["genome stresses", "PROBLEM", 61, 76]]], ["Based on the previous models [9] [10] [11] [12] [13] [14] and stimulated by the impact of bioinformatics approaches on the biomedicine [15] , a dynamic model of p53 stress response networks under continuous ion radiation (IR) at the cellular level is proposed along with the kinetics of double-strand breaks (DSBs) generation and repair, ataxia telangiectasia mutated (ATM) activation, p53-MDM2 (murine double mimute2) feedback loop, as well as the toxins elimination module.", [["cellular", "ANATOMY", 233, 241], ["ataxia telangiectasia", "DISEASE", 338, 359], ["[9] [10] [11] [12] [13] [14]", "SIMPLE_CHEMICAL", 29, 57], ["p53", "GENE_OR_GENE_PRODUCT", 161, 164], ["cellular", "CELL", 233, 241], ["DSBs", "CELLULAR_COMPONENT", 309, 313], ["ataxia telangiectasia mutated", "GENE_OR_GENE_PRODUCT", 338, 367], ["ATM", "GENE_OR_GENE_PRODUCT", 369, 372], ["p53", "GENE_OR_GENE_PRODUCT", 386, 389], ["MDM2", "GENE_OR_GENE_PRODUCT", 390, 394], ["murine double mimute2", "GENE_OR_GENE_PRODUCT", 396, 417], ["p53", "PROTEIN", 161, 164], ["ATM", "PROTEIN", 369, 372], ["p53", "PROTEIN", 386, 389], ["MDM2", "PROTEIN", 390, 394], ["murine", "SPECIES", 396, 402], ["the previous models", "TEST", 9, 28], ["continuous ion radiation (IR", "TREATMENT", 196, 224], ["double-strand breaks (DSBs) generation", "TREATMENT", 287, 325], ["repair", "TREATMENT", 330, 336], ["ataxia telangiectasia", "PROBLEM", 338, 359], ["p53", "TEST", 386, 389], ["MDM2 (murine double mimute2) feedback loop", "TREATMENT", 390, 432], ["strand breaks", "OBSERVATION", 294, 307], ["ataxia telangiectasia", "OBSERVATION", 338, 359]]], ["Furthermore, the plausible outcomes of cellular responses were analyzed under different IR dose domains.IntroductionThe combined approaches of system analysis, control theory, and computer science can simulate the complicated mechanisms of cellular response to genome stresses [15, 16] .", [["cellular", "ANATOMY", 39, 47], ["cellular", "ANATOMY", 240, 248], ["cellular", "CELL", 39, 47], ["cellular", "CELL", 240, 248], ["system analysis", "TEST", 143, 158], ["cellular response", "OBSERVATION", 240, 257]]], ["Using differential equations and graphic approaches to study various dynamical and kinetic processes of biological systems has provided insights into a series of important biological topics such as enzyme-catalyzed reactions [18] [19] [20] [21] , diffusion-controlled reactions in enzyme systems [22, 23] , protein-folding kinetics [24] , inhibition kinetics of processive nucleic acid polymerases and nucleases [25, 26] , base frequencies in the anti-sense strands [27] , hepatitis B viral infections [28] , HBV virus gene missense mutation [29] , and visual analysis of SARS-CoV [30, 31] .", [["nucleic acid", "CHEMICAL", 373, 385], ["hepatitis B viral infections", "DISEASE", 473, 501], ["SARS", "DISEASE", 572, 576], ["[18] [19] [20] [21]", "SIMPLE_CHEMICAL", 225, 244], ["hepatitis B viral", "ORGANISM", 473, 490], ["HBV virus", "ORGANISM", 509, 518], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 572, 580], ["processive nucleic acid polymerases", "PROTEIN", 362, 397], ["nucleases", "PROTEIN", 402, 411], ["HBV virus", "SPECIES", 509, 518], ["HBV virus", "SPECIES", 509, 518], ["SARS-CoV", "SPECIES", 572, 580], ["differential equations", "TEST", 6, 28], ["graphic approaches", "TEST", 33, 51], ["enzyme-catalyzed reactions", "TEST", 198, 224], ["diffusion-controlled reactions in enzyme systems", "TEST", 247, 295], ["protein-folding kinetics", "TEST", 307, 331], ["inhibition kinetics", "TEST", 339, 358], ["processive nucleic acid polymerases", "TREATMENT", 362, 397], ["nucleases", "TEST", 402, 411], ["base frequencies", "TEST", 423, 439], ["the anti-sense strands", "TEST", 443, 465], ["hepatitis B viral infections", "PROBLEM", 473, 501], ["HBV virus gene missense mutation", "PROBLEM", 509, 541], ["visual analysis", "TEST", 553, 568]]], ["In this study, we used differential equations and graphic methods to investigate the dynamic and kinetic processes of cellular responses to DNA damage under continuous IR.Model overviewUnder genome stress, numerous co-factors are involved in enhancing p53-mediated transcription [32] .", [["cellular", "ANATOMY", 118, 126], ["cellular", "CELL", 118, 126], ["DNA", "CELLULAR_COMPONENT", 140, 143], ["p53", "GENE_OR_GENE_PRODUCT", 252, 255], ["p53", "PROTEIN", 252, 255], ["this study", "TEST", 3, 13], ["differential equations", "TEST", 23, 45], ["graphic methods", "TEST", 50, 65], ["DNA damage", "PROBLEM", 140, 150], ["continuous IR", "TREATMENT", 157, 170], ["genome stress", "OBSERVATION", 191, 204]]], ["In the DSBs generation and repair module, acute IR induces DSBs stochastically and forms DSB-protein complexes (DSBCs) at each of the damaged sites by interaction of the DSB with the DNA repair proteins (RPs).", [["sites", "ANATOMY", 142, 147], ["DSBs", "CELLULAR_COMPONENT", 7, 11], ["DSBs", "CELLULAR_COMPONENT", 59, 63], ["DSB-protein complexes", "GENE_OR_GENE_PRODUCT", 89, 110], ["DSB", "CELLULAR_COMPONENT", 170, 173], ["DNA", "CELLULAR_COMPONENT", 183, 186], ["DSB-protein complexes", "PROTEIN", 89, 110], ["DSBCs", "PROTEIN", 112, 117], ["DSB", "PROTEIN", 170, 173], ["DNA repair proteins", "PROTEIN", 183, 202], ["RPs", "PROTEIN", 204, 207], ["repair module", "TREATMENT", 27, 40], ["acute IR induces DSBs stochastically", "PROBLEM", 42, 78], ["DSB-protein complexes", "TEST", 89, 110], ["DSBCs", "TEST", 112, 117], ["the DNA repair proteins", "TREATMENT", 179, 202], ["DSBs generation", "OBSERVATION", 7, 22], ["repair module", "OBSERVATION", 27, 40], ["acute", "OBSERVATION_MODIFIER", 42, 47], ["DSBs stochastically", "OBSERVATION", 59, 78]]], ["As a sensor of genome stress, ATM is activated by the DSBCs signal transferred from DSBs.", [["ATM", "GENE_OR_GENE_PRODUCT", 30, 33], ["DSBCs", "GENE_OR_GENE_PRODUCT", 54, 59], ["DSBs", "CELLULAR_COMPONENT", 84, 88], ["ATM", "PROTEIN", 30, 33], ["DSBCs", "PROTEIN", 54, 59], ["genome stress", "PROBLEM", 15, 28]]], ["ATM activation switches on or off the p53-MDM2 feedback loop, further regulating the downstream genes to control cell cycle arrest and apoptosis in response to genome stress [33, 34] .DSB generation and repairUnder the continuous effect of acute IR, DSBs occur and trigger two major repair mechanisms in eukaryotic cells: homologous recombination (HR) and non-homologous end joining (NHEJ) [35, 36] .", [["cell", "ANATOMY", 113, 117], ["cells", "ANATOMY", 315, 320], ["DSB", "CHEMICAL", 184, 187], ["ATM", "GENE_OR_GENE_PRODUCT", 0, 3], ["p53", "GENE_OR_GENE_PRODUCT", 38, 41], ["MDM2", "GENE_OR_GENE_PRODUCT", 42, 46], ["cell", "CELL", 113, 117], ["DSB", "CELLULAR_COMPONENT", 184, 187], ["DSBs", "CELLULAR_COMPONENT", 250, 254], ["cells", "CELL", 315, 320], ["ATM", "PROTEIN", 0, 3], ["p53", "PROTEIN", 38, 41], ["MDM2", "PROTEIN", 42, 46], ["downstream genes", "DNA", 85, 101], ["eukaryotic cells", "CELL_TYPE", 304, 320], ["ATM activation switches", "TREATMENT", 0, 23], ["the p53", "TREATMENT", 34, 41], ["MDM2 feedback loop", "TREATMENT", 42, 60], ["the downstream genes", "TREATMENT", 81, 101], ["cell cycle arrest", "TREATMENT", 113, 130], ["apoptosis", "PROBLEM", 135, 144], ["genome stress", "TEST", 160, 173], ["DSB generation", "TREATMENT", 184, 198], ["repairUnder", "TREATMENT", 203, 214], ["acute IR", "TREATMENT", 240, 248], ["DSBs", "PROBLEM", 250, 254], ["two major repair", "TREATMENT", 273, 289], ["homologous recombination", "TREATMENT", 322, 346], ["cell cycle arrest", "OBSERVATION", 113, 130], ["acute", "OBSERVATION_MODIFIER", 240, 245], ["eukaryotic cells", "OBSERVATION", 304, 320]]], ["About 60-80% of DSBs are rejoined quickly, whereas the remaining 20-40% of DSBs are rejoined more slowly [37, 38] .", [["DSBs", "ANATOMY", 16, 20], ["DSBs", "CELLULAR_COMPONENT", 16, 20], ["DSBs", "CELLULAR_COMPONENT", 75, 79], ["DSBs", "TEST", 75, 79]]], ["As shown in Fig. 2 , the module of DSBs repair process contains both the fast kinetics and the slow kinetics, each is composed of a reversible binding of RPs and DSB lesions into DSBCs, and an irreversible process from the DSBCs to the fixed DSBs [35, 38] .", [["lesions", "ANATOMY", 166, 173], ["DSBCs", "ANATOMY", 179, 184], ["DSBs", "CELLULAR_COMPONENT", 35, 39], ["RPs", "GENE_OR_GENE_PRODUCT", 154, 157], ["DSBCs", "PATHOLOGICAL_FORMATION", 179, 184], ["DSBCs", "SIMPLE_CHEMICAL", 223, 228], ["DSBCs", "CELL_TYPE", 179, 184], ["DSBs repair process", "TREATMENT", 35, 54], ["the slow kinetics", "PROBLEM", 91, 108], ["a reversible binding of RPs", "PROBLEM", 130, 157], ["DSB lesions into DSBCs", "PROBLEM", 162, 184], ["an irreversible process", "PROBLEM", 190, 213], ["the fixed DSBs", "TEST", 232, 246], ["Fig", "OBSERVATION", 12, 15], ["DSBs repair", "OBSERVATION", 35, 46], ["both", "OBSERVATION_MODIFIER", 64, 68], ["fast kinetics", "OBSERVATION", 73, 86], ["slow kinetics", "OBSERVATION", 95, 108], ["reversible", "OBSERVATION_MODIFIER", 132, 142], ["DSB lesions", "OBSERVATION", 162, 173], ["irreversible", "OBSERVATION_MODIFIER", 193, 205], ["process", "OBSERVATION", 206, 213]]], ["DSBCs are synthesized by binding the resulting DSBs with RPs, which is the main signal source to transfer the DNA damage to the p53-MDM2 feedback loop by ATM activation [2, 39, 40] .DSB generation and repairIn our model, we assume that the same repair enzymes are used in both the fast and slow repair processes.", [["DSBCs", "ANATOMY", 0, 5], ["DSBCs", "SIMPLE_CHEMICAL", 0, 5], ["DSBs", "CELLULAR_COMPONENT", 47, 51], ["RPs", "GENE_OR_GENE_PRODUCT", 57, 60], ["DNA", "CELLULAR_COMPONENT", 110, 113], ["p53", "GENE_OR_GENE_PRODUCT", 128, 131], ["MDM2", "GENE_OR_GENE_PRODUCT", 132, 136], ["ATM", "GENE_OR_GENE_PRODUCT", 154, 157], ["DSBCs", "CELL_TYPE", 0, 5], ["RPs", "PROTEIN", 57, 60], ["p53", "PROTEIN", 128, 131], ["MDM2", "PROTEIN", 132, 136], ["ATM", "PROTEIN", 154, 157], ["repair enzymes", "PROTEIN", 245, 259], ["RPs", "TEST", 57, 60], ["the DNA damage", "PROBLEM", 106, 120], ["the same repair enzymes", "TEST", 236, 259], ["slow repair processes", "TREATMENT", 290, 311], ["slow", "OBSERVATION_MODIFIER", 290, 294], ["repair", "OBSERVATION", 295, 301]]], ["Especially, DSBCs and RPs are treated as the dynamic variables [7] [8] [9] [10] , and limited RPs are available around DNA damage sites [12] [13] [14] .", [["DSBCs", "SIMPLE_CHEMICAL", 12, 17], ["RPs", "CELLULAR_COMPONENT", 22, 25], ["[7] [8] [9] [10]", "SIMPLE_CHEMICAL", 63, 79], ["DNA", "CELLULAR_COMPONENT", 119, 122], ["DSBCs", "CELL_TYPE", 12, 17], ["DSBCs", "TEST", 12, 17], ["RPs", "TEST", 22, 25], ["the dynamic variables", "TEST", 41, 62], ["DNA damage sites", "TEST", 119, 135]]], ["Considering that the misrepair part of DSBs (F w ) has profound consequences for subsequent cellular viability and the cellular response to genome stress [1, 3] , we obviously distinguish between the correct repair part of DSBs (F r ) and F w [12] [13] [14] .", [["cellular", "ANATOMY", 92, 100], ["cellular", "ANATOMY", 119, 127], ["DSBs", "CELLULAR_COMPONENT", 39, 43], ["cellular", "CELL", 92, 100], ["cellular", "CELL", 119, 127], ["DSBs", "CELLULAR_COMPONENT", 223, 227], ["subsequent cellular viability", "PROBLEM", 81, 110], ["genome stress", "TEST", 140, 153], ["DSBs (F r ) and F w", "TEST", 223, 242], ["cellular viability", "OBSERVATION", 92, 110], ["repair", "OBSERVATION", 208, 214]]], ["Moreover, we further deal with the total F w in both repair processes as parts of the toxins within the cell [2, 4, 15] , which can be eliminated by the regulatory functions of p53, and are used as an indicator of outcomes in cellular response to genome stress [32] [33] [34] [35] .DSB generation and repairSome experimental data suggest that the quantity of the resulting DSBs induced by different IR doses obey a Poisson distribution [10] .", [["cell", "ANATOMY", 104, 108], ["cellular", "ANATOMY", 226, 234], ["cell", "CELL", 104, 108], ["p53", "GENE_OR_GENE_PRODUCT", 177, 180], ["cellular", "CELL", 226, 234], ["DSBs", "CELLULAR_COMPONENT", 373, 377], ["p53", "PROTEIN", 177, 180], ["the total F w in both repair processes", "TREATMENT", 31, 69], ["genome stress", "TEST", 247, 260], ["DSB generation", "TREATMENT", 282, 296], ["repairSome experimental data", "TEST", 301, 329], ["the resulting DSBs", "PROBLEM", 359, 377], ["different IR doses", "TREATMENT", 389, 407], ["repair", "OBSERVATION", 53, 59], ["DSBs", "OBSERVATION", 373, 377]]], ["In accordance with those experiments, we assume that the stochastic number of the resulting DSBs per time scale is proportional to the number generated by a Poisson random function during the period of acute radiation [10] .", [["DSBs", "CELLULAR_COMPONENT", 92, 96], ["acute radiation", "TREATMENT", 202, 217]]], ["The DSBs generation process is formulated as follows:DSB generation and repairwhere [DT] is the concentration of total resulting DSBs induced by IR in both the fast and the slow repair processes. k t is the parameter to set the number of DSBs per time scale, and a ir is the parameter to set the number of DSBs per IR dose.", [["DSBs", "CELLULAR_COMPONENT", 4, 8], ["DSB", "CELLULAR_COMPONENT", 53, 56], ["DSBs", "CELLULAR_COMPONENT", 129, 133], ["DSBs", "CELLULAR_COMPONENT", 238, 242], ["DSBs", "CELLULAR_COMPONENT", 306, 310], ["DT", "PROBLEM", 85, 87], ["total resulting DSBs", "PROBLEM", 113, 133], ["the slow repair processes", "TREATMENT", 169, 194], ["DSBs", "OBSERVATION", 129, 133], ["slow", "OBSERVATION_MODIFIER", 173, 177], ["repair", "OBSERVATION", 178, 184]]], ["Moreover, we assume that limited RPs are available around DSBs sites, and 70% of the initial DSBs are fixed by the fast repair process.", [["DSBs", "CELLULAR_COMPONENT", 58, 62], ["DSBs", "CELLULAR_COMPONENT", 93, 97], ["limited RPs", "PROBLEM", 25, 36], ["DSBs sites", "TEST", 58, 68], ["the fast repair process", "TREATMENT", 111, 134], ["DSBs", "OBSERVATION", 93, 97], ["fast repair", "OBSERVATION", 115, 126]]], ["Each DSB can be in one of the following four states: intact DSB, DSBC, F r , and F w .", [["DSB", "CELLULAR_COMPONENT", 5, 8], ["Each DSB", "PROBLEM", 0, 8], ["DSBC", "TEST", 65, 69], ["intact DSB", "OBSERVATION", 53, 63]]], ["Thus, we have the following differential equations:DSB generation and repairwhere [D], [C], and [F w ] denote, respectively, the concentrations of DSBs, DSBCs, and F w ; k dc , k cd , k cf , and k fw are the transition rates among the above three states; k dc and k cross represent the first-order and second-order repair rates, respectively [38] .", [["[C]", "SIMPLE_CHEMICAL", 87, 90], ["DSBs", "CELLULAR_COMPONENT", 147, 151], ["DSB generation", "TEST", 51, 65], ["repairwhere", "TEST", 70, 81], ["DSBs", "TEST", 147, 151], ["DSBCs", "TEST", 153, 158], ["k dc", "TEST", 170, 174], ["k cd", "TEST", 177, 181], ["k cf", "TEST", 184, 188], ["k fw", "TEST", 195, 199], ["the transition rates", "TEST", 204, 224], ["k dc", "TEST", 255, 259], ["k cross", "TEST", 264, 271], ["second-order repair rates", "TREATMENT", 302, 327]]], ["S rp is the basal induction rate of repair mRNA, and subscripts '1' and '2,' respectively, refer to the fast and the slow kinetics.ATM activationAs a DNA damage detector, ATM exists as a dimer in unstressed cells.", [["cells", "ANATOMY", 207, 212], ["S rp", "GENE_OR_GENE_PRODUCT", 0, 4], ["ATM", "GENE_OR_GENE_PRODUCT", 131, 134], ["DNA", "CELLULAR_COMPONENT", 150, 153], ["ATM", "GENE_OR_GENE_PRODUCT", 171, 174], ["cells", "CELL", 207, 212], ["rp", "DNA", 2, 4], ["repair mRNA", "RNA", 36, 47], ["ATM", "PROTEIN", 131, 134], ["ATM", "PROTEIN", 171, 174], ["dimer", "PROTEIN", 187, 192], ["unstressed cells", "CELL_TYPE", 196, 212], ["repair mRNA", "TREATMENT", 36, 47], ["a DNA damage detector", "PROBLEM", 148, 169], ["a dimer in unstressed cells", "PROBLEM", 185, 212], ["basal", "ANATOMY_MODIFIER", 12, 17], ["repair mRNA", "OBSERVATION", 36, 47], ["unstressed cells", "OBSERVATION", 196, 212]]], ["After IR is applied, intermolecular autophosphorylation occurs causing the dimer to dissociate rapidly into the active monomers.", [["dimer", "PROTEIN", 75, 80], ["IR", "TREATMENT", 6, 8], ["intermolecular autophosphorylation", "PROBLEM", 21, 55], ["the dimer", "PROBLEM", 71, 80], ["active", "OBSERVATION_MODIFIER", 112, 118], ["monomers", "OBSERVATION_MODIFIER", 119, 127]]], ["The active ATM monomer (ATM * ) can prompt further p53 expression [37, 38] .", [["ATM", "GENE_OR_GENE_PRODUCT", 11, 14], ["ATM", "GENE_OR_GENE_PRODUCT", 24, 27], ["p53", "GENE_OR_GENE_PRODUCT", 51, 54], ["ATM monomer", "PROTEIN", 11, 22], ["ATM", "PROTEIN", 24, 27], ["p53", "PROTEIN", 51, 54], ["active", "OBSERVATION_MODIFIER", 4, 10], ["ATM", "OBSERVATION_MODIFIER", 11, 14], ["monomer", "OBSERVATION_MODIFIER", 15, 22]]], ["Here, we use the superscript \u00c3 to denote the activate state.ATM activationBased on the existing model of the ATM switch [10] , we present an ATM activation module under continuous IR (Fig. 3) , which includes three components: the ATM dimer, the inactive ATM monomer, and ATM * .", [["ATM", "GENE_OR_GENE_PRODUCT", 60, 63], ["ATM", "GENE_OR_GENE_PRODUCT", 109, 112], ["ATM", "GENE_OR_GENE_PRODUCT", 141, 144], ["ATM", "GENE_OR_GENE_PRODUCT", 231, 234], ["ATM", "GENE_OR_GENE_PRODUCT", 255, 258], ["ATM", "GENE_OR_GENE_PRODUCT", 272, 275], ["ATM", "PROTEIN", 60, 63], ["ATM", "PROTEIN", 109, 112], ["ATM", "PROTEIN", 141, 144], ["ATM dimer", "PROTEIN", 231, 240], ["inactive ATM monomer", "PROTEIN", 246, 266], ["ATM", "PROTEIN", 272, 275], ["the ATM switch", "TREATMENT", 105, 119], ["an ATM activation module", "TREATMENT", 138, 162], ["the ATM dimer", "TREATMENT", 227, 240], ["the inactive ATM monomer", "TREATMENT", 242, 266], ["inactive ATM", "OBSERVATION", 246, 258]]], ["Here, we assume that DSBCs are the main signal transduction from DSBs to the p53-MDM2 feedback loop through ATM activation, and the rate of ATM activation is a function of the amount of DSBCs and the self-feedback of ATM * .", [["DSBCs", "GENE_OR_GENE_PRODUCT", 21, 26], ["DSBs", "CELLULAR_COMPONENT", 65, 69], ["p53", "GENE_OR_GENE_PRODUCT", 77, 80], ["MDM2", "GENE_OR_GENE_PRODUCT", 81, 85], ["ATM", "GENE_OR_GENE_PRODUCT", 108, 111], ["ATM", "GENE_OR_GENE_PRODUCT", 140, 143], ["DSBCs", "GENE_OR_GENE_PRODUCT", 186, 191], ["ATM", "GENE_OR_GENE_PRODUCT", 217, 220], ["DSBCs", "PROTEIN", 21, 26], ["p53", "PROTEIN", 77, 80], ["MDM2", "PROTEIN", 81, 85], ["ATM", "PROTEIN", 108, 111], ["ATM", "PROTEIN", 140, 143], ["DSBCs", "PROTEIN", 186, 191], ["ATM", "PROTEIN", 217, 220], ["DSBCs", "TEST", 21, 26], ["the p53", "TEST", 73, 80], ["ATM activation", "TREATMENT", 108, 122], ["ATM activation", "TREATMENT", 140, 154]]], ["Furthermore, the total concentration of ATM is a constant including the ATM dimer, ATM monomer, and ATM * [10] .ATM activationAs a detector of DNA damage, ATM activation plays an important role in triggering the regulatory mechanisms of p53 stress response networks [34, 41, 42] .", [["ATM", "CHEMICAL", 40, 43], ["ATM", "GENE_OR_GENE_PRODUCT", 40, 43], ["ATM", "GENE_OR_GENE_PRODUCT", 72, 75], ["ATM", "GENE_OR_GENE_PRODUCT", 83, 86], ["ATM", "GENE_OR_GENE_PRODUCT", 100, 103], ["ATM", "GENE_OR_GENE_PRODUCT", 112, 115], ["DNA", "CELLULAR_COMPONENT", 143, 146], ["ATM", "GENE_OR_GENE_PRODUCT", 155, 158], ["p53", "GENE_OR_GENE_PRODUCT", 237, 240], ["ATM", "PROTEIN", 40, 43], ["ATM dimer", "PROTEIN", 72, 81], ["ATM monomer", "PROTEIN", 83, 94], ["ATM", "PROTEIN", 100, 103], ["ATM", "PROTEIN", 112, 115], ["ATM", "PROTEIN", 155, 158], ["p53", "PROTEIN", 237, 240], ["the total concentration of ATM", "TREATMENT", 13, 43], ["the ATM dimer", "TREATMENT", 68, 81], ["ATM monomer", "TREATMENT", 83, 94], ["DNA damage", "PROBLEM", 143, 153], ["ATM activation", "TREATMENT", 155, 169]]], ["After acute IR is applied, phosphorylation of inactive ATM dimers is promoted first by DSBCs and then rapidly by means of the positive feedback from ATM * , accounting for the intermolecular autophosphorylation [10] .", [["ATM", "GENE_OR_GENE_PRODUCT", 55, 58], ["ATM", "GENE_OR_GENE_PRODUCT", 149, 152], ["inactive ATM dimers", "PROTEIN", 46, 65], ["DSBCs", "PROTEIN", 87, 92], ["ATM", "PROTEIN", 149, 152], ["acute IR", "TREATMENT", 6, 14], ["phosphorylation of inactive ATM dimers", "TREATMENT", 27, 65]]], ["The main formulas are as follows:ATM activationwhere [ATM D ], [ATM m ], and [ATM * ] represent the concentrations of the ATM dimer, ATM monomer, and active ATM monomer, respectively; k undim is the rate of ATM undimerization, and k dim is the rate of ATM dimerization; k ar is the rate of ATM monomer inactivation, and k af is the rate of ATM monomer activation.", [["ATM", "CHEMICAL", 33, 36], ["ATM", "GENE_OR_GENE_PRODUCT", 33, 36], ["[ATM * ]", "SIMPLE_CHEMICAL", 77, 85], ["ATM", "GENE_OR_GENE_PRODUCT", 122, 125], ["ATM", "GENE_OR_GENE_PRODUCT", 133, 136], ["ATM", "GENE_OR_GENE_PRODUCT", 157, 160], ["ATM", "GENE_OR_GENE_PRODUCT", 207, 210], ["ATM", "GENE_OR_GENE_PRODUCT", 252, 255], ["ATM", "GENE_OR_GENE_PRODUCT", 290, 293], ["ATM", "GENE_OR_GENE_PRODUCT", 340, 343], ["ATM", "PROTEIN", 33, 36], ["ATM D", "PROTEIN", 54, 59], ["ATM", "PROTEIN", 78, 81], ["ATM dimer", "PROTEIN", 122, 131], ["ATM monomer", "PROTEIN", 133, 144], ["ATM monomer", "PROTEIN", 157, 168], ["ATM", "PROTEIN", 207, 210], ["ATM", "PROTEIN", 252, 255], ["ATM", "PROTEIN", 290, 293], ["ATM", "PROTEIN", 340, 343], ["the ATM dimer", "TREATMENT", 118, 131], ["ATM monomer", "TREATMENT", 133, 144], ["active ATM monomer", "PROBLEM", 150, 168], ["k dim", "TEST", 231, 236], ["ATM dimerization", "PROBLEM", 252, 268], ["k ar", "TEST", 270, 274], ["ATM monomer inactivation", "PROBLEM", 290, 314], ["k af", "TEST", 320, 324], ["main", "OBSERVATION_MODIFIER", 4, 8], ["active", "OBSERVATION_MODIFIER", 150, 156], ["ATM", "OBSERVATION_MODIFIER", 157, 160], ["monomer", "OBSERVATION_MODIFIER", 161, 168], ["monomer inactivation", "OBSERVATION", 294, 314], ["monomer activation", "OBSERVATION", 344, 362]]], ["In addition, f is the function of ATM activation, the term a 1 C implies the fact that DSBs somehow activate ATM molecules at a distance, a 2 [ATM * ] indicates the mechanism of autophosphorylation of ATM, and a 3 C[ATM * ] represents the interaction between the DSBCs and ATM * [2,10].Regulation of the p53-MDM2 feedback loopThe p53-MDM2 feedback loop is the vital part in the integrated networks.", [["ATM", "GENE_OR_GENE_PRODUCT", 34, 37], ["DSBs", "CELLULAR_COMPONENT", 87, 91], ["ATM", "GENE_OR_GENE_PRODUCT", 109, 112], ["ATM", "GENE_OR_GENE_PRODUCT", 201, 204], ["ATM", "GENE_OR_GENE_PRODUCT", 273, 276], ["p53", "GENE_OR_GENE_PRODUCT", 304, 307], ["MDM2", "GENE_OR_GENE_PRODUCT", 308, 312], ["p53", "GENE_OR_GENE_PRODUCT", 330, 333], ["MDM2", "GENE_OR_GENE_PRODUCT", 334, 338], ["ATM", "PROTEIN", 34, 37], ["ATM molecules", "PROTEIN", 109, 122], ["ATM", "PROTEIN", 201, 204], ["DSBCs", "PROTEIN", 263, 268], ["ATM", "PROTEIN", 273, 276], ["p53", "PROTEIN", 304, 307], ["MDM2", "PROTEIN", 308, 312], ["p53", "PROTEIN", 330, 333], ["MDM2", "PROTEIN", 334, 338], ["ATM activation", "PROBLEM", 34, 48], ["autophosphorylation of ATM", "PROBLEM", 178, 204], ["a 3 C[ATM *", "TREATMENT", 210, 221], ["The p53-MDM2 feedback loop", "TREATMENT", 326, 352], ["MDM2", "OBSERVATION", 334, 338], ["feedback loop", "OBSERVATION", 339, 352]]], ["As shown in Fig. 4 , p53 and its principal antagonist, Mdm2, is trans-activated by p53 and form a p53-MDM2 feedback loop.", [["p53", "GENE_OR_GENE_PRODUCT", 21, 24], ["Mdm2", "GENE_OR_GENE_PRODUCT", 55, 59], ["p53", "GENE_OR_GENE_PRODUCT", 83, 86], ["p53", "GENE_OR_GENE_PRODUCT", 98, 101], ["MDM2", "GENE_OR_GENE_PRODUCT", 102, 106], ["p53", "PROTEIN", 21, 24], ["Mdm2", "PROTEIN", 55, 59], ["p53", "PROTEIN", 83, 86], ["p53", "PROTEIN", 98, 101], ["MDM2", "PROTEIN", 102, 106]]], ["ATM * can elevate the transcriptional activity of p53 by prompting phosphorylation of p53 and degradation of the MDM2 protein [9] .Regulation of the p53-MDM2 feedback loopTo account for a decreased binding affinity between inactive p53 and p53 * , we assume that MDM2-induced degradation of inactive p53 is faster than that of p53 * [10, 12] .", [["ATM", "GENE_OR_GENE_PRODUCT", 0, 3], ["p53", "GENE_OR_GENE_PRODUCT", 50, 53], ["p53", "GENE_OR_GENE_PRODUCT", 86, 89], ["MDM2", "GENE_OR_GENE_PRODUCT", 113, 117], ["p53", "GENE_OR_GENE_PRODUCT", 149, 152], ["MDM2", "GENE_OR_GENE_PRODUCT", 153, 157], ["p53", "GENE_OR_GENE_PRODUCT", 232, 235], ["p53", "GENE_OR_GENE_PRODUCT", 240, 243], ["MDM2", "GENE_OR_GENE_PRODUCT", 263, 267], ["p53", "GENE_OR_GENE_PRODUCT", 300, 303], ["p53", "GENE_OR_GENE_PRODUCT", 327, 330], ["ATM", "PROTEIN", 0, 3], ["p53", "PROTEIN", 50, 53], ["p53", "PROTEIN", 86, 89], ["MDM2 protein", "PROTEIN", 113, 125], ["p53", "PROTEIN", 149, 152], ["MDM2", "PROTEIN", 153, 157], ["p53", "PROTEIN", 232, 235], ["p53", "PROTEIN", 240, 243], ["MDM2", "PROTEIN", 263, 267], ["inactive p53", "PROTEIN", 291, 303], ["p53", "PROTEIN", 327, 330], ["phosphorylation of p53", "TREATMENT", 67, 89], ["the MDM2 protein", "TEST", 109, 125], ["a decreased binding affinity", "PROBLEM", 186, 214], ["MDM2", "TEST", 263, 267], ["inactive p53", "PROBLEM", 291, 303]]], ["Only p53 * can regulate the target genes to eliminate the toxins within the cell [9, 10, 19] .", [["cell", "ANATOMY", 76, 80], ["p53", "GENE_OR_GENE_PRODUCT", 5, 8], ["cell", "CELL", 76, 80], ["p53", "PROTEIN", 5, 8], ["target genes", "DNA", 28, 40]]], ["This negative feedback loop can produce oscillations in response to sufficiently strong IR doses [9] [10] [11] [12] [13] [14] .", [["[9] [10] [11] [12] [13] [14]", "SIMPLE_CHEMICAL", 97, 125], ["strong IR doses", "TREATMENT", 81, 96]]], ["The formulas used in this module are as follows: Tables 1-3 .Simulation results and discussionTo ensure the accuracy of the simulation results, let us consider the fact that the valid parameter sets should obey the following rules [9, 10, 41] : (i) the model must contain oscillations.", [["The formulas", "TREATMENT", 0, 12], ["oscillations", "OBSERVATION", 272, 284]]], ["This is important as there has been experimen-tal evidence that oscillations occur between p53 and MDM2 after cell stress; (ii) the mechanism used to mathematically describe the degradation of p53 by MDM2 is accurate only for low concentrations of p53; and (iii) the concentration of p53 * is much higher than that of inactive p53 after the system reaches an equilibrium.", [["cell", "ANATOMY", 110, 114], ["p53", "GENE_OR_GENE_PRODUCT", 91, 94], ["MDM2", "GENE_OR_GENE_PRODUCT", 99, 103], ["cell", "CELL", 110, 114], ["p53", "GENE_OR_GENE_PRODUCT", 193, 196], ["MDM2", "GENE_OR_GENE_PRODUCT", 200, 204], ["p53", "GENE_OR_GENE_PRODUCT", 248, 251], ["p53", "GENE_OR_GENE_PRODUCT", 284, 287], ["p53", "GENE_OR_GENE_PRODUCT", 327, 330], ["p53", "PROTEIN", 91, 94], ["MDM2", "PROTEIN", 99, 103], ["p53", "PROTEIN", 193, 196], ["MDM2", "PROTEIN", 200, 204], ["p53", "PROTEIN", 248, 251], ["p53", "PROTEIN", 284, 287], ["inactive p53", "PROTEIN", 318, 330], ["cell stress", "TEST", 110, 121], ["low concentrations of p53", "PROBLEM", 226, 251], ["much higher", "OBSERVATION_MODIFIER", 293, 304]]], ["Based on these three rules and the existing parameter sets used in [10] , we obtained the kinetics of p53 stress response networks under continuous IR dose using the simulation platform in MAT-LAB7.0.", [["p53", "GENE_OR_GENE_PRODUCT", 102, 105], ["p53", "PROTEIN", 102, 105], ["continuous IR dose", "TREATMENT", 137, 155], ["the simulation platform", "TEST", 162, 185]]], ["The detailed parameter sets used in our model can be found in Tables 1-3.Cellular response under continuous IRDuring the simulation process, we applied 5-Gy IR to generate the DSBs fraction.", [["Cellular", "ANATOMY", 73, 81], ["Gy IR", "TREATMENT", 154, 159], ["the DSBs fraction", "TEST", 172, 189], ["DSBs fraction", "OBSERVATION", 176, 189]]], ["To agree with the experimental results that showed 30-40 DSBs per Gy occurred in a single cell [10] , the stochastic number of resulting DSBs was generated using a Poisson random function with a mean of 35x as a continuous IR dose of x-Gy was applied.", [["cell", "ANATOMY", 90, 94], ["cell", "CELL", 90, 94], ["DSBs", "CELLULAR_COMPONENT", 137, 141], ["resulting DSBs", "PROBLEM", 127, 141], ["a continuous IR dose", "TREATMENT", 210, 230], ["x-Gy", "TREATMENT", 234, 238], ["resulting DSBs", "OBSERVATION", 127, 141]]], ["Fig. 5 (a) displays a stochastic trace of the resulting DSBs versus the constant radiation time, and Fig. 5(b) shows the kinetics of ATM activation triggered by DSBCs transfer, and the ATM * switch to the ''on\" state and the tendency to reach the saturation state after about 15 min at 5-Gy IR.", [["ATM", "CHEMICAL", 133, 136], ["ATM", "GENE_OR_GENE_PRODUCT", 133, 136], ["DSBCs", "SIMPLE_CHEMICAL", 161, 166], ["ATM", "GENE_OR_GENE_PRODUCT", 185, 188], ["ATM", "PROTEIN", 133, 136], ["ATM", "PROTEIN", 185, 188], ["the resulting DSBs", "PROBLEM", 42, 60], ["the constant radiation time", "TREATMENT", 68, 95], ["ATM activation", "PROBLEM", 133, 147], ["DSBs", "OBSERVATION", 56, 60]]], ["The step-like traces suggest that the ATM module can produce an on-off switching signal and further transfer the damage signal to the p53-MDM2 feedback loop [7] [8] [9] [10] [11] [12] [13] [14] .Cellular response under continuous IRMeanwhile, Fig. 5(c) shows the dynamic traces of p53 and MDM2 in response to continuous applications of 5-Gy IR from time zero.", [["ATM", "GENE_OR_GENE_PRODUCT", 38, 41], ["p53", "GENE_OR_GENE_PRODUCT", 134, 137], ["MDM2", "GENE_OR_GENE_PRODUCT", 138, 142], ["[7] [8] [9] [10] [11] [12] [13] [14]", "SIMPLE_CHEMICAL", 157, 193], ["p53", "GENE_OR_GENE_PRODUCT", 281, 284], ["MDM2", "GENE_OR_GENE_PRODUCT", 289, 293], ["ATM", "PROTEIN", 38, 41], ["p53", "PROTEIN", 134, 137], ["MDM2", "PROTEIN", 138, 142], ["p53", "PROTEIN", 281, 284], ["MDM2", "PROTEIN", 289, 293], ["the ATM module", "PROBLEM", 34, 48], ["the damage signal", "TEST", 109, 126], ["the p53", "TEST", 130, 137], ["MDM2", "PROBLEM", 289, 293], ["continuous applications", "TREATMENT", 309, 332]]], ["Upon the activation by ATM * , and decreased degradation by Mdm2, the total amount of p53 proteins increases quickly.", [["ATM", "GENE_OR_GENE_PRODUCT", 23, 26], ["Mdm2", "GENE_OR_GENE_PRODUCT", 60, 64], ["p53", "GENE_OR_GENE_PRODUCT", 86, 89], ["ATM", "PROTEIN", 23, 26], ["Mdm2", "PROTEIN", 60, 64], ["p53 proteins", "PROTEIN", 86, 98], ["decreased degradation", "PROBLEM", 35, 56], ["p53 proteins", "TEST", 86, 98], ["increases", "OBSERVATION_MODIFIER", 99, 108], ["quickly", "OBSERVATION_MODIFIER", 109, 116]]], ["Due to p53-dependent induction of Mdm2 transcription, the increase in Mdm2 proteins is sufficiently large to lower the p53 level, which in turn reduces the amount of the MDM2 proteins.", [["p53", "GENE_OR_GENE_PRODUCT", 7, 10], ["Mdm2", "GENE_OR_GENE_PRODUCT", 34, 38], ["Mdm2", "GENE_OR_GENE_PRODUCT", 70, 74], ["p53", "GENE_OR_GENE_PRODUCT", 119, 122], ["MDM2", "GENE_OR_GENE_PRODUCT", 170, 174], ["p53", "PROTEIN", 7, 10], ["Mdm2", "PROTEIN", 34, 38], ["Mdm2 proteins", "PROTEIN", 70, 83], ["p53", "PROTEIN", 119, 122], ["MDM2 proteins", "PROTEIN", 170, 183], ["p53-dependent induction of Mdm2 transcription", "TREATMENT", 7, 52], ["the increase in Mdm2 proteins", "PROBLEM", 54, 83], ["the MDM2 proteins", "PROBLEM", 166, 183], ["increase", "OBSERVATION_MODIFIER", 58, 66], ["Mdm2", "OBSERVATION", 70, 74], ["large", "OBSERVATION_MODIFIER", 100, 105], ["amount", "OBSERVATION_MODIFIER", 156, 162], ["MDM2 proteins", "OBSERVATION", 170, 183]]], ["The oscillation pulses shown in Fig. 5(c) have a period of about 400 min, the phase difference between p53 and MDM2 is about 100-min, moreover, the first pulse is slightly higher than the second, which is quite similar to the experimental observations [17] [18] [19] and the simulation results [7] [8] [9] [10] [11] [12] [13] [14] .Cellular response under different IR dosesDuring the simulation process, we applied 2-, 6-, and 10-Gy IR to analyze the different kinetics of cellular response to different IR doses.", [["Cellular", "ANATOMY", 332, 340], ["cellular", "ANATOMY", 474, 482], ["p53", "GENE_OR_GENE_PRODUCT", 103, 106], ["MDM2", "GENE_OR_GENE_PRODUCT", 111, 115], ["[17] [18] [19]", "SIMPLE_CHEMICAL", 252, 266], ["[7] [8] [9] [10] [11] [12] [13] [14]", "SIMPLE_CHEMICAL", 294, 330], ["cellular", "CELL", 474, 482], ["p53", "PROTEIN", 103, 106], ["MDM2", "PROTEIN", 111, 115], ["The oscillation pulses", "TEST", 0, 22], ["MDM2", "TEST", 111, 115], ["the first pulse", "TEST", 144, 159], ["the simulation results", "TEST", 271, 293], ["Gy IR", "TREATMENT", 431, 436], ["different IR doses", "TREATMENT", 495, 513], ["MDM2", "OBSERVATION", 111, 115], ["slightly", "OBSERVATION_MODIFIER", 163, 171], ["higher", "OBSERVATION", 172, 178], ["cellular response", "OBSERVATION", 474, 491]]], ["As shown in Fig. 6(a) , RPs available around damage sites keep increasing under 2-Gy IR, whereas, RPs begin to decrease from initial value as the IR dose increases to 6-Gy.", [["RPs", "TREATMENT", 24, 27], ["damage sites", "PROBLEM", 45, 57], ["the IR dose", "TREATMENT", 142, 153]]], ["Fig. 6(b) shows that the rate of DSBCs synthesis begins to decrease after about 70 min of 10-Gy IR.", [["DSBCs", "CHEMICAL", 33, 38], ["DSBCs", "SIMPLE_CHEMICAL", 33, 38], ["DSBCs", "PROTEIN", 33, 38], ["the rate", "TEST", 21, 29], ["DSBCs synthesis", "PROBLEM", 33, 48], ["decrease", "OBSERVATION_MODIFIER", 59, 67]]], ["Meanwhile, as shown in Fig. 6(c) , without the degradation effect of p53 * , F w are accumulated dramatically at IR doses above 6-Gy.", [["p53", "GENE_OR_GENE_PRODUCT", 69, 72], ["F w", "GENE_OR_GENE_PRODUCT", 77, 80], ["p53", "PROTEIN", 69, 72], ["the degradation effect of p53", "PROBLEM", 43, 72], ["dramatically", "OBSERVATION_MODIFIER", 97, 109]]], ["These simulations suggest that the capabilities of cellular response to fight against DNA damage begin to decrease at a certain IR dose threshold.", [["cellular", "ANATOMY", 51, 59], ["cellular", "CELL", 51, 59], ["DNA", "CELLULAR_COMPONENT", 86, 89], ["DNA damage", "PROBLEM", 86, 96]]], ["Table 1 The parameters used in the DSBs generation and repair process.", [["the DSBs generation", "TREATMENT", 31, 50], ["repair process", "TREATMENT", 55, 69], ["repair process", "OBSERVATION", 55, 69]]], ["The rate of DSBs transition to DSBCs in D 2 0.2 k cd1Parameters Description ConstantThe rate of DSBCs transition to DSBs in D 1 0.5 k cd2Parameters Description ConstantThe rate of DSBCs transition to DSBs in D 2 0.05 k cf1Parameters Description ConstantThe rate of DSCs transition to F r in D 1 0.001 k cf2Parameters Description ConstantThe rate of DSCs transition to F r in D 2 0.0001 k fw1Parameters Description ConstantThe rate of DSCs transition to F w in D 1 0.001 k fw2Parameters Description ConstantThe rate of DSCs transition to F w in D 2 0.0001 k crossParameters Description ConstantThe rate of DSB binary mismatch in secondorder kinetics 0.001Prediction for cellular response under IRThe p53-MDM2 feedback loop is vital for the control of downstream genes and regulation pathways to fight against genome stress [8, 9, 33] .", [["cellular", "ANATOMY", 669, 677], ["cellular", "CELL", 669, 677], ["p53", "GENE_OR_GENE_PRODUCT", 699, 702], ["MDM2", "GENE_OR_GENE_PRODUCT", 703, 707], ["p53", "PROTEIN", 699, 702], ["MDM2", "PROTEIN", 703, 707], ["downstream genes", "DNA", 750, 766], ["DSBCs", "TEST", 31, 36], ["DSBs", "TEST", 116, 120], ["DSBCs", "TEST", 180, 185], ["DSBs in D", "TREATMENT", 200, 209], ["The rate of DSCs transition to F r in D", "TREATMENT", 253, 292], ["DSCs transition to F r in D", "TREATMENT", 349, 376], ["The rate of DSCs transition to F w in D", "TREATMENT", 422, 461], ["DSB binary mismatch in secondorder kinetics", "TREATMENT", 605, 648], ["cellular response", "TEST", 669, 686], ["IRThe p53", "TREATMENT", 693, 702], ["MDM2 feedback loop", "TREATMENT", 703, 721], ["genome stress", "TEST", 808, 821]]], ["In response to the input signal of ATM * , the p53-Mdm2 module generates one or more oscillations.", [["ATM", "GENE_OR_GENE_PRODUCT", 35, 38], ["p53", "GENE_OR_GENE_PRODUCT", 47, 50], ["Mdm2", "GENE_OR_GENE_PRODUCT", 51, 55], ["ATM", "PROTEIN", 35, 38], ["p53", "PROTEIN", 47, 50], ["Mdm2", "PROTEIN", 51, 55], ["the p53", "TEST", 43, 50]]], ["The response traces of the p53 protein under continuous applications of 2-, 6-, and 10-Gy IR from time zero are shown in Fig. 7(a) , which shows that two or more pulses of p53 and MDM2 are generated after increasing the IR doses.", [["p53", "GENE_OR_GENE_PRODUCT", 27, 30], ["p53", "GENE_OR_GENE_PRODUCT", 172, 175], ["MDM2", "GENE_OR_GENE_PRODUCT", 180, 184], ["p53 protein", "PROTEIN", 27, 38], ["p53", "PROTEIN", 172, 175], ["MDM2", "PROTEIN", 180, 184], ["MDM2", "TEST", 180, 184], ["increasing the IR doses", "TREATMENT", 205, 228]]], ["Our simulations are fully in accordance with the observations that, on average, the greater the number of p53 pulses, the more severe the damage that can be triggered [8, 9, 33] , whereas the intensity of the oscillations begins to decrease under 10-Gy IR.", [["p53", "GENE_OR_GENE_PRODUCT", 106, 109], ["p53", "PROTEIN", 106, 109], ["p53 pulses", "TEST", 106, 116], ["the more severe the damage", "PROBLEM", 118, 144], ["the oscillations", "PROBLEM", 205, 221], ["more severe", "OBSERVATION_MODIFIER", 122, 133], ["damage", "OBSERVATION", 138, 144], ["oscillations", "OBSERVATION", 209, 221], ["decrease", "OBSERVATION_MODIFIER", 232, 240]]], ["Meanwhile, Fig. 7(b) shows the kinetics of F w elimination induced by the degra-dation functions of p53 * , compared with Fig. 6(c) , F w are eliminated dramatically and tends towards dynamic equilibrium versus radiation doses of 2-and 6-Gy IR, whereas F w begin to decrease at the first climax, and then maintain a higher level under continuous application of 10-Gy IR.", [["F w", "GENE_OR_GENE_PRODUCT", 43, 46], ["p53", "GENE_OR_GENE_PRODUCT", 100, 103], ["F w", "GENE_OR_GENE_PRODUCT", 134, 137], ["p53", "PROTEIN", 100, 103], ["radiation doses", "TREATMENT", 211, 226]]], ["These simulations suggest that p53 * does play important roles in fighting against DNA damage, whereas the abilities of the cellular response to fight against genome stress begins to decrease as the IR dose overtakes a certain Table 2 The parameters used in the module of the ATM activation process.Parameters Description ConstantScale of the activation function of ATM phosphorylation 1 a 2 Scale of the activation function of ATM phosphorylation 0.08Parameters Description ConstantScale of the activation function of ATM phosphorylation 0.8 Table 3 The parameters used in the p53-MDM2 feedback regulatory loop. maximal threshold under different circumstances, such as in different cell types.", [["cellular", "ANATOMY", 124, 132], ["cell", "ANATOMY", 683, 687], ["ATM", "CHEMICAL", 366, 369], ["p53", "GENE_OR_GENE_PRODUCT", 31, 34], ["DNA", "CELLULAR_COMPONENT", 83, 86], ["cellular", "CELL", 124, 132], ["ATM", "GENE_OR_GENE_PRODUCT", 276, 279], ["ATM", "GENE_OR_GENE_PRODUCT", 366, 369], ["ATM", "GENE_OR_GENE_PRODUCT", 428, 431], ["ATM", "GENE_OR_GENE_PRODUCT", 519, 522], ["p53", "GENE_OR_GENE_PRODUCT", 578, 581], ["MDM2", "GENE_OR_GENE_PRODUCT", 582, 586], ["cell", "CELL", 683, 687], ["p53", "PROTEIN", 31, 34], ["ATM", "PROTEIN", 276, 279], ["ATM", "PROTEIN", 366, 369], ["ATM", "PROTEIN", 428, 431], ["ATM", "PROTEIN", 519, 522], ["p53", "PROTEIN", 578, 581], ["MDM2", "PROTEIN", 582, 586], ["DNA damage", "PROBLEM", 83, 93], ["genome stress", "PROBLEM", 159, 172], ["the IR dose", "TREATMENT", 195, 206], ["the ATM activation process", "TREATMENT", 272, 298], ["ATM phosphorylation", "TREATMENT", 366, 385], ["ATM phosphorylation", "TREATMENT", 428, 447], ["ATM phosphorylation", "TREATMENT", 519, 538], ["The parameters", "TEST", 551, 565], ["loop", "OBSERVATION_MODIFIER", 607, 611], ["different cell types", "OBSERVATION", 673, 693]]], ["Moreover, our model can quantitatively predict how perturbations of some vital parameters in the system affect the cellular response under some abnormal circumstances.", [["cellular", "ANATOMY", 115, 123], ["cellular", "CELL", 115, 123], ["some vital parameters", "TEST", 68, 89], ["some abnormal circumstances", "PROBLEM", 139, 166], ["cellular response", "OBSERVATION", 115, 132]]], ["As shown in Fig. 7(c) , a plausible prediction is made that an abnormal basal transcription rate of p53 (S P53 ) will disable cellular response under 5-Gy IR.", [["cellular", "ANATOMY", 126, 134], ["p53", "GENE_OR_GENE_PRODUCT", 100, 103], ["S P53", "GENE_OR_GENE_PRODUCT", 105, 110], ["cellular", "CELL", 126, 134], ["p53", "PROTEIN", 100, 103], ["S P53", "PROTEIN", 105, 110], ["an abnormal basal transcription rate of p53", "PROBLEM", 60, 103]]], ["The oscillations of p53 * will consequently disappear as S P53 decreases from its abnormal initial value (Fig. 7(c) ).", [["p53", "GENE_OR_GENE_PRODUCT", 20, 23], ["P53", "GENE_OR_GENE_PRODUCT", 59, 62], ["p53", "PROTEIN", 20, 23], ["S P53", "PROTEIN", 57, 62], ["S P53", "TEST", 57, 62], ["its abnormal initial value", "PROBLEM", 78, 104]]], ["F w are accumulated dramatically without normal elimination effects of p53 * , which means that the cellular self-defense mechanisms in response to genome stress have been broken due to the abnormal S P53 within the abnormal cell.Parameters Description ConstantIf oscillations are of importance for triggering the cellular self-defensive mechanisms of DNA damage repair or abnormal cell apoptosis, this prediction implies that cells with abnormal basal transcription rates of high Mdm2 or low p53 should be associated with enhanced tumorigenesis [8, 10] .", [["cellular", "ANATOMY", 100, 108], ["cell", "ANATOMY", 225, 229], ["cellular", "ANATOMY", 314, 322], ["cell", "ANATOMY", 382, 386], ["cells", "ANATOMY", 427, 432], ["F w", "GENE_OR_GENE_PRODUCT", 0, 3], ["p53", "GENE_OR_GENE_PRODUCT", 71, 74], ["cellular", "CELL", 100, 108], ["P53", "GENE_OR_GENE_PRODUCT", 201, 204], ["cell", "CELL", 225, 229], ["cellular", "CELL", 314, 322], ["DNA", "CELLULAR_COMPONENT", 352, 355], ["cell", "CELL", 382, 386], ["cells", "CELL", 427, 432], ["Mdm2", "GENE_OR_GENE_PRODUCT", 481, 485], ["p53", "GENE_OR_GENE_PRODUCT", 493, 496], ["p53", "PROTEIN", 71, 74], ["abnormal S P53", "PROTEIN", 190, 204], ["abnormal cell", "CELL_TYPE", 216, 229], ["Mdm2", "PROTEIN", 481, 485], ["p53", "PROTEIN", 493, 496], ["the cellular self-defense mechanisms", "PROBLEM", 96, 132], ["genome stress", "PROBLEM", 148, 161], ["the abnormal S P53", "PROBLEM", 186, 204], ["the abnormal cell", "PROBLEM", 212, 229], ["DNA damage repair", "TREATMENT", 352, 369], ["abnormal cell apoptosis", "PROBLEM", 373, 396], ["abnormal basal transcription rates", "PROBLEM", 438, 472], ["high Mdm2", "PROBLEM", 476, 485], ["low p53", "PROBLEM", 489, 496], ["enhanced tumorigenesis", "PROBLEM", 523, 545], ["dramatically", "OBSERVATION_MODIFIER", 20, 32], ["elimination", "OBSERVATION_MODIFIER", 48, 59], ["abnormal cell", "OBSERVATION", 216, 229], ["abnormal cell apoptosis", "OBSERVATION", 373, 396], ["high Mdm2", "OBSERVATION", 476, 485], ["low p53", "OBSERVATION_MODIFIER", 489, 496]]], ["In addition, our model can predict the consequences of perturbations in other vital components, for example, eliminating ATM will lead to an enhanced variability in the number of oscillations in response to a given IR dose.ConclusionsA set of differential equations, combined with graphic approaches, was proposed to model the p53 stress response networks under continuous IR.", [["ATM", "GENE_OR_GENE_PRODUCT", 121, 124], ["p53", "GENE_OR_GENE_PRODUCT", 327, 330], ["ATM", "PROTEIN", 121, 124], ["p53", "PROTEIN", 327, 330], ["ATM", "PROBLEM", 121, 124], ["an enhanced variability", "PROBLEM", 138, 161], ["a given IR dose", "TREATMENT", 207, 222], ["differential equations", "TEST", 243, 265], ["continuous IR", "TREATMENT", 362, 375], ["enhanced", "OBSERVATION_MODIFIER", 141, 149], ["variability", "OBSERVATION_MODIFIER", 150, 161]]], ["Our model demonstrated that ATM exhibits a strong sensitivity and switch-like behaviour in response to the number of DSBs.", [["ATM", "GENE_OR_GENE_PRODUCT", 28, 31], ["DSBs", "CELLULAR_COMPONENT", 117, 121], ["ATM", "PROTEIN", 28, 31], ["ATM", "PROBLEM", 28, 31], ["a strong sensitivity", "PROBLEM", 41, 61], ["strong", "OBSERVATION_MODIFIER", 43, 49]]], ["Also, the p53-MDM2 feedback loop will produce oscillations, and the number and amplitude of the oscillations are different according to cell type and the IR dose [10] .", [["cell", "ANATOMY", 136, 140], ["p53", "GENE_OR_GENE_PRODUCT", 10, 13], ["MDM2", "GENE_OR_GENE_PRODUCT", 14, 18], ["cell", "CELL", 136, 140], ["p53", "PROTEIN", 10, 13], ["MDM2", "PROTEIN", 14, 18], ["the p53-MDM2 feedback loop", "TREATMENT", 6, 32]]], ["Especially, plausible predictions are made for toxins elimination under different IR doses, and the outcomes of cellular response under some abnormal circumstances.", [["cellular", "ANATOMY", 112, 120], ["cellular", "CELL", 112, 120], ["toxins elimination", "PROBLEM", 47, 65], ["different IR doses", "TREATMENT", 72, 90], ["some abnormal circumstances", "PROBLEM", 136, 163]]], ["Our model, although simple, does provide a mathematical framework for the theoretical analysis and prediction of the cellular response to DNA damage under continuous IR.", [["cellular", "ANATOMY", 117, 125], ["cellular", "CELL", 117, 125], ["DNA", "CELLULAR_COMPONENT", 138, 141], ["the theoretical analysis", "TEST", 70, 94], ["DNA damage", "PROBLEM", 138, 148], ["continuous IR", "TREATMENT", 155, 168]]]], "e5a518ef4a41119b034ec04f68a5b0806b831485": [["INTRODUCTIONIn Korea, since the first report of coronavirus disease 2019 in January 20, 2020, 11,065 cases of COVID-19 have been confirmed as of May 18, 2020.", [["coronavirus disease", "DISEASE", 48, 67], ["coronavirus", "ORGANISM", 48, 59], ["coronavirus disease", "PROBLEM", 48, 67], ["COVID", "TEST", 110, 115], ["coronavirus disease", "OBSERVATION", 48, 67]]], ["1 The government of Korea declared the highest alert level (Level IV) in February 23, 2020 because the confirmed number of COVID-19 cases were increasing.", [["COVID", "TEST", 123, 128]]], ["Both subclinical manifestations and early high viral loads have been suggested as important factors contributing to the sudden outbreak in Korea.", [["Both subclinical manifestations", "PROBLEM", 0, 31], ["early high viral loads", "PROBLEM", 36, 58], ["the sudden outbreak in Korea", "PROBLEM", 116, 144], ["subclinical", "OBSERVATION_MODIFIER", 5, 16], ["manifestations", "OBSERVATION", 17, 31], ["early", "OBSERVATION_MODIFIER", 36, 41], ["high", "OBSERVATION_MODIFIER", 42, 46], ["viral loads", "OBSERVATION", 47, 58]]], ["2,3 control practices, assessment of viral shedding is required in a diverse range of body fluids.Patients and samplesFrom hospital days 1-9, serial clinical specimens were collected every 2 days from two patients diagnosed with COVID-19.", [["body fluids", "ANATOMY", 86, 97], ["samples", "ANATOMY", 111, 118], ["specimens", "ANATOMY", 158, 167], ["body", "ORGANISM_SUBDIVISION", 86, 90], ["Patients", "ORGANISM", 98, 106], ["patients", "ORGANISM", 205, 213], ["Patients", "SPECIES", 98, 106], ["patients", "SPECIES", 205, 213], ["2,3 control practices", "TREATMENT", 0, 21], ["assessment", "TEST", 23, 33], ["viral shedding", "PROBLEM", 37, 51], ["a diverse range of body fluids", "TREATMENT", 67, 97], ["serial clinical specimens", "TEST", 142, 167], ["COVID", "TEST", 229, 234], ["viral shedding", "OBSERVATION", 37, 51]]], ["Nasopharyngeal and oropharyngeal samples were collected using polyester flocked swabs.", [["Nasopharyngeal", "ANATOMY", 0, 14], ["oropharyngeal samples", "ANATOMY", 19, 40], ["polyester", "CHEMICAL", 62, 71], ["Nasopharyngeal", "CANCER", 0, 14], ["oropharyngeal samples", "CANCER", 19, 40], ["Nasopharyngeal and oropharyngeal samples", "TEST", 0, 40], ["polyester flocked swabs", "TREATMENT", 62, 85], ["oropharyngeal", "ANATOMY", 19, 32]]], ["Saliva and sputum specimens were sampled by the patients themselves after teaching them the collection method.", [["Saliva", "ANATOMY", 0, 6], ["sputum specimens", "ANATOMY", 11, 27], ["Saliva", "ORGANISM_SUBSTANCE", 0, 6], ["sputum specimens", "ORGANISM_SUBSTANCE", 11, 27], ["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["Saliva and sputum specimens", "TEST", 0, 27], ["the collection method", "TEST", 88, 109]]], ["Each collected sample was inserted into separated tubes containing 2 mL of the virus transport medium.", [["sample", "ANATOMY", 15, 21], ["separated tubes", "TREATMENT", 40, 55], ["the virus transport medium", "TREATMENT", 75, 101], ["tubes", "OBSERVATION", 50, 55]]], ["The urine was sampled in a covered collection cup and sealed for safe transportation to the laboratory.Patients and samplesOn hospital days 3 and 6, the patients used the chlorhexidine gluconate solution mouthwash (0.12%, 15 mL) for 30 seconds after baseline specimen sampling.", [["urine", "ANATOMY", 4, 9], ["specimen", "ANATOMY", 259, 267], ["chlorhexidine gluconate", "CHEMICAL", 171, 194], ["chlorhexidine gluconate", "CHEMICAL", 171, 194], ["urine", "ORGANISM_SUBSTANCE", 4, 9], ["Patients", "ORGANISM", 103, 111], ["patients", "ORGANISM", 153, 161], ["chlorhexidine gluconate", "SIMPLE_CHEMICAL", 171, 194], ["Patients", "SPECIES", 103, 111], ["patients", "SPECIES", 153, 161], ["The urine", "TEST", 0, 9], ["a covered collection cup", "TREATMENT", 25, 49], ["the chlorhexidine gluconate solution mouthwash", "TREATMENT", 167, 213], ["baseline specimen sampling", "TEST", 250, 276], ["urine", "OBSERVATION", 4, 9]]], ["Patients were educated on the entire process of gargling and saliva sampling and were directly supervised by the investigator.", [["Patients", "ORGANISM", 0, 8], ["saliva", "ORGANISM_SUBSTANCE", 61, 67], ["Patients", "SPECIES", 0, 8], ["saliva sampling", "TREATMENT", 61, 76]]], ["Additional samples of the saliva were taken at 0 hour (before gargle), 1 hour, 2 hours, and 4 hours after using the chlorhexidine mouthwash.SARS-CoV-2 rRT-PCRThe presence of SARS-CoV-2 was confirmed by real-time reverse transcriptase polymerase chain reaction (rRT-PCR).", [["samples", "ANATOMY", 11, 18], ["saliva", "ANATOMY", 26, 32], ["chlorhexidine", "CHEMICAL", 116, 129], ["SARS", "DISEASE", 140, 144], ["SARS", "DISEASE", 174, 178], ["chlorhexidine", "CHEMICAL", 116, 129], ["saliva", "ORGANISM_SUBSTANCE", 26, 32], ["chlorhexidine", "SIMPLE_CHEMICAL", 116, 129], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 174, 184], ["SARS-CoV-2 rRT", "DNA", 140, 154], ["SARS-CoV-2", "DNA", 174, 184], ["reverse transcriptase", "PROTEIN", 212, 233], ["SARS-CoV", "SPECIES", 174, 182], ["the saliva", "TREATMENT", 22, 32], ["the chlorhexidine mouthwash", "TREATMENT", 112, 139], ["SARS", "TEST", 140, 144], ["CoV", "TEST", 145, 148], ["SARS", "PROBLEM", 174, 178], ["CoV", "TEST", 179, 182], ["reverse transcriptase polymerase chain reaction", "PROBLEM", 212, 259]]], ["RNA was extracted from the clinical samples using NucliSENS easyMAG platform (bioM\u00e9rieux, Marcy-l'\u00c9toile, France). rRT-PCR was performed using CFX96 real-time PCR detection system (Bio-rad, Hercules, CA, USA) and PowerChek 2019-nCoV real-time PCR kit (Kogenebiotech, Seoul, Korea), which targeted the E and RdRP genes of SARS-CoV-2.", [["samples", "ANATOMY", 36, 43], ["SARS", "DISEASE", 321, 325], ["E", "GENE_OR_GENE_PRODUCT", 301, 302], ["SARS-CoV-2", "ORGANISM", 321, 331], ["RNA", "RNA", 0, 3], ["E and RdRP genes", "DNA", 301, 317], ["SARS-CoV-2", "DNA", 321, 331], ["SARS-CoV", "SPECIES", 321, 329], ["NucliSENS easyMAG platform", "TREATMENT", 50, 76], ["bioM\u00e9rieux", "TREATMENT", 78, 88], ["Marcy", "TREATMENT", 90, 95], ["rRT-PCR", "TEST", 115, 122], ["CFX96", "TEST", 143, 148], ["Hercules", "TEST", 190, 198], ["CA", "TEST", 200, 202], ["PowerChek", "TEST", 213, 222], ["SARS", "PROBLEM", 321, 325], ["CoV", "TEST", 326, 329]]], ["The primer and probe sequences were designed according to the previous study.", [["primer and probe sequences", "DNA", 4, 30], ["The primer and probe sequences", "TEST", 0, 30], ["the previous study", "TEST", 58, 76]]], ["7 The sample was defined as negative if the cycle threshold (Ct) value exceeded 35 cycles.", [["sample", "ANATOMY", 6, 12], ["The sample", "TEST", 2, 12], ["the cycle threshold", "TEST", 40, 59], ["Ct) value", "TEST", 61, 70]]], ["Details regarding the rRT-PCR protocol are provided in the Supplementary Appendix.", [["rRT", "DNA", 22, 25], ["the rRT-PCR protocol", "TREATMENT", 18, 38], ["Appendix", "ANATOMY", 73, 81]]], ["The RNA copy number was calculated from the Ct values using the standard curve generated by dilution of the plasmid DNA.Ethics statementThis study was approved by the Institutional Review Board of Korea University Guro Hospital (approval number: 2020GR0123).", [["plasmid", "ANATOMY", 108, 115], ["DNA", "CELLULAR_COMPONENT", 116, 119], ["plasmid DNA", "DNA", 108, 119], ["the Ct values", "TEST", 40, 53], ["the plasmid DNA", "TREATMENT", 104, 119], ["This study", "TEST", 136, 146], ["plasmid DNA", "OBSERVATION", 108, 119]]], ["Informed consent was waived.Patient informationTwo patients with COVID-19 were admitted to our hospital.", [["patients", "ORGANISM", 51, 59], ["Patient", "SPECIES", 28, 35], ["patients", "SPECIES", 51, 59]]], ["Patient 1, a 46-year-old female, presented with mild dizziness and fatigue, while patient 2, a 65-year-old female, complained of mild sore throat followed by general weakness before COVID-19 confirmation.", [["dizziness", "DISEASE", 53, 62], ["fatigue", "DISEASE", 67, 74], ["sore throat", "DISEASE", 134, 145], ["female", "ORGANISM", 25, 31], ["patient", "ORGANISM", 82, 89], ["female", "ORGANISM", 107, 113], ["Patient", "SPECIES", 0, 7], ["patient", "SPECIES", 82, 89], ["mild dizziness", "PROBLEM", 48, 62], ["fatigue", "PROBLEM", 67, 74], ["mild sore throat", "PROBLEM", 129, 145], ["general weakness", "PROBLEM", 158, 174], ["COVID", "TEST", 182, 187], ["mild", "OBSERVATION_MODIFIER", 48, 52], ["dizziness", "OBSERVATION", 53, 62], ["mild", "OBSERVATION_MODIFIER", 129, 133], ["sore throat", "ANATOMY", 134, 145], ["weakness", "OBSERVATION", 166, 174]]], ["Both patients did not have fever, and the laboratory test results were unremarkable (Supplementary Table 1 ).", [["fever", "DISEASE", 27, 32], ["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["fever", "PROBLEM", 27, 32], ["the laboratory test", "TEST", 38, 57]]], ["On hospital day 1 (illness day 4), the chest radiograph of patient 2 showed pneumonia in the left lower lung field (Supplementary Fig. 1 ).", [["chest", "ANATOMY", 39, 44], ["left lower lung", "ANATOMY", 93, 108], ["pneumonia", "DISEASE", 76, 85], ["patient", "ORGANISM", 59, 66], ["lung", "ORGAN", 104, 108], ["patient", "SPECIES", 59, 66], ["the chest radiograph", "TEST", 35, 55], ["pneumonia in the left lower lung field", "PROBLEM", 76, 114], ["chest", "ANATOMY", 39, 44], ["pneumonia", "OBSERVATION", 76, 85], ["left", "ANATOMY_MODIFIER", 93, 97], ["lower", "ANATOMY_MODIFIER", 98, 103], ["lung", "ANATOMY", 104, 108], ["field", "ANATOMY_MODIFIER", 109, 114]]], ["During the study period from hospital days 1-9, patients were administered an antiviral agent for 10 days after the first sampling of the diverse body fluids; patient 1 received lopinavir/ritonavir 400 mg/100 mg twice a day and hydroxychloroquine 400 mg once daily, while patient 2 received only lopinavir/ritonavir 400 mg/100 mg twice a day.Viral load kinetics in diverse body fluidsOn hospital day 1, SARS-CoV-2 was detected from all five specimens (nasopharynx, oropharynx, saliva, sputum, and urine) of both patients using rRT-PCR ( Fig. 1 and Supplementary Table 2 ).", [["body fluids", "ANATOMY", 146, 157], ["body fluids", "ANATOMY", 373, 384], ["specimens", "ANATOMY", 441, 450], ["nasopharynx", "ANATOMY", 452, 463], ["oropharynx", "ANATOMY", 465, 475], ["saliva", "ANATOMY", 477, 483], ["sputum", "ANATOMY", 485, 491], ["urine", "ANATOMY", 497, 502], ["lopinavir/ritonavir", "CHEMICAL", 178, 197], ["hydroxychloroquine", "CHEMICAL", 228, 246], ["lopinavir/ritonavir", "CHEMICAL", 296, 315], ["lopinavir", "CHEMICAL", 178, 187], ["ritonavir", "CHEMICAL", 188, 197], ["hydroxychloroquine", "CHEMICAL", 228, 246], ["lopinavir", "CHEMICAL", 296, 305], ["ritonavir", "CHEMICAL", 306, 315], ["patients", "ORGANISM", 48, 56], ["body", "ORGANISM_SUBDIVISION", 146, 150], ["fluids", "ORGANISM_SUBSTANCE", 151, 157], ["patient", "ORGANISM", 159, 166], ["lopinavir", "SIMPLE_CHEMICAL", 178, 187], ["ritonavir", "SIMPLE_CHEMICAL", 188, 197], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 228, 246], ["patient", "ORGANISM", 272, 279], ["lopinavir", "SIMPLE_CHEMICAL", 296, 305], ["ritonavir", "SIMPLE_CHEMICAL", 306, 315], ["body", "ORGANISM_SUBDIVISION", 373, 377], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 403, 413], ["nasopharynx", "ORGAN", 452, 463], ["oropharynx", "ORGAN", 465, 475], ["saliva", "ORGANISM_SUBSTANCE", 477, 483], ["sputum", "ORGANISM_SUBSTANCE", 485, 491], ["urine", "ORGANISM_SUBSTANCE", 497, 502], ["patients", "ORGANISM", 512, 520], ["patients", "SPECIES", 48, 56], ["patient", "SPECIES", 159, 166], ["patient", "SPECIES", 272, 279], ["patients", "SPECIES", 512, 520], ["SARS-CoV", "SPECIES", 403, 411], ["an antiviral agent", "TREATMENT", 75, 93], ["the diverse body fluids", "TREATMENT", 134, 157], ["lopinavir", "TREATMENT", 178, 187], ["ritonavir", "TREATMENT", 188, 197], ["hydroxychloroquine", "TREATMENT", 228, 246], ["lopinavir", "TREATMENT", 296, 305], ["ritonavir", "TREATMENT", 306, 315], ["Viral load kinetics", "TREATMENT", 342, 361], ["diverse body fluids", "TREATMENT", 365, 384], ["SARS-CoV", "TEST", 403, 411], ["all five specimens (nasopharynx, oropharynx, saliva, sputum, and urine", "TEST", 432, 502], ["rRT-PCR", "TREATMENT", 527, 534], ["load kinetics", "OBSERVATION", 348, 361], ["nasopharynx", "ANATOMY", 452, 463], ["oropharynx", "ANATOMY", 465, 475]]], ["The viral load was the highest in the nasopharynx (patient 1 = 8.41 log 10 copies/mL; patient 2 = 7.49 log 10 copies/mL), but it was also remarkably high in the oropharynx (patient 1 = 6.65 log 10 copies/mL; patient 2 = 5.99 log 10 copies/mL), saliva (patient 1 = 6.63 log 10 copies/mL; patient 2 = 7.10 log 10 copies/mL), and sputum (patient 1 = 8.22 log 10 copies/mL; patient 2 = 7.33 log 10 copies/mL).", [["nasopharynx", "ANATOMY", 38, 49], ["oropharynx", "ANATOMY", 161, 171], ["sputum", "ANATOMY", 327, 333], ["nasopharynx", "ORGAN", 38, 49], ["patient", "ORGANISM", 51, 58], ["patient", "ORGANISM", 86, 93], ["oropharynx", "ORGAN", 161, 171], ["patient", "ORGANISM", 173, 180], ["patient", "ORGANISM", 208, 215], ["saliva", "ORGANISM_SUBSTANCE", 244, 250], ["patient", "ORGANISM", 252, 259], ["patient", "ORGANISM", 287, 294], ["patient", "ORGANISM", 335, 342], ["patient", "ORGANISM", 370, 377], ["patient", "SPECIES", 51, 58], ["patient", "SPECIES", 86, 93], ["patient", "SPECIES", 173, 180], ["patient", "SPECIES", 208, 215], ["patient", "SPECIES", 252, 259], ["patient", "SPECIES", 287, 294], ["patient", "SPECIES", 335, 342], ["patient", "SPECIES", 370, 377], ["The viral load", "TEST", 0, 14], ["sputum", "TEST", 327, 333], ["viral load", "OBSERVATION", 4, 14], ["highest", "OBSERVATION_MODIFIER", 23, 30], ["nasopharynx", "ANATOMY", 38, 49], ["high", "OBSERVATION", 149, 153], ["oropharynx", "ANATOMY", 161, 171]]], ["SARS-CoV-2 was detected initially in the urine samples (patient 1 = 5.48 log 10 copies/mL; patient 2 = 5.79 log 10 copies/mL), but it was not detected from hospital day 3.", [["urine samples", "ANATOMY", 41, 54], ["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["urine samples", "ORGANISM_SUBSTANCE", 41, 54], ["patient", "ORGANISM", 56, 63], ["patient", "ORGANISM", 91, 98], ["patient", "SPECIES", 56, 63], ["patient", "SPECIES", 91, 98], ["SARS-CoV", "SPECIES", 0, 8], ["SARS-CoV", "TEST", 0, 8], ["the urine samples", "TEST", 37, 54]]], ["The viral load in each specimen decreased gradually in the serial samples.", [["specimen", "ANATOMY", 23, 31], ["samples", "ANATOMY", 66, 73], ["The viral load in each specimen", "TEST", 0, 31], ["the serial samples", "TEST", 55, 73], ["viral load", "OBSERVATION", 4, 14], ["decreased", "OBSERVATION_MODIFIER", 32, 41], ["gradually", "OBSERVATION_MODIFIER", 42, 51]]], ["SARS-CoV-2 was detected up to hospital day 6 (illness day 9 for patient 2) from the saliva in both patients (Figs.", [["SARS", "DISEASE", 0, 4], ["illness", "DISEASE", 46, 53], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["patient", "ORGANISM", 64, 71], ["saliva", "ORGANISM_SUBSTANCE", 84, 90], ["patients", "ORGANISM", 99, 107], ["patient", "SPECIES", 64, 71], ["patients", "SPECIES", 99, 107], ["SARS-CoV", "SPECIES", 0, 8], ["saliva", "ANATOMY", 84, 90]]], ["1, 2 and Supplementary Table 2 ).Impact of chlorhexidine mouthwash on viral loadsThe viral load in the saliva decreased transiently for 2 hours after using the chlorhexidine mouthwash, but it increased again at 2-4 hours post-mouthwash ( Fig. 2 Days since admissionDISCUSSIONIn this study, we have shown that the SARS-CoV-2 viral load is consistently high in the saliva; it was relatively higher than that in the oropharynx during the early stage of COVID-19.", [["saliva", "ANATOMY", 103, 109], ["oropharynx", "ANATOMY", 413, 423], ["chlorhexidine mouthwash", "CHEMICAL", 43, 66], ["chlorhexidine", "CHEMICAL", 160, 173], ["SARS", "DISEASE", 313, 317], ["chlorhexidine", "CHEMICAL", 43, 56], ["chlorhexidine", "CHEMICAL", 160, 173], ["chlorhexidine", "SIMPLE_CHEMICAL", 43, 56], ["saliva", "ORGANISM_SUBSTANCE", 103, 109], ["chlorhexidine", "SIMPLE_CHEMICAL", 160, 173], ["SARS-CoV-2", "ORGANISM", 313, 323], ["saliva", "ORGANISM_SUBSTANCE", 363, 369], ["oropharynx", "ORGAN", 413, 423], ["SARS-CoV", "SPECIES", 313, 321], ["chlorhexidine mouthwash", "TREATMENT", 43, 66], ["viral loads", "TREATMENT", 70, 81], ["The viral load", "TEST", 81, 95], ["the chlorhexidine mouthwash", "TREATMENT", 156, 183], ["this study", "TEST", 278, 288], ["the SARS", "TEST", 309, 317], ["CoV-2 viral load", "TEST", 318, 334], ["COVID", "TEST", 450, 455], ["chlorhexidine mouthwash", "OBSERVATION", 43, 66], ["viral loads", "OBSERVATION_MODIFIER", 70, 81], ["viral load", "OBSERVATION", 85, 95], ["increased", "OBSERVATION_MODIFIER", 192, 201], ["higher", "OBSERVATION_MODIFIER", 389, 395], ["oropharynx", "ANATOMY", 413, 423]]], ["This finding suggests that SARS-CoV-2 might be secreted from the salivary gland rather than the nasopharynx.", [["salivary gland", "ANATOMY", 65, 79], ["nasopharynx", "ANATOMY", 96, 107], ["SARS", "DISEASE", 27, 31], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 27, 37], ["salivary gland", "ORGAN", 65, 79], ["nasopharynx", "ORGAN", 96, 107], ["SARS-CoV", "SPECIES", 27, 35], ["SARS", "PROBLEM", 27, 31], ["SARS", "OBSERVATION", 27, 31], ["salivary gland", "ANATOMY", 65, 79], ["nasopharynx", "ANATOMY", 96, 107]]], ["Chlorhexidine mouthwash was effective in reducing the SARS-CoV-2 viral load in the saliva for a short-term period.DISCUSSIONTransmission of coronaviruses occurs primarily by close contact via respiratory droplets, which are generated by sneezing, coughing, breathing, and talking.", [["saliva", "ANATOMY", 83, 89], ["respiratory droplets", "ANATOMY", 192, 212], ["Chlorhexidine", "CHEMICAL", 0, 13], ["coughing", "DISEASE", 247, 255], ["Chlorhexidine", "CHEMICAL", 0, 13], ["Chlorhexidine", "SIMPLE_CHEMICAL", 0, 13], ["CoV-2", "ORGANISM", 59, 64], ["saliva", "ORGANISM_SUBSTANCE", 83, 89], ["coronaviruses", "ORGANISM", 140, 153], ["Chlorhexidine mouthwash", "TREATMENT", 0, 23], ["the SARS", "TEST", 50, 58], ["CoV", "TEST", 59, 62], ["coronaviruses", "PROBLEM", 140, 153], ["sneezing", "PROBLEM", 237, 245], ["coughing", "PROBLEM", 247, 255], ["coronaviruses", "OBSERVATION", 140, 153]]], ["According to a study measuring the respiratory droplets, the size was approximately the same among sneezing, coughing, and talking, but the amount was the largest when sneezing.", [["respiratory droplets", "ANATOMY", 35, 55], ["sneezing", "DISEASE", 99, 107], ["sneezing", "DISEASE", 168, 176], ["a study", "TEST", 13, 20], ["the respiratory droplets", "TEST", 31, 55], ["sneezing", "PROBLEM", 99, 107], ["coughing", "PROBLEM", 109, 117], ["sneezing", "PROBLEM", 168, 176], ["respiratory droplets", "OBSERVATION", 35, 55], ["size", "OBSERVATION_MODIFIER", 61, 65], ["approximately", "OBSERVATION_MODIFIER", 70, 83], ["sneezing", "OBSERVATION", 99, 107], ["coughing", "OBSERVATION", 109, 117], ["largest", "OBSERVATION_MODIFIER", 155, 162], ["sneezing", "OBSERVATION", 168, 176]]], ["8 Contrary to seasonal coronavirus infections, nasal symptoms are infrequent and less prominent in the cases of novel coronavirus infections, including Middle Eastern respiratory syndrome and COVID-19.", [["nasal", "ANATOMY", 47, 52], ["coronavirus infections", "DISEASE", 23, 45], ["nasal symptoms", "DISEASE", 47, 61], ["coronavirus infections", "DISEASE", 118, 140], ["Middle Eastern respiratory syndrome", "DISEASE", 152, 187], ["coronavirus", "ORGANISM", 23, 34], ["nasal", "ORGAN", 47, 52], ["coronavirus", "ORGANISM", 118, 129], ["seasonal coronavirus", "SPECIES", 14, 34], ["seasonal coronavirus infections", "PROBLEM", 14, 45], ["nasal symptoms", "PROBLEM", 47, 61], ["novel coronavirus infections", "PROBLEM", 112, 140], ["Middle Eastern respiratory syndrome", "PROBLEM", 152, 187], ["COVID", "TEST", 192, 197], ["seasonal", "OBSERVATION_MODIFIER", 14, 22], ["coronavirus", "OBSERVATION_MODIFIER", 23, 34], ["infections", "OBSERVATION", 35, 45], ["nasal", "ANATOMY", 47, 52], ["less prominent", "OBSERVATION_MODIFIER", 81, 95], ["coronavirus infections", "OBSERVATION", 118, 140], ["Middle", "ANATOMY_MODIFIER", 152, 158], ["respiratory syndrome", "OBSERVATION", 167, 187]]], ["9, 10 The Middle Eastern respiratory syndrome coronavirus (MERS-CoV) transmission was relatively limited in the community, but a large number of community-acquired SARS-CoV-2 infections have been reported in many countries worldwide, such as China, Korea, Italy and Spain.", [["respiratory syndrome coronavirus", "DISEASE", 25, 57], ["MERS-CoV) transmission", "DISEASE", 59, 81], ["SARS-CoV-2 infections", "DISEASE", 164, 185], ["Middle Eastern respiratory syndrome coronavirus", "ORGANISM", 10, 57], ["MERS-CoV", "ORGANISM", 59, 67], ["SARS-CoV-2", "ORGANISM", 164, 174], ["CoV-2", "SPECIES", 169, 174], ["Middle Eastern respiratory syndrome coronavirus", "SPECIES", 10, 57], ["MERS-CoV", "SPECIES", 59, 67], ["The Middle Eastern respiratory syndrome coronavirus", "PROBLEM", 6, 57], ["acquired SARS", "PROBLEM", 155, 168], ["2 infections", "PROBLEM", 173, 185], ["Middle", "ANATOMY_MODIFIER", 10, 16], ["respiratory syndrome", "OBSERVATION", 25, 45], ["large", "OBSERVATION_MODIFIER", 129, 134], ["number", "OBSERVATION_MODIFIER", 135, 141]]], ["Similar to the two cases in this study, several cases of SARS-CoV-2 infection have occurred in Korea even after a short conversation with patients with subclinical respiratory symptoms.", [["respiratory", "ANATOMY", 164, 175], ["SARS-CoV-2 infection", "DISEASE", 57, 77], ["respiratory symptoms", "DISEASE", 164, 184], ["SARS-CoV-2", "ORGANISM", 57, 67], ["patients", "ORGANISM", 138, 146], ["CoV-", "SPECIES", 62, 66], ["patients", "SPECIES", 138, 146], ["SARS-CoV", "SPECIES", 57, 65], ["this study", "TEST", 28, 38], ["SARS", "PROBLEM", 57, 61], ["CoV", "PROBLEM", 62, 65], ["2 infection", "PROBLEM", 66, 77], ["subclinical respiratory symptoms", "PROBLEM", 152, 184], ["SARS", "OBSERVATION", 57, 61], ["infection", "OBSERVATION", 68, 77]]], ["1 Owing to its high viral load in the saliva, SARS-CoV-2 might be transmitted to other people during a conversation.", [["saliva", "ANATOMY", 38, 44], ["saliva", "ORGANISM_SUBSTANCE", 38, 44], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 46, 56], ["people", "ORGANISM", 87, 93], ["people", "SPECIES", 87, 93], ["SARS-CoV", "SPECIES", 46, 54], ["viral load", "OBSERVATION", 20, 30]]], ["This difference in transmission might be related to the receptor binding tropism; MERS-CoV binds to the dipeptidyl peptidase 4 (DPP4) receptor, while SARS-CoV-2 binds to the angiotensin converting enzyme 2 (ACE2) receptor, similar to seasonal coronaviruses.", [["angiotensin", "CHEMICAL", 174, 185], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 82, 90], ["dipeptidyl peptidase 4", "GENE_OR_GENE_PRODUCT", 104, 126], ["DPP4", "GENE_OR_GENE_PRODUCT", 128, 132], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 150, 160], ["angiotensin converting enzyme 2", "GENE_OR_GENE_PRODUCT", 174, 205], ["ACE2", "GENE_OR_GENE_PRODUCT", 207, 211], ["MERS-CoV", "PROTEIN", 82, 90], ["dipeptidyl peptidase 4 (DPP4) receptor", "PROTEIN", 104, 142], ["SARS-CoV-2", "PROTEIN", 150, 160], ["angiotensin converting enzyme 2 (ACE2) receptor", "PROTEIN", 174, 221], ["MERS-CoV", "SPECIES", 82, 90], ["the receptor binding tropism", "PROBLEM", 52, 80], ["the dipeptidyl peptidase 4 (DPP4) receptor", "TREATMENT", 100, 142], ["SARS", "TEST", 150, 154], ["CoV", "TEST", 155, 158], ["the angiotensin converting enzyme", "TEST", 170, 203], ["seasonal coronaviruses", "PROBLEM", 234, 256], ["might be related to", "UNCERTAINTY", 32, 51], ["seasonal coronaviruses", "OBSERVATION", 234, 256]]], ["11 In humans, ACE2 is expressed both in the respiratory tract and the salivary gland duct epithelium, whereas DPP4 is exclusively expressed in the lower respiratory tract epithelium.", [["respiratory tract", "ANATOMY", 44, 61], ["salivary gland duct epithelium", "ANATOMY", 70, 100], ["lower respiratory tract epithelium", "ANATOMY", 147, 181], ["humans", "ORGANISM", 6, 12], ["ACE2", "GENE_OR_GENE_PRODUCT", 14, 18], ["respiratory tract", "ORGAN", 44, 61], ["salivary gland duct epithelium", "TISSUE", 70, 100], ["DPP4", "GENE_OR_GENE_PRODUCT", 110, 114], ["lower respiratory tract epithelium", "TISSUE", 147, 181], ["ACE2", "PROTEIN", 14, 18], ["DPP4", "PROTEIN", 110, 114], ["humans", "SPECIES", 6, 12], ["humans", "SPECIES", 6, 12], ["DPP4", "TEST", 110, 114], ["respiratory tract", "ANATOMY", 44, 61], ["salivary gland", "ANATOMY", 70, 84], ["duct", "ANATOMY_MODIFIER", 85, 89], ["epithelium", "ANATOMY_MODIFIER", 90, 100], ["lower", "ANATOMY_MODIFIER", 147, 152], ["respiratory tract", "ANATOMY", 153, 170], ["epithelium", "ANATOMY_MODIFIER", 171, 181]]], ["12,13DISCUSSIONCoronaviruses are a group of enveloped positive-sense single-stranded RNA viruses.DISCUSSIONConsidering that chlorhexidine compounds are effective against lipid-enveloped viruses, we prescribed a chlorhexidine (0.12%, 15 mL) mouthwash and found viral suppression for 2 hours after using the mouthwash once.", [["chlorhexidine", "CHEMICAL", 124, 137], ["chlorhexidine", "CHEMICAL", 211, 224], ["chlorhexidine", "CHEMICAL", 124, 137], ["chlorhexidine", "CHEMICAL", 211, 224], ["chlorhexidine compounds", "SIMPLE_CHEMICAL", 124, 147], ["lipid", "SIMPLE_CHEMICAL", 170, 175], ["chlorhexidine", "SIMPLE_CHEMICAL", 211, 224], ["chlorhexidine compounds", "TREATMENT", 124, 147], ["a chlorhexidine", "TREATMENT", 209, 224], ["mouthwash", "TREATMENT", 240, 249], ["the mouthwash", "TREATMENT", 302, 315], ["viruses", "OBSERVATION", 186, 193], ["viral suppression", "OBSERVATION", 260, 277]]], ["However, in patient 1, there was no decrease in viral load in the saliva 1 hour after using the mouthwash (hospital day 6), which might be due to mixing of the saliva specimen with the postnasal drip or incomplete gargling.", [["specimen", "ANATOMY", 167, 175], ["patient", "ORGANISM", 12, 19], ["saliva", "ORGANISM_SUBSTANCE", 66, 72], ["saliva", "ORGANISM", 160, 166], ["patient", "SPECIES", 12, 19], ["decrease in viral load", "PROBLEM", 36, 58], ["mixing of the saliva specimen", "PROBLEM", 146, 175], ["the postnasal drip", "TREATMENT", 181, 199], ["incomplete gargling", "PROBLEM", 203, 222], ["no", "UNCERTAINTY", 33, 35], ["decrease", "OBSERVATION_MODIFIER", 36, 44], ["viral load", "OBSERVATION", 48, 58]]], ["Therefore, chlorhexidine mouthwash might be beneficial for the control of SARS-CoV-2 transmission in both the community and hospital setting.DISCUSSIONSaliva can be easily collected from patients without performing any invasive procedures.", [["chlorhexidine", "CHEMICAL", 11, 24], ["SARS", "DISEASE", 74, 78], ["chlorhexidine", "CHEMICAL", 11, 24], ["chlorhexidine", "SIMPLE_CHEMICAL", 11, 24], ["SARS-CoV-2", "ORGANISM", 74, 84], ["patients", "ORGANISM", 187, 195], ["patients", "SPECIES", 187, 195], ["SARS-CoV-2", "SPECIES", 74, 84], ["chlorhexidine mouthwash", "TREATMENT", 11, 34], ["SARS", "PROBLEM", 74, 78], ["any invasive procedures", "TREATMENT", 215, 238]]], ["The time and cost associated with the collection of saliva were reported to be 2.26-fold and 2.59fold lower than that of nasopharyngeal sampling.", [["nasopharyngeal", "ANATOMY", 121, 135], ["saliva", "ORGANISM_SUBSTANCE", 52, 58], ["nasopharyngeal", "ORGANISM_SUBDIVISION", 121, 135], ["nasopharyngeal sampling", "TEST", 121, 144], ["nasopharyngeal", "ANATOMY", 121, 135]]], ["14 In addition, collecting the saliva specimen is safe and efficient during a novel infectious disease epidemic because patients are able to provide samples of their saliva themselves.", [["saliva specimen", "ANATOMY", 31, 46], ["saliva", "ORGANISM", 31, 37], ["patients", "ORGANISM", 120, 128], ["saliva", "ORGANISM_SUBSTANCE", 166, 172], ["patients", "SPECIES", 120, 128], ["collecting the saliva specimen", "TEST", 16, 46], ["a novel infectious disease epidemic", "PROBLEM", 76, 111]]], ["Recent studies have shown that the saliva might be a valuable specimen for the diagnosis of respiratory virus infections compared to nasopharyngeal swabs.", [["specimen", "ANATOMY", 62, 70], ["nasopharyngeal swabs", "ANATOMY", 133, 153], ["respiratory virus infections", "DISEASE", 92, 120], ["saliva", "ORGANISM_SUBSTANCE", 35, 41], ["respiratory virus", "ORGANISM", 92, 109], ["nasopharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 133, 153], ["Recent studies", "TEST", 0, 14], ["the saliva", "PROBLEM", 31, 41], ["respiratory virus infections", "PROBLEM", 92, 120], ["nasopharyngeal swabs", "TEST", 133, 153], ["respiratory", "ANATOMY", 92, 103], ["virus", "OBSERVATION", 104, 109]]], ["14, 15 Similarly, the results in this study also suggest that saliva specimens can be used for the diagnosis of SARS-CoV-2 infection.", [["saliva specimens", "ANATOMY", 62, 78], ["SARS-CoV-2 infection", "DISEASE", 112, 132], ["saliva specimens", "ORGANISM_SUBSTANCE", 62, 78], ["SARS-CoV-2", "ORGANISM", 112, 122], ["SARS-CoV-2", "SPECIES", 112, 122], ["this study", "TEST", 33, 43], ["saliva specimens", "TEST", 62, 78], ["SARS", "PROBLEM", 112, 116], ["CoV", "PROBLEM", 117, 120], ["2 infection", "PROBLEM", 121, 132], ["infection", "OBSERVATION", 123, 132]]], ["However, the viral load in the saliva might decrease during the late stage of the infection.", [["saliva", "ANATOMY", 31, 37], ["infection", "DISEASE", 82, 91], ["saliva", "ORGANISM_SUBSTANCE", 31, 37], ["the viral load", "TEST", 9, 23], ["the saliva", "PROBLEM", 27, 37], ["the infection", "PROBLEM", 78, 91], ["viral load", "OBSERVATION", 13, 23], ["decrease", "OBSERVATION_MODIFIER", 44, 52], ["late stage", "OBSERVATION_MODIFIER", 64, 74], ["infection", "OBSERVATION", 82, 91]]], ["Further research is needed to determine whether saliva specimens can help diagnose SARS-CoV-2 infection in patients with advanced pneumonia.DISCUSSIONLopinavir/ritonavir appears to suppress viremia, but it might be ineffective in controlling respiratory tract infections.", [["specimens", "ANATOMY", 55, 64], ["respiratory tract", "ANATOMY", 242, 259], ["SARS-CoV-2 infection", "DISEASE", 83, 103], ["pneumonia", "DISEASE", 130, 139], ["DISCUSSIONLopinavir/ritonavir", "CHEMICAL", 140, 169], ["viremia", "DISEASE", 190, 197], ["respiratory tract infections", "DISEASE", 242, 270], ["DISCUSSIONLopinavir", "CHEMICAL", 140, 159], ["ritonavir", "CHEMICAL", 160, 169], ["saliva", "ORGANISM", 48, 54], ["SARS-CoV-2", "ORGANISM", 83, 93], ["patients", "ORGANISM", 107, 115], ["DISCUSSIONLopinavir", "SIMPLE_CHEMICAL", 140, 159], ["ritonavir", "SIMPLE_CHEMICAL", 160, 169], ["respiratory tract", "ORGANISM_SUBDIVISION", 242, 259], ["patients", "SPECIES", 107, 115], ["SARS-CoV-2", "SPECIES", 83, 93], ["saliva specimens", "TEST", 48, 64], ["SARS", "PROBLEM", 83, 87], ["CoV-2 infection", "PROBLEM", 88, 103], ["advanced pneumonia", "PROBLEM", 121, 139], ["DISCUSSIONLopinavir", "TREATMENT", 140, 159], ["ritonavir", "TREATMENT", 160, 169], ["viremia", "PROBLEM", 190, 197], ["controlling respiratory tract infections", "PROBLEM", 230, 270], ["infection", "OBSERVATION", 94, 103], ["advanced", "OBSERVATION_MODIFIER", 121, 129], ["pneumonia", "OBSERVATION", 130, 139], ["viremia", "OBSERVATION", 190, 197], ["respiratory tract", "ANATOMY", 242, 259]]], ["In a mouse study for MERS-CoV, lopinavir/ritonavir did not reduce virus replication or severe pathology in the lung tissue, contrary to remdesivir.", [["lung tissue", "ANATOMY", 111, 122], ["lopinavir", "CHEMICAL", 31, 40], ["ritonavir", "CHEMICAL", 41, 50], ["remdesivir", "CHEMICAL", 136, 146], ["lopinavir", "CHEMICAL", 31, 40], ["ritonavir", "CHEMICAL", 41, 50], ["remdesivir", "CHEMICAL", 136, 146], ["mouse", "ORGANISM", 5, 10], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 21, 29], ["lopinavir", "SIMPLE_CHEMICAL", 31, 40], ["ritonavir", "SIMPLE_CHEMICAL", 41, 50], ["lung tissue", "TISSUE", 111, 122], ["remdesivir", "SIMPLE_CHEMICAL", 136, 146], ["mouse", "SPECIES", 5, 10], ["mouse", "SPECIES", 5, 10], ["MERS-CoV", "SPECIES", 21, 29], ["a mouse study", "TEST", 3, 16], ["MERS", "PROBLEM", 21, 25], ["lopinavir", "TREATMENT", 31, 40], ["ritonavir", "TREATMENT", 41, 50], ["virus replication", "PROBLEM", 66, 83], ["severe pathology in the lung tissue", "PROBLEM", 87, 122], ["remdesivir", "TREATMENT", 136, 146], ["severe", "OBSERVATION_MODIFIER", 87, 93], ["pathology", "OBSERVATION", 94, 103], ["lung", "ANATOMY", 111, 115]]], ["16 ritonavir is an anti-HIV drug, developed to achieve a high concentration in the plasma and lymphatic tissue, but not in the lung tissue.", [["plasma", "ANATOMY", 83, 89], ["lymphatic tissue", "ANATOMY", 94, 110], ["lung tissue", "ANATOMY", 127, 138], ["ritonavir", "CHEMICAL", 3, 12], ["ritonavir", "CHEMICAL", 3, 12], ["ritonavir", "SIMPLE_CHEMICAL", 3, 12], ["plasma", "ORGANISM_SUBSTANCE", 83, 89], ["lymphatic tissue", "TISSUE", 94, 110], ["lung tissue", "TISSUE", 127, 138], ["HIV", "SPECIES", 24, 27], ["ritonavir", "TREATMENT", 3, 12], ["an anti-HIV drug", "TREATMENT", 16, 32], ["a high concentration in the plasma and lymphatic tissue", "PROBLEM", 55, 110], ["plasma", "ANATOMY", 83, 89], ["lymphatic tissue", "ANATOMY", 94, 110], ["lung", "ANATOMY", 127, 131], ["tissue", "OBSERVATION", 132, 138]]], ["Pharmacokinetic data on the respiratory tract concentration of lopinavir/ritonavir are lacking, and further research is, therefore, warranted.DISCUSSIONThere are several limitations to this study.", [["respiratory tract", "ANATOMY", 28, 45], ["lopinavir/ritonavir", "CHEMICAL", 63, 82], ["lopinavir", "CHEMICAL", 63, 72], ["ritonavir", "CHEMICAL", 73, 82], ["respiratory tract", "ORGANISM_SUBDIVISION", 28, 45], ["lopinavir", "SIMPLE_CHEMICAL", 63, 72], ["ritonavir", "SIMPLE_CHEMICAL", 73, 82], ["Pharmacokinetic data", "TEST", 0, 20], ["lopinavir", "TREATMENT", 63, 72], ["ritonavir", "TREATMENT", 73, 82], ["this study", "TEST", 185, 195]]], ["The study was only conducted in a small number of patients and did not include controls (gargling with saline) for comparison.", [["patients", "ORGANISM", 50, 58], ["saline", "SIMPLE_CHEMICAL", 103, 109], ["patients", "SPECIES", 50, 58], ["The study", "TEST", 0, 9], ["saline", "TREATMENT", 103, 109]]], ["Large-scale studies, including control subjects, are required to minimize the confounding effects of disease severity, sampling errors, and other factors.", [["Large-scale studies", "TEST", 0, 19], ["disease severity", "PROBLEM", 101, 117], ["sampling errors", "PROBLEM", 119, 134], ["-scale", "OBSERVATION_MODIFIER", 5, 11]]], ["In addition, environmental surveillance should be included in the study design of future studies.", [["environmental surveillance", "TEST", 13, 39], ["future studies", "TEST", 82, 96]]], ["Although rRT-PCR results were not positive for the 15 environmental specimens at day 4 and day 14 (data not shown), the possibility of environmental contamination should be considered.", [["specimens", "ANATOMY", 68, 77], ["rRT", "DNA", 9, 12], ["rRT-PCR", "TEST", 9, 16], ["environmental contamination", "PROBLEM", 135, 162]]], ["Second, a viral culture test was not conducted in this study.", [["a viral culture test", "TEST", 8, 28], ["this study", "TEST", 50, 60]]], ["Therefore, it was not possible to determine the survival of the virus over time.", [["the virus", "PROBLEM", 60, 69], ["virus", "OBSERVATION", 64, 69]]], ["Finally, the standardized plasmid DNA was not use.", [["plasmid", "ANATOMY", 26, 33], ["DNA", "CELLULAR_COMPONENT", 34, 37], ["standardized plasmid DNA", "DNA", 13, 37], ["the standardized plasmid DNA", "TREATMENT", 9, 37]]], ["Ct values were converted to RNA copy number using plasmid DNA for an intuitive comparison of changes in the viral concentration.", [["DNA", "CELLULAR_COMPONENT", 58, 61], ["plasmid DNA", "DNA", 50, 61], ["Ct values", "TEST", 0, 9], ["plasmid DNA", "TREATMENT", 50, 61], ["the viral concentration", "TREATMENT", 104, 127], ["viral concentration", "OBSERVATION", 108, 127]]], ["Since standardized plasmid DNA was not available, a self-constructed plasmid DNA was used.DISCUSSIONIn summary, we analyzed the serial viral load in the nasopharynx, oropharynx, saliva, sputum, and urine samples of two patients with COVID-19.", [["plasmid", "ANATOMY", 19, 26], ["plasmid", "ANATOMY", 69, 76], ["nasopharynx", "ANATOMY", 153, 164], ["oropharynx", "ANATOMY", 166, 176], ["saliva", "ANATOMY", 178, 184], ["sputum", "ANATOMY", 186, 192], ["urine samples", "ANATOMY", 198, 211], ["DNA", "CELLULAR_COMPONENT", 27, 30], ["DNA", "CELLULAR_COMPONENT", 77, 80], ["nasopharynx", "ORGAN", 153, 164], ["oropharynx", "ORGAN", 166, 176], ["saliva", "ORGANISM_SUBSTANCE", 178, 184], ["sputum", "ORGANISM_SUBSTANCE", 186, 192], ["urine samples", "ORGANISM_SUBSTANCE", 198, 211], ["patients", "ORGANISM", 219, 227], ["plasmid DNA", "DNA", 19, 30], ["self-constructed plasmid DNA", "DNA", 52, 80], ["patients", "SPECIES", 219, 227], ["standardized plasmid DNA", "TREATMENT", 6, 30], ["a self-constructed plasmid DNA", "TREATMENT", 50, 80], ["the serial viral load in the nasopharynx, oropharynx, saliva, sputum", "TEST", 124, 192], ["urine samples", "TEST", 198, 211], ["COVID", "TEST", 233, 238], ["nasopharynx", "ANATOMY", 153, 164], ["oropharynx", "ANATOMY", 166, 176], ["saliva", "ANATOMY", 178, 184]]], ["During the early stage of infection, the viral load of SARS-CoV-2 was remarkably high in the nasopharynx and the saliva.", [["nasopharynx", "ANATOMY", 93, 104], ["saliva", "ANATOMY", 113, 119], ["infection", "DISEASE", 26, 35], ["SARS", "DISEASE", 55, 59], ["SARS-CoV-2", "ORGANISM", 55, 65], ["nasopharynx", "ORGAN", 93, 104], ["saliva", "ORGANISM_SUBSTANCE", 113, 119], ["SARS-CoV", "SPECIES", 55, 63], ["infection", "PROBLEM", 26, 35], ["the viral load", "TEST", 37, 51], ["SARS", "TEST", 55, 59], ["CoV", "TEST", 60, 63], ["early stage", "OBSERVATION_MODIFIER", 11, 22], ["infection", "OBSERVATION", 26, 35], ["viral load", "OBSERVATION", 41, 51], ["high", "OBSERVATION_MODIFIER", 81, 85], ["nasopharynx", "ANATOMY", 93, 104], ["saliva", "ANATOMY", 113, 119]]], ["Chlorhexidine mouthwash could be beneficial in controlling droplet transmission in addition to mask wearing and hand washing.", [["hand", "ANATOMY", 112, 116], ["Chlorhexidine", "CHEMICAL", 0, 13], ["Chlorhexidine", "CHEMICAL", 0, 13], ["Chlorhexidine", "SIMPLE_CHEMICAL", 0, 13], ["hand", "ORGANISM_SUBDIVISION", 112, 116], ["Chlorhexidine mouthwash", "TREATMENT", 0, 23], ["mask wearing", "TREATMENT", 95, 107], ["hand washing", "TREATMENT", 112, 124]]]], "PMC7202828": [["Among patients with coronavirus disease 2019 (COVID-19), parameters for the prediction of the need for admission to intensive care units (ICUs) are urgently needed to enable appropriate resource allocation.", [["coronavirus disease", "DISEASE", 20, 39], ["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["coronavirus disease", "PROBLEM", 20, 39], ["COVID", "TEST", 46, 51], ["coronavirus disease", "OBSERVATION", 20, 39]]], ["Here we report that analysis of a urine sample on admission to hospital can be used to detect systemic capillary leak syndrome, which can be a predictor of fluid overload, respiratory failure, need for ICU admission, and death.", [["urine sample", "ANATOMY", 34, 46], ["capillary", "ANATOMY", 103, 112], ["fluid", "ANATOMY", 156, 161], ["respiratory", "ANATOMY", 172, 183], ["fluid overload", "DISEASE", 156, 170], ["respiratory failure", "DISEASE", 172, 191], ["death", "DISEASE", 221, 226], ["urine", "ORGANISM_SUBSTANCE", 34, 39], ["capillary", "TISSUE", 103, 112], ["fluid", "ORGANISM_SUBSTANCE", 156, 161], ["a urine sample", "TEST", 32, 46], ["systemic capillary leak syndrome", "PROBLEM", 94, 126], ["fluid overload", "PROBLEM", 156, 170], ["respiratory failure", "PROBLEM", 172, 191], ["death", "PROBLEM", 221, 226], ["systemic", "OBSERVATION_MODIFIER", 94, 102], ["capillary", "OBSERVATION", 103, 112], ["leak syndrome", "OBSERVATION", 113, 126], ["fluid overload", "OBSERVATION", 156, 170], ["respiratory failure", "OBSERVATION", 172, 191]]]], "PMC7197034": [["IntroductionThe World Health Organization (WHO) on March 11, 2020, has communicated the novel coronavirus (Covid-19) outbreak a global pandemic.", [["coronavirus", "DISEASE", 94, 105], ["coronavirus", "ORGANISM", 94, 105], ["a global pandemic", "PROBLEM", 126, 143]]], ["The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already assumed pandemic proportions, affecting over 100 countries in few weeks.", [["acute respiratory syndrome coronavirus", "DISEASE", 21, 59], ["SARS-CoV-2", "ORGANISM", 63, 73], ["severe acute respiratory syndrome coronavirus", "SPECIES", 14, 59], ["SARS-CoV-2", "SPECIES", 63, 73], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 14, 59], ["SARS-CoV", "TEST", 63, 71], ["spread", "OBSERVATION_MODIFIER", 4, 10], ["severe", "OBSERVATION_MODIFIER", 14, 20], ["acute", "OBSERVATION_MODIFIER", 21, 26], ["respiratory syndrome coronavirus", "OBSERVATION", 27, 59], ["pandemic", "OBSERVATION", 95, 103]]], ["Although containment measures in China have reduced all new cases, this reduction has not occurred elsewhere and Italy has been particularly hard hit.", [["containment", "OBSERVATION_MODIFIER", 9, 20], ["new", "OBSERVATION_MODIFIER", 56, 59], ["hard", "OBSERVATION_MODIFIER", 141, 145], ["hit", "OBSERVATION", 146, 149]]], ["There is now serious concern regarding the ability of the Italian national health system to respond effectively to the needs of infected patients requiring intensive care for Covid-19 pneumonia.", [["pneumonia", "DISEASE", 184, 193], ["patients", "ORGANISM", 137, 145], ["patients", "SPECIES", 137, 145], ["Covid-19", "SPECIES", 175, 183], ["intensive care", "TREATMENT", 156, 170], ["Covid", "TEST", 175, 180], ["pneumonia", "PROBLEM", 184, 193], ["serious", "OBSERVATION_MODIFIER", 13, 20], ["pneumonia", "OBSERVATION", 184, 193]]], ["The percentage of intensive care unit (ICU) patients reported daily in Italy between March 1 and March 11, 2020, was constantly between 9 and 11% of the patients infected.", [["patients", "ORGANISM", 44, 52], ["patients", "ORGANISM", 153, 161], ["patients", "SPECIES", 44, 52], ["patients", "SPECIES", 153, 161], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["infected", "OBSERVATION", 162, 170]]], ["Since February 21, in Italy the number of patients infected closely follows an exponential trend [3, 4] and Covid-19 diagnosis is performed by detecting pathogenic samples and traces of the specific immune response by means of a saliva sample in symptomatic patients.", [["samples", "ANATOMY", 164, 171], ["saliva sample", "ANATOMY", 229, 242], ["patients", "ORGANISM", 42, 50], ["saliva", "ORGANISM_SUBSTANCE", 229, 235], ["patients", "ORGANISM", 258, 266], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 258, 266], ["Covid", "TEST", 108, 113], ["pathogenic samples", "TEST", 153, 171], ["a saliva sample", "TEST", 227, 242], ["infected", "OBSERVATION", 51, 59]]], ["Usually it takes 2 days to get the result of the swab which is why you are not timely in response.", [["the swab", "TREATMENT", 45, 53]]], ["Currently, the screening work is passive and is mainly based on symptoms, but unfortunately as the number of asymptomatic patients increases, prevention and control of the epidemic become even more difficult.", [["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 122, 130], ["the screening work", "TEST", 11, 29], ["symptoms", "PROBLEM", 64, 72], ["the epidemic", "PROBLEM", 168, 180]]], ["Overcrowded medical establishments are further difficulties in preventing the epidemic and seriously exposed.", [["further difficulties", "PROBLEM", 39, 59]]], ["Therefore, there is a very high risk of cross-infection between medical staff and patients [5, 6].", [["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["very", "OBSERVATION_MODIFIER", 22, 26], ["high", "OBSERVATION_MODIFIER", 27, 31], ["cross-infection", "OBSERVATION", 40, 55]]], ["Covid-19 can be diagnosed both on chest X-ray and on computed tomography (CT) [7].", [["Covid", "TEST", 0, 5], ["chest X-ray", "TEST", 34, 45], ["computed tomography (CT)", "TEST", 53, 77], ["chest", "ANATOMY", 34, 39]]], ["Asymptomatic patients may also have lung lesions on imaging.", [["lung lesions", "ANATOMY", 36, 48], ["patients", "ORGANISM", 13, 21], ["lung lesions", "PATHOLOGICAL_FORMATION", 36, 48], ["patients", "SPECIES", 13, 21], ["lung lesions", "PROBLEM", 36, 48], ["imaging", "TEST", 52, 59], ["lung", "ANATOMY", 36, 40], ["lesions", "OBSERVATION", 41, 48]]], ["CT investigation in patients with suspicion Covid-19 pneumonia involves the use of the high-resolution technique (HRCT).", [["pneumonia", "DISEASE", 53, 62], ["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["CT investigation", "TEST", 0, 16], ["suspicion Covid", "TEST", 34, 49], ["pneumonia", "PROBLEM", 53, 62], ["the high-resolution technique", "TREATMENT", 83, 112], ["pneumonia", "OBSERVATION", 53, 62]]], ["HRCT is the most accurate technique in identifying pathognomic findings of interstitial pneumonia as ground glass areas, crazy paving, nodules and consolidations, mono- or bilateral, patchy or multifocal, central and/or peripheral distribution, declivous or non-declivous [7\u201311].", [["interstitial", "ANATOMY", 75, 87], ["nodules", "ANATOMY", 135, 142], ["interstitial pneumonia", "DISEASE", 75, 97], ["nodules", "CANCER", 135, 142], ["HRCT", "TEST", 0, 4], ["interstitial pneumonia", "PROBLEM", 75, 97], ["ground glass areas", "PROBLEM", 101, 119], ["crazy paving", "PROBLEM", 121, 133], ["nodules", "PROBLEM", 135, 142], ["consolidations", "PROBLEM", 147, 161], ["mono", "TEST", 163, 167], ["bilateral, patchy or multifocal, central and/or peripheral distribution", "PROBLEM", 172, 243], ["interstitial", "ANATOMY_MODIFIER", 75, 87], ["pneumonia", "OBSERVATION", 88, 97], ["ground glass", "OBSERVATION", 101, 113], ["areas", "OBSERVATION_MODIFIER", 114, 119], ["crazy", "OBSERVATION_MODIFIER", 121, 126], ["nodules", "OBSERVATION", 135, 142], ["consolidations", "OBSERVATION", 147, 161], ["mono", "OBSERVATION_MODIFIER", 163, 167], ["bilateral", "ANATOMY_MODIFIER", 172, 181], ["patchy", "OBSERVATION_MODIFIER", 183, 189], ["multifocal", "OBSERVATION_MODIFIER", 193, 203], ["central", "OBSERVATION_MODIFIER", 205, 212], ["peripheral", "ANATOMY_MODIFIER", 220, 230], ["distribution", "OBSERVATION_MODIFIER", 231, 243]]], ["Other findings, such as pleural effusion, pericardial effusion and mediastinal lymphadenopathy, are also possible.", [["pleural effusion", "ANATOMY", 24, 40], ["pericardial", "ANATOMY", 42, 53], ["mediastinal lymphadenopathy", "ANATOMY", 67, 94], ["pleural effusion", "DISEASE", 24, 40], ["pericardial effusion", "DISEASE", 42, 62], ["mediastinal lymphadenopathy", "DISEASE", 67, 94], ["pleural", "PATHOLOGICAL_FORMATION", 24, 31], ["pleural effusion", "PROBLEM", 24, 40], ["pericardial effusion", "PROBLEM", 42, 62], ["mediastinal lymphadenopathy", "PROBLEM", 67, 94], ["pleural", "ANATOMY", 24, 31], ["effusion", "OBSERVATION", 32, 40], ["pericardial", "ANATOMY", 42, 53], ["effusion", "OBSERVATION", 54, 62], ["mediastinal", "ANATOMY", 67, 78], ["lymphadenopathy", "OBSERVATION", 79, 94]]], ["Often Covid-19 patients already suffer from other lung diseases [12, 13].", [["lung", "ANATOMY", 50, 54], ["lung diseases", "DISEASE", 50, 63], ["patients", "ORGANISM", 15, 23], ["lung", "ORGAN", 50, 54], ["patients", "SPECIES", 15, 23], ["other lung diseases", "PROBLEM", 44, 63], ["lung", "ANATOMY", 50, 54], ["diseases", "OBSERVATION", 55, 63]]], ["CT is widely used, has rapid acquisition speed and high sensitivity, which has led to a large number of patients referred to imaging and the number of confirmed patients whose evolution must be followed.", [["patients", "ORGANISM", 104, 112], ["patients", "ORGANISM", 161, 169], ["patients", "SPECIES", 104, 112], ["patients", "SPECIES", 161, 169], ["CT", "TEST", 0, 2], ["imaging", "TEST", 125, 132], ["large", "OBSERVATION_MODIFIER", 88, 93]]], ["However, after examination, disinfection of CT room is mandatory and wait on average 20 min, time necessary for the exchange of air to secure the equipment and the environments.", [["examination", "TEST", 15, 26], ["disinfection of CT room", "TEST", 28, 51], ["the exchange of air", "TREATMENT", 112, 131], ["the equipment", "TREATMENT", 142, 155]]], ["Therefore, CT use should be limited to the resolution of complex clinical problems or to patients with first negative swab, whose symptoms need urgent therapy.", [["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["CT", "TEST", 11, 13], ["complex clinical problems", "PROBLEM", 57, 82], ["whose symptoms", "PROBLEM", 124, 138], ["urgent therapy", "TREATMENT", 144, 158]]], ["Artificial intelligence (AI) software has been employed to facilitate CT diagnosis.", [["CT diagnosis", "TEST", 70, 82]]], ["Unfortunately, Covid-19 patients have similar imaging characteristics as interstitial pneumonia caused by other viruses and AI software programs are not able to differentiate Covid-19 from other viral pneumonias.", [["interstitial", "ANATOMY", 73, 85], ["interstitial pneumonia", "DISEASE", 73, 95], ["pneumonias", "DISEASE", 201, 211], ["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["Covid-19", "SPECIES", 175, 183], ["interstitial pneumonia", "PROBLEM", 73, 95], ["other viruses", "PROBLEM", 106, 119], ["AI software programs", "TREATMENT", 124, 144], ["Covid", "TEST", 175, 180], ["other viral pneumonias", "PROBLEM", 189, 211], ["interstitial", "ANATOMY_MODIFIER", 73, 85], ["pneumonia", "OBSERVATION", 86, 95], ["viruses", "OBSERVATION", 112, 119], ["viral", "OBSERVATION_MODIFIER", 195, 200], ["pneumonias", "OBSERVATION", 201, 211]]], ["Furthermore, common to all big data-based applications, all deep learning methods have lack of transparency and interpretability and it is impossible to determine what imaging features are being used to determine the output.IntroductionHowever, advantages of software are automated measurements of wall thickness for intuitive airway analysis, lobe segmentation and visualization.", [["wall", "ANATOMY", 298, 302], ["airway", "ANATOMY", 327, 333], ["lobe", "ANATOMY", 344, 348], ["wall", "TISSUE", 298, 302], ["airway", "MULTI-TISSUE_STRUCTURE", 327, 333], ["lobe", "MULTI-TISSUE_STRUCTURE", 344, 348], ["imaging features", "TEST", 168, 184], ["wall thickness", "TEST", 298, 312], ["intuitive airway analysis", "TEST", 317, 342], ["lobe segmentation", "TEST", 344, 361], ["visualization", "TEST", 366, 379], ["wall", "ANATOMY_MODIFIER", 298, 302], ["airway", "ANATOMY", 327, 333], ["lobe", "ANATOMY", 344, 348]]], ["Beside clinical procedures and treatments, AI promises a new paradigm for health care, with different tools that are built upon machine learning (ML) algorithms and support the decision-making processes.", [["clinical procedures", "TREATMENT", 7, 26], ["treatments", "TREATMENT", 31, 41], ["AI", "TREATMENT", 43, 45], ["health care", "TREATMENT", 74, 85]]], ["AI software must be useful categorizing the disease into different severities, integrating the structured report [14], prepared according to subjective considerations, with quantitative, objective assessments of the extent of the lesions.IntroductionIn this communication, we present an example of a good tool for the radiologist (Thoracic VCAR software, GE Healthcare, Italy) in Covid-19 diagnosis [1].", [["lesions", "ANATOMY", 230, 237], ["lesions", "PATHOLOGICAL_FORMATION", 230, 237], ["the disease into different severities", "PROBLEM", 40, 77], ["objective assessments", "TEST", 187, 208], ["the lesions", "PROBLEM", 226, 237], ["disease", "OBSERVATION", 44, 51], ["lesions", "OBSERVATION", 230, 237], ["Thoracic", "ANATOMY", 331, 339]]], ["Thoracic VCAR offers quantitative measurements of the lung involvement.", [["Thoracic", "ANATOMY", 0, 8], ["lung", "ANATOMY", 54, 58], ["lung", "ORGAN", 54, 58], ["the lung involvement", "PROBLEM", 50, 70], ["lung", "ANATOMY", 54, 58], ["involvement", "OBSERVATION", 59, 70]]], ["Thoracic VCAR can generate a clear, fast and concise report that communicates vital medical information to referring physicians.", [["clear", "OBSERVATION", 29, 34]]], ["In the post-processing phase, software, thanks to the help of a colorimetric map, recognizes the ground glass and differentiates it from consolidation and quantifies them as a percentage with respect to the healthy parenchyma.", [["parenchyma", "ANATOMY", 215, 225], ["parenchyma", "TISSUE", 215, 225], ["a colorimetric map", "TEST", 62, 80], ["consolidation", "PROBLEM", 137, 150], ["ground glass", "OBSERVATION", 97, 109], ["consolidation", "OBSERVATION", 137, 150], ["parenchyma", "ANATOMY_MODIFIER", 215, 225]]], ["This \u201cobjective\u201d information is useful for evaluating regression or progression disease in response to drug therapy as well as evaluating the effectiveness of pronation maneuvers for alveolar recruitment in ICU patients.", [["alveolar", "ANATOMY", 183, 191], ["alveolar", "MULTI-TISSUE_STRUCTURE", 183, 191], ["patients", "ORGANISM", 211, 219], ["patients", "SPECIES", 211, 219], ["progression disease", "PROBLEM", 68, 87], ["drug therapy", "TREATMENT", 103, 115], ["pronation maneuvers", "TREATMENT", 159, 178], ["alveolar recruitment", "PROBLEM", 183, 203], ["alveolar", "ANATOMY", 183, 191], ["recruitment", "OBSERVATION", 192, 203]]], ["It is therefore desirable to have an automatic system to perform and accurate detection of the Covid-19 using chest-CT.", [["Covid-19", "DNA", 95, 103], ["the Covid", "TEST", 91, 100], ["chest-CT", "TEST", 110, 118], ["chest", "ANATOMY", 110, 115]]], ["Moreover, during the follow-up HRCT examination could precisely quantify the course of the disease and evaluates the effectiveness of the experimental trial and the patient\u2019s prognosis (Figs.", [["patient", "ORGANISM", 165, 172], ["patient", "SPECIES", 165, 172], ["the follow-up HRCT examination", "TEST", 17, 47], ["the disease", "PROBLEM", 87, 98], ["the experimental trial", "TREATMENT", 134, 156], ["disease", "OBSERVATION", 91, 98]]], ["On the basis of the scientific evidence acquired so far, it is also intended to underline that, considering the nonspecificity of HRCT patterns of Covid-19 pneumonia that do not allow to express a diagnostic judgment of certainty, the chest HRCT examination cannot be considered a substitute for the RT-PCR test in the diagnosis of Covid-19 nor used as a means of clinical screening, but it represents a good support [15].ConclusionTherefore, keeping in mind that CT has high diagnostic sensitivity in identifying lesions, but not specific for Covid-19 and similar to other infectious viral diseases, it is mandatory to have an AI software that expresses objective evaluations of the percentage of ventilated lung parenchyma compared to the affected one.", [["lesions", "ANATOMY", 514, 521], ["lung parenchyma", "ANATOMY", 709, 724], ["pneumonia", "DISEASE", 156, 165], ["viral diseases", "DISEASE", 585, 599], ["lesions", "PATHOLOGICAL_FORMATION", 514, 521], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 709, 724], ["Covid-19", "SPECIES", 147, 155], ["HRCT patterns", "TEST", 130, 143], ["Covid-19 pneumonia", "PROBLEM", 147, 165], ["the chest HRCT examination", "TEST", 231, 257], ["the RT-PCR test", "TEST", 296, 311], ["Covid", "TEST", 332, 337], ["clinical screening", "TEST", 364, 382], ["CT", "TEST", 464, 466], ["high diagnostic sensitivity", "PROBLEM", 471, 498], ["lesions", "PROBLEM", 514, 521], ["Covid", "TEST", 544, 549], ["other infectious viral diseases", "PROBLEM", 568, 599], ["objective evaluations", "TEST", 655, 676], ["ventilated lung parenchyma", "PROBLEM", 698, 724], ["pneumonia", "OBSERVATION", 156, 165], ["chest", "ANATOMY", 235, 240], ["lesions", "OBSERVATION", 514, 521], ["infectious", "OBSERVATION_MODIFIER", 574, 584], ["viral", "OBSERVATION", 585, 590], ["ventilated", "ANATOMY_MODIFIER", 698, 708], ["lung", "ANATOMY", 709, 713], ["parenchyma", "ANATOMY_MODIFIER", 714, 724]]]]}